Abstract #,Poster #,Title,Authors,Institutions
834,G30,Extracellular DNA in patients with urothelial carcinoma of the bladder.,"Patrik Palacka , Hana Kováčová , Iveta Mikolášková , Magda Suchánková , Mária Paulovičová , Boris Kollárik , Peter Celec , Ľuba Hunákova","2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, Institute of Immunology, Faculty of Medicine, Comenius University, 2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Department of Urology, Bory Hospital, 5 Institute of Molecular Biomedicine, Faculty of Medicine, Comenius University 6 Institute of Pathophysiology, Faculty of Medicine, Comenius University"
36,A14,Evaluation of the impact on overall survival curves of patients with metastatic castration-sensitive prostate cancer staged with PET-PSMA and classified according to current prognostic criteria by volume and risk.,"Isadora Sousa , Luciana Leite , André Ribeiro , Eduardo Lima , José Rinck Jr.",A.C. Camargo Cancer Center
249,G22,Clinical significance of urotensin 2 plasma level in patients diagnosed with prostate cancer.,"Cigdem Dinckal , Zeynep Guc , Mustafa Dinckal , Gamze Ozkan , Sinan Unal , Yasar Yildiz , Utku Oflazoglu , Tarik Salman , Ahmet Alacacioglu , Yuksel Kucukzeybek","İzmir Katip Celebi University, Department of Medical Oncology, Ege University, Department of Urology, İzmir Katip Celebi University, Department of Internal Medicine"
670,C3,Survival disparities by sex with contemporary advanced urothelial carcinoma (aUC) therapy: A real-world analysis.,"Adam Barsouk , Omar Elghawy , Jonathan Sussman , Jessica Xu , Ronac Mamtani , Lin Mei","Abramson Cancer Center, Penn Medicine, Hospital of the University of Pennsylvania, Abramson Cancer Center, Hospital of University of Pennsylvania"
668,C1,Survival disparities by race in advanced urothelial carcinoma (aUC): A real-world analysis.,"Adam Barsouk , Omar Elghawy , Jonathan Sussman , Jessica Xu , Ronac Mamtani , Lin Mei","Abramson Cancer Center, Penn Medicine, Hospital of the University of Pennsylvania, Abramson Cancer Center, University of Pennsylvania, Abramson Cancer Center, Hospital of University of Pennsylvania"
311,,"Gut health and prostate cancer: The influence of a specific phytochemical-rich food capsule plus or minus a probiotic/prebiotic blend on symptoms and progression—A randomised, double-blind placebo-controlled trial.","Robert Thomas , Stacey Kenfield , Paul Newton , Simon Russell , Jeffrey Aldous , Madeleine Williams , Anita Mitra , Zahoor Fazili","Addenbrooke's Hospital, University of California, San Francisco, Edith Cowan University, Western Australia, Hills Rd, School of Sport Science and Physical Activity, University of Bedfordshire, The Primrose Oncology Lifestyle Research Unit, Department of Oncology, University College London and University College London Hospital, Department of Urology, Bedford and Luton NHS Hospitals"
719,D16,Patient profiles as drivers of physician choice for first-line (1L) treatment (tx) in locally advanced or metastatic urothelial cancer (la/mUC): Perspectives from a US study.,"Neil Milloy , Maria Walley , Amber Simpson , Cameron Forshaw , Valerie Morris , Mairead Kearney","Adelphi Real World, EMD Serono, The Healthcare Business of Merck KGaA"
635,J20,Severity of bleomycin-induced lung toxicity in Indian patients with intermediate and poor-risk non-seminomatous germ cell tumors (NSGCT): A clinical perspective.,"Himanshu Gujarathi , Aditya Dhanawat , Bhagyashri Jadhav , Atul Tiwari , Kunal Jobanputra , Kriti YC , Pallavi Rane , Minit Shah , Nandini Menon , Priyamvada Maitre , Mahendra Pal , Amandeep Arora , Aparna Ringe-Katdare , Santosh Menon , Gagan Prakash , Vedang Murthy , Vanita Noronha , Kumar Prabhash , Saneep Tandon , Amit Joshi","Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) and Tata Memorial Hospital (TMH), Tata Memorial Hospital"
TPS433,M31,Neoadjuvant darolutamide and relugolix combination preceding radical prostatectomy for high risk localized and locally advanced prostate cancer: A phase I/Ib trial.,"Guru Sonpavde , Marcio Moschovas , Carlos Alemany , Rajesh Sehgal , Qamar Khan , Christopher Russell , Zachary Smith , Steve Williams , John Andrich , Neley Morales , Ritika Behera , Felipe Valerio , Lindley Mosqueda , Jianbin Zhu , Vipul Patel , Justin Emtage","AdventHealth Cancer Institute and University of Central Florida, AdventHealth Global Robotics Institute, AdventHealth Cancer Institiute Orlando, AdventHealth Cancer Institute, AdventHealth Orlando, Adventhealth"
TPS893,J21,Phase 1/2 INTerpath-005 study: V940 (mRNA-4157) plus pembrolizumab with or without enfortumab vedotin (EV) for resected high-risk muscle-invasive urothelial carcinoma (MIUC).,"Guru Sonpavde , Begoña Valderrama , Karim Chamie , Shilpa Gupta , Maria De Santis , Joydeep Banerjee , Laureen Ojalvo , Yixin Ren , Abhishek Bavle , Thomas Powles","AdventHealth Cancer Institute and University of Central Florida, Hospital Universitario Virgen del Rocío, Insitute of Urological Oncology, UCLA, Taussig Cancer Institute, Cleveland Clinic, Charité Universitätsmedizin Berlin, Moderna Inc., Merck & Co., Inc., Barts Cancer Institute, Queen Mary University of London"
TPS291,M10,Carboplatin in patients with metastatic castration-resistant prostate cancer harboring somatic or germline homologous recombination repair gene mutations: Phase II single-arm trial (CiPHeR).,"Rishabh Jain , Atul Batra , Akash Kumar , Atul Sharma , Ranjit Sahoo , Aparna Sharma , Amlesh Seth , Brusabhanu Nayak , Shamim Ahmed Shamim , Seema Kaushal , Haresh Kunhi Parambath , Chandan Das","All India Institute of Medical Sciences, Dr. B.R.A. Institute-Rotary Cancer Hospital, All India Institute of Medical Sciences, Department of Medical Oncology, All India Institute of Medical Sciences, Department of Medical Oncology, Dr. B.R.A. Institute-Rotary Cancer Hospital, Urology, All India Institute of Medical Sciences, Pathology, All India Institute of Medical Science"
57,B3,Survival outcomes among metastatic castration-resistant prostate cancer patients treated with androgen receptor pathway inhibitor and docetaxel.,"Yunji Hwang , Travis Wheeling , Mark Hatfield , Christopher Kim","Amgen, Inc."
168,E7,"Efficacy and safety of nanosomal docetaxel lipid suspension in Indian patients with metastatic castration-resistant prostate cancer (mCRPC): A multicenter, open-label, single-arm phase 4 study.","Prabrajya Mohapatra , Bharat Vaswani , Padmaj Kulkarni , Rakesh Reddy , Nikhil Ghadyalpatil , Chandan Das , Ranga Raman Ganta , Radhika Parimkayala , Sourav Mishra , Francis James , Bhushan Nemade , Rajeev Sood , Ateeq Ahmad , Saifuddin Sheikh , Shoukath Ali , Mahesh Paithankar , Anil Rajani , Alok Chaturvedi , Imran Ahmad , Deepak Bunger","Apollo Gleneagles Hospitals, Yashoda Hospitals, Secunderabad, Deenanath Mangeshkar Hospital and Research Centre, Mahatma Gandhi Cancer Hospital and Research Institute, Yashoda Hospital, Post Graduate Institute of Medical Education and Research, HCG City Cancer Centre, MNJ Institute of Oncology and Regional Cancer Centre, All India Institute of Medical Sciences, Bhubaneswar, Regional Cancer Centre, Trivandrum, Navsanjeevani Hospital Nashik, Dr. Ram Manohar Lohia Hospital and Postgraduate Institute of Medical Research, Jina Pharmaceuticals Inc, Jina Pharmaceuticals, Intas Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd. (Biopharma Division)"
669,C2,"Understanding diversity and disparities in a real-world locally advanced/metastatic urothelial carcinoma (la/mUC): Clinical characteristics, genomic landscape, and self-reported social determinants of health (SDOH).","Nimira Alimohamed , Amanda Gibson , Michelle Dean , Tracy Xu , Megha Murali , Roba Banjaw , Naveen Basappa , Tarek Bismar , Navdeep Dehar , Safiya Karim , Michael Kolinsky , Daniel Heng , Richard Lee-Ying , Vishal Navani , Scott North , Joseph Ruether , Amina Taleb , Brendan Osborne , Pinaki Bose , Steven Yip","Arthur JE Child Comprehensive Cancer Centre, POET Oncology, Cumming School of Medicine, University of Calgary, Cross Cancer Institute, University of Alberta, Cumming School of Medicine, University of Calgary, Cross Cancer Institute, Jack Ady Cancer Centre, Alberta Health Services, Janssen Inc. Canada"
656,K4,"Paclitaxel, ifosfamide, cisplatin (TIP) in patients with advanced urethral adenocarcinoma: A single center, retrospective analysis.","Gwanhyun Park , Inkeun Park , Shinkyo Yoon , Jae Lyun Lee","Asan Medical Center, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine"
640,J25,Clinical experience with EMACO chemotherapy in male choriocarcinoma: A single-center study.,"Gwanhyun Park , Inkeun Park , Shinkyo Yoon , Jae Lyun Lee","Asan Medical Center, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Asan Medical Center, University of Ulsan College of Medicine"
547,G14,"Cabozantinib as subsequent therapy to an immune checkpoint-based therapy in renal cell carcinoma, phase 2 interventional study (AT ASIA, KCSG GU21-02).","Jae Lyun Lee , Sang Joon Shin , Inkeun Park , Woo Kyun Bae , Shinkyo Yoon , In-Ho Kim , Hong Jae Chon , Byoung Young Shim , Jin Young Kim , Jung Hoon Kim , Joo-Hwan Park , Il Hwan Kim , Miso Kim , Kwonoh Park , Hyo Jin Lee","Asan Medical Center, University of Ulsan College of Medicine, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Chonnam National University Hwasun Hospital, Asan Medical Center, Division of Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, CHA Bundang Medical Center, CHA University, St. Vincent's Hospital, Keimyung University Dongsan Hospital, Division of Hematology/Oncology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Division of Medical Oncology, Department of Internal Medicine, Gachon University School of Medicine, Gil Medical Center, Division of Oncology, Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Hanyang University Seoul Hospital, Hanyang University College of Medicine, Department of Medical Science and Internal Medicine, College of Medicine, Chungnam National University"
258,G31,A liquid biopsy-based proteomic assay to identify circulating tumor cell (CTC) –derived druggable targets in cancer patients.,"Alec Horrmann , Ali Arafa , Kaylee Kamalanathan , Alexa Hesch , Grant Schaap , Zikora Izuora , Mahdi Ahmadi , Badrinath Konety , Howard Scher , Emmanuel Antonarakis , Jiarong Hong , Justin Drake","Astrin Biosciences, University of MInnesota, University of Minnesota, Memorial Sloan Kettering Cancer Center, University of Minnesota, Masonic Cancer Center"
777,F4,Treatment of low-grade intermediate-risk non-muscle-invasive bladder cancer with UGN-102: Results of the phase 3 ATLAS and ENVISION studies.,"Sandip Prasad , Brian Hu , Marc Bjurlin , Dimitar Shishkov , Nikola Mihaylov , Alexandre Khuskivadze , Pencho Genov , Vasyl Terzi , Max Kates , William Huang , Michael Louie , Sunil Raju , Brent Burger , Andrew Meads , Mark Schoenberg","Atlantic Medical Center, Department of Urology, Loma Linda University, Department of Urology, University of North Carolina, Department of Urology, University Multiprofile Hospital for Active Treatment, Urology Department, Georgia Israel Joint Clinic Gidmedi, Urology Department, University Multiprofile Hospital for Active Treatment Kanev, Multiprofile Hospital for Active Treatment Varna Military Medical Academy, The Johns Hopkins University School of Medicine, New York University Langone Medical Center, UroGen Pharma, The Department of Urology, Montefiore Einstein"
776,F3,Impact of tumor burden or focality in recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer on response to treatment with UGN-102: A substudy of the phase 3 ENVISION trial.,"Sandip Prasad , Dimitar Shishkov , Nikola Mihaylov , Alexandre Khuskivadze , Pencho Genov , Vasyl Terzi , Max Kates , William Huang , Michael Louie , Sunil Raju , Brent Burger , Andrew Meads , Mark Schoenberg","Atlantic Medical Center, Department of Urology, University Multiprofile Hospital for Active Treatment, University Multiprofile Hospital for Active Treatment, Urology Department, Georgia Israel Joint Clinic Gidmedi, Urology Department, University Multiprofile Hospital for Active Treatment Kanev, Multiprofile Hospital for Active Treatment Varna Military Medical Academy, The Johns Hopkins University School of Medicine, New York University Langone Medical Center, UroGen Pharma, The Department of Urology, Montefiore Einstein"
397,K27,Impact of BRCA status in patients with castrate-resistant prostate cancer undergoing abiraterone +/- stereotactic body radiotherapy: ARTO trial.,"Giulio Francolini , Vanessa Di Cataldo , Pietro Garlatti , Niccolò Bertini , Michele Aquilano , Saverio Caini , Gianluca Ingrosso , Alessio Bruni , Rolando D'Angelillo , Luca Tagliaferri , Matteo Augugliaro , Luca Triggiani , Silvana Parisi , Gabriele Simontacchi , Barbara Jereczek-Fossa , Filippo Alongi , Fabio Arcidiacono , Andrea Lancia , Marta Scorsetti , Lorenzo Livi","Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence, Department of Biomedical, Experimental and Clinical Sciences ""Mario Serio"", University of Florence, IFCA, Radiation Oncology Department, Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPO), Radiation Oncology Section, Department of Medicine and Surgery, University of Perugia, Radiation Oncology Unit, Department of Oncology and Hematology, University Hospital of Modena, Radiation Oncology, Department of Biomedicine and Prevention University of Rome ""Tor Vergata"", Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Unit of Radiotherapy, Azienda USL, IRCCS di Reggio Emilia, Università degli Studi di Brescia, Department of Radiation Oncology, Brescia University, Radiation Oncology Unit - Department of Biomedical, Dental Science and Morphological and Functional Images, University of Messina, University of Milan and European Institute of Oncology, IRCCS, IRCCS Sacro Cuore Don Calabria Hospital, Department of Advanced Radiation Oncology, Negrar, Radiation Oncology Centre, S. Maria Hospital, Fondazione IRCCS Policlinico San Matteo, Department of Radiation Oncology, Department of Radiotherapy and Radiosurgery, IRCCS - Humanitas Clinical and Research Center -"
444,,Final overall survival and new ctDNA analysis in MET-driven advanced papillary renal cancer (CALYPSO).,"Francesca Jackson-Spence , James Larkin , Poulam Patel , Begoña Valderrama , Alejo Rodriguez-Vida , Maria Jose Mendez-Vidal , Merrida Childress , Wenshu Li , Patrick Boyle , Amaya Gasco , Aleksandra Markovets , Ryan Hartmaier , Charlotte Ackerman , Bernadett Szabados , Garima Priyadarshini , Fahmida Jamal , Thomas Powles , Cristina Suárez","Barts Cancer Centre, Royal Marsden Hospital, Nottingham University Hospital NHS Trust, Hospital Universitario Virgen del Rocío, Hospital del Mar, Hospital Reina Sofia, Foundation Medicine Inc., Foundation Medicine, Foundation Medicine, Inc., Oncology Data Science, Oncology R&D, AstraZeneca, AstraZeneca R&D Boston, Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, Barts Cancer Centre, Queen Mary University of London, Barts Cancer Institure, Barts Cancer Institute, Medical Oncology, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital"
525,F23,Improving health related quality of life (HRQoL) assessment and immune related adverse event (irAE) classification with novel tools in renal cancer.,"Elizabeth Nally , Gemma Ainsworth , Sarah Brown , Cristiane Bergerot , Connor Wells , Matthew Young , Tanith Westerman , Sara Coca , Francesca Jackson-Spence , Bernadett Szabados , Sumanta Pal , Thomas Powles , Naveen Vasudev","Barts Cancer Institute, Leeds Institute of Clinical Trials Research, University of Leeds, Oncoclinicas & Co, Medica Scientia Innovation Research (MEDSIR), Barts Cancer Institute, Queen Mary University of London, Barts Cancer Centre, Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Barts Cancer Centre, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, St James's University Hospital"
451,D19,Systemic therapy clinical trial participation in patients with bladder and kidney cancers.,"Connor Wells , Elizabeth Nally , Francesca Jackson-Spence , Sara Coca , Tanith Westerman , Matthew Young , Bernadett Szabados , Thomas Powles","Barts Cancer Institute, Queen Mary University of London, Barts Cancer Institute, Barts Cancer Centre, Barts Cancer Centre, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London"
664,,EV-302: Updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).,"Thomas Powles , Michiel Van Der Heijden , Yohann Loriot , Jens Bedke , Begoña Valderrama , Gopa Iyer , Eiji Kikuchi , Jeannie Hoffman-Censits , Christof Vulsteke , Alexandra Drakaki , Steffen Rausch , Waddah Arafat , Se Hoon Park , Umang Swami , Jian-Ri Li , Seema Gorla , Blanca Homet Moreno , Xuesong Yu , Yi-Tsung Lu , Shilpa Gupta","Barts Cancer Institute, Queen Mary University of London, Department of Medical Oncology, Netherlands Cancer Institute, Gustave Roussy, Département de Médecine Oncologique et Département des Essais Précoces, Université Paris-Saclay, Department of Urology & Eva Mayr-Stihl Cancer Center, Hospital Universitario Virgen del Rocío, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, Department of Urology, St Marianna University School of Medicine, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Department of Medical Oncology, Maria Middelares Hospital, University of California, Los Angeles Medical Center, Department of Urology, Eberhard Karls University, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Medicine, Huntsman Cancer Institute at the University of Utah, Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Astellas Pharma, Inc., Merck & Co., Inc., Pfizer Inc., Cleveland Clinic"
99,C9,Real-world treatment patterns and survival in men with metastatic castration-resistant prostate cancer (mCRPC) who previously progressed from metastatic hormone-sensitive prostate cancer (mHSPC) between 2020 to 2023 in the United States.,"Amit Raval , Guifang Chen , Matthew Korn , Andreas Bernthaler , Niculae Constantinovici , Stephen Freedland","Bayer HealthCare Pharmaceuticals, Inc., Bayer AG, Bayer Consumer Care AG, Department of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center"
99,C9,Real-world treatment patterns and survival in men with metastatic castration-resistant prostate cancer (mCRPC) who previously progressed from metastatic hormone-sensitive prostate cancer (mHSPC) between 2020 to 2023 in the United States.,"Amit Raval , Guifang Chen , Matthew Korn , Andreas Bernthaler , Niculae Constantinovici , Stephen Freedland","Bayer HealthCare Pharmaceuticals, Inc., Bayer AG, Bayer Consumer Care AG, Department of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center"
101,C11,Treatment patterns and survival in men with metastatic castration-resistant prostate cancer (mCRPC): A systematic literature review of 35 real-world observational studies.,"Amit Raval , Viji Queen V , Matthew Korn , Vanessa Quintero , Stephen Freedland","Bayer HealthCare Pharmaceuticals, Inc., CapeStart Inc, Department of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center"
116,C26,Evaluating clinical tools to monitor cardiovascular (CV) risk in men with localized high-risk or locally advanced prostate cancer (LHRPC) treated with hormone therapy (HT).,"Neha Venkatesh , Pankaj Chauhan , Kabir Grewal , Ana Aparicio , Patrick Pilié , Sumit Subudhi , Paul Corn , Bilal Siddiqui , Amado Zurita , Daniel Frigo , Christopher Logothetis , Pavlos Msaouel , Efstratios Koutroumpakis , Andrew Hahn","Baylor College of Medicine, The University of Texas MD Anderson Cancer Center, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Cardiology Department, The University of Texas MD Anderson Cancer Center"
545,G12,The influence of body composition on the survival of patients with metastatic clear cell renal carcinoma (mccRCC) treated with nivolumab (nivo) + ipilimumab (ipi).,"Kabir Grewal , Pankaj Chauhan , Sagar Mukhida , Nizar Tannir , Neha Venkatesh , Amishi Shah , Amado Zurita , Andrew Johns , Matthew Campbell , Sangeeta Goswami , Jianjun Gao , Eric Jonasch , Jennifer McQuade , Omar Alhalabi , Pavlos Msaouel , Andrew Hahn","Baylor College of Medicine, The University of Texas MD Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center"
189,E28,Prostate cancer liver metastases: Genomic profiling and clinical outcomes.,"Hayley Roberts , Yi Jou Ruby Liao , Cameron Herberts , Sofie Tolmeijer , Catherine Wang , Anna Riminchan , Elsa Sartori-Muller , Edmond Kwan , Matti Annala , Nicolette Fonseca , Joanna Vergidis , Krista Noonan , Daygen Finch , Muhammad Zulfiqar , Miller Stacy , Gillian Vandekerkhove , Alexander Wyatt , Corinne Maurice-Dror , Kim Chi","BC Cancer, Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver Prostate Centre, University of British Columbia, BC Cancer, Victoria, Department of Medical Oncology, BC Cancer, British Columbia Cancer Agency, BC Cancer Agency, The University of British Columbia, BC Cancer, Vancouver Cancer Centre, University of British Columbia, BC Cancer, Vancouver Cancer Centre"
62,B8,Reflexive paired somatic and germline testing at time of medical oncology referral in mCSPC: Impact on timely treatment.,"Richard Gagnon , Emma Hoag , Alexandra Olsen , Andrew Attwell , Adam Fundytus , Joanna Vergidis , Sunil Parimi , Eric Sonke , Nimira Alimohamed , Steven Yip , Corinne Maurice Dror , Kim Chi , Madison Hinkley , Jean-Michel Lavoie","BC Cancer, Victoria, British Columbia Cancer Agency, University of Calgary, Tom Baker Cancer Centre, Department of Medical Oncology, BC Cancer, University of British Columbia, BC Cancer, Vancouver Cancer Centre, University of British Columbia"
657,,"Nectin-4 targeted ADC, SHR-A2102, in patients with advanced or metastatic urothelial carcinoma: A phase 1 study.","Bixia Tang , Xinan Sheng , Jun Guo , Haitao Niu , Yali Shen , Shusuan Jiang , Bin Fu , Jianming Guo , Wasilijiang Wahafu , Kai Yao , Nan Liu , Jiang Gu , Yu Chen , Zhenhua Li , Tianxin Lin , Liping Ma , Jiaqin Lin , Chi Zhang , Wenliang Wang","Beijing Cancer Hospital, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University, The Affiliated Hospital of Qingdao University, West China Hospital, Sichuan University, Hunan Cancer Hospital, The First Affiliated Hospital of Nanchang University, Zhongshan Hospital, Fudan University, Shanxi Provincial Cancer Hospital, Sun Yat-sen University Cancer  Center, Chongqing University Cancer Hospital, The Affiliated Hospital of Guizhou Medical University, Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Shengjing Hospital Of China Medical University, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Peking University Shougang Hospital, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Jiangsu Hengrui Pharmaceuticals Co., Ltd"
27,A5,Treatment patterns and survival outcomes in metastatic castration-resistant prostate cancer in the Brazilian population: LACOG 1818.,"Fernando Maluf , Suelen Martins , Deusdedit Silva Neto , Daniel Girardi , Jose Augusto Rinck Jr , Ana Caroline Alves , Thiago Almeida , Andréa de Souza , Daniel Araujo , Aline Lara Gongora , Diogo Bastos , Cristina Sampaio , Augusto Mota , Andre Fay , Roberto Rocha , Douglas Dias e Silva , Tainá Cabalheiro , Pablo Barrios , Gustavo Gössling , Andrey Soares","BP - A Beneficência Portuguesa de São Paulo, Centro de Estudos e Pesquisas de Hematologia e Oncologia (CEPHO), Faculdade de Medicina do ABC (FMABC), Irmandade Santa Casa de Misericórdia de São Paulo, Hospital Sírio-Libanês, and Hospital de Base do Instituto de Gestão Estratégica em Saúde do Distrito Federal (IGESDF), A.C. Camargo Cancer Center, Hospital de Oncologia do Maranhão Dr. Tarquínio Lopes Filho, Hospital Napoleão Laureano, Universidade Federal da Paraiba, Instituto de Medicina Integral Professor Fernando Figueira (IMIP), and Instituto Santa Joana de Ensino e Pesquisa, Hospital Santa Joana Recife, Hospital de Base - Faculdade de Medicina de São José do Rio Preto (FAMERP), Hospital do Câncer de Cascavel - União Oeste Paranaense de Estudos e Combate ao Cancer (UOPECCAN), Hospital Sírio-Libanês, Clinica Prognóstica, Centro de Pesquisa Clínica Onconeo, Instituto ETICA, Clínica AMO (Assistência Multidisciplinar em Oncologia), Centro de Pesquisa em Oncologia (CPO) - Hospital São Lucas da PUCRS, Porto Alegre, Brazil and Hospital Nora Teixeira - Santa Casa de Porto Alegre, Hospital Santa Marcelina, Hospital Israelita Albert Einstein (HIAE), Latin American Cooperative Oncology Group (LACOG), Centro Paulista de Oncologia (CPO), and Hospital Israelita Albert Einstein (HIAE)"
590,H25,Association between PD-1 expression on tumor-infiltrating regulatory T cells and resistance to first-line nivolumab in advanced clear cell renal cell carcinoma: Insights from the HCRN GU16-260 clinical trial.,"Razan Mohanna , Berkay Simsek , Nourhan El Ahmar , Opeyemi Jegede , Sayed Matar , Morgan Paul , Yasmin Nabil Laimon , Gabriel Roberti De Oliveira , Andrew Delcea , Toni Choueiri , David Braun , Naomi Haas , Hans Hammers , Mehmet Bilen , Mark Stein , Jeffrey Sosman , Catherine Wu , David McDermott , Michael Atkins , Sabina Signoretti","Brigham and Women's Hospital, Brigham and Women's Hospital, Harvard Medical School, DFCI, Yale School of Medicine, Dana-Farber Cancer Institute, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School, Center of Molecular and Cellular Oncology, Yale University, Abramson Cancer Center, University of Pennsylvania, Department of Internal Medicine, Division of Hematology and Oncology, UT Southwestern, Winship Cancer Institute of Emory University, Columbia University Medical Center, Northwestern University, Beth Israel Deaconess Medical Center, Georgetown Lombardi Comprehensive Cancer Center"
598,H33,Evaluating the combined role of HHLA2 and PD-L1 as biomarkers in first-line nivolumab therapy in advanced clear cell renal cell carcinoma.,"Yasmin Nabil Laimon , Nourhan El Ahmar , Opeyemi Jegede , Aseman Baghari Sheshdeh , Gordon Freeman , David McDermott , Michael Atkins , Sabina Signoretti , Kathleen Mahoney","Brigham and Women's Hospital, DFCI, Kansas City University College of Osteopathic Medicine, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Georgetown Lombardi Comprehensive Cancer Center, Beth Israel Deaconess Medical Center"
83,B29,Efficacy outcomes 12 months after initiation of darolutamide in non-metastatic castrate resistant prostate cancer (nmCRPC) from the real world UK multi-centre RECORD study.,"Amarnath Challapalli , Amit Bahl , Manreet Randhawa , Omi Parikh , Santhanam Sundar , Alison Birtle , Jahangeer Malik , Mark Prentice , Dakshinmoorthy Muthukumar , Rajanee Bhana , Kamalram Jayaprakash , Isabel Syndikus , Anita Mitra , Thiraviyam Elumalai , Emma Gray , Hilary Glen , Mark Beresford , Vincent Khoo , Emily Foulstone , Paul White","Bristol Haematology and Oncology Centre, University Hospitals Bristol and Weston NHS Foundation Trust, Beatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde, Royal Blackburn Teaching Hospital, East Lancashire Hospitals NHS Foundation Trust, Nottingham City Hospital, Nottingham University Hospitals NHS Trust, Royal Preston Hospital, Lancashire Teaching Hospitals NHS Foundation Trust, Edinburgh Cancer Centre, Western General Hospital, Royal Free Hospital, Colchester General Hospital, East Suffolk and North Essex NHS Foundation Trust, Royal Stoke University Hospital, University Hospitals of North Midlands NHS Trust, The Queen Elizabeth Hospital King's Lynn, Clatterbridge Cancer Centre NHS Foundation Trust, UCLH - University College London Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Musgrove Park Hospital, Somerset NHS Foundation Trust, Ninewells Hospital and Medical School,  NHS Tayside, Royal United Hospital Bath, The Royal Marsden NHS Foundation Trust, University of the West of England"
1,,EPIC-A: Phase II trial of cemiplimab plus standard of care chemotherapy followed by maintenance cemiplimab in locally advanced or metastatic penile carcinoma.,"Amit Bahl , Amarnath Challapalli , Balaji Venugopal , Mehran Afshar , Constantine Alifrangis , Alastair Thomson , Anna Tran , Andrew Hudson , Christopher Kent , Jim Barber , Helen Dearden , Rachel Pearson , Vivekanandan Kumar , Robert Wade , Alicia Bravo , Emily Foulstone , Paul White","Bristol Haematology and Oncology Centre, University Hospitals Bristol and Weston NHS Foundation Trust, Beatson West of Scotland Cancer Centre, St. George's University Hospitals NHS FT, University College London Hospitals NHS Foundation Trust, Royal Cornwall Hospitals NHS Trust, The Christie NHS Foundation Trust, Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust, Velindre Cancer Centre, Leeds Teaching Hospitals NHS trust, Northern Centre for Cancer Care (NCCC), Norfolk and Norwich University Hospital, University of the West of England"
9,D8,EPIC-B: Phase II trial of cemiplimab as first-line treatment in advanced penile carcinoma.,"Amarnath Challapalli , Amit Bahl , Balaji Venugopal , Mehran Afshar , Constantine Alifrangis , Alastair Thomson , Anna Tran , Andrew Hudson , Christopher Kent , Jim Barber , Helen Dearden , Rachel Pearson , Vivekanandan Kumar , Robert Wade , Alicia Bravo , Paul White , Emily Foulstone","Bristol Haematology and Oncology Centre, University Hospitals Bristol and Weston NHS Foundation Trust, Beatson West of Scotland Cancer Centre, St. George's University Hospitals NHS FT, University College London Hospitals NHS Foundation Trust, Royal Cornwall Hospitals NHS Trust, The Christie NHS Foundation Trust, Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust, Velindre Cancer Centre, Leeds Teaching Hospitals NHS trust, Northern Centre for Cancer Care (NCCC), Norfolk and Norwich University Hospital, University of the West of England"
89,B35,Prospective real world data evaluation of clinical outcomes in metastatic hormone sensitive prostate cancer (MHSPC) patients treated as part of triplet therapy with darolutamide: UK multicenter RECOMMEND study.,"Amit Bahl , Amarnath Challapalli , Prantik Das , Anand Sharma , Rajanee Bhana , Alison Birtle , Dakshinmoorthy Muthukumar , Manreet Randhawa , Santhanam Sundar , Mark Prentice , Diletta Bianchini , Emily Renninson , Miguel CapoMir , Isabel Syndikus , Kamalram Jayaprakash , Thiraviyam Elumalai , Sarah Goodwin , Omi Parikh , Paul White , Emily Foulstone","Bristol Haematology and Oncology Centre, University Hospitals Bristol and Weston NHS Foundation Trust, Royal Derby Hospital, University Hospitals of Derby and Burton NHS Foundation Trust, Mount Vernon Hospital, Royal Stoke University Hospital, University Hospitals of North Midlands NHS Trust, Royal Preston Hospital, Lancashire Teaching Hospitals NHS Foundation Trust, Colchester General Hospital, East Suffolk and North Essex NHS Foundation Trust, Beatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde, Nottingham City Hospital, Nottingham University Hospitals NHS Trust, Royal Free Hospital NHS Foundation Trust, Maidstone Hospital, Maidstone and Tunbridge Wells NHS Trust, Cheltenham General Hospital, East Kent Hospitals NHS Foundation Trust, Clatterbridge Cancer Centre NHS Foundation Trust, The Queen Elizabeth Hospital King's Lynn, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Conquest Hospital, East Sussex Healthcare NHS Trust, Royal Blackburn Teaching Hospital, East Lancashire Hospitals NHS Foundation Trust, University of the West of England"
647,J32,Machine learning model integrating CT radiomics and circulating microRNAs to predict residual disease histology in metastatic non-seminoma testicular cancer (mNSTC).,"Guliz Ozgun , Neda Abdalvand , Gizem Ozcan , Ka Mun Nip , Nastaran Khazamipour , Arman Rahmim , Robert Bell , Maryam Soleimani , Corinne Maurice-Dror , Kim Chi , Bernhard Eigl , Craig Nichols , Christian Kollmannsberger , Ren Yuan , Lucia Nappi","British Columbia Cancer Agency, BC Cancer Research Centre, Vancouver Prostate Center, BC Cancer, Vancouver, BC Cancer, Vancouver Cancer Centre, University of British Columbia, BC Cancer, Vancouver Cancer Centre, Testicular Cancer Commons"
478,E11,Site-specific disease progression in patients with metastatic renal cell carcinoma treated with first-line nivolumab plus ipilimumab or axitinib-based immunotargeted combinations.,"Ilya Tsimafeyeu , Fuad Guliyev , Gunel Musayeva , Ramil Abdrakhmanov , Viacheslav Chubenko , Olga Baklanova , Ruslan Zukov , Vladislav Petkau , Igor Myslevtsev , Alisher Kahharov , Bakytzhan Ongarbayev , Dilyara Kaidarova","Bureau for Cancer Research - BUCARE, National Center of Oncology, Kazakh Institute of Oncology and Radiology, St. Petersburg Clinical and Research Center of Specialized Types of Oncological Medical Care, Irkutsk Regional Cancer Center, V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Sverdlovskiy Regional Oncological Dispensary, St. Alexei Central Clinical Hospital, Tashkent State Dental Institute"
536,G3,Efficacy of nivolumab plus ipilimumab in T1aN0M0 renal cell carcinoma (RCC) patients: Results from 3-year follow-up of the phase 2 pilot study.,"Ilya Tsimafeyeu , Rustem Gafanov , Igor Myslevtsev , Andrey Andrianov , Axel Bex","Bureau for Cancer Research - BUCARE, Russian Scientific Center of Roentgenology and Radiology, St. Alexei Central Clinical Hospital, Royal Free London NHS Foundation Trust"
371,K1,AI-driven prediction of prostate cancer risk: A comparative analysis with C the Signs in the Mayo Clinic data platform.,"Bea Bakshi , Sana Raoof , Tufia Haddad , Tushar Patel , Charles Ryan , Irbaz Riaz , Seema Dadhania , Brian Herrick , Miles Payling","C the Signs, Memorial Sloan Kettering Cancer Center, Mayo Clinic, Mayo Clinic Comprehensive Care Center, University of Minnesota, Mayo Clinic in Arizona, Imperial College, London, Harvard Medical School"
721,D18,Modified transurethral resection of bladder tumors: A comparison study of chemotherapy-enhanced endoscopic submucosal en bloc dissection versus conventional resection.,"Xi Liu , Yiding Wang , Zhe Wang , Bo Shao , Qiang Liu , Changqi Li , Chengcheng Lv , Huan Bi , Guangyi Shan , Ang Chen , Yu Zeng",Cancer Hospital of China Medical University; Cancer Hospital of Dalian University of Technology; Liaoning Cancer Hospital & Institute
41,A19,The role of conventional imaging and piflufolastat F18 in newly diagnosed and recurrent prostate cancer patients: Preliminary observations from the PYLARIFY Registry.,"Neal Shore , Lorraine O'Donnell , Basil Wilson , Shashank Dave , Arpit Kashyap , Nicholas Lazarou","Carolina Urologic Research Center, Cardinal Health"
267,H8,Population-adjusted network meta-analyses (NMA) to evaluate the efficacy of treatment alternatives for metastatic hormone-sensitive prostate cancer (mHSPC).,"Neal Shore , Alicia Morgans , Noman Paracha , Howard Thom , Edna Keeney , Philip Orishaba , David Phillippo , David Aceituno , Christopher Wallis , Martin Boegemann","Carolina Urologic Research Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Bayer Consumer Care AG, University of Bristol, Clifton Insight, Division of Urology and Surgical Oncology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Department of Urology, Münster University Hospital"
85,B31,Real-world clinical practice gaps in timely homologous recombination repair gene mutation (HRRm) testing and poly (ADP-ribose) polymerase inhibitor (PARPi) treatment of patients with metastatic castration resistant prostate cancer (mCRPC).,"Neal Shore , Anupama Vasudevan , John Li , Husain Qureshi , Pratheesh Sathyan , Lindsay Aton , Simon Blanc , Prateesh Varughese , Marni Tierno","Carolina Urologic Research Center, LLC, Integra Connect PrecisionQ, Illumina Inc."
TPS888,J16,"ABLE-32: A randomized, controlled, phase 3b clinical trial of nadofaragene firadenovec-vncg versus observation in patients with intermediate-risk non–muscle-invasive bladder cancer.","Neal Shore , Rian Dickstein , Mark Tyson , Vikram Narayan , Gautum Agarwal , Evan Goldfischer , Michael Williams , Corine Baayen , Kristian Juul , Per Sandstrom , Trinity Bivalacqua","Carolina Urologic Research Center, University of Maryland, Mayo Clinic in Arizona, Department of Urology, Emory University School of Medicine, Urologic Oncology and Precision Medicine, Mercy Oncology and Hematology—David C. Pratt Cancer Center, Premier Medical Group of the Hudson Valley, Urology of Virginia, Eastern Virginia Medical School, Ferring Pharmaceuticals A/S, Department of Urology, Hospitals of the University of Pennsylvania"
448,D16,Access to immune checkpoint inhibitors (ICI) in patients randomized to the control arm of ICI phase 3 trials in urothelial and renal cell cancers.,"Abby Grier , Albert Jang , Jeffrey Zhong , Hamsa Kumar , Tanya Jindal , Adam Calaway , Angela Jia , Pingfu Fu , Laura Bukavina , Rashed Ghandour , Jonathan Shoag , Amanda Nizam , Christopher Wee , Moshe Ornstein , Jason Brown , Shilpa Gupta , Jorge Garcia , Pedro Barata","Case Western Reserve University School of Medicine, Division of Solid Tumor Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, School of Medicine, Case Western Reserve University School of Medicine, Department of Urology, University Hospitals Cleveland Medical Center, Department of Population and Quantitative Health Sciences, Case Western Reserve University, Department of Urology, Cleveland Clinic, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, University Hospitals Seidman Cancer Center"
206,F10,Analysis of gene expression signatures in prostate cancer prior to liver metastases.,"Joshua Watson , Sungyong You , Neil Bhowmick , Edwin Posadas","Cedars-Sinai Medical Center, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Cedars-Sinai Cancer, Cedars-Sinai Medical Center"
207,F11,Effects of emerin dysregulation on the very-small-nuclear phenotype and neuronal differentiation and its association with a clinically aggressive subtype of prostate cancer.,"Le Zhang , Pai-Chi Teng , Karen Cavassani , Catherine Grasso , Joshua Watson , Jasmine Wang , Zijing Chen , Kai Tu , Brenda Salumbides , Lilit Gevorkian , Minhyung Kim , Sungyong You , Dolores Di Vizio , Howard Sandler , Timothy Daskivich , Neil Bhowmick , Michael Freeman , Hsian-Rong Tseng , Jie-Fu Chen , Edwin Posadas","Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Cancer, Cedars-Sinai Medical Center, Cedars Sinai Medical Center, Division of Cancer Systems Biology, Department of Surgery, Cedars-Sinai Medical Center, Department of Biomedical Sciences, Cedars-Sinai Medical Center, California NanoSystems Institute, University of California, Memorial Sloan Kettering Cancer Center"
562,G29,Comprehensive proteomic profiling of plasma samples associated with response or resistance to immune checkpoint inhibitors (ICI) in patients with renal cell carcinoma (RCC).,"Soki Kashima , Wenxin Xu , John Canniff , Renee Maria Saliby , Maxine Sun , Gwo-Shu Lee , Marc Machaalani , Sabina Signoretti , Bradley McGregor , Rana McKay , Toni Choueiri , David Braun","Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Dana-Farber Cancer Institute, Center of Molecular and Cellular Oncology, Yale University, Department of Medical Oncology, Dana-Farber Cancer Institute, University of California, San Diego"
583,H18,Investigation of ferroptosis and mTOR signaling in chromophobe renal cell carcinoma (ChRCC).,"Katrine Madsen , Chris Labaki , Eddy Saad , Michel Alchoueiry , Kevin Bi , Charbel Hobeika , Ziad Bakouny , Carmen Priolo , Damir Khabibullin , Nicholas Schindler , Sabrina Camp , Renee Maria Saliby , Daniel Heng , Eliezer Van Allen , Sachet Shukla , Elizabeth Henske , Toni Choueiri , David Braun","Center of Molecular and Cellular Oncology, Yale University, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Memorial Sloan Kettering Cancer Center, Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, Tom Baker Cancer Centre, University of Calgary, Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute and Harvard Medical School"
219,F23,Efficacy of olaparib (ola) plus abiraterone (abi) versus placebo (pbo) plus abi in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with a germline or somatic BRCA mutation in the PROpel trial.,"Fred Saad , Andrew Armstrong , Mototsugu Oya , Neal Shore , Cagatay Arslan , Karina Vianna , Gary Buchschacher Jr., Craig Gedye , Emma Brown , Urban Emmenegger , Friederike Schlürmann , Ji Youl Lee , Jae Young Joung , Mustafa Özgüroğlu , Elizabeth Harrington , Alan Barnicle , David McGuinness , Arnold Degboe , Christian Hosius , Noel Clarke","Centre Hospitalier de l’Université de Montréal/CRCHUM, Université de Montreal, Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University, Keio University School of Medicine, Carolina Urologic Research Center, LLC, Izmir Economy University Medical Park Hospital, Centro Integrado de Oncologia de Curitiba, Kaiser Permanente Southern California, Los Angeles Medical Center, Calvary Mater Newcastle, University Hospital Southampton, Sunnybrook Research Institute, Centre Hospitalier de Cornouaille, The Catholic University of Korea Seoul St Mary's Hospital, National Cancer Center, Istanbul University Cerrahpasa, Cerrahpasa Faculty of Medicine, Translational Medicine, Oncology R&D, AstraZeneca, Global Medicines Development, Oncology R&D, AstraZeneca, MSD Sharp & Dohme GmbH, The Christie and Salford Royal NHS Foundation Trusts"
151,D25,Darolutamide plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC) by disease volume: Subgroup analysis of the phase 3 ARANOTE trial.,"Fred Saad , Neal Shore , Egils Vjaters , David Olmos , Natasha Littleton , Anna Liu , Isabella Testa , Mindy Mo , Shankar Srinivasan , Kunhi Parambath Haresh","Centre Hospitalier de l'Université de Montréal, Université de Montréal, Carolina Urologic Research Center, P. Stradinš Clinical University Hospital, Department of Medical Oncology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (Imas12), Bayer Ltd, Bayer Inc., Bayer S.p.A, Bayer HealthCare Pharmaceuticals, Inc., All India Institute of Medical Sciences"
310,,Impact of testosterone recovery after androgen deprivation therapy on overall survival in patients with high-risk prostate cancer: Long-term data from a phase III trial.,"Abdenour Nabid , Nathalie Carrier , Andre-Guy Martin , Jean-Paul Bahary , Peter Vavassis , Sylvie Vass , Boris Bahoric , Robert Archambault , Francois Vincent , Redouane Bettahar , Marie Duclos , Luis Souhami","Centre Hospitalier Universitaire de Sherbrooke, CHU de Quebec, Université Laval, Centre hospitalier de l'Université de Montréal (CHUM), Hôpital Maisonneuve-Rosemont de Montréal, Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay-Lac-Saint-Jean, Hôpital Général Juif de Montréal, Centre Intégré de Santé et de Services Sociaux de l'Outaouais, Centre Intégré Universitaire de Sante et Services Sociaux, Mauricie-Centre-du Quebec, Centre de Santé et de Services Sociaux de Rimouski-Neigette, Cedars Cancer Centre, McGill University Health Centre, McGill University Health Centre"
518,F16,Association between baseline and changes in hemoglobin levels and treatment response and prognosis in metastatic renal cell carcinoma: A Mexican retrospective study.,"Saul Campos Gomez , Sandra Vargas Melendez , Arturo Gonzalez Santana","Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Centro Oncologico Estatal Instituto de Seguridad Social del Estado de Mexico y Municipios, Centro Oncologico Estatal ISSEMyM"
166,E5,Impact of Medicare Advantage (MA) on timely hormonal intensification in metastatic hormone sensitive prostate cancer.,"Baqir Jafry , Chuan Lu , Jonathan Ji , Raj Bhanvadia , Qian Qin , Joseph Vento , Kevin Courtney , Jue Wang , Waddah Arafat , Daniel Yang , Suzanne Cole , Tian Zhang , Changchuan Jiang","Charleston Area Medical Center, UT Southwestern Medical Center, UT Southwestern Medical School, Department of Urology, UT Southwestern Medical Center, Department of Internal Medicine, Division of Hematology and Oncology, UT Southwestern, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Department of Radiation Oncology, UT Southwestern Medical Center"
688,C21,Predictive value of neoadjuvant therapy combined with VI-RADS re-scoring in bladder preservation for muscle-invasive bladder cancer.,Fang Yuan,Chongqing University Cancer Hospital
805,F32,"Safety and efficacy of bladder preservation therapy for very high-risk non-muscle-invasive bladder cancer: A single-center, single-arm prospective study (CIP-1).",Fang Yuan,Chongqing University Cancer Hospital
TPS653,K21,P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell tumours (GCTs).,"Blossom Mak , Ben Tran , Hayley Thomas , Farzana Pashankar , Aaron Hansen , Darren Feldman , Robert Huddart , Matthew Wheater , Elaine Dunwoodie , Danish Mazhar , Nicola Lawrence , Amanda Stevanovic , Alison Birtle , Olabode Oladipo , David Wyld , Jay Michael Balagtas , Martin Stockler , Peter Grimison","Chris O'Brien Lifehouse, Peter MacCallum Cancer Centre, NHMRC Clinical Trials Centre, University of Sydney, Yale-New Haven Hospital, Division of Cancer Services, Princess Alexandra Hospital, Memorial Sloan Kettering Cancer Center, Section of Radiotherapy and Imaging, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Southampton Oncology Centre, Leeds Teaching Hospitals NHS Trust, Cambridge University Hospital NHS Foundation Trust, Te Pūriri o Te Ora Cancer and Blood, Te Toka Tumai Auckland, Te Whatu Ora, Nepean Cancer Care Centre, Lancashire Teaching Hospitals NHS Foundation Trust, Northern Ireland Cancer Centre, Royal Brisbane and Women's Hospital, Lucile Packard Children's Hospital at Stanford University, NHMRC Clinical Trials Centre, The University of Sydney"
TPS880,J8,EORTC GUCG 2418 - STARBURST: Strategies for treatment adaptation following re-evaluation of the bladder after using primary neoadjuvant systemic therapies—An EORTC platform trial.,"Guillaume Grisay , Alexandra Masson-Lecomte , Verane Achard , Julien Van Damme , Yves Allory , Valeria Panebianco , Saskia Litiere , Anne-Sophie Govaerts , Fanny Grillet , Beatrice Fournier , Bertrand Tombal , Yohann Loriot","CHU Helora, Service d'Urologie Hôpital Saint Louis, Université Paris Cité, Service de Recherche en Hémato-Immunologie CEA - INSERM U976 HIPI, Department of Radiation Oncology, HFR Fribourg, Villars-sur-Glâne, Switzerland, Cliniques Universitaires Saint-Luc, Institut Curie Saint Cloud (France), Sapienza University of Rome, European Organisation of Reseach and Treatment for Cancer (EORTC), EORTC Headquarters, European Organization for Research and Cancer (EORTC) Headquarters, Gustave Roussy, Département de Médecine Oncologique et Département des Essais Précoces, Université Paris-Saclay"
314,H14,Clinical outcomes disparities in prostate cancer in the Caribbean: Results from 504 patients from the Martinique cohort.,"Lauriane Noly , Johan ROSE Dite Modestine , Ainara Martin Martinez , Mickaelle Rose , Mélanie Percot , Celine Minchaca , Obubé Amegayibor , Mylene Annonay , Xavier Promeyrat , Quentin Hurlot , Stefanos Bougas , Karim Fard , Soizic Masson , Karim Fizazi , Sylvie Merle , Odile Bera , Jean-Samuel Loger , Alexis Vallard , Emeline Colomba , Régine Marlin","CHU Martinique, Service D'urologie de Mangot Vulcin, CHU Martinique, CHU Pierre Zobda Quitman, Institut Gustave Roussy, University of Paris-Saclay, Radiation Oncology Department, CHU Martinique, Gustave Roussy Institute"
167,E6,Impact of PSA nadir on long-term survival in metastatic hormone-sensitive prostate cancer: Final 10-year analysis of the ECOG-ACRIN E3805 CHAARTED trial.,"Abhishek Tripathi , Yu-Hui Chen , David Jarrard , Jorge Garcia , Robert Dreicer , Glenn Liu , Maha Hussain , Daniel Shevrin , Matthew Cooney , Mario Eisenberger , Manish Kohli , Elizabeth Plimack , Nicholas Vogelzang , Joel Picus , Michael Carducci , Robert DiPaola , Christopher Sweeney","City of Hope Comprehensive Cancer Center, Dana-Farber Cancer Institute, University of Wisconsin-Madison, Division of Solid Tumor Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, University of Virginia School of Medicine, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Northwestern University, Feinberg School of Medicine, Endeavor Health, Tempus AI, Johns Hopkins University, Huntsman Cancer Institute at the University of Utah, Fox Chase Cancer Center, Temple Health, Comprehensive Cancer Centers of Nevada, Washington University in St. Louis, Johns Hopkins, University of Kentucky College of Medicine"
449,D17,Assessing global disparities in clinical trial availability for renal cell carcinoma (RCC).,"Regina Barragan-Carrillo , Miguel Zugman , Daniela Castro , Xiaochen Li , Koral Shah , Lily Lau , Ruchi Agarwal , Aaron Lee , Skylar Reid , Nasr Chaudhary , Shivanee Kooner , Salvador Jaime-Casas , Hedyeh Ebrahimi , Gabriela Regalado Porras , Sharon Choi , Nora Sobrevilla , Erika Ruiz-Garcia , Rana McKay , Sumanta Pal","City of Hope Comprehensive Cancer Center, Hospital Israelita Albert Einstein, University of Southern California, University of Pennsylvania, University of California Berkeley, University of California, San Diego, Clovis North High School, ABC Medical Center, Instituto Nacional de Cancerologia, Instituto Nacional de Cancerología, Moores Cancer Center, University of California San Diego, Department of Medical Oncology, City of Hope Comprehensive Cancer Center"
813,G9,Efficacy and toxicity profile of antibody-drug conjugate (ADC) based combination therapy in patients with advanced urothelial carcinoma (aUC): A systematic review of clinical trials.,"Salvador Jaime-Casas , Miguel Zugman , Regina Barragan-Carrillo , Peter Zang , Hedyeh Ebrahimi , Benjamin Mercier , Daniela Castro , Wesley Yip , Xiaochen Li , Nazli Dizman , Nicholas Salgia , Joann Hsu , Charles Nguyen , Alex Chehrazi-Raffle , Zeynep Zengin , Luis Meza , Sumanta Pal , Abhishek Tripathi","City of Hope Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, Department of Immunology, Roswell Park Comprehensive Cancer Center, Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Yale University School of Medicine, Department of Medical Oncology, City of Hope Comprehensive Cancer Center"
877,J5,Evaluating clinical and pathologic predictors for pathologic lymph node positivity (pN+) in patients with clinical T1-4N0M0 bladder cancer undergoing cystectomy.,"Salvador Jaime-Casas , Regina Barragan-Carrillo , Miguel Zugman , Peter Zang , Hedyeh Ebrahimi , Daniela Castro , Benjamin Mercier , Xiaochen Li , Nazli Dizman , Nicholas Salgia , Joann Hsu , Charles Nguyen , Wesley Yip , Alex Chehrazi-Raffle , Zeynep Zengin , Luis Meza , Sumanta Pal , Abhishek Tripathi","City of Hope Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, Department of Immunology, Roswell Park Comprehensive Cancer Center, Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Yale University School of Medicine, Department of Medical Oncology, City of Hope Comprehensive Cancer Center"
672,C5,Evaluating worldwide disparities in bladder cancer clinical trial availability.,"Koral Shah , Daniela Castro , Xiaochen Li , Miguel Zugman , Jalen Patel , Teebro Paul , Jaya Goud , Lea Dickter , Ishaan Bhatnagar , Salvador Jaime-Casas , Hedyeh Ebrahimi , Benjamin Mercier , Joann Hsu , Nazli Dizman , Alex Chehrazi-Raffle , Abhishek Tripathi , Regina Barragan-Carrillo , Sumanta Pal , Samuel Dickter","City of Hope Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center"
402,K32,Feasibility of enriched amplicon circulating tumor DNA sequencing to detect minimal residual disease (MRD) after prostatectomy in localized prostate cancer.,"Peter Zang , Daniel Lama , Ziyi Huang , Salvador Jaime-Casas , Tania Contente-Cuomo , Mojca Stampar , Adriana Marshall , Devin Dinwiddie , Michael Berens , Stephanie Pond , Jeffrey Trent , Bertram Yuh , Clayton Lau , Muhammed Murtaza , Yun Li , Tanya Dorff","City of Hope Comprehensive Cancer Center, Translational Genomics Research Institute (TGen), City of Hope National Medical Center, University of Wisconsin-Madison"
631,J16,Multicenter analysis of high-dose chemotherapy (HDCT) regimens for recurrent germ cell tumors (GCTs).,"Miguel Zugman , Michael Shodiya , Edward Maldonado , Tamer Othman , Hedyeh Ebrahimi , Regina Barragan-Carrillo , Xiaochen Li , Adam Rock , Abhishek Tripathi , Sumanta Pal , Tanya Dorff , Ali Zhumkhawala , Rasmus Hoeg , Caspian Oliai , Matthew Mei , Alex Chehrazi-Raffle","City of Hope Comprehensive Cancer Center, UCLA Medical Center, University of California, San Francisco, UC San Francisco, City of Hope National Medical Center, Department of Medical Oncology, City of Hope Comprehensive Cancer Center, University of California, Davis Comprehensive Cancer Center, University of California, Los Angeles, Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center"
543,G10,Cabozantinib (cabo) and nivolumab (nivo) with or without CBM588 in patients with metastatic renal cell carcinoma: Updated clinical outcomes of a phase I study.,"Hedyeh Ebrahimi , Luis Meza , Nazli Dizman , Regina Barragan-Carrillo , Xiaochen Li , Marian Llamas-Quitiquit , Joann Hsu , Zeynep Zengin , Daniela Castro , Benjamin Mercier , Miguel Zugman , Salvador Jaime-Casas , Alex Chehrazi-Raffle , Jeffrey Trent , Peter Lee , Motomichi Takahashi , Tanya Dorff , Gregory Caporaso , Keehoon Lee , Sumanta Pal","City of Hope Comprehensive Cancer Center, Yale University School of Medicine, The University of Texas MD Anderson Cancer Center, Translational Genomics Research Institute (TGen), Miyarisan Pharmaceutical Co., Ltd., Translational Genomics Research Institute (TGen North)"
7,D6,Cardiovascular mortality risk in primary penile cancer patients: A retrospective cohort study from 2000 to 2021.,"Asfand Yar Cheema , Mishaal Munir , Aashray Mandala , Oboseh Ogedegbe , Serhan Unlu , Praveena Thiagarajan","Cleveland Clinic Foundation/Fairview Hospital, Lahore Medical And Dental College, Cleveland Clinic, Trinity Health Ann Arbor, Cleveland Clinic Children's Hospital Therapy Services West"
823,G19,Association between neutrophil and tumor-infiltrating lymphocyte count and bladder cancer stage and treatment response in BCG-treated mice models.,"Betty Wang , Devika Nandwana , Rebecca Campbell , Christopher Weight , Nima Almassi , Samuel Haywood , Robert Abouassaly , Philip Abbosh , Laura Bukavina","Cleveland Clinic Glickman Urologic Institute, Case Western Reserve School of Medicine, Fox Chase Cancer Center"
822,G18,Genome-scale metabolic reconstruction of urinary microbiome: Pathway for personalized medicine.,"Betty Wang , Devika Nandwana , Mohit Sindhani , Christopher Weight , Nima Almassi , Vignesh Packiam , Alexander Kutikov , Daniel Geynisman , Pooja Ghatalia , Philip Abbosh , Laura Bukavina","Cleveland Clinic Glickman Urologic Institute, Case Western Reserve School of Medicine, Rutgers Cancer Institute and Rutgers Robert Wood Johnson Medical School, Fox Chase Cancer Center"
840,H4,Deciphering immune-genomic markers of hyperprogression in patients (Pts) with metastatic urothelial cancer (mUC) treated with immune checkpoint inhibitors (ICIs).,"Nikhil Pramod , Paul Pavicic Jr., Scott Dawsey , Ubenthira Patgunarajah , Kimberly Maroli , Riya Malhotra , Moshe Ornstein , Christopher Wee , Omar Mian , Amanda Nizam , Ying Ni , Jane Nguyen , C. Marcela Diaz-Montero , Shilpa Gupta , Timothy Gilligan","Cleveland Clinic Lerner College of Medicine, Cleveland Clinic Lerner Research Institute, John D. Dingell VA Hospital, Taussig Cancer Institute, Cleveland Clinic, Cleveland Clinic, Cleveland Clinic Taussig Cancer Institute, Fred Hutchinson Cancer Center, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Center for Immunotherapy and Precision Immuno-Oncology (CITI), Lerner Research Institute, Cleveland Clinic"
327,H27,"PSMA-based PET imaging in newly diagnosed, high-risk localized prostate cancer, a National Cancer Institute (NCI) Cancer Moonshot trial.","Nikhil Pramod , Baris Turkbey , Peter Choyke , Liza Lindenberg , Esther Mena , Ravi Madan , Michele Reed , Philip Eclarinal , Maria Merino , Adam Sowalsky , Krishnan Patel , Deborah Citrin , James Gulley , William Figg , William Dahut , Peter Pinto , Fatima Karzai","Cleveland Clinic Lerner College of Medicine, National Cancer Institute, National Institutes of Health, Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, American Cancer Society"
TPS896,J24,RAD-SG: Adaptive radiation therapy with concurrent sacituzumab govitecan (SG) for bladder preservation in patients (pts) with muscle invasive bladder cancer (MIBC).,"Shilpa Gupta , Nima Almassi , Laura Bukavina , Christopher Wee , Kevin Stephans , C. Marcela Diaz-Montero , Rahul Tendulkar , Omar Mian , Timothy Chan","Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic Glickman Urologic Institute, Cleveland Clinic Foundation, Taussig Cancer Institute, Cleveland Clinic, Center for Immunotherapy and Precision Immuno-Oncology (CITI), Lerner Research Institute, Cleveland Clinic, Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Fred Hutchinson Cancer Center, Cleveland Clinic Lerner Research Institute"
759,E21,Real-world safety of first-line (1L) therapies for locally advanced or metastatic urothelial cancer (la/mUC) in the US.,"Amanda Nizam , Mairead Kearney , Valerie Morris , Seyed Hamidreza Mahmoudpour , Carroline Lobo , Jason Hoffman , Ilian Iliev , Prakirthi Yerram , Mark Guinter","Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, The Healthcare Business of Merck KGaA, EMD Serono, the healthcare business of Merck KGaA, EMD Serono, Inc., Flatiron Health, Inc."
869,H33,Avelumab first-line maintenance (1LM) in patients (pts) with advanced urothelial carcinoma (aUC) with or without diabetes mellitus (DM): Long-term outcomes from JAVELIN Bladder 100.,"Shilpa Gupta , Petros Grivas , Se Hoon Park , Daniel Petrylak , Karin Tyroller , Jason Hoffman , Joaquim Bellmunt","Cleveland Clinic Taussig Cancer Institute, University of Washington and Fred Hutchinson Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Yale School of Medicine, EMD Serono, EMD Serono, Inc., Bladder Cancer Center, Dana Farber Cancer Institute, Harvard Medical School"
TPS882,J10,"A phase 2, randomized, open-label study of gemcitabine/cisplatin plus cemiplimab (REGN2810, anti-PD-1) with or without fianlimab (REGN3767, anti-LAG-3) for organ preservation in patients with localized muscle-invasive bladder cancer (NeoSTOP-IT).","Alexander Wei , Basil Bakir , Andrew Lenis , Christopher Anderson , Karie Runcie , Guarionex DeCastro , Samuel Pan , Michael Shen , James McKiernan , Mark Stein","Columbia University Irving Medical Center, Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center"
551,G18,Updated results of the Tide-A study evaluating avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients with metastatic renal cell carcinoma (mRCC).,"Daniela Arduini , Chiara Ciccarese , Alessandro Acunzo , Matteo Perrino , Marco Maruzzo , Elena Verzoni , Caterina Accettura , Lucia Bonomi , Consuelo Buttigliero , Malvina Cremante , Stefania Pipitone , Mario Scartozzi , Cristina Masini , Veronica Mollica , Francesca Primi , Alessandro Strusi , Sebastiano Buti , Paolo Andrea Zucali , Emanuela Fantinel , Roberto Iacovelli","Comprehensive Cancer Center, Medical Oncology Department, Fondazione Policlinico Universitario ""Agostino Gemelli"" IRCCS, Comprehensive Cancer Center, Oncology Unit, Fondazione Policlinico Universitario ""A. Gemelli"" IRCCS, Medical Oncology Unit, University Hospital of Parma, Medical Oncology, Humanitas Research Hospital, Humanitas Cancer Center, Oncology Unit 1, Istituto Oncologico Veneto, IOV - IRCCS, Genitourinary Medical Oncology, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Medical Oncology, Vito Fazzi Hospital, Unit of Oncology, ASST Papa Giovanni XXIII Hospital, Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Medical Oncology Unit, Department of Oncology and Hemathology, University Hospital of Modena, Medical Oncology Unit, University Hospital and University of Cagliari, Medical Oncology, Comprehensive Cancer Centre Azienda USL-IRCCS di Reggio Emilia, Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Medical Oncology, Central Hospital of Belcolle, Comprehensive Cancer Center, Medical Oncology, Fondazione Policlinico Gemelli, Department of Oncology, IRCCS Humanitas Research Hospital, Medical Oncology Department, University and Hospital Trust of Verona"
797,F24,Final overall survival of ARIES trial evaluating first line avelumab monotherapy for patients with advanced urothelial cancer (aUC) unfit for cisplatin and outcome analysis based on baseline characteristics.,"Denis Occhipinti , Chiara Ciccarese , Matteo Santoni , Silvia Puglisi , Consuelo Buttigliero , Claudia Mosillo , Sebastiano Buti , Luciano Stumbo , Emanuele Naglieri , Luca Galli , Elena Verri , Emanuela Fantinel , Stefania Di Girolamo , Rocco De Vivo , Laura Milesi , Elisa Biscaldi , Chiara Ligato , Matteo Brunelli , Giampaolo Tortora , Roberto Iacovelli","Comprehensive Cancer Center, Medical Oncology Department, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Comprehensive Cancer Center, Oncology Unit, Fondazione Policlinico Universitario ""A. Gemelli"" IRCCS, Medical Oncology, Ospedale Generale Provinciale di Macerata, Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Medical and Translational Oncology Unit, Azienda Ospedaliera Santa Maria, Medical Oncology Unit, University Hospital of Parma, Department of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Medical Oncology Unit, Istituto Tumori IRCCS Giovanni Paolo II, Medical Oncology Unit 2, Azienda Ospedaliero-Universitaria Pisana, Medical Oncology Division of Urogenital and Head and Neck Tumors, European Institute of Oncology, Section of Oncology, University of Verona - School of Medicine, Medical Oncology Unit, AUSL-IRCCS di Reggio Emilia, Department of Oncology, San Bortolo General Hospital, Azienda ULSS8 Berica, Oncologia Medica Asst Papa Giovanni XXIII, Division of Translational Oncology, I.R.C.C.S. Istituti Clinici Scientifici Maugeri, Oncology Unit, Fondazione Policlinico Universitario ""A. Gemelli"" IRCCS, Department of Diagnostic and Public Health, Section of Pathology, University of Verona"
91,C1,Clinical characterization and treatment patterns in patients with metastatic hormone-sensitive prostate cancer at three third-level centers of the Mexican Institute of Social Security: A retrospective cohort study.,"Samuel Rivera , Libny Martinez-Valdez , Miguel Cuellar Mendoza , Javier Medrano Sanchez , Angelica Sandoval Mendez , Gretel Oropeza , Ivan Alejandro Reyes Garcia , Ramon Velasco , Saúl Gutiérrez De la Torre , Jessica Acevedo-Ibarra , Barbara Ruiz , Isabella Rivas , Marta Zapata Tarres","Coordination of Oncologic Attention, Mexican Institute of Social Security, Department of Economic and Social Benefits, Mexican Institute of Social Security, Research Coordination IMSS Foundation, High Specialty Medical Unit 1 (UMAE) León, Mexican Institute of Social Security, High Specialty Medical Unit 1 (UMAE) Mérida, Mexican Institute of Social Security, High Specialty Medical Unit 25 (UMAE) Monterrey, Mexican Institute of Social Security, Astellas Farma Mexico S. de R.L. de C.V."
681,C14,Understanding metastatic squamous cell carcinoma patients receiving pelvic exenteration vs radical cystectomy: A nationwide context.,"Christopher Bine , Alec Czaplicki , Peter Silberstein","Creighton University School of Medicine, Creighton Hematology Oncology"
441,,"Casdatifan (Cas) monotherapy in patients (pts) with previously treated clear cell renal cell carcinoma (ccRCC): Safety, efficacy and subgroup analysis across multiple doses from ARC-20, a phase 1 open-label study.","Toni Choueiri , Jae Lyun Lee , Jaime Merchan , Amita Patnaik , Benjamin Garmezy , Alexandra Drakaki , Moshe Ornstein , Bradley McGregor , Ralph Hauke , Kai Tsao , Brian Rini , Pedro Barata , Paul Foster , Sutapa Mukhopadhyay , Neal Gupta , Jianfen Chen , Manish Monga , Dimitry Nuyten , Sun Young Rha","Dana-Farber Cancer Institute and Harvard Medical School, Asan Medical Center, University of Ulsan College of Medicine, University of Miami Sylvester Comprehensive Cancer Center, The START Center for Cancer Research, Sarah Cannon Research Institute, University of California, Los Angeles, Taussig Cancer Institute, Cleveland Clinic, Dana-Farber Cancer Institute, Nebraska Cancer Specialists, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Vanderbilt-Ingram Cancer Center, University Hospitals Seidman Cancer Center, Arcus Biosciences, Yonsei Cancer Center"
549,G16,Updated results from the phase 2 LITESPARK-003 study of belzutifan plus cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC).,"Toni Choueiri , Todd Bauer , Jaime Merchan , David McDermott , Robert Figlin , Edward Arrowsmith , M. Dror Michaelson , Elisabeth Heath , Anishka D’Souza , Song Zhao , Laurent Kassalow , Rodolfo Perini , Donna Vickery , Scott Tykodi","Dana-Farber Cancer Institute and Harvard Medical School, Sarah Cannon Cancer Center and Tennessee Oncology, Department of Medical Oncology, University of Miami Leonard M. Miller School of Medicine, University of Miami, Beth Israel Deaconess Medical Center, Cedars-Sinai Medical Center, Tennessee Oncology, Massachusetts General Hospital, Harvard Medical School, Karmanos Cancer Institute, Wayne State University, University of Southern California, Swedish Cancer Institute, Merck & Co., Inc., Merck and Co, Inc., University of Washington and Fred Hutchinson Cancer Research Center"
591,H26,A comprehensive evaluation of gene expression-based signatures for detecting tertiary lymphoid structures (TLS) in metastatic renal cell carcinoma (mRCC).,"Eddy Saad , Nourhan El Ahmar , Berkay Simsek , Opeyemi Jegede , Sayed Matar , Razan Mohanna , Emre Yekeduz , David McDermott , Elizabeth Plimack , Jeffrey Sosman , Naomi Haas , Michael Hurwitz , Hans Hammers , Eliezer Van Allen , Toni Choueiri , Michael Atkins , Sabina Signoretti , David Braun","Dana-Farber Cancer Institute, Brigham and Women's Hospital, Brigham and Women's Hospital, Harvard Medical School, Yale School of Medicine, Beth Israel Deaconess Medical Center, Fox Chase Cancer Center, Temple Health, Northwestern University, Abramson Cancer Center, University of Pennsylvania, Department of Medical Oncology, Yale School of Medicine, Department of Internal Medicine, Division of Hematology and Oncology, UT Southwestern, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School, Georgetown Lombardi Comprehensive Cancer Center, Center of Molecular and Cellular Oncology, Yale University"
330,H30,Artificial intelligence–derived tumor volume from baseline MRI and postprostatectomy outcomes following neoadjuvant hormonal therapy for patients with high-risk prostate cancer.,"David Yang , Leslie Lee , Praful Ravi , Saahil Rastogi , Fiona Fennessy , Adam Kibel , Quoc-Dien Trinh , Rana McKay , Anthony DAmico , Paul Nguyen , Eliezer Van Allen , Mary-Ellen Taplin , Martin King","Dana-Farber Cancer Institute, Brigham and Women's Hospital, Brigham and Women's Hospital/Dana Farber-Cancer Institute, Harvard Medical School, University of California, San Diego"
TPS304,M23,LuCarbo: A phase 1a/1b trial of 177Lu-PSMA-617 (LuPSMA) with carboplatin in advanced prostate cancer.,"Praful Ravi , Wanling Xie , Morgan Paul , Erin Healy , Amanda Lilienfeld , Nicole LaBrecque , Andrew Wolanski , Jolivette Ritzer , Michael Serzan , Alok Tewari , Heather Jacene","Dana-Farber Cancer Institute, Dana Farber Cancer Institute, Dana-Farber Cancer Institute/Brigham and Women's Hospital"
505,F3,Low versus low-intermediate risk metastatic renal cell carcinoma (mRCC): Contemporary data from the International mRCC Database Consortium (IMDC).,"Razane El Hajj Chehade , Wanling Xie , Karl Semaan , Marc Eid , Marc Machaalani , Rashad Nawfal , Eddy Saad , Renee Maria Saliby , Clara Steiner , Emre Yekeduz , Connor Wells , David Maj , Martin Zarba , Sumanta Pal , Cristina Suárez , Kosuke Takemura , Naveen Basappa , Sylvan Baca , Daniel Heng , Toni Choueiri","Dana-Farber Cancer Institute, Dana-Farber Cancer Institute, Harvard Medical School, Center of Molecular and Cellular Oncology, Yale University, BC Cancer Agency, Tom Baker Cancer Centre, University of Calgary, Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Medical Oncology, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Cross Cancer Institute, University of Alberta, Dana-Farber Cancer Institute and Harvard Medical School"
55,B1,"T suppression and recovery with AAP after early discontinuation of LHRH-A in high-risk localized (HRL), lymph node-positive (N+), or oligometastatic (OM) prostate cancer (PC).","Autumn Gagnon , Caiwei Zhong , Wanling Xie , Lynne Morlock , Dory Freeman , Rachel Trowbridge , Kerry Kilbridge , Bradley McGregor , Mary-Ellen Taplin , Atish Choudhury","Dana-Farber Cancer Institute, Dana-Farber Cancer Institute, Harvard Medical School, Department of Medical Oncology, Dana-Farber Cancer Institute"
461,D29,Integrated efficacy and safety exposure response (ER) analysis of tivozanib (TIVO) for the treatment of renal cell cancer (RCC).,"Bradley McGregor , Toni Choueiri , Laurence Albiges , Katy Beckermann , Philippe Barthelemy , Roberto Iacovelli , Sheik Emambux , Javier Molina-Cerrillo , Benjamin Garmezy , Pedro Barata , Rana McKay , Alex Chehrazi-Raffle , Hans Hammers , Daniel Heng , Klaas Prins , Bo Jin , Monette Cotreau , Edgar Braendle , Claudia Lebedinsky , Robert Motzer","Dana-Farber Cancer Institute, Dana-Farber Cancer Institute, Harvard Medical School, Institut Gustave Roussy, Vanderbilt University Medical Center, Institut de Cancérologie Strasbourg Europe, Comprehensive Cancer Center, Oncology Unit, Fondazione Policlinico Universitario ""A. Gemelli"" IRCCS, Centre Hospitalier Universitaire de Poitiers, Medical Oncology Department, Hospital Universitario Ramón y Cajal, Sarah Cannon Research Institute, University Hospitals Seidman Cancer Center, Department of Medicine, University of California San Diego, City of Hope Comprehensive Cancer Center, Department of Internal Medicine, Division of Hematology and Oncology, UT Southwestern, Tom Baker Cancer Centre, University of Calgary, qPharmetra, Aveo Oncology, MMC Biopartners, AVEO Oncology, Memorial Sloan Kettering Cancer Center"
593,H28,Correlates of immunotherapy response in metastatic clear cell renal cell carcinoma from circulating cell-free epigenomes.,"Razane El Hajj Chehade , Karl Semaan , Ze Zhang , Noa Phillips , Lexi Grisham , Rebecca Prather , Katy Beckermann , Ulka Vaishampayan , Naomi Haas , Hans Hammers , David McDermott , Lauren Wood , Travis Solley , Brian Rini , Eric Jonasch , Toni Choueiri , Matthew Freedman , Scott Haake , Sylvan Baca , Jacob Berchuck","Dana-Farber Cancer Institute, Dana-Farber Cancer Institute, Harvard Medical School, Vanderbilt University Medical Center, Gadsden Regional Medical Center, Vanderbilt University, Division of Hematology/Oncology, University of Michigan, Abramson Cancer Center, University of Pennsylvania, Department of Internal Medicine, Division of Hematology and Oncology, UT Southwestern, Beth Israel Deaconess Medical Center, The University of Texas MD Anderson Cancer Center, Department of Medicine, Vanderbilt University Medical Center, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute and Harvard Medical School, DFCI/PCC Fellowship Program - Attendings, Winship Cancer Institute of Emory University"
539,G6,HIF2α gene expression and clinical outcomes in patients with clear cell renal cell carcinoma with and without sarcomatoid differentiation.,"Rashad Nawfal , Karl Semaan , Talal El Zarif , Razane El Hajj Chehade , Marc Eid , Damien Vasseur , John Canniff , Noa Phillips , Hunter Savignano , Gwo-Shu Lee , Gunsagar Gulati , Ji-Heui Seo , Bradley McGregor , Matthew Freedman , Sylvan Baca , Toni Choueiri","Dana-Farber Cancer Institute, Department of Internal Medicine, Yale University School of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Dana-Farber Cancer Institute and Harvard Medical School"
506,F4,Association of clinical characterization of renal cell carcinoma (RCC) with merlin protein deficiency and biallelic loss of NF2.,"Emre Yekeduz , Marc Machaalani , Stephanie Siegmund , Eddy Saad , Razane El Hajj Chehade , Clara Steiner , Stephanie Berg , Bradley McGregor , Charlene Mantia , Praful Ravi , Wenxin Xu , Michelle Hirsch , Toni Choueiri , Michael Serzan","Dana-Farber Cancer Institute, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Dana-Farber Cancer Institute, Harvard Medical School, Department of Medical Oncology, Dana-Farber Cancer Institute"
TPS892,J20,Phase 1 dose escalation (DEs) & expansion (DEx) study to evaluate the safety & efficacy of IDE397 plus sacituzumab-govitecan in patients with advanced urothelial carcinoma (UC) with MTAP deletion (MTAPdel).,"Charlene Mantia , Chang Gon Kim , Jordi Rodon Ahnert , Omar Alhalabi , Alexander Wei , Mark Stein , Melissa Johnson , Benjamin Garmezy , Alok Tewari , Sid Devarakonda , Abhishek Tripathi , Benedito Carneiro , Inkeun Park , Valentina Boni , Emily Liu , Jasgit Sachdev , Mick O'Quigley , Michael White , Darrin Beaupre , Hye Ryun Kim","Dana-Farber Cancer Institute, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, The University of Texas MD Anderson Cancer Center, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Columbia University Irving Medical Center, Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, Sarah Cannon Research Institute Tennessee Oncology, Sarah Cannon Research Institute, Dana Farber Cancer Institute, Swedish Cancer Institute First Hill, City of Hope Comprehensive Cancer Center, Legorreta Cancer Center at Brown University, Lifespan Cancer Institute, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, NEXT Madrid- Universitary Hospital Quironsalud Madrid, IDEAYA Biosciences, Ideaya Biosciences, Severance Hospital"
437,,Evaluation of circulating kidney injury marker-1 (KIM-1) as a prognostic and predictive biomarker in advanced renal cell carcinoma (aRCC): Post-hoc analysis of CheckMate 214.,"Wenxin Xu , Sai Vikram Vemula , Robert Motzer , Aparna Chhibber , Deepthi Chowbene , Nahuel Perrot , Xiaowen Liu , Joseph Bonventre , Toni Choueiri , David McDermott , Saurabh Gupta , Rupal Bhatt","Dana-Farber Cancer Institute, Harvard Medical School, Bristol Myers Squibb, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School"
253,G26,Epigenomic profiling of circulating chromatin for early detection and monitoring of neuroendocrine prostate cancer.,"Karl Semaan , Rashad Nawfal , Marc Eid , Travis Clark , Razane El Hajj Chehade , John Canniff , Noa Phillips , Marc Machaalani , Paulo Cordeiro , Renee Maria Saliby , Talal El Zarif , Katelyn Kuczmarski , Gwo-Shu Lee , Jacob Berchuck , Mark Pomerantz , Corrie Painter , J. Barrett , Toni Choueiri , Matthew Freedman , Sylvan Baca","Dana-Farber Cancer Institute, Harvard Medical School, Dana-Farber Cancer Institute, Precede Biosciences, Center of Molecular and Cellular Oncology, Yale University, Department of Internal Medicine, Yale New Haven Hospital, Winship Cancer Institute of Emory University, Dana-Farber Cancer Institute and Harvard Medical School"
131,D5,Cognitive effects of androgen receptor (AR) directed therapies for advanced cancer of the prostate (COGCaP): A comparison of enzalutamide vs abiraterone acetate.,"Alicia Morgans , Yangruijue Ma , James Jackson , Charles Ryan , Kelvin Moses , Pedro Barata , Tanya Dorff , Masha Kocherginsky , David VanderWeele","Dana-Farber Cancer Institute, Harvard Medical School, Division of Biostatistics, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Vanderbilt University Medical Center, Memorial Sloan Kettering Cancer Center, University Hospitals Seidman Cancer Center, City of Hope Comprehensive Cancer Center, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine"
694,C27,Assessing practice gaps and challenges for immunotherapy integration in treatment of metastatic urothelial carcinoma.,"Bradley McGregor , Taral Patel , Thandiwe Chavula , Ilona Dewald , Jeffrey Carter , Cherilyn Heggen , Kelly McKinnon","Dana-Farber Cancer Institute, Mark H. Zangmeister Center, PRIME Education, LLC, PRIME Education"
595,H30,Roles of HIF2 and PTHrP in cancer-induced cachexia (CIC) in metastatic clear-cell renal cell carcinoma (ccRCC).,"Muhannad Abu-Remaileh , Eddy Saad , Laura Stransky , Nitin Shirole , Chris Labaki , Renee Maria Saliby , Marc Machaalani , Razane El Hajj Chehade , Rashad Nawfal , Clara Steiner , Hilina Woldemichael , Charles Xu , Namrata Udeshi , Marc Eid , Karl Semaan , Gwo-Shu Lee , Eliezer Van Allen , Steven Carr , Toni Choueiri , William Kaelin","Dana-Farber Cancer Institute, Odyssey Therapeutics, Beth Israel Deaconess Medical Center, Yale School of Medicine, Dana Farber Cancer Institute, Broad Institute, Dana-Farber Cancer Institute, Harvard Medical School, Broad Institute of MIT and Harvard, Department of Medical Oncology, Dana-Farber Cancer Institute, Dana-Farber Cancer Institute, Harvard Medical School, and Howard Hughes Medical Institute"
509,F7,Comorbidity burden and effectiveness of immunotherapy in patients with metastatic renal cell carcinoma.,"Emre Yekeduz , Martin Zarba , Eddy Saad , Connor Wells , Marc Machaalani , Razane El Hajj Chehade , Marc Eid , Chris Labaki , Rashad Nawfal , Renee Maria Saliby , Karl Semaan , Clara Steiner , Daniel Heng , Toni Choueiri","Dana-Farber Cancer Institute, Tom Baker Cancer Centre, University of Calgary, Beth Israel Deaconess Medical Center, Center of Molecular and Cellular Oncology, Yale University, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute"
58,B4,Time burden and healthcare costs associated with docetaxel in patients with metastatic castration-sensitive prostate cancer (mCSPC) initiating an androgen receptor pathway inhibitor (ARPI) –based regimen.,"Daniel Sentana Lledo , Arjun Gupta , Carmine Rossi , Sabree Burbage , Lilian Diaz , Gordon Wong , Dominic Pilon , Ibrahim Khilfeh , Alicia Morgans","Dana-Farber Cancer Institute, University of Minnesota, Analysis Group, Inc., Johnson & Johnson Innovative Medicine, Department of Medical Oncology, Dana-Farber Cancer Institute"
582,H17,Circulating kidney injury molecule-1 (KIM-1) in association with kidney injury biomarkers and outcomes in metastatic renal cell carcinoma.,"Clara Steiner , Eddy Saad , Renee Maria Saliby , Marc Eid , Karl Semaan , Marc Machaalani , Emre Yekeduz , Jack Horst , Jasmine Lee , Noa Phillips , Rachel Trowbridge , Marta Pirovano , Carolina Saldanha Neves Horta Lima , Shruti Gupta , Gwo-Shu Lee , Yehonatan Elon , Adam Dicker , Joseph Bonventre , Toni Choueiri , Wenxin Xu","Dana-Farber Cancer Institute, Yale Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School, Brigham and Women's Hospital, OncoHost LTD, Thomas Jefferson University, Dana-Farber Cancer Institute and Harvard Medical School"
594,H29,KIM-1 as a circulating biomarker in metastatic RCC: Post-hoc analysis of JAVELIN Renal 101.,"Marc Machaalani , Renee Maria Saliby , Caiwei Zhong , Eddy Saad , Clara Steiner , Xiaowen Liu , Ti Cai , Maxine Sun , Gwo-Shu Lee , Wanling Xie , David McDermott , Toni Choueiri , Wenxin Xu","Dana-Farber Cancer Institute, Yale School of Medicine, Beth Israel Deaconess Medical Center, EMD Serono Research and Development Institute, Department of Medical Oncology, Dana-Farber Cancer Institute, Dana-Farber Cancer Institute and Harvard Medical School, Dana-Farber Cancer Institute, Harvard Medical School"
513,F11,Mortality risk in clinical T1a renal cell carcinoma (RCC) with synchronous metastasis (SM): A comparative analysis of National Cancer Database (NCDB).,"Melis Gür , Luke Wang , Franklin Liu , Dhruv Puri , Margaret Meagher , Juan Javier-Desloges , James Murphy , Brent Rose , Aditya Bagrodia , Ithaar Derweesh , Rana McKay","Department for Urology, Urooncology, Robot-Assisted and Focal Treatment, University of Madgeburg, Department of Urology, University of California, San Diego, Department of Medicine, University of Arizona College of Medicine, Department of Urology, University of California San Diego School of Medicine, UC San Diego School of Medicine, University of California, San Diego, University of California San Diego Health, Department of Urology, UC San Diego School of Medicine, Moores Cancer Center, University of California San Diego"
648,J33,Evaluation of MIR-371A-3P for clinical implementation in a CLIA-certified laboratory.,"Melis Gür , Kshitij Pandit , John Lafin , Cinzia Scarpini , Armon Amini , Bendu Konneh , Jeffrey Howard , Thomas Gerald , Michelle Nuno , Jin Piao , Nicholas Coleman , Lindsay Frazier , Matthew Murray , Sarah Murray , Aditya Bagrodia","Department for Urology, Urooncology, Robot-Assisted and Focal Treatment, University of Madgeburg, University of California, San Diego, UT Southwestern Medical Center, Department of Pathology, University of Cambridge, Cambridge, CB2 1QP, United Kingdom, UT Southwestern, University of Southern California, Los Angeles, Keck School of Medicine, University of Southern California, University of Cambridge, Dana-Farber Cancer Institute, UC San Diego, University of California San Diego Health"
731,D28,Real-world time on treatment (rwTOT) with first-line (1L) enfortumab vedotin and pembrolizumab (EV+P) after U.S. Food and Drug Administration approval for advanced urothelial cancer (aUC).,"Melanie Mayer , Nicholas Seewald , Ernesto Perez , Blanca Homet Moreno , Chethan Ramamurthy , Aram Babcock , Haojie Li , Ronac Mamtani","Department of Biostatistics, Epidemiology, & Informatics, University of Pennsylvania, Merck & Co., Inc., Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania"
TPS607,K8,The CABOLD study: A real life prospective cohort evaluating the combination of cabozantinib and nivolumab among older patients with renal-cell carcinoma.,"Maxime Frelaut , Natacha Naoun , Arnaud Pages , Ronan Flippot , Zoé AP Thomas , Capucine Baldini , Laurence Albiges","Department of Cancer Medicine, Gustave Roussy, Thoracic Group and International Center for Thoracic Cancers (CICT), Paris-Saclay University, Gustave Roussy Institute, Department of Biostatistics and Epidemiology, Gustave Roussy, Department of Medical Oncology, Gustave Roussy, Paris Saclay University, Gustave Roussy, Drug Development Department (DITEP), Institut Gustave Roussy, Gustave Roussy, Paris Saclay University"
576,H11,Mass cytometry-based deep immune cell profiling of metastatic clear cell renal cell carcinoma patients refractory to combined immune checkpoint and tyrosine kinase inhibitor therapy.,"Luigi Formisano , Stefania Belli , Angela Vallefuoco , Giovanna Pecoraro , Fortuna Migliaccio , Chiara Barraco , Arianna Scipilliti , Daniela Esposito , Giovanna Attanasio , Marjolijn Hameetman , Tamar Tak , Ernesto Lopez , Sarah Scagliarini , Alberto Servetto , Roberto Bianco","Department of Clinical Medicine and Surgery, University of Naples ""Federico II"", Department of Clinical Oncology and Surgery, University of Naples ""Federico II"", Flow Cytometry Core Facility, Leiden University Medical Center, Standard BioTools Canada Inc., Department of Medical Oncology, AORN Antonio Cardarelli, Napoli, Department of Clinical Medicine and Surgery, University of Naples Federico II"
227,F31,Transcriptional profiling of patients with metastatic hormone-sensitive prostate cancer to uncover specific signatures linked to the transition from androgen-dependent to androgen-independent phenotype.,"Giovanna Pecoraro , Daniela Esposito , Stefania Belli , Fabrizio Di Costanzo , Fortuna Migliaccio , Francesca Messina , Felice Pepe , Silvia Varricchio , Marco Caruso , Sarah Scagliarini , Sabrina Rossetti , Felice Crocetto , Vincenza Conteduca , Francesca Sanguedolce , Umberto Malapelle , Ciro Imbimbo , Alberto Servetto , Roberto Bianco , Luigi Formisano","Department of Clinical Medicine and Surgery, University of Naples ""Federico II"", Department of Clinical Oncology and Surgery, University of Naples ""Federico II"", University of Naples ""Federico II"", AORN Antonio Cardarelli, Department of Medical Oncology, AORN Antonio Cardarelli, Napoli, Fondazione Pascale, IRCCS, Istituto Nazionale dei Tumori, Unit of Medical Oncology and Biomolecular Therapy, Department of Medical and Surgical Sciences, University of Foggia, Policlinico Riuniti, University of Foggia, Public Health, Azienda Ospedaliera Universitaria Federico II, Department of Clinical Medicine and Surgery, University of Naples Federico II, Oncologia Medica, University of Naples ""Federico II"""
TPS605,K6,"First-in-human phase 0 safety, imaging, pharmacokinetics, and dosimetry study of 64Cu-PD-32766, a carbonic anhydrase IX (CAIX)-targeting peptide, in patients with clear cell renal cell carcinoma (ccRCC).","Toshihiro Horii , Mitsuyoshi Yoshimoto , Akinori Kobayashi , Chihiro Kondo , Nobuaki Matsubara , Chikako Funasaka , Hiromichi Nakajima , Yasutoshi Kuboki , Kimiteru Ito , Masato Murakami , Shoko Ito , Tomoaki Higuchi , Naoki Kanazawa , Yuichi Funase , Daisuke Kano , Akira Inagaki , Saeko Mochinaga , Hikari Inagawa , Tatsushi Kobayashi , Anri Inaki","Department of Diagnostic Radiology, National Cancer Center Hospital East, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Functional Imaging Division, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center Hospital East, Department of Medical Oncology, National Cancer Center Hospital East, Department of Experimental Therapeutics/ Medical Oncology, National Cancer Center Hospital East, Department of General Internal Medicine, National Cancer Center Hospital East, Department of Experimental Therapeutics, National Cancer Center Hospital East, Department of Diagnostic Radiology, National Cancer Center Hospital, PeptiDream Inc, PDRadiopharma Inc., PeptiDream Inc, PDRadiopharma Inc., Department of Pharmacy, National Cancer Center Hospital East, Department of Radiological Technology, Radiological Diagnosis, National Cancer Center Hospital East, Department of Diagnostic Radiology, National Cancer Center Hospital Japan East, National Cancer Center Hospital East"
581,H16,Optimizing clear cell renal cell carcinoma tumor-infiltrating lymphocytes under controlled hypoxic conditions.,"Jad Chahoud , Marine Potez , Christopher Guske , Justin Miller , Johannes Ali , Michael Carter , Fatema Khambati , Jeffrey Johnson , Adnan Fazili , Keerthi Gullapalli , Wade Sexton , Logan Zemp , Brandon Manley , Gabriel Roman Souza , Matthew Beatty , Philippe Spiess , Shari Pilon-Thomas","Department of Genitourinary Medical Oncology, H. Lee Moffitt Cancer Center and Research Institute, H. Lee Moffitt Cancer Center, Department of Immunology, University of South Florida Morsani College of Medicine, H. Lee Moffitt Cancer Center and Research Institute, Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, H. Lee Moffitt Cancer Center, Department of Hematology/Oncology, H. Lee Moffitt Cancer Center and Research Institute/University of South Florida Morsani, Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center & Research Institute, Department of Immuno-Oncology, H. Lee Moffitt Cancer Center and Research Institute"
558,G25,Efficacy and safety of nivolumab plus ipilimumab (Nivo/Ipi) in patients with metastatic variant histology renal cell carcinoma.,"Mohammad Jad Moussa , Jaanki Khandelwal , Nate Wilson , Kiran Malikayil , Devaki Surasi , Tharakeswara Bathala , Yiyun Lin , Helen Ajufo , Khaled Elsayes , Amishi Shah , Andrew Johns , Sangeeta Goswami , Elshad Hasanov , Eric Jonasch , Pavlos Msaouel , Matthew Campbell , Omar Alhalabi , Nizar Tannir","Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Baylor, Scott and White Health, Baylor University Medical Center, Division of Hematology and Oncology, University of Michigan Ann Arbor, Kelsey-Seybold Clinic, The University of Texas MD Anderson Cancer Center, Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Department of Genetics, The University of Texas MD Anderson Cancer Center, Division of Hematology, Washington University School of Medicine, Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Division of Medical Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University"
10,D9,Expression of tissue factor (TF) in penile squamous cell carcinoma (PSCC) and enrichment in HPV-negative cases.,"Andrew Johns , Jamaal Jackson , Leticia Campos Clemente , Luisa Maren Solis , Priya Rao , Christopher Manuel , Wei Qiao , Matthew Campbell , Jad Chahoud , Niki Zacharias , Curtis Pettaway","Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Department of Urology, The University of Texas MD Anderson Cancer Center, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Department of Pathology, The University of Texas MD Anderson Cancer Center, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Department of Genitourinary Medical Oncology, H. Lee Moffitt Cancer Center and Research Institute"
818,G14,Immune checkpoint inhibitors (ICIs) in advanced upper tract urothelial cancer (UTUC) with mismatch repair deficiency (dMMR) or microsatellite instability (MSI).,"Mohammad Jad Moussa , Alexander Andreev-Drakhlin , Amishi Shah , Surena Matin , Ana Adriazola , Leah Shaw , Marihella Campbell , Pavlos Msaouel , Paul Corn , John Lin , Sangeeta Goswami , Jianjun Gao , Charles Guo , Nizar Tannir , Arlene Siefker-Radtke , Omar Alhalabi , Matthew Campbell","Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Genentech Inc, The University of Texas MD Anderson Cancer Center, Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Department of Pathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, University of Texas MD Anderson Cancer Center"
462,D30,Patterns of hospital admissions and readmissions due to immune-related adverse events in patients with genitourinary cancers.,"Hongchao He , Saivaroon Gajagowni , Sheeba Varughese , Wenhong Ren , Anna Jan , Emily Wang , Anishia Rawther-Karedath , Eric Jonasch , Matthew Campbell , Sumit Subudhi , Omar Alhalabi , Bilal Siddiqui","Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center"
TPS614,K15,Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC.,"Eric Jonasch , Elshad Hasanov , Lesley Flynt , Rebecca Tidwell , Hyunsoo Hwang , Roserika Brooks , Lauren Wood , Travis Solley , Dahlia Mack , Yuko Yamamura , Aradhana Venkatesan","Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center"
494,E27,Updated outcomes of patients with metastatic non-clear cell renal cell carcinoma (mnccRCC) treated with first-line (1L) therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).,"Kosuke Takemura , Jeffrey Graham , David Maj , Martin Zarba , Connor Wells , Razane El Hajj Chehade , Marc Eid , Eddy Saad , Renee Maria Saliby , Jae Lyun Lee , Frede Donskov , Benoit Beuselinck , Evon Jude , Rana McKay , Naveen Basappa , Sumanta Pal , Camillo Porta , Neeraj Agarwal , Toni Choueiri , Daniel Heng","Department of Genitourinary Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, CancerCare Manitoba, University of Manitoba, Tom Baker Cancer Centre, University of Calgary, Barts Cancer Institute, Queen Mary University of London, Dana-Farber Cancer Institute, Harvard Medical School, Dana-Farber Cancer Institute, Asan Medical Center, University of Ulsan College of Medicine, University Hospital of Southern Denmark, Leuven Cancer Institute, KU Leuven, Olivia Newton-John Cancer Research Institute, Moores Cancer Center, University of California, San Diego, Cross Cancer Institute, University of Alberta, Department of Medical Oncology, City of Hope Comprehensive Cancer Center, University of Bari Aldo Moro, Huntsman Cancer Institute at the University of Utah"
733,D30,A retrospective real-world study of disitamab vedotin combined with tislelizumab versus chemotherapy in patients with previously untreated metastatic urothelial carcinoma.,"Han Se , Xiaomeng Gui , Lin Wang , Jing Jing , Riguleng Si , Haojing Li , Dongchen Lv , Jia Li , Ning Chi , Sanxiang Li , Hong Yang","Department of Graduate School, Baotou Medical College, Department of Inner Mongolia Clinical Medical College, Inner Mongolia Medical university, Department of Urology, Huhhot First Hospital, Department of oncology, Inner Mongolia People's Hospital, People's Hospital of Inner Mongolia University, Department of Urology, Inner Mongolia People's Hospital, People's Hospital of Inner Mongolia University"
666,,Clinically advanced urothelial bladder cancer (CAUBC) in young onset bladder cancer (YOUC) patients: A genomic landscape study.,"Alina Basnet , Ashish Kamat , Andrea Necchi , Roger Li , Philippe Spiess , Petros Grivas , Neeraj Agarwal , Liang Cheng , Dean Pavlick , Jeffrey Ross , Douglas Lin , Ole Gjoerup , Joseph Jacob , Tamara Jamaspishvili , Gennady Bratslavsky , Shilpa Gupta","Department of Hematology/Oncology, SUNY Upstate Medical University, The University of Texas MD Anderson Cancer Center, Department of Medical Oncology, IRCCS San Raffaele Hospital, Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center & Research Institute, H. Lee Moffitt Cancer Center and Research Institute, Department of Medicine, Division of Oncology, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, Huntsman Cancer Institute at the University of Utah, Warren Alpert Medical School of Brown University, Foundation Medicine, Inc., Department of Pathology, SUNY Upstate Medical University, Department of Urology, Upstate Medical University, Department of Urology, SUNY Upstate Medical University, Taussig Cancer Institute, Cleveland Clinic"
308,,Gene signature predictor of dose-response to prostate radiation: Validation of PORTOS in phase III trials.,"Shuang Zhao , Hyunnam Ryu , James Proudfoot , Elai Davicioni , Jeff Michalski , Daniel Spratt , Stefanie Hayoz , Jeffry Simko , Howard Sandler , Alan Pollack , Matthew Parliament , Ian Dayes , Rohann Correa , Theodore Karrison , William Hall , Daniel Aebersold , Felix Feng , Pirus Ghadjar , Phuoc Tran , Alan Dal Pra","Department of Human Oncology, University of Wisconsin-Madison, Veracyte, Inc., Washington University School of Medicine in St. Louis, University Hospitals Seidman Cancer Center, Case Western Reserve University, Swiss Group for Clinical Cancer Research (SAKK), University of California, San Francisco, Cedars-Sinai Medical Center, University of Miami Health System, Division of Radiation Oncology, Cross Cancer Institute, Department of Oncology, University of Alberta, Juravinski Cancer Centre, London  Regional Cancer Program, NRG Oncology Statistics and Data Management Center, Medical College of Wisconsin, University of Bern, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, Charité Universitätsmedizin Berlin, University of Maryland, University of Miami"
52,A30,Long follow-up quality of life outcomes from an investigator-initiated randomized trial of enzalutamide versus abiraterone plus prednisolone in docetaxel-untreated castration-resistant prostate cancer.,"Kouji Izumi , Atsushi Mizokami","Department of Integrative Cancer Therapy and Urology, Kanazawa University, Kanazawa University"
736,D33,"Treatment, tolerability and outcomes of enfortumab vedotin plus pembrolizumab in advanced urothelial carcinoma: An analysis of the Austrian enfortumab registry.","Dora Niedersuess -Beke , Renate Pichler , Johanna Krauter , Ferdinand Luger , Dominik Vais , Roman Taedcke , Stefan Aufderklamm , Franz Stoiber , Shahrokh Shariat , Susanne Schnabel , Simon Gampenrieder , Josef Muehlmann , Jasmin Spiegelberg , Thomas Bauernhofer , Andreas Banner , Sabine Weibrecht , Clemens Wiesinger , Jan Miechowiecki , Daniel Heintel , Karl Mayrhofer","Department of Internal Medicine I., Centre for Oncology and Haematology, Vienna Healthcare Group, Ottakring, Medical University Innsbruck, Department of Urology, University Hospital Vienna, Department of Internal Medicine I with Haematology, Medical Oncology, Ordensklinikum Linz Elisabethinen, Linz, Austria and Johannes Kepler University, Department of Internal Medicine Oncology and Haematology, State Hospital Klagenfurt, Department of Urology, State Hospital Bregenz, Bregenz, Austria and Department of Urology, Eberhard Karls University Tübingen, Germany, Department of Urology, State Hospital Salzkammergut, Medical University of Vienna, Vienna General Hospital, Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, Department of Internal Medicine St. John of God Hospital, Division of Clinical Oncology, Department of Internal Medicine, Medical University Graz, Department of Urology, Vienna Healthcare Group, Favoriten, Department of Internal Medicine II, St. John of God Hospital, Klinikum Wels, Hanusch Hospital, Karl Landsteiner Institute for Bioanalytical Oncology, Karl Landsteiner Society"
TPS612,K13,A phase II study bolstering outcomes by optimizing immunotherapy strategies with evolocumab and nivolumab in patients with metastatic renal cell carcinoma (BOOST-RCC).,"Tian Zhang , Qian Qin , Suzanne Cole , Andrew Wang , Pavlos Msaouel , Andrew Hahn , Amishi Shah , Matthew Campbell , Song Zhang , Rebecca Tidwell , Wadih Issa , Andrew DeVilbiss , Changchuan Jiang , Joseph Vento , Kevin Courtney , Hans Hammers , James Brugarolas , Nizar Tannir , Eric Jonasch","Department of Internal Medicine, Division of Hematology and Oncology, UT Southwestern, Department of Radiation Oncology, UT Southwestern Medical Center, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Peter O’Donnell Jr. School of Public Health, UT Southwestern, UT Southwestern Medical Center, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, University of Texas MD Anderson Cancer Center"
573,H8,Association between molecular changes and perioperative immunotherapy in patients with advanced clear cell renal cell carcinoma undergoing cytoreductive nephrectomy.,"Wadih Issa , Navneet Kaur , Andrew DeVilbiss , Ze Yu , Qinhan Zhou , Damla Gunenc , Chao Xing , Andrew Wang , Tian Zhang","Department of Internal Medicine, Division of Hematology and Oncology, UT Southwestern, UT Southwestern Medical Center, Eugene McDermott Center for Human Growth and Development, UT Southwestern Medical Center, Eugene McDermott Center for Human Growth and Development; Lyda Hill Department of Bioinformatics; O'Donnell School of Public Health, UT Southwestern Medical Center, Department of Radiation Oncology, UT Southwestern Medical Center"
671,C4,Racial disparities in secondary metastasis in patients with bladder cancer: A 5-year National Inpatient Sample study.,"Sakditad Saowapa , Natchaya Polpichai , Manasawee Tanariyakul , Chalothorn Wannaphut , Chanakarn Kanitthamniyom , Hector Garcia Pleitez , Diego Alonso Olavarria Bernal , Watsachon Pangkanon , Vivie Tran , Pharit Siladech , Lukman Tijani","Department of Internal Medicine, Texas Tech University Health Sciences Center, Department of Medicine, Weiss Memorial Hospital, Department of Internal Medicine, John A. Burns School of Medicine, University of Hawaii, Department of Medicine, Texas Tech University Health Sciences Center, Texas Tech University Health Sciences Center, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Hematology and Oncology Department, Texas Tech University Health Sciences Center"
463,D31,Application of ML models to predict postoperative outcomes in renal cell carcinoma.,"Atulya Khosla , Mohammad Arfat Ganiyani , Manas Pustake , Nitya Batra , Akshit Chitkara , Venkataraghavan Ramamoorthy , Muni Rubens , Anshul Saxena , Rohan Garje , Ishmael Jaiyesimi , Karan Jatwani","Department of Internal Medicine, William Beaumont University Hospital, Miami Cancer Institute, Baptist Health South Florida, Texas Tech University Health Science Center, Corewell Health William Beaumont University Hospital, Sidney Kimmel Comprehensive Cancer Institute, Thomas Jefferson University, The George Washington University Hospital"
663,,Datopotamab deruxtecan (Dato-DXd) in locally advanced/metastatic urothelial cancer: Updated results from the phase 1 TROPIONPanTumor01 study.,"Funda Meric-Bernstam , Omar Alhalabi , Aaron Lisberg , Alexandra Drakaki , Benjamin Garmezy , Takahiro Kogawa , Alexander Spira , Mohamad Salkeni , Xin Gao , Anthony Tolcher , Manali Bhave , Deborah Doroshow , Jeannie Hoffman-Censits , Gunnar Klauss , Yoshiaki Kaga , Yasuyuki Kakurai , Takahiro Kojima","Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, UCLA Health Cancer Care, Thoracic Medical Oncology, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California, Los Angeles, Sarah Cannon Research Institute, Department of Advanced Medical Development, The Cancer Institute Hospital of JFCR, NEXT Virginia, Virginia Cancer Specialists, Massachusetts General Hospital, Harvard Medical School, NEXT Oncology, Department of Hematology/Oncology, Emory University, Division of Hematology & Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Departments of Medical Oncology & Urology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Medical Institutions, Global Oncology, R&D, Daiichi Sankyo, Inc., Clinical Science, Daiichi Sankyo, Inc., Data Intelligence, Daiichi Sankyo, Co., Ltd., Department of Urology, Aichi Cancer Center"
533,F31,Cabozantinib in patients (pts) with non-locally pretreated brain metastases (BM) from renal cell carcinoma (RCC): Results of the multicenter CABRAMET phase II trial (NCT03967522).,"Sylvie Negrier , Loic Mourey , Ellen Blanc , Marine Gross-Goupil , Aude Flechon , Ronan Flippot , Philippe Barthelemy , Stephane Oudard , Emeline Colomba , Constance Thibault , Alain Ravaud , Christine Chevreau , Mathilde Donnat , Helen Boyle , Cécile Dalban , David Pérol , Bernard Escudier , Laurence Albiges","Department of Medical Oncology, Centre Léon Bérard, University of Lyon, Institut Claudius Regaud/IUCT-Oncopole, Clinical Research and Innovation Department, Centre Léon Bérard, Department of Medical Oncology, Bordeaux University Hospital, Cancérologie Médicale, Centre Léon-Bérard, Department of Medical Oncology, Gustave Roussy, Department of Medical Oncology, Institut de Cancérologie Strasbourg Europe (ICANS), Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP.Centre – Université Paris Cité, Medical Oncology Department, Gustave Roussy, Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP Centre, Université de Paris Cité, Bordeaux University Hospital, Bordeaux University, Centre Leon Berard, Centre Leon Bérard, Centre Léon Bérard, Department of Clinical Research, Centre Léon Bérard, Gustave Roussy, Gustave Roussy, Paris Saclay University"
61,B7,Real-world outcomes among patients with metastatic castration-resistant prostate cancer (mCRPC) receiving guideline-recommended therapies after treatment with 177Lu-PSMA-617: A real-world prostate cancer disease observation (PRECISION) data platform analysis.,"Xiao Wei , Neal Shore , Daniel George , Elisabeth Heath , Jennifer Nguyen , Jeetvan Patel , Amrita Sawhney , Barinder Kang , Clare Byrne , Jackson Tang , Alton Sartor","Department of Medical Oncology, Dana-Farber Cancer Institute, Carolina Urologic Research Center, Department of Medicine, Duke Cancer Institute, Duke University School of Medicine, Karmanos Cancer Center, Novartis Pharmaceuticals Corporation, Asclepius Analytics, Mayo Clinic"
354,J18,Impact of physicians’ awareness of prostate-specific antigen doubling time (PSADT) on treatment (Tx) decisions in high-risk (HR) biochemically recurrent (BCR) prostate cancer (PC).,"Alicia Morgans , Maelys Touya , Nader El-Chaar , Dina Elsouda , Krishnan Ramaswamy , Kelechi Adejumo , Danielle Gentile , Bruce Feinberg , Parisa Asgarisabet , Prathamesh Pathak , Stephen Freedland","Department of Medical Oncology, Dana-Farber Cancer Institute, Global Product Development, Astellas Pharma Inc., Astellas Pharma Inc., Pfizer Inc., Cardinal Health, Department of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles; Durham VA Medical Center"
TPS432,M30,"Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP).","Alicia Morgans , Tamim Niazi , Neal Shore , Juergen Gschwend , Ashley Ross , Thomas Hope , Alex Chehrazi-Raffle , Stephane Supiot , Philippe Barthelemy , Andreas Røder , Andrea Gomes , Bernardo Herrera Imbroda , Matthieu Gratton , Carmen Belen Congregado Ruiz , Heikki Joensuu , Miryana Dimova-Dobreva , Marie-Aude Le Berre , Iris Kuss , Karim Fizazi","Department of Medical Oncology, Dana-Farber Cancer Institute, McGill University, Carolina Urologic Research Center, Universitätsklinikum rechts der Isar, Technical University Munich, Northwestern Medicine, Radiology School of Medicine, University of California at San Francisco, Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, University Hospital Strasbourg, Copenhagen Prostate Cancer Center, Copenhagen University Hospital – Rigshospitalet, Liga Norte Riograndense Contra O Cancer, Virgen de la Victoria Hospital, Urology Unit, Hôpital Hôtel-Dieu de Lévis, Virgen del Rocío University Hospital, Orion Corporation, Bayer Consumer Care AG, Bayer HealthCare SAS, Bayer AG, Institut Gustave Roussy, University of Paris-Saclay"
324,H24,Evaluating the impact of a community-based prostate cancer screening program.,"Amy Leader , Kristine Pham , Nicola Cianci , Fatuma Doka , Suzanne Barron , Katie Bradley , Oleksandr Kolesnikov , Jordan DeHoratius , Olivia Dahlgren , Le'Ann Robles , Robert Giamboy , Hannah Knapp , Leonard Gomella","Department of Medical Oncology, Division of Population Science, Sidney Kimmel Medical College, Thomas Jefferson University, Sidney Kimmel Cancer Center at Jefferson, Department of Urology, Jefferson Health, Thomas Jefferson University, Department of Urology, Carleton College, Jefferson Kimmel Cancer Center"
510,F8,Lenvatinib's efficacy in heavily pre-treated metastatic renal cell carcinoma: Insights from a European multicenter study.,"Javier Gavira , Edouard Auclin , Macarena Rey , Pritha Roy , Jose Tapia , Paula Nay , Armelle Vinceneux , Simon Nannini , Adela Randis , Delphine Borchiellini , Guillermo de Velasco , Philippe Barthelemy , Sylvie Negrier , Stephane Oudard , Ricky Frazer , Ronan Flippot , Laurence Albiges","Department of Medical Oncology, Gustave Roussy, Paris Saclay University, Department of Medical Oncology, Institut Bergonié, Velindre Cancer Centre, Velindre University NHS Trust, Velindre Cancer Centre, Department of Medical Oncology, Hôpital Européen Georges-Pompidou, University of Paris, Department of Medical Oncology, Centre Léon Bérard, University of Lyon, Department of Medical Oncology, Institut de Cancérologie Strasbourg Europe (ICANS), Department of Medical Oncology, Hospital Universitario 12 de Octubre, Department of Medical Oncology, Centre Antoine Lacassagne, Université Côte d’Azur, Medical Oncology Department, Hospital 12 de Octubre, Gustave Roussy, Paris Saclay University"
483,E16,Impact of site of metastatic involvement on IMDC classification in metastatic renal cell carcinoma patients treated with immunotherapy.,"Laia Fernandez-Mañas , Irene Ortiz , Javier Pozas , Chloe Beland , James Larkin , Alba Moll-Febrer , Laura González-Aguado , Judit Sanz Beltran , Georgia Anguera , Nil Navarro , Alejo Rodriguez-Vida , Silvia Rubio Novella , Marina Sierra , Alicia Carrasco , Nuria Sala González , Eleonor Paola Murata Yonamine , Iria González Maeso , Mariona Figols , Maria Marin Alcalá , Òscar Reig","Department of Medical Oncology, Hospital Clinic of Barcelona, Medical Oncology Department, Catalan Institute of Oncology l’Hospitalet, Skin and Renal Cancer Unit, Medical Oncology Department, Royal Marsden Hospital, Royal Marsden Hospital, Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Hospital de la Santa Creu i Sant Pau, Medical Oncology Department, Hospital del Mar, Medical Oncology Department, Hospital de Manises, Medical Oncology Department, Hospital Parc Taulí, Medical Oncology Department, Catalan Institute of Oncology Girona, Medical Oncology Department, Hospital Arnau de Vilanova, Medical Oncology Department, University Hospital Son Llàtzer, Medical Oncology Department, Fundació Althaia, Xarxa Assistencial Universitària de Manresa, Medical Oncology Department, Consorci Sanitari de Terrassa, Medical Oncology Department, Hospital Clínic, Translational Genomics and Targeted Therapeutics in Solid Tumors Group (IDIBAPS)"
226,F30,Chromosomal instability in tumor suppressor genes–altered prostate cancer.,"Marta Garcia de Herreros , Natalia Jiménez , Joan Padrosa , Òscar Reig , Laia Fernandez-Mañas , Laura Ferrer-Mileo , Samuel García-Esteve , Albert Font Pous , Vicente Ruiz de Porras , Begoña Mellado","Department of Medical Oncology, Hospital Clinic of Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic Barcelona, Department of Medical Oncology, Hospital Clinic of  Barcelona, Medical Oncology Department, Catalan Institute of Oncology-Badalona, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Badalona-Applied Research Group in Oncology (B-ARGO), Germans Trias I Pujol Research Institute, Institut Català d'Oncologia, Hospital Germans Trias i Pujol"
718,D15,AVENANCE real-world study of avelumab first-line (1L) maintenance treatment for advanced urothelial carcinoma (UC): Analyses in low tumor burden subgroups.,"Philippe Barthelemy , Yohann Loriot , Constance Thibault , Aude Flechon , Eric Voog , Jean Christophe Eymard , Camille Simon , Damien Pouessel , Matthieu Chasseray , Veronique Lorgis , Constant Josse , Prisca Lambert , Laurent Paret , Marine Gross-Goupil","Department of Medical Oncology, Institut de Cancérologie Strasbourg Europe (ICANS), Gustave Roussy, Département de Médecine Oncologique et Département des Essais Précoces, Université Paris-Saclay, Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP Centre, Université de Paris Cité, Centre Léon Bérard, Clinique Victor Hugo Centre Jean Bernard, Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, Institut de Cancérologie de Lorraine, Oncopole Claudius Régaud–IUCT Oncopole, Centre Finistérien de Radiothérapie et d’Oncologie–Clinique Pasteur, Medical Oncology, Institut de Cancérologie de Bourgogne, eXYSTAT, Pfizer Oncology, Merck Santé S.A.S., Lyon, France, an affiliate of Merck KGaA, Department of Medical Oncology, Bordeaux University Hospital"
94,C4,Evaluating the association between bone pain and radiologic progression-free survival (rPFS) in patients with metastatic castration-sensitive prostate cancer (mCSPC).,"Deniz Tural , Caner Kapar , Selçuk Şahin , Kamil Şeker , Volkan Tuğcu","Department of Medical Oncology, Koç University Medical School, Department of Medical Oncology, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey, Urology Department, Bakirköy Research and Education Hospital, Liv Vadi İstanbul, Istinye University, Urology Department"
708,D5,Avelumab maintenance in patients with metastatic urothelial carcinoma in a real-life expanded-access program (EAP).,"Deniz Tural , Oğuzcan Özkan , Sendag Yaslikaya , Ali Tatli , Goncagül Akdağ , Hacer Demir , Irem Bilgetekin , Fatih Selcukbiricik , Fatih Köse , Murat Sari , Gökmen Erdem , Zehra Sucuoğlu İşleyen , Cagatay Arslan , Sinemis Celik , Türkan Evrensel , Mustafa Erman , Seher Kazaz , Banu Ozturk , Caner Kapar , Yüksel Ürün","Department of Medical Oncology, Koç University Medical School, Ege University, Cukurova University Faculty of Medicine Department of Medical Oncology, Akdeniz University, DR Lutfi Kirdar Kartal Education and Research Hosp, Kayseri Egitim ve Arastirma Hastanesi, Department of Medical Oncology, University of Health Sciences, Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Koc University Hospital, Başkent University, Marmara University Faculty of Medicine, Basakşehir Cam and Sakura City Hospital, Bezmialem Vakif Universitesi Tip Fakultesi, Izmir Economy University Medical Point Hospital, Istanbul Oncology Hospital, Uludağ University, Department of Medical Oncology, Hacettepe University Cancer Institute, Istinye university, Antalya Educaion and Research Hospital, Department of Medical Oncology, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey, Ankara University School of Medicine, Department of Medical Oncology, Ankara, Turkey; Ankara University Cancer Institute, Ankara, Turkey"
112,C22,Outcomes for 177Lu-PSMA-617 with and without concurrent use of ARPIs in patients with mCRPC.,"Miguel Muniz , Alton Sartor , Jacob Orme , Regina Koch , Fernando Quevedo , Adam Kase , Irbaz Riaz , Syed Arsalan Ahmed Naqvi , Jack Andrews , Matthew Thorpe , Ayse Kendi , Gokce Bilgin , Geoffrey Johnson , Eugene Kwon , Daniel Childs","Department of Medical Oncology, Mayo Clinic in Rochester, Mayo Clinic in Rochester, Mayo Clinic in Florida, Mayo Clinic in Arizona, Division of Hematology and Medical Oncology, Mayo Clinic, Department of Nuclear Medicine, Mayo Clinic in Rochester"
114,C24,Utility of post-treatment SPECT/CT for identifying disease progression in patients with mCRPC treated with 177Lu-PSMA-617.,"Miguel Muniz , Alton Sartor , Jacob Orme , Regina Koch , Fernando Quevedo , Adam Kase , Irbaz Riaz , Matthew Thorpe , Ayse Kendi , Gokce Bilgin , Yalda Nikanpour , Geoffrey Johnson , Eugene Kwon , Daniel Childs","Department of Medical Oncology, Mayo Clinic in Rochester, Mayo Clinic, Mayo Clinic in Rochester, Mayo Clinic in Florida, Mayo Clinic in Arizona, Department of Radiology, Mayo Clinic in Rochester, Department of Nuclear Medicine, Mayo Clinic in Rochester"
498,E31,Comparing the effectiveness of IO-based combination regimens as first-line treatment for advanced clear-cell renal cell carcinoma (ccRCC).,"Ramona Stelmach , Stefanie Zschaebitz , Stella Erdmann , Katrin Schlack , Linus Materna , Thomas Hilser , Philipp Ivanyi , Margitta Retz , Jozefina Casuscelli , Pia Paffenholz , Marco Schnabel , Timo Egenolf , Arne Strauß , Richard Cathomas , Berna Özdemir , Anton Moderegger , Stephanie Neuberger , Florian Roghmann , Viktor Grünwald , Christopher Darr","Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Institute of Medical Biometry, University of Heidelberg, Department of Urology, University Hospital Muenster, Department of Medical Oncology, West German Cancer Center, University Hospital Essen and German Cancer Consortium (DKTK), Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Claudia-von Schilling Comprehensive Cancer Center, Hannover Medical School, Department of Urology, Rechts der Isar Medical Center, Technical University Munich, Department of Urology, LMU University Hospital, LMU Munich, Department of Urology, Uro-Oncology, Robot Assisted and Reconstructive Urologic Surgery, University of Cologne Faculty of Medicine and University Hospital Cologne, Department of Urology, University Hospital of Regensburg, Department of Urology and Pediatric Urology, University Hospital Wuerzburg, Department of Urology, University Medicine Goettingen, Division of Oncology/Hematology, Cantonal Hospital Grisons, Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Department of Urology, University Hospital Schleswig-Holstein, Campus Luebeck, Department of Urologie and Pediatric Urology, University Medical Center of Johannes Gutenberg University, Department of Urology,  University Hospital of Ruhr-University Bochum, Marien Hospital, Department of Medical Oncology and Clinic for Urology, West-German Cancer Center Essen, University Hospital Essen and German Cancer Consortium (DKTK), Department of Urology, University Hospital Essen, and German Cancer Consortium (DKTK)"
TPS435,M33,"A phase 1b, open-label, multicenter study of xaluritamig in patients with biochemical recurrence of prostate cancer after definitive therapy.","Ben Tran , Kevin Courtney , Alexandra Sokolova , Lisa Horvath , Daniel Danila , Jessica Hawley , David Pook , Landon Brown , Young Whang , Simon Buetikofer , Kejia Wang , Nicholas Zorko","Department of Medical Oncology, Peter MacCallum Cancer Centre, Department of Internal Medicine, Division of Hematology and Oncology, UT Southwestern, Oregon Health & Science University, Chris O’Brien Lifehouse, University of Sydney, Memorial Sloan Kettering Cancer Center, Division of Hematology & Oncology, Department of Medicine, University of Washington; Clinical Research Division, Fred Hutch Cancer Center, Cabrini Monash University Department of Medical Oncology, Cabrini Health, Atrium Health Levine Cancer, Department of Medicine, Division of Oncology, University of North Carolina School of Medicine, Amgen, Inc, Amgen, Inc., Department of Hematology, and Oncology and Transplantation, Masonic Cancer Center, University of Minnesota"
165,E4,Efficacy and safety of apalutamide in metastatic castration sensitive prostate cancer patients with a prior history of cardiovascular or metabolic risk factors: A post-hoc analysis of the TITAN study.,"Arun Azad , Ding-Wei Ye , Hiroji Uemura , Amitabha Bhaumik , Michael Eisbacher , Anildeep Singh , Sharon McCarthy , Suneel Dinkar Mundle , Kim Chi , Neeraj Agarwal","Department of Medical Oncology, Peter MacCallum Cancer Centre, Fudan University Shanghai Cancer Center, Yokohama City University Medical Center, Johnson & Johnson Research and Development, Johnson & Johnson - Australia and New Zealand, Johnson & Johnson, University of British Columbia, BC Cancer, Vancouver Cancer Centre, Huntsman Cancer Institute (NCI-CCC), University of Utah"
147,D21,"Deep prostate-specific antigen (PSA) decline among early participants (pts) in LIBERTAS, a phase 3 study of apalutamide (APA) plus continuous versus intermittent androgen deprivation therapy (ADT) in metastatic castration-sensitive prostate cancer (mCSPC).","Arun Azad , Marco Badillo , Qiang Dong , Alicia Morgans , Dana Rathkopf , Karie Runcie , Tian Zhang , Geoffrey Gotto , Axel Merseburger , Alex Dos Santos , Sukie Shopeju , Amitabha Bhaumik , Suneel Dinkar Mundle , Sharon McCarthy , Neeraj Agarwal","Department of Medical Oncology, Peter MacCallum Cancer Centre, Hospital Aranda de la Parra, West China Hospital, Sichuan University, Department of Medical Oncology, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, NewYork-Presbyterian Hospital, Columbia University Medical Center, UT Southwestern University, University of Calgary, University Hospital Schleswig-Holstein, Janssen Research & Development, LLC, University of Utah Health Hospitals and Clinics"
163,E2,"Osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with denosumab in a randomized phase III trial comparing 4 vs. 12 weekly administration (REDUSE, SAKK 96/12).","Arnoud Templeton , Stefanie Hayoz , Simone Wyss-Neyer , Richard Cathomas , Ricardo Pereira Mestre , Christian Rothermundt , Sandro Anchisi , Christoph Ackermann , Katharina Reichel , Beat Mueller , Claudine Egger , Augusto Pedrazzini , Razvan Popescu , Lena Züllig , Regina Woelky , Priska Bützberger , Florian Schmid , Roger Von Moos , Silke Gillessen","Department of Medical Oncology, St. Claraspital Basel and Faculty of Medicine, University of Basel, Swiss Group for Clinical Cancer Research (SAKK), Division of Oncology, Cantonal Hospital Graubunden, Oncology Institute of Southern Switzerland (IOSI), Kantonsspital St.Gallen, Hôpital du Valais-CHVR, Spital STS AG Thun, Stadtspital Triemli Zürich, Luzerner Kantonsspital, Spital Limmattal, Schlieren, Oncologia Lago Maggiore, Tumor Center Aarau, Kantonsspital Winterthur, Kantonsspital Frauenfeld, Kantonsspital Baden, University Hospital Zürich, Cancer Center, Cantonal Hospital Graubuenden"
TPS298,M17,Bipolar androgen therapy (BAT) for nonmetastatic castration-resistant prostate (nmCRPC) cancer progressing on darolutamide: Working Out M0 BAT (WOMBAT; ANZUP 2201).,"Megan Crumbaker , Laurence Krieger , David Pook , Ian Davis , Antoinette Fontela , Christopher Oldmeadow , Josh Hurwitz , Andrisha Inderjeeth , Haryana Dhillon , Teesha Downton , Gavin Marx , Samantha Shekar , Emmanuel Antonarakis , Samuel Denmeade , Angelyn Anton , Thean Tan , Sharad Sharma , Jeffrey Goh , Lisa Horvath , Anthony Joshua","Department of Medical Oncology, The Kinghorn Cancer Centre, St Vincent’s Hospital, Genesis Care, North Shore, Royal North Shore Hospital, Monash Cancer Centre, Monash University Eastern Health Clinical School, The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Hunter Medical Research Institute, The Kinghorn Cancer Centre, South Metropolitan Health Campus Perth WA Australia, Faculty of Science, School of Psychology, Centre for Medical Psychology & Evidence-based Decision-making, Psycho-Oncology Cooperative Research Group, The University of Sydney, Sydney Adventist Hospital, The Kinghorn Cancer Centre, St Vincent's Hospital, University of Minnesota Masonic Cancer Center, Johns Hopkins University School of Medicine, Eastern Health, Department of Medical Oncology, Royal Adelaide Hospital, Ballarat Regional Integrated Cancer Centre, Ballarat Health Services, Royal Brisbane and Women's Hospital, Chris O’Brien Lifehouse, University of Sydney"
218,F22,A phase II single arm prospective study of high dose testosterone in combination with carboplatin chemotherapy in late line metastatic castrate-resistant prostate cancer (HIGH-TeCH study).,"Megan Crumbaker , Samantha Shekar , Mitchell Lawrence , Leonard Goldstein , Andrew Yam , Teesha Downton , Stephen Begbie , Rob Zielinski , William Fox , Nicole Araiza , Jacob Yousif , Lalith Ratnayake , Emmanuel Antonarakis , Samuel Denmeade , Anthony Joshua","Department of Medical Oncology, The Kinghorn Cancer Centre, St Vincent’s Hospital, The Kinghorn Cancer Centre, St Vincent's Hospital, Prostate Cancer Research Group, Monash University, The Garvan Institute of Medical Research (Australia), The Kinghorn Cancer Centre, Port Macquarie Base Hospital, Central West Cancer Centre, Mid North Coast Cancer Institute, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center; University of Minnesota Masonic Cancer Center, Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center"
496,E29,Real world evidence from a retrospective multi-center analysis on first-line therapy for metastatic papillary renal cell carcinoma: A GUARDIANS project.,"Thomas Hilser , Can Aydogdu , Stefanie Zschaebitz , Emily Rinderknecht , Angelika Mattigk , Anna-Lisa Volk , Philipp Ivanyi , Jonas Wiegmann , Christopher Darr , Subhajit Mandal , Katrin Schlack , Daniel Seidl , Analena Handke , Melanie Klee , Tim Nestler , Marc Rehlinghaus , Sameh Hijazi , Axel Heidenreich , Viktor Grünwald , Pia Paffenholz","Department of Medical Oncology, West German Cancer Center, University Hospital Essen and German Cancer Consortium (DKTK), Department of Urology, University Hospital, Ludwig Maximilian University of Munich, Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Department of Urology, Caritas-St. Josef Medical Center, University of Regensburg, Department of Urology, University Hospital Ulm, Department for Urology, Urooncology, Robot-assisted an focal treatment, University of Madgeburg, Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Claudia-von Schilling Comprehensive Cancer Center, Hannover Medical School, Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Claudia-von Schelling Comprehensive Cancer Center, Hannover Medical School, Department of Urology, University Hospital Essen, and German Cancer Consortium (DKTK), Department of Urology, University of Marburg, Department of Urology, University Hospital Muenster, Department of Urology, Diakonie-Klinikum Stuttgart, Department of Urology, Ruhr University Bochum, Marienhospital Herne, Department of Urology, University Hospital Schleswig-Holstein, Campus Luebeck, Department of Urology, Federal Armed Services Hospital Koblenz, Department of Urology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Department of Urology, Ibbenbueren Hospital, Department of Urology, Uro-Oncology, Robot Assisted and Reconstructive Urologic Surgery, University of Cologne Faculty of Medicine and University Hospital Cologne, Department of Medical Oncology and Clinic for Urology, West-German Cancer Center Essen, University Hospital Essen and German Cancer Consortium (DKTK)"
806,G2,A phase I first-in-human clinical trial with PLZ4-coated paclitaxel-loaded micelles (PPM) in therapy-resistant non-muscle-invasive bladder cancer (NMIBC).,"Chong-xian Pan , Juan Garisto , Lori Lerner , Matthew Mossanen , Marc Dall'Era , Hizra Farrukh , Colleen Hynes , Mamta Parikh , Primo Lara Jr., Urvashi Bhardwaj , Ai-Hong Ma , Joyce Lee , Yuanpei Li , Tzu-yin Lin , Yanxiao Jiao , Junwei Zhao , Ruiwu Liu , Kit Lam","Department of Medicine and Urology, Brigham and Women’s Hospital, Harvard Medical School, and VA Boston Healthcare System, Department of Urology, Weill Cornell Medicine, NewYork-Presbyterian Hospital, VA Boston Healthcare System, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Department of Urology, University of California, Davis, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, University of California, Davis Comprehensive Cancer Center, University of California, Davis, UC Davis Cancer Center"
800,F27,"A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer, (HCRN GU18-343) ABATE study.","Deepak Kilari , Aniko Szabo , Kathryn Bylow , Ariel Nelson , Peter Langenstroer , Scott Johnson , Arjun Sivaraman , Kenneth Jacobsohn , Chunkit Fung , Sindhuja Kadambi , Brian Rini , Melissa Reimers , Robert Alter , Asit Paul , Brendan Guercio , Matthew Milowsky","Department of Medicine, Division of Hematology and Oncology, The Medical College of Wisconsin, Division of Biostatistics, Froedtert and The Medical College of Wisconsin, Medical College of Wisconsin, MCW, University of Rochester School of Medicine & Dentistry, James P. Wilmot Cancer Center, University of Rochester Medical Center, Department of Medicine, Vanderbilt University Medical Center, Department of Medicine, Division of Oncology, Washington University School of Medicine, Regional Cancer Care Associates, Virginia Commonwealth University - Massey Cancer Center, Department of Medicine, University of North Carolina School of Medicine"
821,G17,TP53 Y220C mutations in advanced urothelial bladder cancer (UBC): A genomic landscape study.,"Rosa Nadal , Joseph Jacob , Gennady Bratslavsky , Alina Basnet , Jeffrey Ross , Douglas Lin , Ole Gjoerup , Liang Cheng , Shilpa Gupta , Neeraj Agarwal , Philippe Spiess , Roger Li , Ashish Kamat , Andrea Necchi , Petros Grivas","Department of Medicine, Division of Hematology/Oncology, University of Washington, Fred Hutchinson Cancer Center, Department of Urology, Upstate Medical University, SUNY Upstate Medical University, Department of Pathology, SUNY Upstate Medical University, Foundation Medicine, Inc., Indiana University, Cleveland Clinic Taussig Cancer Institute, Huntsman Cancer Institute (NCI-CCC), University of Utah, H. Lee Moffitt Cancer Center and Research Institute, Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, The University of Texas MD Anderson Cancer Center, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, University of Washington and Fred Hutchinson Cancer Center"
63,B9,Patient characteristics and overall survival with lutetium (Lu177) vipivotide tetraxetan (177Lu-PSMA-617): A real-world analysis of early adopters.,"Daniel George , Neal Shore , Jennifer Nguyen , Jeetvan Patel , Amrita Sawhney , Barinder Kang , Chi-Chang Chen , Magdaliz Gorritz , Xiao Wei","Department of Medicine, Duke Cancer Institute, Duke University School of Medicine, Carolina Urologic Research Center, Novartis Pharmaceuticals Corporation, IQVIA Inc., Department of Medical Oncology, Dana-Farber Cancer Institute"
145,D19,Cabozantinib (C) ± atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Expansion cohorts from the open-label phase 1b COSMIC-021 study.,"Neeraj Agarwal , Ulka Vaishampayan , Jingsong Zhang , Xavier Artignan , Begoña Mellado , Shirley Wong , Omi Parikh , Daniel Castellano , Joaquina Baranda , Denise Williamson , Lavanya Gunachandran , Xiang Guo , Prachi Nandoskar , Bradley McGregor , Sumanta Pal","Department of Medicine, Huntsman Cancer Institute at the University of Utah, Division of Hematology/Oncology, University of Michigan, Department of Genito-Urology Oncology, University of South Florida H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Centre Hospitalier Privé Saint-Grégoire, Medical Oncology, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Western Health, Royal Blackburn Teaching Hospital, East Lancashire Hospitals NHS Foundation Trust, Department of Medical Oncology, Hospital Universitario 12 de Octubre, Department of Internal Medicine, University of Kansas Cancer Center, Exelixis, Inc., Dana-Farber Cancer Institute, Department of Medical Oncology, City of Hope Comprehensive Cancer Center"
TPS285,M4,PRO-XL: A phase II study of zanzalintinib (XL092) in patients with metastatic castration-resistant prostate cancer (mCRPC) after progression on lutetium-177 (177Lu)-PSMA-617.,"Umang Swami , Kenneth Boucher , Yeonjung Jo , Colin Moynier , Susan Clement , Tenzin Phunrab , Julia Batten , Joshua Quertinmont , Jon Mahlow , Vinay Mathew Thomas , Sumati Gupta , Manish Kohli , Benjamin Maughan , Neeraj Agarwal","Department of Medicine, Huntsman Cancer Institute at the University of Utah, Hunstman Cancer Institute at the University of Utah, Huntsman Cancer Institute at the University of Utah, University of Utah"
95,C5,Real-world use of bone-modifying agents (BMA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the US.,"Umang Swami , Yeonjung Jo , Chadi Hage Chehade , Zeynep Ozay , Nicolas Sayegh , Georges Gebrael , Micah Ostrowski , Patrick Campbell , Siqi HU , Gliceida Galarza Fortuna , Vinay Mathew Thomas , Haoran Li , Ryon Graf , Soumyajit Roy , Benjamin Maughan , Avirup Guha , Irbaz Riaz , Emmanuel Antonarakis , Rana McKay , Neeraj Agarwal","Department of Medicine, Huntsman Cancer Institute at the University of Utah, Huntsman Cancer Institute at the University of Utah, Hunstman Cancer Institute at the University of Utah, Huntsman Cancer Insititute at the University of Utah, Weill Medical College, Cornell University, NewYork-Presbyterian Hospital, University of Kansas Cancer Center, Foundation Medicine, Inc., Rush University Medical Center, Department of Medicine, Division of Cardiology, Medical College of Georgia at Augusta University, Mayo Clinic in Arizona, University of Minnesota, Masonic Cancer Center, University of California San Diego, Moores Cancer Center, Huntsman Cancer Institute (NCI-CCC), University of Utah"
104,C14,Recent treatment patterns in US-based real-world patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC).,"Umang Swami , Yeonjung Jo , Zeynep Ozay , Chadi Hage Chehade , Georges Gebrael , Nicolas Sayegh , Micah Ostrowski , Ethan Anderson , Diya Garg , Ayana Srivastava , Beverly Chigarira , Siqi HU , Vinay Mathew Thomas , Sumati Gupta , Benjamin Maughan , Avirup Guha , Irbaz Riaz , Soumyajit Roy , Neeraj Agarwal","Department of Medicine, Huntsman Cancer Institute at the University of Utah, Huntsman Cancer Institute at the University of Utah, Huntsman Cancer Insititute at the University of Utah, Hunstman Cancer Institute at the University of Utah, Department of Medicine, Division of Cardiology, Medical College of Georgia at Augusta University, Mayo Clinic in Arizona, Rush University Medical Center, Huntsman Cancer Institute (NCI-CCC), University of Utah"
662,,"A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with FGFR3 alterations: Initial results from FORAGER-1.","Gopa Iyer , Hiromichi Ebi , Natalie Cook , Xin Gao , Shigehisa Kitano , Nobuaki Matsubara , Melissa Reimers , Arlene Siefker-Radtke , Miso Kim , Matthew Galsky , Debbie Robbrecht , Jun Guo , Bernhard Eigl , Clare Schaverien , Brent Butts , Eunice Yuen , Sylwia Szymczak , Xiang Zhao , Ryan Widau , Alexandra Drakaki","Department of Medicine, Memorial Sloan Kettering Cancer Center, Division of Molecular Therapeutics, Aichi Cancer Center Research Institute, The Christie NHS Foundation Trust and, University of Manchester, Massachusetts General Hospital Cancer Center, Department of Advanced Medical Development, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Department of Medical Oncology, National Cancer Center Hospital East, Department of Internal Medicine, Washington University in St. Louis, Department of Medicine, The University of Texas MD Anderson Cancer Center, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Department of Medical Oncology, Erasmus MC Cancer Institute, Peking University Cancer Hospital and Institute, British Columbia Cancer Agency, Eli Lilly and Company, Division of Hematology/Oncology, Department of Medicine, UCLA David Geffen School of Medicine"
447,D15,Temporal trends and socioeconomic determinants of cytoreductive nephrectomy (CN) utilization for metastatic renal cell carcinoma (mRCC) in the United States (US).,"Stepan Esagian , Pavlos Msaouel , Jose Karam , Benjamin Gartrell , Dimitrios Makrakis","Department of Medicine, NYC Health + Hospitals/Jacobi, Albert Einstein College of Medicine, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Montefiore Einstein Cancer Center"
49,A27,Effects of integrating palliative care on the uptake of advance care planning among elderly patients with advanced genitourinary cancers.,"Phichai Chansriwong , Tanin Tiyanont , Siriporn Semsarn , Nintita Sripaibookij Thokanit","Department of Medicine, Ramathibodi Hospital, Ramathibodi Hospital, Ramathibodi Palliative Care Center, Ramathibodi Comprehensive Cancer Center, Ramathibodi Hospital, Mahidol  University"
372,K2,Incidence of EMBARK and EAU high-risk biochemical recurrence and prostate cancer mortality: A real-life population-based study.,"Ugo Falagario , Francesco Pellegrino , Giuseppe Carrieri , Anna Lantz , Olof Akre , Peter Wiklund","Department of Molecular Medicine and Surgery, Karolinska Institutet, Department of Urology, University of Foggia"
366,J30,PSA-based intermediate endpoints to compare radiotherapy and radical prostatectomy for the treatment of localized prostate cancer.,"Ugo Falagario , Francesco Pellegrino , Giuseppe Carrieri , Anna Lantz , Olof Akre , Peter Wiklund","Department of Molecular Medicine and Surgery, Karolinska Institutet, Department of Urology, University of Foggia, Karolinska Institutet"
485,E18,"Trends in kidney cancer: Exploring the impact of sex and age on stage of disease, and prognosis during the past three decades in Denmark—A DaRenCa study.","Johanne Ahrenfeldt , Jesper Jespersen , Jens Tønder , Laura Iisager , Anna Krarup Keller , Niels Fristrup , Tinne Laurberg , Iben Lyskjær","Department of Molecular Medicine, Aarhus University Hospital, Department of Clinical Medicine, Aarhus University, Steno Diabetes Centre Aarhus, Aarhus University Hospital, Department of Urology, Aarhus University Hospital, Department of Oncology, Aarhus University Hospital"
39,A17,Clinical protocols to monitor efficacy of [177Lu]Lu-PSMA radiopharmaceutical therapy in metastatic castration-resistant prostate cancer.,"Lena Unterrainer , NIcolas De Leiris , Marcus Unterrainer , Harun Ilhan , Astrid Delker , Linus Hempel , Zachary Ells , Joseph Zahner , Adrien Holzgreve , Mathias J. Zacherl , Jozefina Casuscelli , Kevin Kiraz , Julien Leenhardt , Emmanuelle Jacquet , Jerome Long , Mathieu Laramas , Channing Paller , Lilja Solnes , Andrei Gafita , Loic Djaileb","Department of Nuclear Medicine, University Hospital, LMU Munich, CHU Grenoble Alpes, Department of Radiology, Ludwig-Maximilians-University Munich, Ludwig-Maximilians-University, Department of Nuclear Medicine, LMU University Hospital, LMU Munich, LMU Munich, Nuclear Medicine, LMU, University of Munich, Department of Urology, LMU University Hospital, LMU Munich, University of Grenoble, Groupe Hospitalier Mutualiste de Grenoble, Grenoble University Hospital Centre, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University, Johns Hopkins Hospital, Universite Grenoble Alpes"
457,D25,"68Ga-FAPI-46 PET/CT for cancer imaging: Results of a single-center, prospective, interventional, single-arm clinical trial.","Kim Pabst , Timo Bartel , Patrick Sandach , Christina Laschinsky , Manuel Weber , Lukas Kessler , Alina Küper , Boris Hadaschik , Claudia Kesch , Rainer Hamacher , Stefan Kasper , Lars Podleska , Jens Siveke , Markus Eckstein , Bastian von Tresckow , Sherko Kuemmel , Anke Reinacher-Schick , Waldemar Uhl , Ken Herrmann , Wofgang Fendler","Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Medizin Center Bonn, Department of Diagnostic and Interventional Radiology, University Hospital Essen, Department of Nuclear Medicine, University of Duisburg-Essen, and German Cancer Consortium (DKTK), University Hospital Essen, Department of Urology, University Hospital Essen, University of Duisburg-Essen, Department of Medical Oncology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen, Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Department of Orthopedic Oncology, West German Cancer Center, University Hospital Essen, Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen and Division of Solid Tumor Translational Oncology, German Cancer Research Center, Heidelberg, Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Department of Hematology and Stem Cell Transplantation, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Breast Unit, Kliniken Essen-Mitte, Department of Hematology and Oncology with Palliative Care, Ruhr-University Bochum, Department of General and Visceral Surgery, St. Josef Hospital Bochum, Ruhr University Bochum, Clinic for Nuclear Medicine and German Cancer Consortium, University Hospital Essen"
266,H7,Prostate cancer risk groups by PSMA-PET PROMISE (PPP): Results from an international multi-center registry study.,"Wolfgang Fendler , Madeleine Karpinski , Sebastian Hoberück , Isabel Rauscher , Lena Unterrainer , Sazan Rasul , Anders Bjartell , Francesco Lanfranchi , Andrea Di Giorgio , Christian Pfob , Timo Soeterik , Karolien Goffin , Felix Kind , Jonathan Miksch , Jeremie Calais , Michael Hofman , Thomas Hope , Ken Herrmann , Kambiz Rahbar , Boris Hadaschik","Department of Nuclear Medicine, University of Duisburg-Essen, and German Cancer Consortium (DKTK), University Hospital Essen, Department of Nuclear Medicine, University of Duisburg-Essen, and German Cancer Consortium (DKTK), NCT, University Hospital Essen, Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Technical University Dresden, Department of Nuclear Medicine, Technical University Munich, Department of Nuclear Medicine, University Hospital, LMU Munich, Medical University of Vienna, Skåne University Hospital, Nuclear Medicine, Department of Health Sciences (DISSAL), University of Genova, Genova, Italy, Nuclear Medicine, Alma Mater Studiorum University of Bologna, Nuclear Medicine, Faculty of Medicine, University of Augsburg, Department of Urology, St Antonius Ziekenhuis Nieuwegein/Utrecht, The Netherlands, Department of Nuclear Medicine, Division of Nuclear Medicine and Molecular Imaging, University Hospital Leuven, KU Leuven, Department of Nuclear Medicine, Medical Center, University of Freiburg, Department of Nuclear Medicine, University Hospital Ulm, Ahmanson Translational Theranostics Division, University of California, Los Angeles, Peter MacCallum Cancer Centre, University of California, San Francisco, Clinic for Nuclear Medicine and German Cancer Consortium, University Hospital Essen, Department of Nuclear Medicine, University Hospital Münster"
851,H15,Urine-derived bladder cancer organoids (urinoids) for longitudinal evaluation of treatment-induced changes during enfortumab vedotin/durvalumab/tremelimumab therapy.,"Alba Zuidema , Bastiaan Viergever , Britt Suelmann , Onno Kranenburg , Richard Meijer","Department of Oncological Urology, University Medical Center Utrecht (UMCU), Department of Medical Oncology, University Medical Center Utrecht, Department of Surgical Oncology, University Medical Center Utrecht, Utrecht University, Department of Oncological Urology, University Medical Center Utrecht"
171,E10,Targeting TROP2 in aggressive variant and neuroendocrine prostate cancer.,"Gunhild Von Amsberg , Moritz Kaune , Lina Bergmann , Tobias Busenbender , Nadja Strewinsky , Finn-Ole Paulsen , David Dum , Derya Tilki , Markus Graefen , Carsten Bokemeyer , Stefan Werner , Sergey Dyshlovoy","Department of Oncology and Hematology, University Cancer Center Hamburg Eppendorf and Martini-Klinik, Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Department of Oncology and Hematology, University Cancer Center Hamburg-Eppendorf, University Medical Center Hamburg-Eppendorf, Germany, Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Department of Pathology, University Medical Center Hamburg-Eppendorf, Martini-Klinik Prostate Cancer Center and Department of Urology, University Hospital Hamburg-Eppendorf, Martini-Klinik, University Medical Center Hamburg-Eppendorf, Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Department of Oncology and Hematology, University Cancer Center Hamburg-Eppendorf, University Medical Center Hamburg-Eppendorf"
773,E35,A phase Ib window of opportunity study of atezolizumab administered intravesically or direct injection in patients undergoing radical cystectomy for bladder cancer: Results of the single dose cohorts.,"Syed Hussain , Jamie Oughton , Ruby Smith Whelan , Angela Green , Irbaz Riaz , Rachel Hubbard , Steven Kennish , Dominic McCready , Jon Griffin , Ethan Senior , Helen Bowler , Jessica Kendall , Fiona Collinson , James Catto","Department of Oncology and Metabolism, University of Sheffield, Leeds Institute of Clinical Trials Research, University of Leeds, Sheffield Teaching Hospitals, Mayo Clinic Department of Medical Oncology, University of Sheffield, Sheffield Teaching Hospitals NHS Foundation Trust, Department of Oncology & Metabolism, University of Sheffield"
762,E24,Body composition and immunotherapy outcomes in patients with advanced urothelial carcinoma.,"Sojin Kim , Shinkyo Yoon , Inkeun Park , Jae Lyun Lee , Hyehyun Jeong , Kyung Won Kim , Sun Young Kim","Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine"
642,J27,Implementing Indiana regimen salvage high-dose chemotherapy in relapsed germ cell tumors in Slovakia.,"Michal Chovanec , Zuzana Rusinakova , Miriam Ladicka , Jana Obertova , Patrik Palacka , Katarina Rejlekova , Zuzana Sycova-Mila , Zuzana Orszaghova , Peter Lesko , Jozef Mardiak , Andrej Vranovsky , Michal Mego , Lubos Drgona","Department of Oncology, Comenius University and National Cancer Institute, National Cancer Institute, 2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, Klenová 1, Oncology, Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, 2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Department of Oncohematology, Faculty of Medicine, Comenius University and National Cancer Institute"
643,J28,Association between post-orchiectomy systemic inflammatory indexes and tumor characteristics in clinical stage I germ cell tumours.,"Peter Lesko , Michal Mego","Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, National Cancer Institute"
35,A13,A prospective provincial registry of PSMA PET CT for recurrent prostate cancer (PREP): Results for 4135 men.,"Glenn Bauman , Mohammed Rashid , Deanna Langer , Pamela MacCrostie , Bo Green , Victor Mak , Girish Kulkarni , Bobby Shayegan , Laurence Klotz , Stephen Pautler , Antonio Finelli , Marlon Hagerty , William Luke , Andres Kohan , Vivian Tan , Luke Lavallee , Katherine Zukotynski , Joseph Chin , Ur Metser","Department of Oncology, Western University, Clinical Institutes and Quality Programs, Ontario Health (Cancer Care Ontario), Princess Margaret Cancer Center, University Health Network, Department of Surgery, McMaster University, Department of Surgery, University of Toronto, Division of Urology, Department of Surgery, Western University, Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Department of Radiation Oncology, Thunder Bay Regional Health Sciences Centre, Division of Urology, Department of Surgery, University of Western Ontario, Department of Medical Imaging, University of Toronto, Department of Urology, University of Ottawa, McMaster University, Department of Radiology, Division of Urology, London Health Sciences Centre"
844,H8,Use of urinary cell-free DNA methylation assay to identify tumor fraction for early detection and recurrence monitoring in urothelial carcinoma.,"Huan Zhao , Hang Dong , Haoran Tang , Zhihui Zhang , Na Wei , Jingjing Xu , Pan Du , Shidong Jia , Ting Xiao , Huiqin Guo","Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Huidu Shanghai Medical Sciences, Ltd., Huidu (Shanghai) Medical Sciences, Ltd., Department of Pathology, The First Affiliated Hospital of Zhengzhou University"
846,H10,Use of urinary cell-free DNA fragmentomics in urothelial carcinoma diagnosis.,"Huan Zhao , Shuang Gan , Hang Dong , Haoran Tang , Zhihui Zhang , Na Wei , Jingjing Xu , Pan Du , Shidong Jia , Ting Xiao , Huiqin Guo","Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Huidu Shanghai Medical Sciences, Ltd., Huidu (Shanghai) Medical Sciences, Ltd., Department of Pathology, The First Affiliated Hospital of Zhengzhou University"
260,H1,"Assessing the impact of PTEN loss on outcomes in high-/very high-risk, advanced hormone-sensitive prostate cancer patients: Institutional retrospective study.","Tamara Jamaspishvili , Palak Patel , Mackenzie Bennett , Jonathan Bearden , Amber Bixby , Devashish Desai , Michel Nasr , Gennady Bratslavsky , Hanan Goldberg , Alina Basnet","Department of Pathology, SUNY Upstate Medical University, SUNY Upstate Medical University, Department of Urology, SUNY Upstate Medical University, Department of Urology, SUNY Upstate, Department of Hematology/Oncology, SUNY Upstate Medical University"
148,D22,Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancer.,"Catharina Op't Hoog , Niven Mehra , Anouk van Kleef , Diederik Somford , Inge van Oort , Alex Imholz , Paul Hamberg , Nielka Van Erp , Emmy Boerrigter","Department of Pharmacy, Radboud University Medical Center, Radboud University Medical Center, Department of Urology, Canisius Wilhelmina Hospital, Department of Medical Oncology, Deventer Ziekenhuis, Department of Medical Oncology, Franciscus Gasthuis & Vlietland"
507,F5,Multimodal management of oligometastatic and oligoprogressive renal cancer patients with extra-lung metastases: The KAIROS study.,"Alessandra Dimino , Mimma Rizzo , Ivan Fazio , Carmelo Carlo Arcara , Gianluca Mortellaro , Lorenzo Antonuzzo , Vincenza Conteduca , Helga Lipari , Antonella Mazzonello , Mikol Modesti , Giuseppe Badalamenti , Grazia Sirgiovanni , Sara Inguglia , Laura Algeri , Tancredi Didier Bazan Russo , Sergio Bracarda , Camillo Porta , Antonio Russo , Lorena Incorvaia","Department of Precision Medicine in Medical, Surgical, and Critical Care (Me.Pre.C.C.), University of Palermo, Division of Medical Oncology, Policlinico di Bari, Radiation Therapy Unit, Clinica Macchiarella, Medical Oncology Unit, La Maddalena Hospital, Radiation Oncology, ARNAS Civico Hospital, Clinical Oncology Unit, Careggi University Hospital - Department of Experimental and Clinical Medicine, University of Florence, Unit of Medical Oncology and Biomolecular Therapy, Department of Medical and Surgical Sciences, University of Foggia, Policlinico Riuniti, Azienda Ospedaliera Cannizzaro, Department of Experimental and Clinical Medicine, University of Florence, Department of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo, Medical and Translational Oncology, Azienda Ospedaliera Santa Maria Terni, Department of Precision Medicine in Medical, Surgical and Critical Care, University of Palermo, Medical and Translational Oncology Unit, Department of Oncology, Azienda Ospedaliera Santa Maria di Terni, Chair of Oncology, Department of Biomedical Sciences and Human Oncology, University of Bari 'A. Moro'; Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari"
348,J12,Natural history and risk-stratification of biochemical recurrence in prostate cancer treated with definitive radiotherapy.,"Paul Riviere , Kylie Morgan , Tyler Nelson , Daniel Sabater Minarim , Leah Deshler , Matthew Banegas , Tyler Stewart , Rana McKay , Juan Javier-Desloges , Kellogg Parsons , Brent Rose","Department of Radiation Medicine and Applied Sciences, University of California, San Diego, University of California, San Diego Health, VA San Diego Health Care System, Center for Health Equity Education and Research, UCSD Health, CHEER, University of California, San Diego Health, University of California, San Diego, Department of Medicine, University of California San Diego, Department of Urology, University of California, San Diego, University of Michigan"
427,L23,Automated classification of treatment state of patients with prostate cancer from structured medical record data to help enhance care.,"Richard Boyajian , Ashleigh Kowtoniuk , Sharon Hensley Alford , Tarun Kumar , Shilpa Mahatma , Pravin Solankar , Shrey Kumar , Paul Nguyen","Department of Radiation Oncology, Brigham and Women's Hospital, Brigham and Women's Hospital, Cancer Insights"
153,D27,Impact of geographic and demographic characteristics on treatment with Lu-PSMA for metastatic castrate-resistant prostate cancer (mCRPC).,"Abigail Pepin , Abigail Doucette , Samuel Takvorian , Vivek Narayan , Sophia O'Brien , David Mankoff , Philipose Mulugeta , Daniel Pryma , Neil Taunk","Department of Radiation Oncology, Hospital of University of Pennsylvania, Abramson Cancer Center, Penn Medicine, Abramson Cancer Center and Perelman School of Medicine, Abramson Cancer Center, University of Pennsylvania, Perelman School of Medicine at the University of Pennsylvania, Abramson Cancer Center, Hospital of University of Pennsylvania, Department of Radiation Oncology, University of Pennsylvania"
737,D34,Bayesian re-analysis: Comparing radical cystectomy with trimodality therapy in patients with muscle invasive bladder cancer.,"Abigail Pepin , Ronac Mamtani , John Christodouleas , Daniel Lee","Department of Radiation Oncology, Hospital of University of Pennsylvania, Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania, University of Pennsylvania"
129,D3,Safety evaluation of stereotactic body radiation therapy (SBRT) during lutetium-177-PSMA-617 (177Lu-PSMA-617) treatment for patients with metastatic prostate cancer.,"Adam Kessel , Miguel Muniz , Jamie O'Byrne , Ryan Phillips , Sean Park , Brian Davis , Brad Stish , Chunhee Choo , Kenneth Merrell , Eugene Kwon , Geoffrey Johnson , Fernando Quevedo , Jacob Orme , Daniel Childs , Jessica Wilson","Department of Radiation Oncology, Mayo Clinic in Rochester, Department of Medical Oncology, Mayo Clinic in Rochester, Mayo Clinic in Rochester, Department of Nuclear Medicine, Mayo Clinic in Rochester, Department of Radiation Oncology, Mayo Clinic"
425,L21,RadOnc-GPT (gpt-4o) versus human data extraction for prostate cancer clinical research.,"Mohammad Javad Namazi , Mariana Borras Osorio , Jason Holmes , David Routman , Daniel Ebner , Peilong Wang , Wei Liu , Mark Waddle","Department of Radiation Oncology, Mayo Clinic in Rochester, Department of Radiation Oncology, Mayo Clinic in Arizona, Department of Pediatric and Adolescent Medicine, Mayo Clinic in Rochester"
424,L20,PSA dynamics: Enhancing predictive models in prostate cancer follow-up.,"Lydia Ekama , Mariana Borras Osorio , Mohammad Javad Namazi , Aaron Bogan , Bryce Comstock , Benjamin Kamdem Talom , Taylor Weiskittel , Dalton Griner , Brian Davis , Brad Stish , Chunhee Choo , Ryan Phillips , Thomas Pisansky , Daniel Ebner , David Routman , Mark Waddle","Department of Radiation Oncology, Mayo Clinic in Rochester, Quantitative Health Science Research, Mayo Clinic in Arizona, Mayo Clinic College of Medicine and Science, Mayo Clinic, Department of Radiation Oncology, Mayo Clinic"
24,A2,National cancer system characteristics and prostate cancer outcomes: A global analysis.,"Edward Christopher Dee , Ranvir Iyengar , Aditya Narayan , Erin Jay Feliciano , Himanshu Nagar , Brandon Mahal , Paul Nguyen","Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Stanford Medicine, Department of Medicine, NYC Health + Hospitals/Elmhurst, Icahn School of Medicine at Mount Sinai, University of Miami Miller School of Medicine, Brigham and Women's Hospital"
557,G24,A phase II clinical study of camrelizumab plus apatinib in combination with stereotactic body radiotherapy (SBRT) for advanced non-clear cell renal cell carcinoma (nccRCC).,"Xinyue Zhang , Ruiqi Liu , Yang Liu , Wensu Wei , Zhiling Zhang , Jianming Gao , Shengjie Guo , Hui Han , Fangjian Zhou , Pei Dong , Liru He","Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Department of Urology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Department of Urology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Urology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Department of Urology Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer"
375,K5,PORTOS gene signature as a predictor of risk of adverse events after dose-escalated vs. lower-dose prostate radiation therapy in NRG/RTOG 0126.,"Karen Hoffman , Sophia Kamran , Hyunnam Ryu , James Proudfoot , Elai Davicioni , Paul Nguyen , Stephanie Pugh , Daniel Spratt , Jeff Michalski , Matthew Parliament , Ian Dayes , Rohann Correa , John Robertson , Elizabeth Gore , Desiree Doncals , Eric Vigneault , Luis Souhami , Felix Feng , Phuoc Tran , Shuang Zhao","Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Massachusetts General Hospital, Harvard Medical School, Veracyte, Inc., Brigham and Women's Hospital, NRG Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Washington University School of Medicine in St. Louis, University of Alberta, Juravinski Cancer Centre, London Health Sciences Centre, Beaumont CCOP, Milwaukee VAMC and the Medical College of Wisconsin, Summa Health Medical Group, CHU de Quebec, McGill University Health Centre, Radiology School of Medicine, University of California, San Francisco, University of Maryland, University of Wisconsin Carbone Cancer Center"
15,,World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): An analysis from the X-MET collaboration.,"Chad Tang , Alexander Sherry , Hyunsoo Hwang , Giulio Francolini , Lorenzo Livi , Phuoc Tran , Paul Corn , Ana Aparicio , Gabriele Simontacchi , Ana Kiess , Jarey Wang , Valerie Fonteyne , Renée Bultijnck , Robert Olson , Stephen Harrow , Ethan Ludmir , Pierre Blanchard , Ryan Sun , David Palma , Piet Ost","Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Azienda Ospedaliero Universitaria Careggi, University of Florence, University of Maryland, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Ghent University, British Columbia Cancer Agency, Edinburgh Cancer Centre, Western General Hospital, Gustave Roussy Cancer Centre, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Department of Radiation Oncology, London Regional Cancer Center"
254,G27,The prognostic impact of prostate-specific antigen at 6 months after post-prostatectomy radiotherapy: An individual patient data analysis of two NRG oncology randomized trials.,"Osama Mohamad , David Swanson , Alan Pollack , Himanshu Lukka , Alan Dal Pra , Ian Dayes , Andre-Guy Martin , Michael Greenberg , Alexander Balogh , Jeff Michalski , Peter Vavassis , Adam Currey , Robert Dess , Jason Efstathiou , Nirav Kapadia , Samir Patel , Belal Ahmad , Howard Sandler , Stephanie Pugh , Paul Nguyen","Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, University of Miami Health System, McMaster University, University of Miami, Juravinski Cancer Centre, CHU de Quebec, Université Laval, Thomas Jefferson University Hospital, Tom Baker Cancer Centre, Washington University School of Medicine in St. Louis, Hôpital Maisonneuve-Rosemont de Montréal, Medical College of Wisconsin, Michigan Medicine, Massachusetts General Hospital, Dartmouth-Hitchcock Medical Center, Cross Cancer Institute, London Regional Cancer Program, Cedars-Sinai Medical Center, NRG Oncology, Brigham and Women's Hospital"
385,K15,Hypofractionated radiotherapy for prostate cancer (HYDRA): An individual patient data meta-analysis of randomized trials in the MARCAP consortium.,"Amar Kishan , Yilun Sun , David Dearnaley , Emma Hall , Alison Tree , Charles Catton , Himanshu Lukka , William Lee , Howard Sandler , Luca Incrocci , Wilma Heemsbergen , Jessica Wong , Eric Horwitz , Karen Hoffman , Comron Hassanzadeh , Deborah Kuban , Giuseppe Sanguineti , Stefano Arcangeli , John Nikitas , Daniel Spratt","Department of Radiation Oncology, University of California, Los Angeles, Department of Population Quantitative Health Sciences, Case Western Reserve University School of Medicine, The Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, Clinical Trials and Statistics Unit, The Royal Marsden Hospital NHS Foundation Trust, Radiation Oncology Department, Princess Margaret Cancer Centre, McMaster University, Duke University School of Medicine, Cedars-Sinai Medical Center, Erasmus MC Cancer Institute, Erasmus University Medical Center, Fox Chase Cancer Center, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Regina Elena Institute-Istituti Fisioterapici Ospitalieri (IRE-IFO), University of Milano-Bicocca, University of California, Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University"
64,B10,Comparing progression following systemic and tumor-directed therapy for de novo versus recurrent PSMA PET–defined oligo-M1 prostate cancer: A pooled analysis of SOLAR and SATURN clinical trials.,"Jesus Juarez Casillas , John Nikitas , Matthew Rettig , Robert Reiter , Alan Lee , Michael Steinberg , Luca Valle , Tahmineh Romero , Jeremie Calais , Johannes Czernin , Sonny Tsai , Nathanael Kane , Abhishek Solanki , Rachael Sexton , Sai Duriseti , Gholam Berenji , William Aronson , Isla Garraway , Nicholas Nickols , Amar Kishan","Department of Radiation Oncology, University of California, Los Angeles, VA Greater Los Angeles Healthcare System, Department of Urology, University of California, Los Angeles, Department of Medicine Statistics Core, University of California, Los Angeles, Ahmanson Translational Theranostics Division, University of California, Los Angeles, Loyola University Chicago, Cancer Research and Biostatistics, University of California, Los Angeles"
413,L9,Improving prostate cancer risk stratification using spatial single-cell tumor profiling.,"William Chen , Mikhail Dias , Chien-Kuang Ding , Stefanie Engler , Sophie Déglise , Aishwarya Subramanian , Haolong Li , Andrea Jacobs , Martin Sjöström , Jonathan Chou , Julian Hong , Shuang Zhao , Jeffry Simko , Eric Small , Alan Ashworth , David Quigley , Peter Carroll , Matthew Cooperberg , Bernd Bodenmiller , Felix Feng","Department of Radiation Oncology, University of California, San Francisco, University of California, San Francisco, University of Zurich, Fred Hutchinson Cancer Center, University of Wisconsin Carbone Cancer Center, University of California San Francisco"
105,C15,Patterns of next-generation sequencing and associated next-line systemic therapy use in metastatic prostate cancer.,"Julia Shi , Changchuan Jiang , Hamid Ghaderi , James Yu , Daniel Yang","Department of Radiation Oncology, UT Southwestern Medical Center, UT Southwestern Medical Center, Section of Medical Oncology, Department of Internal Medicine, Yale School of Medicine"
384,K14,Evaluation of post radiotherapy PSA as a prognostic and predictive biomarker in high risk prostate cancer: A secondary analysis of RTOG 0521.,"Paul Koffer , Christina Raker , Thomas DiPetrillo , Benedito Carneiro , Anthony Mega , Howard Sandler , George Rodrigues , Amit Shah , Jason Efstathiou , Susan Chafe , Alexander Balogh , Scott Williams , Deborah Kuban , Elizabeth Gore , Jessica Wong , Marie Duclos , Paul Nguyen , Felix Feng","Department of Radiation Oncology, Warren Alpert Medical School of Brown University, Brown University Health, Department of Medical Oncology, Warren Alpert Medical School of Brown University, Cedars-Sinai Medical Center, Verspeeten Family Cancer Centre, London Health Sciences Centre, Wellspan Health, York Cancer Center, Massachusetts General Hospital/Mass General Brigham and Women's Hospital, Cross Cancer Institute, Tom Baker Cancer Centre, Peter MacCallum Cancer Centre, The University of Texas MD Anderson Cancer Center, Milwaukee VAMC and the Medical College of Wisconsin, Fox Chase Cancer Center, Cedars Cancer Centre, McGill University Health Centre, Brigham and Women's Hospital, UCSF Medical Center- Mission Bay"
40,A18,PSMA PET vs. pelvic MRI in biochemically recurrent prostate cancer.,"Ida Sonni , Vishnu Murthy , Raj Mehta , Alex Chung , Lena Unterrainer , Masatoshi Hotta , Andrea Farolfi , Cecil Benitez , Wesley Armstrong , Sahith Doddipalli , Anishka Bandara , Luca Valle , Amar Kishan , Matthias Benz , Steven Raman","Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, University of California, Los Angeles, Ahmanson Translational Theranostics Division, University of California, Los Angeles, Department of Radiological Sciences, University of California, Los Angeles, Department of Radiation Oncology, University of California, Los Angeles"
175,E14,Assessing the clinical impact of tumor volume on response to 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer.,"Yalda Nikanpour , Mohamed Ahmed , Carter Day , Mindie Mahon , Rimki Haloi , Zeina Wael , Eugene Kwon , Jack Andrews","Department of Radiology, Mayo Clinic in Rochester, Department of Urology, Mayo Clinic in Rochester, Mayo Clinic in Rochester, Mayo Clinic in Arizona"
17,,"Overall survival and quality of life with [177Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901).","Louise Emmett , Shalini Subramaniam , Megan Crumbaker , Andrew Nguyen , Anthony Joshua , Andrew Weickhardt , Sze Ting Lee , Siobhan Ng , Roslyn Francis , Jeffrey Goh , David Pattison , Thean Tan , Ian Kirkwood , Shahneen Sandhu , Alison Zhang , Michael Hofman , Hayley Thomas , Andrew Martin , Ian Davis , Martin Stockler","Department of Theranostics and Nuclear Medicine, St Vincent's Hospital; Faculty of Medicine, UNSW, NHMRC Clinical Trials Centre, University of Sydney, Department of Medical Oncology, The Kinghorn Cancer Centre, St Vincent’s Hospital, Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Department of Medical Oncology, Kinghorn Cancer Centre, St Vincent’s Hospital, Olivia Newton John Cancer Wellness & Research Centre, Austin Health, Department of Molecular Imaging and Therapy, Austin Health, Department of Oncology, Sir Charles Gairdner Hospital and University of Western Australia, Department Nuclear Medicine, Sir Charles Gairdner Hospital, Department of Oncology, Cancer Care Services, Royal Brisbane and Women’s Hospital, Department of Nuclear Medicine & Specialised PET Services, Royal Brisbane and Women’s Hospital, Department of Medical Oncology, Royal Adelaide Hospital, Nuclear Medicine, PET and Bone Densitometry, Royal Adelaide Hospital, Sir Peter MacCallum Department of Oncology, The University of Melbourne, Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, The University of Queensland, Monash University Eastern Health Clinical School, NHMRC Clinical Trials Centre, The University of Sydney"
717,D14,"Global real-world patients characteristics, treatment patterns, and impact of BCG shortage in patients with high-risk non-muscle invasive bladder cancer.","Jens Bedke , Anthony Eccleston , Julia Brinkmann , Jane Chang , Abin Koshy , Neil Milloy , Laure Manuel , Jacob Skilling , Emilia Biondi , Elliott Brown , Gary Steinberg , Oscar Rodriguez Faba , Yohann Loriot , Paolo Gontero , Yair Lotan","Department of Urology & Eva Mayr-Stihl Cancer Center, Pfizer Ltd, Pfizer Pharma GmbH, Pfizer Inc., Adelphi Real World, Department of Urology, Rush University, Fundació Puigvert, Universitat Autònoma de Barcelona, Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, Dipartimento di Discipline Medico Chirurgiche, Clinica Urologica, University of Torino, Department of Urology, UT Southwestern Medical Center"
214,F18,The prognostic significance of circulating tumor DNA in prostate cancer: A systematic review and meta-analysis.,Haolin Liu,"Department of Urology and Institute of Urology, West China Hospital, Sichuan University"
521,F19,Global and regional burden of kidney cancer: Analysis and future predictions based on GBD data from 1990 to 2021.,"Haochen Zhao , Qiang Wei","Department of Urology and Institute of Urology, West China Hospital, Sichuan University"
TPS616,K17,VORSIN-RCC: Vorolanib plus sintilimab for advanced renal cell carcinoma after failure of prior immune checkpoint inhibitors-based combination therapy.,"Yu Shen , Xingming Zhang , Xinyuan Wei , Jiayu Liang , Guangxi Sun , Junjie Zhao , Haoyang Liu , Junru Chen , Xu Hu , Yuntian Chen , Jin Yao , Ni Chen , Ling Nie , Peng Zhang , Xiang Li , Qiang Wei , Pengfei Shen , Jiyan Liu , Zhenhua Liu , Hao Zeng","Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Department of Radiology, West China Hospital, Sichuan University, Department of Pathology, West China Hospital, Sichuan University, Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University"
544,G11,"Cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) combined with axitinib for the first-line treatment of advanced or metastatic non-clear renal cell carcinoma: A prospective, single-arm, phase Ib/II study.","Xu Hu , Fengnian Zhao , Yuntian Chen , Junjie Zhao , Yifu Shi , Yanfeng Tang , Yongquan Wang , Xingming Zhang , Jiayu Liang , Jinge Zhao , Junru Chen , Qiang Wei , Xiang Li , Jiyan Liu , Ni Chen , Pengfei Shen , Jin Yao , Guangxi Sun , Zhenhua Liu , Hao Zeng","Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Department of Radiology, West China Hospital, Sichuan University, Department of Urology, Southwest Hospital, Army Medical University, Chongqing, Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Department of Pathology, West China Hospital, Sichuan University"
6,D5,Risk factors of complications after inguinal lymph node dissection in patients with penile cancer.,"Yilong Gao , Yanxiang Shao , Xiang Li","Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Department of Urology, West China Hospital, Sichuan University"
841,H5,Pathological subclassification of T3 upper tract urothelial carcinoma: Complementary evidence for existing guidelines.,"Lei Zheng , Jianjun Ye , Qihao Wang , Qiang Wei , Yige Bao","Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Department of Urology, West China Hospital, Sichuan University, Department of Urology and Institute of Urology, West China Hospital,  Sichuan University"
794,F21,Comprehensive modalities of kidney-sparing treatment in a carefully selected cohort of localized high-risk upper tract urothelial carcinoma: A potential paradigm shift.,"Zeyu Chen , Jianjun Ye , Xiang Tu , Xinyang Liao , Qihao Wang , Lei Zheng , Kai Chen , Qiang Wei , Yige Bao","Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Department of Urology, West China Hospital, Sichuan University, Department of Urology and Institute of Urology, West China Hospital,  Sichuan University"
729,D26,Survival impact of concomitant squamous differentiation in upper tract urothelial carcinoma patients receiving adjuvant chemotherapy.,"Jianjun Ye , Xinyang Liao , Shiyu Zhang , Qiang Wei , Yige Bao","Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Department of Urology, West China Hospital, Sichuan University, West China Hospital, Sichuan University"
500,E33,Safety and efficacy of immune checkpoint inhibitor rechallenge in metastatic fumarate hydratase-deficient renal cell carcinoma: A retrospective study.,"Yanfeng Tang , Minghao Wang , Jiayu Liang , Hao Zeng","Department of Urology and Institute of Urology, West China Hospital, Sichuan University, West China Hospital of Sichuan University"
333,H33,Interpretable machine learning for prostate biopsy: Cohort study.,"Jindong Dai , Jinge Zhao , Pengfei Shen , Hao Zeng","Department of Urology and Institute of Urology, West China Hospital, Sichuan University, West China Hospital of Sichuan University"
78,B24,The prognostic significance of prostate-specific antigen dynamics during abiraterone therapy in patients with high-risk metastatic hormone-sensitive prostate cancer.,"Qian Wang , Hong Zeng , Jindong Dai , Qiyu Zhu , Jinge Zhao , Xingming Zhang , Hao Zeng , Pengfei Shen","Department of Urology and Institute of Urology, West China Hospital, Sichuan University, West China Hospital of Sichuan University"
191,E30,Genomic features of prostate cancer patients with and without ductal adenocarcinoma (DA) based on liquid biopsy.,"Qiyu Zhu , Jinge Zhao , Yifu Shi , Hao Zeng","Department of Urology and Institute of Urology, West China Hospital, Sichuan University, West China Hospital of Sichuan University"
550,G17,Efficacy of systemic treatments for advanced non-clear cell renal cell carcinoma: A single-arm systematic review and meta-analysis.,"Xinyuan Wei , Yu Shen , Jiayu Liang , Xingming Zhang , Junru Chen , Guangxi Sun , Xu Hu , Pengfei Shen , Hao Zeng , Zhenhua Liu , Jinge Zhao","Department of Urology and Institute of Urology, West China Hospital, Sichuan University, West China Hospital of Sichuan University"
404,K34,Phenotypic and genetically predicted leukocyte telomere length and prostate cancer risk: Results from a large-scale longitudinal cohort study.,"Xiaoyang Liu , Shengzhuo Liu , Xin Yan , Jing Zhou , Yunfei Yu , Qiang Dong","Department of Urology and Institute of Urology, West China Hospital, Sichuan University, West China Hospital, Sichuan University"
411,L7,The impact of neoadjuvant therapy on the formation of tertiary lymphatic structures and the distinct prognosis in prostate cancer.,"Shengzhuo Liu , Jing Zhou , Xin Yan , Yunfei Yu , Xiaoyang Liu , Qiang Dong","Department of Urology and Institute of Urology, West China Hospital, Sichuan University, West China Hospital, Sichuan University"
839,H3,Discordance in HER2 expression in primary and recurrent/metastatic lesions of upper tract urothelial carcinoma: A study focusing on temporal heterogeneity.,"Jianjun Ye , Xinyang Liao , Qihao Wang , Lei Zheng , Kai Chen , Qiang Wei , Yige Bao","Department of Urology and Institute of Urology, West China Hospital, Sichuan University, West China Hospital, Sichuan University, Department of Urology and Institute of Urology, West China Hospital,  Sichuan University"
791,F18,Kidney-sparing approach for selected localized high-risk upper tract urothelial carcinoma: A pilot study combining endoscopic thulium laser ablation with perioperative disitamab vedotin and immune checkpoint inhibitors.,"Jianjun Ye , Zeyu Chen , Xinyang Liao , Xiang Tu , Qihao Wang , Lei Zheng , Kai Chen , Qiang Wei , Yige Bao","Department of Urology and Institute of Urology, West China Hospital, Sichuan University, West China Hospital, Sichuan University, Department of Urology and Institute of Urology, West China Hospital,  Sichuan University"
390,K20,Evaluating the efficacy and safety of pelvic lymph node dissection in high-risk prostate cancer patients undergoing radical prostatectomy: A systematic review and meta-analysis.,"Qihao Wang , Jianjun Ye , Lei Zheng , Kai Chen , Qiang Wei , Yige Bao","Department of Urology and Institute of Urology, West China Hospital, Sichuan University, West China Hospital, West China Hospital, Sichuan University, Department of Urology and Institute of Urology, West China Hospital,  Sichuan University"
827,G23,NECTIN4 RNA expression and clinical outcomes with first-line (1L) platinum-based chemotherapy (PBC) and avelumab 1L maintenance in locally advanced or metastatic urothelial carcinoma (la/mUC): Exploratory analyses from JAVELIN Bladder 100.,"Niklas Klümper , Markus Eckstein , Petros Grivas , Enrique Grande , Johannes Brägelmann , Jason Hoffman , Parantu Shah , Olga Bogatyrova , Viktor Grünwald","Department of Urology and Paediatric Urology, University Hospital, Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, University of Washington and Fred Hutchinson Cancer Center, Department of Medical Oncology, MD Anderson Cancer Center Madrid, University of Cologne and University Hospital Cologne, EMD Serono, Inc., EMD Serono R&D Inc., The Healthcare Business of Merck KGaA, Essen University Hospital"
465,D33,"First preliminary results of artificial intelligence-generated, explainable treatment recommendations for renal cell cancer based on multidisciplinary cancer conferences.","Gregor Duwe , Dominique Mercier , Verena Kauth , Kerstin Moench , Markus Junker , Andreas Dengel , Axel Haferkamp , Thomas Höfner","Department of Urology and Pediatric Urology Johannes Gutenberg University Medical Center Mainz, German Research Center For Artificial Intelligence, Smart Data & Knowledge Services, Department of Urology and Pediatric Urology, University Medical Center of the Johannes Gutenberg-University Mainz, Ordensklinikum Linz Elisabethinen, Department of Urology"
645,J30,Development of an miRNA signature for individual prognostic assessment in seminoma patients.,"Julia Heinzelbecker , Farzaneh Zohari , Lea Eckhart , Hiresh Ayoubyan , Hans-Peter Lenhof , Rainer Bohle , Felix Bremmer , Fabian Gayer , Yue Che , Peter Albers , Michael Stöckle , Kerstin Junker","Department of Urology and Pediatric Urology, Saarland University Medical Center and Saarland University, Department of Urology and Pediatric Urology, Saarland University, Center for Bioinformatics, Saarland Informatics Campus, Saarland University, Institute of Pathology, Saarland University Medical Center and Saarland University, Institute of Pathology, University Medical Center Göttingen, Department of Urology, University Medical Center Göttingen, Department of Urology, University Hospital of Duesseldorf"
706,D3,Real-world effectiveness and safety of avelumab first-line maintenance (1LM) treatment in patients with locally advanced or metastatic urothelial carcinoma (la/mUC): Second interim analysis of the AVENUE study.,"Peter Goebell , Alexander Sultanbaev , Anna Brachtel , Aurea Molina , David Lorente , Deborah Zihler , Lusha Wang , Lenka Kostkova , Jason Hoffman , Laura Cremer , Juergen Gschwend","Department of Urology and Pediatric Urology, University Hospital Erlangen, Department of Chemotherapy, Republican Clinical Oncology Dispensary, Department of Urology, Vincent Hospital Hannover, Department of Medical Oncology, University Hospital of A Coruña, Department of Medical Oncology, Insituto Valenciano de Oncología, Department of Medical Oncology, Hematology, and Transfusion Medicine, Cantonal Hospital Aarau, Merck Serono Co., Ltd., Beijing, China, an affiliate of Merck KGaA, The Healthcare Business of Merck KGaA, EMD Serono, Inc., Merck Healthcare Germany GmbH, Weiterstadt, Germany, an affiliate of Merck KgaA, Department of Urology, Technical University of Munich, School of Medicine, Klinikum rechts der Isar"
574,H9,Identification of potential immune evasion mechanisms in aggressive small renal cell carcinomas through single-cell and bulk RNA sequencing.,"Jee Soo Park , Eun Chae Kim , Seol Song , Jongchan Kim , Won Sik Jang , Byungjin Hwang , Won Sik Ham","Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Department of Biomedical Sciences, Brain Korea 21 Project for Medical Sciences, Yonsei University College of Medicine"
530,F28,Cadonilimab combined with lenvatinib for neoadjuvant therapy in early-stage renal cell carcinoma with indications for partial nephrectomy but high surgical risk: A prospective single-arm phase II clinical trial.,"Yulu Peng , Pei Dong , Hui Han , Fangjian Zhou , Zhiling Zhang","Department of Urology Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China, Department of Urology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Department of Urology Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China., Department of Urology, Sun Yat-sen University Cancer Center"
TPS613,K14,"A prospective, single-center, single-arm clinical study of adjuvant toripalimab combined with axitinib in non-clear renal cell carcinoma (nccRCC) patients with high-risk recurrence factors (IUNU-RC-102).","Guangxiang Liu , Shun Zhang , Haixiang Qin , Changwei Ji , Hongqian Guo","Department of Urology, Affiliated Drum Tower Hospital, Medical School of Nanjing University; Institute of Urology, Nanjing University, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School; Institute of Urology, Nanjing University, Nanjing Drum Tower Hospital, Department of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University; Institute of Urology, Nanjing University"
60,B6,Management of metastatic castration-resistant prostate cancer (mCRPC) at the Veterans Affairs Healthcare System (VAHCS): A real-world assessment of patient characteristics and treatment across lines of therapy.,"Renning Zheng , Jennifer Nguyen , Jeetvan Patel , Vamsi Bollu , Barinder Kang , Amanda De Hoedt , Joshua Parrish , Stirling Cummings , Stephen Freedland , Anthony Nguyen","Department of Urology, Cedars-Sinai Medical Center, Novartis Pharmaceuticals Corporation, Department of Surgery, Section of Urology, Durham VA Health Care System, Center for Integrated Research in Cancer and Lifestyle, Cedars-Sinai Cancer Institute, Department of Radiation Oncology, Cedars-Sinai Cancer Institute"
561,G28,PSMA-positive tumor vessels around renal cell carcinoma with high angiogenic potential as therapeutic targets and predictors of tumor recurrence.,"Ryuta Watanabe , Keito Kagimoto , Mami Chosei , Haruna Arai , Tomohisa Sakaue , Mie Kurata , Noriyoshi Miura , Riko Kitazawa , Tadahiko Kikugawa , Shigeki Higashiyama , Takashi Saika","Department of Urology, Ehime University Graduate School of Medicine, Department of Biochemistry and Molecular Genetics, Ehime University Graduate School of Medicine, Department of Cardiovascular and Thoracic Surgery, Ehime University Graduate School of Medicine, Department of Pathology, Ehime University Graduate School of Medicine and Ehime University Proteo-Science Center, Division of Diagnostic Pathology, Ehime University Hospital, Department of Oncogenesis and Growth Regulation, Osaka International Cancer Institute"
826,G22,"Mechanism of action and translation to the clinic of detalimogene voraplasmid (EG-70): A novel, investigational, non-viral immunotherapy for non-muscle-invasive bladder cancer (NMIBC).","Vikram Narayan , Yair Lotan , Marie-Line Goulet , Shauna Dauphinee , Daniel Veilleux , Kristine Louis , David Lazure , Sarah Stevenson , Darius Bilimoria , Fazmina Zamzameer , Ximin Chen , Sébastien Sublemontier , Sahar Amirkhani , Carlos Fleet , Raj Pruthi , Anthony Cheung , James Sullivan , Vignesh Packiam , Ashish Kamat","Department of Urology, Emory University School of Medicine, Department of Urology, UT Southwestern Medical Center, EnGene Inc., enGene, Inc., enGene Inc., Rutgers RWJ Barnabas Health, The University of Texas MD Anderson Cancer Center"
565,G32,The prognostic utility of preoperative β2 microglobulin in patients with renal cell carcinoma.,"Gregory Palmateer , Edouard Nicaise , Taylor Goodstein , Dattatraya Patil , Shreyas Joshi , Vikram Narayan , Kenneth Ogan , Viraj Master","Department of Urology, Emory University School of Medicine, Emory University School of Medicine"
600,H35,Concordance between clinical and pathologic staging of T2a–b and T3a renal cell carcinoma.,"Taylor Goodstein , Rajvi Goradia , Arnav Srivastava , Akshay Sood , Shawn Dason , Viraj Master , Eric Singer","Department of Urology, Emory University School of Medicine, The Ohio State University, Dow Division of Health Services Research, Department of Urology, University of Michigan, The Ohio State University Comprehensive Cancer Center, Emory University School of Medicine"
601,H36,Impact of upstaging from cT2a–b to pT3a on overall survival (OS) among patients with renal cell carcinoma.,"Taylor Goodstein , Rajvi Goradia , Arnav Srivastava , Akshay Sood , Shawn Dason , Viraj Master , Eric Singer","Department of Urology, Emory University School of Medicine, The Ohio State University, Dow Division of Health Services Research, Department of Urology, University of Michigan, The Ohio State University Comprehensive Cancer Center, Emory University School of Medicine"
TPS886,J14,A phase 1/2 study of detalimogene voraplasmid (EG-70) intravesical monotherapy for patients with high-risk non-muscle invasive bladder cancer (NMIBC).,"Shreyas Joshi , Sam Chang , Rian Dickstein , Gautam Jayram , Neal Shore , Jen-Jane Liu , Yair Lotan , Raj Satkunasivam , Anne Schuckman , Gary Steinberg , John Taylor , Tammy Linback , Raj Pruthi , James Sullivan , Christine Tosone , Ashish Kamat","Department of Urology, Emory University, Vanderbilt University Medical Center, University of Maryland, Urology Associates, Carolina Urologic Research Center, Oregon Health & Science University, Department of Urology, UT Southwestern Medical Center, Houston Methodist-Weill-Cornell Medical College, University of Southern California, Department of Urology, Rush University, University of Kansas Cancer Center, enGene Inc., EnGene Inc., The University of Texas MD Anderson Cancer Center"
701,C34,Real-world effectiveness and treatment (tx) patterns in patients (pts) with locally advanced/metastatic urothelial carcinoma (la/mUC) receiving avelumab first-line maintenance (1LM) in Japan: Results from the JAVEMACS chart review study.,"Hiroshi Kitamura , Takashi Kobayashi , Go Kimura , Masaomi Ikeda , Kan Yonemori , Norihiko Kawamura , Atsuko Fujihara , Takashige Abe , Fumitaka Shimizu , Kiyohide Fujimoto , Tohru Nakagawa , Shingo Hatakeyama , Kaoru Murakami , Kiyoaki Nishihara , Daiki Ikarashi , Naoya Masumori , Anzu Kambe , Michihiro Shono , Suguru Shirotake , Eiji Kikuchi","Department of Urology, Faculty of Medicine, University of Toyama, Department of Urology, Kyoto University Graduate School of Medicine, Department of Urology, Nippon Medical School Hospital, Department of Urology, Kitasato University School of Medicine, Department of Medical Oncology, National Cancer Center Hospital, Department of Urology, Osaka International Cancer Institute, Department of Urology, Kyoto Prefectural University of Medicine, Department of Renal and Genitourinary Surgery, Hokkaido University Graduate School of Medicine, Department of Urology, Juntendo University Graduate School of Medicine, Department of Urology, Nara Medical University, Department of Urology, Teikyo University School of Medicine, Department of Urology, Hirosaki University Graduate School of Medicine, Department of Urology, Kyoto University, Graduate School of Medicine, Department of Urology, Kurume University School of Medicine, Department of Urology, Iwate Medical University School of Medicine, Department of Urology, Sapporo Medical University School of Medicine, Medical Department, Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA, Department of Uro-Oncology, Saitama Medical University International Medical Center, Department of Urology, St Marianna University School of Medicine"
625,J10,Validation of new prognostic factors for relapse in patients with clinical stage I seminoma.,"Tim Nestler , Angelina Strauch , Justine Schoch , Hans Schmelz","Department of Urology, Federal Armed Services Hospital Koblenz, Department of Urology, Federal Armed Forces Hospital Koblenz"
334,H34,Influence of MRIs performed in a 6-week interval on the histopathological detection of prostate cancer with different PIRADS classifications: A real-world data analysis.,"Tim Nestler , Justine Schoch , Viola Düring , Michael Wiedmann , Daniel Overhoff , Daniel Dillinger , Stephan Waldeck , Hans Schmelz","Department of Urology, Federal Armed Services Hospital Koblenz, Department of Urology, Federal Armed Forces Hospital Koblenz, Institute of Diagnostic and Interventional Radiology, Federal Armed Forces Hospital Koblenz"
775,F2,"Preliminary efficacy and safety of disitamab vedotin (DV) combined with bacillus Calmette-Guérin (BCG) in the treatment of high-risk non-muscle invasive bladder cancer with HER2 expression: A prospective, open label, single-center study.","Yijun Shen , Liangju Peng , Weijie Gu , Xiaolin Lu , Ying Shen , Dingwei Ye","Department of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Fudan University Shanghai Cancer Center"
378,K8,Five-year changes in urinary function and prostate volume in patients with localized prostate cancer treated with carbon ion radiotherapy: A prospective study.,"Yoshiyuki Miyazawa , Hiroshi Nakayama , Hidemasa Kawamura , Yuhei Miyasaka , Masahiro Onishi , Takuya Kaminuma , Yoshitaka Sekine , Hiroshi Matsui , Tatsuya Ohno , Kazuhiro Suzuki","Department of Urology, Gunma University Graduate School of Medicine, Department of Urology, Isesaki Municipal Hospital, Department of Radiation Oncology, Gunma University, Department of Radiation Oncology, Gunma University Graduate School of Medicine"
395,K25,Cross resistance among novel androgen receptor axis-targeted agents in non-metastatic castration-resistant prostate cancer: A multi-institutional retrospective study.,"Naoki Fujita , Fumiya Yoneyama , Yohei Kawashima , Ryuma Tanaka , Takuya Oishi , Hikari Miura , Kazutaka Okita , Chikara Ohyama , Shingo Hatakeyama","Department of Urology, Hirosaki University Graduate School of Medicine, Ageo Central General Hospital, Department of Urology, Hirosaki University Graduate school of Medicine"
368,J32,Real-world treatment patterns and outcomes of novel androgen receptor axis-targeted agents in non-metastatic castration-resistant prostate cancer: A multi-institutional retrospective study.,"Naoki Fujita , Fumiya Yoneyama , Yohei Kawashima , Ryuma Tanaka , Takuya Oishi , Hikari Miura , Kazutaka Okita , Chikara Ohyama , Shingo Hatakeyama","Department of Urology, Hirosaki University Graduate School of Medicine, Ageo Central General Hospital, Department of Urology, Hirosaki University Graduate school of Medicine"
711,D8,Oncological benefit of avelumab maintenance therapy for advanced or metastatic urothelial carcinoma in comparison with patients with conventional chemotherapy alone era.,"Shingo Hatakeyama , Yuya Sekine , Masanao Shinohara , Kazuyuki Numakura , Takahiro Yoneyama , Yohei Kawashima , Satoshi Sato , Tomonori Habuchi , Chikara Ohyama","Department of Urology, Hirosaki University Graduate School of Medicine, Akita University, Ageo Central General Hospital, Department of Urology, Tsugaru General Hospital, Akita University School of Medicine"
760,E22,Impaired renal function and cisplatin-based regimens as risk factors for neoadjuvant chemotherapy-induced acute kidney injury in muscle-invasive bladder cancer: A multicenter retrospective study.,"Naoki Fujita , Shogo Hosogoe , Toshikazu Tanaka , Noritaka Ishii , Masaki Momota , Hiroyuki Ito , Takahiro Yoneyama , Chikara Ohyama , Shingo Hatakeyama","Department of Urology, Hirosaki University Graduate School of Medicine, Department of Urology, Aomori Prefectural Central Hospital, Department of Urology, Towada City Hospital, Department of Urology, Aomori Rosai Hospital, Department of Urology, Tsugaru General Hospital"
879,J7,Impact of perioperative acute kidney injury on future renal outcomes in patients who undergo radical cystectomy: A multi-institutional retrospective cohort study.,"Naoki Fujita , Shogo Hosogoe , Toshikazu Tanaka , Noritaka Ishii , Masaki Momota , Hiroyuki Ito , Takahiro Yoneyama , Chikara Ohyama , Shingo Hatakeyama","Department of Urology, Hirosaki University Graduate School of Medicine, Department of Urology, Aomori Prefectural Central Hospital, Department of Urology, Towada City Hospital, Department of Urology, Aomori Rosai Hospital, Department of Urology, Tsugaru General Hospital"
788,F15,Association between radiation therapy to the recurrence sites and oncological outcomes in patients who experienced local recurrence and/or pelvic lymph node metastases after radical cystectomy: A multicenter retrospective study.,"Naoki Fujita , Shogo Hosogoe , Toshikazu Tanaka , Noritaka Ishii , Masaki Momota , Hiroyuki Ito , Takahiro Yoneyama , Chikara Ohyama , Shingo Hatakeyama","Department of Urology, Hirosaki University Graduate School of Medicine, Department of Urology, Aomori Prefectural Central Hospital, Department of Urology, Towada City Hospital, Department of Urology, Aomori Rosai Hospital, Department of Urology, Tsugaru General Hospital"
873,J1,Platelet-to-lymphocyte ratio as a useful biomarker of recurrence and mortality risks in patients with muscle-invasive bladder cancer who achieved ypT0 to neoadjuvant chemotherapy: A multicenter retrospective study.,"Naoki Fujita , Shogo Hosogoe , Toshikazu Tanaka , Noritaka Ishii , Hiroyuki Ito , Takahiro Yoneyama , Chikara Ohyama , Shingo Hatakeyama","Department of Urology, Hirosaki University Graduate School of Medicine, Department of Urology, Aomori Prefectural Central Hospital, Department of Urology, Towada City Hospital, Department of Urology, Aomori Rosai Hospital, Department of Urology, Tsugaru General Hospital"
871,H35,Sarcopenia as a marker to assess the surveillance necessity after a 5-year cancer-free period in patients who undergo radical cystectomy: A multi-institutional retrospective study.,"Naoki Fujita , Toshikazu Tanaka , Shogo Hosogoe , Noritaka Ishii , Masaki Momota , Takahiro Yoneyama , Hiroyuki Ito , Chikara Ohyama , Shingo Hatakeyama","Department of Urology, Hirosaki University Graduate School of Medicine, Department of Urology, Towada City Hospital, Department of Urology, Aomori Prefectural Central Hospital, Department of Urology, Tsugaru General Hospital, Department of Urology, Aomori Rosai Hospital"
712,D9,Real-world analysis of the efficacy and safety of enfortumab vedotin in patients with locally advanced or metastatic urothelial carcinoma: A multicenter retrospective study.,"Shingo Hatakeyama , Kai Ozaki , Hayato Yamamoto , Yuya Sekine , Kanami Mori , Mizuki Kobayashi , Kazuyuki Numakura , Takahiro Yoneyama , Satoshi Sato , Tomonori Habuchi , Chikara Ohyama","Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki Univ., Hirosaki University Graduate School of Medicine, Akita University, Department of Urology, Akita University Graduate School of Medicine, Department of Urology, Tsugaru General Hospital, Ageo Central General Hospital, Akita University School of Medicine"
482,E15,External validation of previously reported prognostic classifications for patients treated with second-line axitinib after immuno-oncology combination therapy for advanced renal cell carcinoma: JUOG retrospective study.,"Yu Kujiraoka , Takahiro Osawa , Yuto Matsushita , Takahiro Kojima , Hiroaki Hara , Katsuyoshi Hashine , Hiroshi Kitamura , Hideaki Miyake , Nobuo Shinohara","Department of Urology, Hokkaido University Hospital, Hokkaido University, Department of Urology, Hamamatsu University School of Medicine, Department of Urology, Aichi Cancer Center, Department of Urology, Shinshu University School of Medicine, National Hospital Organization Shikoku Cancer Center, Department of Urology, University of Toyama, Kobe University School of Medicine, Department of Urology, Hokkaido University Graduate School of Medicine"
TPS901,J29,"CORE-008: A phase 2, multi-arm, multi-cohort, open-label study to evaluate intravesical cretostimogene grenadenorepvec in participants with high-risk non-muscle invasive bladder cancer.","Trinity Bivalacqua , Siamak Daneshmand , Neal Shore , Shreyas Joshi , Colin Dinney","Department of Urology, Hospitals of the University of Pennsylvania, Department of Urology, University of Southern California Norris Comprehensive Cancer Center, Carolina Urologic Research Center, Department of Urology, Emory University, The University of Texas MD Anderson Cancer Center"
692,C25,Avelumab maintenance therapy in patients (pts) with advanced urothelial carcinoma (UC) in Japan: Subgroup analyses by prior chemotherapy regimen from post-marketing surveillance (PMS).,"Masayoshi Nagata , Eiji Kikuchi , Taito Ito , Masashi Sato , Mie Ogi , Makiko Morita , Masahiro Kajita , Hiroyuki Nishiyama","Department of Urology, Juntendo University Graduate School of Medicine, Bunkyo-Ku, Department of Urology, St. Marianna University School of Medicine, Medical Department, Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA, Research & Development, Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA, Global Development Operations, Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA, Global Patient Safety Japan, Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA, Department of Urology, Faculty of Medicine, University of Tsukuba"
398,K28,Prognostic significance of tumor immune microenvironment dynamics in prostate cancer induced by androgen deprivation therapy.,"Yoshinori Yanai , Takeo Kosaka , Shuji Mikami , Masashi Arai , Yuto Baba , Keitaro Watanabe , Toshikazu Takeda , Kazuhiro Matsumoto , Makiko Yamashita , Shigehisa Kitano , Mototsugu Oya","Department of Urology, Keio University School of Medicine, Department of Diagnostic Pathology, Keio University School of Medicine, Deparment of Urology, Keio University School of Medicine, Department of Advanced Medical Development, The Cancer Institute Hospital of Japanese Foundation for Cancer Research (JFCR), Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR)"
700,C33,Evaluation of avelumab first-line (1L) maintenance therapy and subsequent treatment (tx) in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) using a large claims database in Japan: JAVEMACS-D.,"Takashi Kobayashi , Hiroshi Kitamura , Yuka Furukawa , Anzu Kambe , Michihiro Shono , Takayuki Ito , Eiji Kikuchi","Department of Urology, Kyoto University Graduate School of Medicine, Department of Urology, Faculty of Medicine, University of Toyama, Medical Solution Division, Ark Medical Solutions Inc., Medical Department, Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA, Department of Urology, St Marianna University School of Medicine"
854,H18,Impact of loss of PRLHR on aneuploidy and initiation of bladder cancer.,"Xi Zheng , Bingjie Yang , Wenya Wang , Anca Azoitei , Felix Wezel , Christian Bolenz , Hongqian Guo , Cagatay Günes","Department of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University; Institute of Urology, Nanjing University, Department of Ultrasound, Zhongda Hospital, Medical School, Southeast University, Department of Urology, Ulm University Hospital, Ulm University, Department of Urology, University of Ulm"
TPS292,M11,A prospective phase II study to evaluate olaparib plus abiraterone and prednisone combination therapy in metastatic hormone sensitive prostate cancer patients with HRR gene mutation: Updated analysis of PROact.,"Junlong Zhuang , Shun Zhang , Xuyu Zhang , Xuefeng Qiu , Xi Zheng , Jie Gao , Hongqian Guo","Department of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University; Institute of Urology, Nanjing University, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Department of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University; Department of Urology, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University"
763,E25,Phase Ib/II clinical trial of oncolytic virus intravesical irrigation for preventing recurrence after TURBT in patients with recurrent high-risk NMIBC.,"Youyan Guan , Xingang Bi , Hongzhe Shi , Binlei Liu , Honglei Cui , Tian Han , Jianzhong Shou","Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Binhui Biopharmaceutical Co., Ltd."
812,G8,Neoadjuvant combined chemotherapy and immunotherapy for upper tract urothelial carcinoma: Preliminary results from a phase II study.,"Xingang Bi , Wen Zhang , Yaoyu Xie , Zhequan Hu , Jie Wu , Honglei Cui , Chuanzhen Cao , Li Lu , Li Wen , Youyan Guan , Hongzhe Shi , Zhendong Xiao , Zhichao Jiang , Yongkun Sun , Shan Zheng , Jin Zhang , Jianzhong Shou , Aiping Zhou","Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Medical Oncology, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Panjiayuan Nanli 17# Chaoyang District, Department of Urology, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, China-Japan Friendship Hospital, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Cancer Center Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College"
852,H16,Protein analysis of urachal carcinoma tissue based on different antibody-drug conjugate therapeutic targets.,"Tian Han , Honglei Cui , Xingang Bi , Hongzhe Shi , Youyan Guan , Jianzhong Shou , Aiping Zhou","Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College"
787,F14,Safety and efficacy of intravesical bacillus Calmette-Guerin instillation for superficial recurrence following bladder-sparing therapy of muscle invasive bladder cancer.,"Gan Du , Rui-Yang Xie , Honglei Cui , Xingang Bi , Hongzhe Shi , Aiping Zhou , Youyan Guan , Jianzhong Shou","Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College"
563,G30,Prognostic value of preoperative fibrinogen in metastatic clear cell renal cell carcinoma patients undergoing cytoreductive nephrectomy: A propensity score-matched study.,"Jianzhong Shou , Honglei Cui , Xingang Bi , Youyan Guan , Hongzhe Shi , Aiping Zhou","Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College"
409,L5,Androgen receptor activity in biopsy specimens at initial diagnosis of prostate cancer and correlation with outcomes and treatment response.,"Nicole Handa , Mohammed Alshalalfa , Yangyang Hao , Hyunnam Ryu , James Proudfoot , Elai Davicioni , Matthew Cooperberg , Alejandro Berlin , Paul Nguyen , Daniel Spratt , Ridwan Alam , Ashley Ross , Edward Schaeffer","Department of Urology, Northwestern University, Feinberg School of Medicine, Veracyte, Inc., University of California, San Francisco, Cancer Digital Intelligence, Princess Margaret Cancer Centre, University Health Network, Dana-Farber Cancer Institute, Harvard Medical School, University Hospitals Seidman Cancer Center, Case Western Reserve University, Northwestern University Feinberg School of Medicine, Department of Urology, Northwestern University Feinberg School of Medicine"
534,F32,Belzutifan monotherapy in Chinese patients (pts) with von Hippel-Lindau (VHL) disease–associated tumors: Results of LITESPARK-015 study.,"Jianhui Qiu , Jingcheng Zhou , Lin Cai , Wen Kong , Wei Xue , Jin Zhang , Pei Dong , Jie Liu , Wanyu Li , Nan Li , Girish S. Naik , Kan Gong","Department of Urology, Peking University First Hospital, Department of Urology, Peking University First Hospital; Institute of Urology, Peking University; Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, National Urological Cancer Center, Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Department of Urology Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China., MSD China, MSD, China, Merck & Co., Inc."
529,F27,Efficacy and safety of SABR with TKI and IO therapy in patients with mRCC.,"Kaiwei Yang , Mingwei Ma , Wei Yu , Zhisong He , Xianshu Gao","Department of Urology, Peking University First Hospital; The Institution of Urology, Peking University; Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center; National Urological Cancer Center, Peking University First Hospital, Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Department of radiotherapy, Peking University First Hospital"
542,G9,"Efficacy and safety of fruquintinib combined with serplulimab as 1st line treatment in metastatic or unresectable non-clear cell renal cell carcinoma (nccRCC): Updated results from a single-arm, multicentre clinical trial.","Jiwei Huang , Xiaoyi Hu , Hang Wang , Jianming Guo , Wei Xue","Department of Urology, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Department of Urology, Zhongshan Hospital, Fudan University, Zhongshan Hospital, Fudan University, Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine"
103,C13,Clinical features and prognostic value of CDK12 mutation in prostate cancer patients.,"Hanyang Tao , Baijun Dong","Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine"
784,F11,"Efficacy and safety of tislelizumab (T) combined with gemcitabine and cisplatin (GC) for patients with localized muscle-invasive bladder cancer (MIBC) after radical transurethral resection of bladder tumor/partial cystectomy: A prospective, phase II study.","Ming Cao , Dongdong Xiao , Wei Xue","Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine"
443,,"Lenvatinib plus tislelizumab as first-line therapy for advanced fumarate hydratase-deficient renal cell carcinoma: A single-center, single-arm, phase II study.","Wen Kong , Guangyu Wu , Yunze Xu Sr., Zaoyu Wang , Jin Zhang","Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Renji Hospital Shanghai Jiaotong University School of Medicine, Dept. of Radiology, Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Department of Pathology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University"
111,C21,Association of androgen deprivation therapy and acute kidney injury in patients with prostate cancer: A systematic review and meta-analysis.,"Gustavo Carvalhal , Iago Pires , Renan Sudo , Marília Gobbo , Nilson Filho","Department of Urology, São Lucas Hospital, Pontifical Catholic University of Rio Grande do Sul, Pontificia Universidade Católica do Rio Grande do Sul, Federal University of Grande Dourados, Pontifical Catholic University of Rio Grande do Sul"
179,E18,Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide (enza) monotherapy (mono): EMBARK post hoc analysis.,"Stephen Freedland , Ugo De Giorgi , Ronald Tutrone , Lawrence Karsh , Miguel Ramirez-Backhaus , Edward Uchio , Yiyun Tang , Ruslan Croitoru , Matt Rosales , Matko Kalac , Fong Wang , Neal Shore","Department of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles; Durham VA Medical Center, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Clinical Research, United Urology Group, AdventHealth Urology, Servicio de Urología, Fundación Instituto Valenciano de Oncologia, Department of Urology, University of California, Irvine Medical Center, Pfizer Inc., Astellas Pharma Inc., Carolina Urologic Research Center"
159,D33,Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide (enza) plus leuprolide (combo): EMBARK post hoc analysis.,"Stephen Freedland , Martin Gleave , Ugo De Giorgi , Antti Rannikko , Swetha Sridharan , Klaus Brasso , Henry Woo , Antonio Gómez Caamaño , Luke Nordquist , Yiyun Tang , Ruslan Croitoru , Matt Rosales , Matko Kalac , Olivier Peraud , Fong Wang , Neal Shore","Department of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles; Durham VA Medical Center, University of British Columbia, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Department of Urology and Research Program in Systems Oncology, University of Helsinki, Department of Radiation Oncology, Calvary Mater Newcastle Hospital, Copenhagen Prostate Cancer Center, Department of Urology, Center for Cancer and Organ Diseases, Copenhagen University Hospital – Rigshospitalet, SAN Prostate Centre, Sydney Adventist Hospital, Department of Radiation Oncology, Complejo Hospitalario Universitario de Santiago, XCancer/Urology Cancer Center, Pfizer Inc., Astellas Pharma Inc., Carolina Urologic Research Center"
197,E36,The significance of androgen receptor signaling pathway in mCRPC patients receiving olaparib monotherapy or combined treatment with abiraterone.,"Bin Yang , Li Ding , Baijun Dong , Wei Chen , Hanxu Guo , Chengqi Jin , Jing Xu , Wentao Luo , Shiyu Mao , Changcheng Guo , Bo Peng , Xudong Yao","Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Department of Urology, The First Affiliated hospital of Wenzhou Medical University, Department of Urology, School of Medicine, Anhui University of Science and Technology"
161,D35,"Updated results from a phase I/II study of CBP-1018, a bi-ligand–drug conjugate (Bi-XDC) as late line therapy for patients with metastatic castration resistant prostate cancer (mCRPC).","Kaiwen Li , Jianming Guo , Hongqian Guo , Qi Zhang , Hang Huang , Junyong Dai , Jimin Chen , Lu Yang , Xudong Yao , Robert Huang , Mo Xu , Jing Zhang , en-Tzu Tang , Yehui Shi , Hai Huang , Liyan Zhou","Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Zhongshan Hospital, Fudan University, Nanjing Drum Tower Hospital, Zhejiang Provincial People's Hospital, The First Affiliated Hospital of Wenzhou Medical University, Chongqing University Cancer Hospital (Chongqing Cancer Hospital), Second Hospital of Zhejiang Uni, Department of Urology, West China Hospital, Sichuan University, Shanghai Tenth People’s Hospital, Coherent Biopharma Co., Ltd., Tianjin Medical University Cancer Institute and Hospital, Sun Yat-sen Memorial Hospital, Sun Yat-sen University"
TPS277,L30,The effect of circadian rhythm–based medication timing adjustments on the efficacy and safety of novel hormonal therapy.,"Junliang Zhao , Diwei Zhao , Yuanwei Li , Xinyang Cai , Zhenyu Yang , Fangjian Zhou , Yonghong Li , Jun Wang","Department of Urology, Sun Yat-sen University Cancer Center"
TPS278,L31,Efficacy and safety of organoid-based drug sensitivity screening to guide the treatment of mCRPC patients progressed after first-line treatment.,"Diwei Zhao , Junliang Zhao , Yuanwei Li , Xinyang Cai , Zhenyu Yang , Meiting Chen , Liru He , Yang Liu , Fangjian Zhou , Yonghong Li , Jun Wang","Department of Urology, Sun Yat-sen University Cancer Center, Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer"
TPS307,M26,Circulating tumor DNA (ctDNA) monitoring in the assessment and prediction of the efficacy of PARP inhibitors (PARPi).,"Diwei Zhao , Junliang Zhao , Yuanwei Li , Xinyang Cai , Zhenyu Yang , Fangjian Zhou , Yonghong Li , Jun Wang","Department of Urology, Sun Yat-sen University Cancer Center, Sun Yat-sen University Cancer Center"
TPS894,J22,Formula-01: A phase Ⅱ study of disitamab vedotin (RC48) intravenous injection combined with BCG intravesical instillation in high-risk non-muscle invasive bladder cancer with HER2 high expression.,"Xingliang Tan , Yanjun Wang , Zhiming Wu , Wensu Wei , Qianghua Zhou , Chichen Zhang , Xinpei Deng , Runhao Zheng , Jiamin Zeng , Qiuhong Chen , Kai Yao","Department of Urology, Sun Yat-sen University Cancer Center, Sun Yat-sen University Cancer Center, Department of Urology Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China."
772,E34,"Impact of adjuvant intraarterial chemotherapy on survival for patients with stage IIIA-IIIB bladder urothelial carcinoma after radical cystectomy: An open-label, prospective, randomized clinical trial.","Zhaohui Zhou , Lijuan Jiang , Kai Yao , Xiangdong Li , Wei Chen , Bin Wang , Yanxia Shi , Zike Qin , Hui Han , Yunlin Ye , Fangjian Zhou , Zhuowei Liu","Department of Urology, Sun Yat-sen University Cancer Center, Sun Yat-sen University Cancer Center, Department of Urology, First Affiliated Hospital, Sun Yat-sen University, Department of Urology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Department of Urology Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China."
767,E29,PUNCH01: Interim results from a phase II study of intra‑arterial chemotherapy (IAC) combined with tislelizumab and bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer (HR NMIBC).,"Zongren Wang , Bin Huang , Cheng Luo , Yuxi Wu , Jiahao Lei , Lingwu Chen , Junxing Chen","Department of Urology, The First Affiliated Hospital, Sun Yat-sen University, Sun Yat-sen University"
466,D34,Comparative assessment of pre- and post-COVID-19 pandemic nephrectomy outcomes for renal cell carcinoma: Analysis of the ACS-NSQIP registry.,"Omer Baker , Kit Yuen , Margaret Meagher , Giacomo Musso , Ithaar Derweesh","Department of Urology, UC San Diego School of Medicine, Department of Urology, University of California San Diego School of Medicine, UC San Diego Health"
176,E15,"Multivisceral surgery in patients with locally advanced castration-naïve and castration-resistant, symptomatic prostate cancer.","Julian Heidenreich , David Pfister , Constantin Rieger , Axel Heidenreich","Department of Urology, University Hospital Cologne, Department of Urology, University Hospital of Cologne"
695,C28,Evaluating cost-effectiveness in the evolving treatment landscape for metastatic urothelial carcinoma.,"Constantin Rieger , David Pfister , Joerg Schluechtermann , Axel Heidenreich , Richard Weiten , Enno Storz","Department of Urology, University Hospital Cologne, Department of Urology, University Hospital of Cologne, Faculty of Law, Business and Economics, University of Bayreuth, Dpt. of Urology, University Clinic Cologne"
641,J26,Functional and oncological outcome of primary nerve sparing retroperitoneal lymph node dissection in marker negative testicular germ cell tumors in clinical stage IIA/B.,"Julian Heidenreich , Axel Heidenreich","Department of Urology, University Hospital Cologne, Department of Urology, Uro-Oncology, Robot Assisted and Reconstructive Urologic Surgery, University of Cologne Faculty of Medicine and University Hospital Cologne"
203,F7,NGS-based molecular panel analysis of metastatic prostate cancer for daily routine: How often do we detect druggable mutations?,"Olivia Steenbock , Constantin Rieger , Julian Heidenreich , Pia Paffenholz , David Pfister , Richard Weiten , Melanie von Brandenstein , Axel Heidenreich","Department of Urology, University Hospital Cologne, Department of Urology, Uro-Oncology, Robot Assisted and Reconstructive Urologic Surgery, University of Cologne Faculty of Medicine and University Hospital Cologne, Department of Urology, University Hospital of Cologne"
804,F31,Frequent overexpression of NECTIN-4 in CNS metastases from urothelial carcinoma.,"Richard Weiten , Constantin Rieger , Melanie von Brandenstein , Enno Storz , Yuri Tolkach , Thomas Stehle , Teresa Schmidt , Martin Glas , Tobias Blau , Kathy Keyvani , Viktor Grünwald , Michael Hölzel , Axel Heidenreich , Markus Eckstein , Niklas Klümper","Department of Urology, University Hospital Cologne, Dpt. of Urology, University Clinic Cologne, Institute of Pathology, University Hospital Cologne, Institute of Neuropathology, University Hospital Cologne, Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), Division of Clinical Neurooncology, University Medicine Essen, University Duisburg-Essen, Division of Clinical Neurooncology, Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Medicine Essen, University Duisburg-Essen, Institute of Neuropathology, University Hospital Essen, Clinic for Internal Medicine (Tumor Research) and Clinic for Urology, Interdisciplinary Genitourinary Oncology at the West-German Cancer Center, University Hospital Essen, Institute of Experimental Oncology, University Hospital Bonn, Department of Urology, Uro-Oncology, Robot Assisted and Reconstructive Urologic Surgery, University of Cologne Faculty of Medicine and University Hospital Cologne, Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Department of Urology and Paediatric Urology, University Hospital"
70,B16,Real-world comparison of cabazitaxel vs. 177-lutetium-PSMA radioligand therapy in metastatic castration resistant prostate cancer.,"Mike Wenzel , Florestan Koll , Benedikt Hoeh , Clara Humke , Carolin Siech , Nicolai Mader , Daniel Groener , Thomas Steuber , Markus Graefen , Tobias Maurer , Christian Brandts , Severine Banek , Felix Chun , Philipp Mandel","Department of Urology, University Hospital Frankfurt, Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Department of Nuclear Medicine, University Hospital Frankfurt, Department of Nuclear Medicine, Goethe University Frankfurt, Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Martini-Clinic, Prostate Cancer Center Hamburg, Goethe University Frankfurt, Department of Urology, Goethe University Frankfurt"
71,B17,Cancer-control outcomes of metastatic castration resistant prostate cancer patients with BRCA-gene or tumor suppressor mutations undergoing 177-lutetium PSMA radioligand therapy.,"Mike Wenzel , Florestan Koll , Benedikt Hoeh , Clara Humke , Henning Reis , Peter Wild , Thomas Steuber , Markus Graefen , Derya Tilki , Amir Sabet , Daniel Groener , Felix Chun , Philipp Mandel","Department of Urology, University Hospital Frankfurt, Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt, Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Martini-Klinik, University Medical Center Hamburg-Eppendorf, Department of Nuclear Medicine, Department of Nuclear Medicine, Goethe University Frankfurt, Department of Urology, Goethe University Frankfurt"
618,,Prospective COTRIMS (Cologne trial of retroperitoneal lymphadectomy in metastatic seminoma) trial: Final results.,"Axel Heidenreich , David Pfister , Pia Paffenholz","Department of Urology, University Hospital of Cologne, Department of Urology, University Hospital Cologne"
626,J11,Reduction of systemic chemotherapy by primary retroperitoneal lymph node dissection in low volume metastatic seminoma.,"David Pfister , Pia Paffenholz , Constantin Rieger , Axel Heidenreich","Department of Urology, University Hospital of Cologne, Department of Urology, University Hospital Cologne"
689,C22,Targeting more than tumors: The impact of enfortumab vedotin and pembrolizumab (EV/P) on skeletal muscle loss and sarcopenia in metastatic urothelial carcinoma (mUC).,"Can Aydogdu , Simon Hahn , Isabel Brinkmann , Melanie Götz , Benazir Enzinger , Marie Semmler , Elena Berg , Frederik Kolligs , Alexander Tamalunas , Christian Stief , Jozefina Casuscelli","Department of Urology, University Hospital, Ludwig Maximilian University of Munich, Department of Urology, LMU University Hospital, LMU Munich"
766,E28,Differences in health-related quality of life between rural and urban bladder cancer patients following radical cystectomy.,"Thilo Westhofen , Alexander Buchner , Gerald Schulz , Lennert Eismann , Severin Rodler , Elena Berg , Can Aydogdu , Darjusch Askari , Armin Becker , Christian Stief , Alexander Kretschmer","Department of Urology, University Hospital, Ludwig Maximilian University of Munich, Department of Urology, University Hospital Schleswig-Holstein, Campus Kiel, Janssen Research & Development, Spring House, PA USA;  Ludwig Maximilian University of Munich"
133,D7,Impact of androgen deprivation therapy with postoperative radiotherapy after radical prostatectomy on health-related quality of life.,"Thilo Westhofen , Alexander Buchner , Lennert Eismann , Severin Rodler , Elena Berg , Can Aydogdu , Darjusch Askari , Armin Becker , Christian Stief , Alexander Kretschmer","Department of Urology, University Hospital, Ludwig Maximilian University of Munich, Department of Urology, University Hospital Schleswig-Holstein, Campus Kiel, Janssen Research & Development, Spring House, PA USA;  Ludwig Maximilian University of Munich"
519,F17,Impact of renal cell cancer histology on outcomes of microscopic positive surgical margins and implications on post-surgical follow-up.,"Margaret Meagher , Giacomo Musso , Dhruv Puri , Kit Yuen , Cesare Saitta , Luke Wang , Dattatraya Patil , Kazutaka Saito , Yosuke Yasuda , Yasuhisa Fujii , Viraj Master , Ithaar Derweesh","Department of Urology, University of California San Diego School of Medicine, Department of Urology, UC San Diego School of Medicine, Department of Urology, UC San Diego Health System, Department of Urology, University of California, San Diego, Department of Urology, Emory University School of Medicine, Tokyo Medical and Dental University, Department of Urology, Institute of Science Tokyo, Emory University School of Medicine"
875,J3,Determining lung cancer screening eligibility in a surgically treated urothelial carcinoma population: Making the case for linking bladder cancer screening to lung cancer screening.,"Aman Arora , Alexei Kopelevich , Serena Ly , Dharminder Ojla , Hanan Goldberg , Marc Dall'Era , Thenappan Chandrasekar","Department of Urology, University of California, Davis, University of California, Davis, Health System, SUNY Upstate Medical University, University of California, Davis"
342,J6,"How unfavorable is AUA unfavorable intermediate-risk prostate cancer? Results from a large, institutional cohort.","Jason Goodloe , Kevin Shee , Janet Cowan , Lufan Wang , Samuel Washington III, Matthew Cooperberg , Peter Carroll","Department of Urology, University of California, San Francisco"
361,J25,Evaluating the spectrum of disease within Gleason grade group 3: Results from a large institutional cohort.,"Kevin Shee , Janet Cowan , Lufan Wang , Chien-Kuang Ding , Samuel Washington III, Katsuto Shinohara , Hao Nguyen , Matthew Cooperberg , Peter Carroll","Department of Urology, University of California, San Francisco, University of California, San Francisco"
362,J26,Determining optimal patient selection for high-intensity focused ultrasound (HIFU) for prostate cancer: Results from a single-institution cohort.,"Kevin Shee , William Pace , Andrew Liu , Janet Cowan , Samuel Washington III, Matthew Cooperberg , Katsuto Shinohara , Peter Carroll , Hao Nguyen","Department of Urology, University of California, San Francisco, University of California, San Francisco"
360,J24,The nature of progression on long term active surveillance for confirmed Gleason grade group 1 prostate cancer in the modern era.,"Kevin Shee , Janet Cowan , Lufan Wang , Chien-Kuang Ding , Samuel Washington III, Katsuto Shinohara , Hao Nguyen , Matthew Cooperberg , Peter Carroll","Department of Urology, University of California, San Francisco, University of California, San Francisco"
323,H23,Evaluating social vulnerability as a key determinant of definitive treatment for Black men with clinically localized prostate cancer.,"Jason Goodloe , Samuel Washington III, Lufan Wang , Janet Cowan , Hao Nguyen , Peter Carroll , June Chan , Salma Shariff-Marco","Department of Urology, University of California, San Francisco, University of California, San Francisco, University of California, San Francisco, Department of Epidemiology and Biostatistics, University of California, San Francisco"
363,J27,Examining community social vulnerability domains and influence on treatment selection for men with prostate cancer.,"Jason Goodloe , Samuel Washington III, Lufan Wang , Janet Cowan , Hao Nguyen , Peter Carroll , June Chan , Salma Shariff-Marco","Department of Urology, University of California, San Francisco, University of California, San Francisco, University of California, San Francisco, Department of Epidemiology and Biostatistics, University of California, San Francisco"
TPS431,M29,"A phase I/II study of neoadjuvant, intra-arterial administration of (177Lu)lutetium vipivotide tetraxetan in subjects with high-risk, localised or locally advanced prostate cancer (LUPUS).","Claudia Kesch , Volker Meyer , Christine Praus , Pedro Fragoso Costa , Marc Ingenwerth , Christopher Darr , Jan Radtke , Jens Theysohn , Benedikt Schaarschmidt , Henning Reis , Wolfgang Fendler , Viktor Grünwald , Boris Hadaschik , Ken Herrmann","Department of Urology, University of Duisburg-Essen, and DKTK-University Hospital Essen, ABX-CRO advanced pharmaceutical serviceas Forschungsgesellschaft mbH, Department of Nuclear Medicine, University of Duisburg-Essen, and German Cancer Consortium (DKTK)-University Hospital Essen, Institute of Pathology, University Hospital Essen, Department of Urology, University Hospital Essen, and German Cancer Consortium (DKTK), University Düsseldorf, Medical Faculty, Department of Urology, Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt, Department of Nuclear Medicine, University of Duisburg-Essen, and German Cancer Consortium (DKTK), University Hospital Essen, Essen University Hospital, Clinic for Nuclear Medicine and German Cancer Consortium, University Hospital Essen"
649,J34,Understanding incidence and outcomes of testicular and ovarian germ cell tumors from 2000–2017 using population-based cancer registries.,"Domenique Escobar , Irene Chen , Lihua Liu , Kimberly Siegmund , Siamak Daneshmand , Anishka D'souza , Victoria Cortessis","Department of Urology, University of Southern California Norris Comprehensive Cancer Center, Department of Preventative Medicine, USC Keck School of Medicine, University of Southern California, Department of Population and Public Health Sciences, Keck School of Medicine, USC, USC Norris Comprehensive Cancer Center"
TPS891,J19,"ABLE-22: Safety and efficacy evaluation of nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy—A randomized, open-label, phase 2 study.","Siamak Daneshmand , Stephen Boorjian , Joshua Meeks , Trinity Bivalacqua , Yair Lotan , Wassim Kassouf , Girish Kulkarni , Paolo Gontero , Peter Albers , Joern Skibsted Jakobsen , Kristian Juul","Department of Urology, University of Southern California Norris Comprehensive Cancer Center, Mayo Clinic in Rochester, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Department of Urology, Hospitals of the University of Pennsylvania, Department of Urology, UT Southwestern Medical Center, McGill University Health Centre, Princess Margaret Cancer Center, University Health Network, Dipartimento di Discipline Medico Chirurgiche, Clinica Urologica, University of Torino, Department of Urology, University Hospital of Duesseldorf, Ferring Pharmaceuticals A/S"
698,C31,Clinical characteristics and treatment patterns of patients with muscle invasive bladder cancer: A real-world cohort study.,"John Gore , Vanessa Shih , Sneha Kelkar , Viktor Chirikov , Kimberly Donnowitz , Stephanie Dubow , Christopher Young , David Nimke , Christina Quicquaro , Candice Willmon , Priti Pednekar","Department of Urology, University of Washington School of Medicine, Pfizer Inc., Open Health Group, Astellas Pharma Global Development, Astellas Pharma Global Development, Inc., Astellas Pharma Inc."
TPS902,J30,Expanded access program of cretostimogene grenadenorepvec in patients with non-muscle invasive bladder cancer unresponsive to bacillus Calmette-Guerin.,"Sarah Psutka , Sima Porten , Kristen Scarpato , Mary Westerman , Suzanne Merrill , Anne Schuckman","Department of Urology, University of Washington, University of California, San Francisco, Vanderbilt University Medical Center, LSUHSC School of Medicine, Milton S. Hershey Medical Center, University of Southern California"
474,E7,Real-world effectiveness and safety of first-line (1L) avelumab + axitinib in patients with advanced renal cell carcinoma (aRCC): Primary analysis of the AVION study.,"Axel Merseburger , Olga Baklanova , Victor Garlonta , Nikolaos Androulakis , Athina Christopoulou , Eleni Timotheadou , Wim Demey , Jan Janssen , Philipp Ivanyi , Barbara Brouwers , Wim Wynendaele , Lusha Wang , Lenka Kostkova , Jason Hoffman , Arndt Manzel , Anna Koumarianou","Department of Urology, University Schleswig-Holstein, Campus Lübeck, Irkutsk Regional Oncology Dispensary, Department of Urology, Pediatric Urology and Urological Oncology, Lahn-Dill Clinics GmbH, Department of Medical Oncology, Venizeleio General Hospital, Medical Oncology Unit, St Andrews Hospital, Papageorgiou Hospital, AZ KLINA, Medical Study Society North-West GmbH, Department of Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School, AZ Sint-Jan Brugge, Imelda Ziekenhuis Bonheiden, Merck Serono Co., Ltd., Beijing, China, an affiliate of Merck, Merck spol. s r.o., Bratislava, Slovakia, an affiliate of Merck KGaA, EMD Serono, The Healthcare Business of Merck KGaA, Fourth Department of Internal Medicine, Attikon University General Hospital of Athens"
488,E21,Real world evidence from a retrospective multi-center analysis on first-line therapy for metastatic renal cell carcinoma with chromophobe histology.,"Pia Paffenholz , Jozefina Casuscelli , Stefanie Zschaebitz , Emily Rinderknecht , Angelika Mattigk , Anna-Lisa Volk , Philipp Ivanyi , Thomas Hilser , Christopher Darr , Luka Flegar , Katrin Schlack , Daniel Seidl , Analena Handke , Melanie Klee , Tim Nestler , Marc Rehlinghaus , Sameh Hijazi , Axel Heidenreich , Viktor Grünwald","Department of Urology, Uro-Oncology, Robot Assisted and Reconstructive Urologic Surgery, University of Cologne Faculty of Medicine and University Hospital Cologne, Department of Urology, LMU University Hospital, LMU Munich, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Department of Urology, Caritas-St. Josef Medical Center, University of Regensburg, Department of Urology, University Hospital Ulm, Department for Urology, Urooncology, Robot-assisted an focal treatment, University of Madgeburg, Department of Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School, Department of Medical Oncology, West German Cancer Center, University Hospital Essen and German Cancer Consortium (DKTK), Department of Urology, University Hospital Essen, and German Cancer Consortium (DKTK), Department of Urology, Philipps-University Marburg, Department of Urology, University Hospital Muenster, Department of Urology, Diakonie-Klinikum Stuttgart, Department of Urology, Ruhr University Bochum, Marienhospital Herne, Department of Urology, University Hospital Schleswig-Holstein, Campus Luebeck, Department of Urology, Federal Armed Services Hospital Koblenz, Department of Urology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Department of Urology, Ibbenbueren Hospital, Essen University Hospital"
639,J24,Post chemotherapy retroperitoneal lymph node dissection (PC-RPLND) for metastatic pure seminoma.,"Axel Heidenreich , David Pfister , Pia Paffenholz , Julian Heidenreich , Stefanie Zschaebitz , Yu Che , Clint Cary , Prof. Marcus Hentrich , Axel Gerdtsson , Helene Negaard , Anders Kjellman , Peter Albers","Department of Urology, Uro-Oncology, Robot Assisted and Reconstructive Urologic Surgery, University of Cologne Faculty of Medicine and University Hospital Cologne, Department of Urology, University Hospital of Cologne, Department of Urology, University Hospital Cologne, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Department of Urology, University Hospital, Indiana University Simon Comprehensive Cancer Center, Redcross Hospital, Department of Urology, Skane University, Department of Oncology, Oslo University Hospital, Karolinska University Hospital, Department of Urology, University Hospital of Duesseldorf"
157,D31,The role of cytoreductive radical prostatectomy in the management of patients with metastatic hormone-sensitive prostate cancer.,"Axel Heidenreich , David Pfister , Pia Paffenholz , Constantin Rieger , Richard Weiten","Department of Urology, Uro-Oncology, Robot Assisted and Reconstructive Urologic Surgery, University of Cologne Faculty of Medicine and University Hospital Cologne, Department of Urology, University Hospital of Cologne, Department of Urology, University Hospital Cologne"
752,E14,Radical cystectomy in female patients: Does the urinary diversion type affect postoperative complications?,"Mazyar Zahir , Farshad Moghaddam , Seyedeh Sanam Ladi Seyedian , Gus Miranda , Jie Cai , Monish Aron , Mihir Desai , Inderbir Gill , Anne Schuckman , Siamak Daneshmand , Hooman Djaladat","Department of Urology, USC/Norris Comprehensive Cancer Center, Department of Urology, Norris Comprehensive Cancer Center, University of Southern California, USC Institute of Urology, USC Norris Comprehensive Cancer Center, University of Southern California, USC Institute of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Institute of Urology, Keck School of Medicine, University of Southern California, USC Norris Comprehensive Cancer Center, University of Southern California, Institute of Urology, USC Norris Cancer Center"
742,E4,Complications after transurethral resection of bladder tumor: Findings from the 2022 ACS NSQIP database.,"Chirag Doshi , Mazyar Zahir , Domenique Escobar , Leilei Xia , Siamak Daneshmand","Department of Urology, USC/Norris Comprehensive Cancer Center, Department of Urology, University of Southern California Norris Comprehensive Cancer Center"
874,J2,Clinicopathological variations between early and late recurrence in bladder cancer post-radical cystectomy.,"Josh Ku , Chirag Doshi , Anosh Dadabhoy , Leilei Xia , Siamak Daneshmand","Department of Urology, USC/Norris Comprehensive Cancer Center, Department of Urology, University of Southern California Norris Comprehensive Cancer Center"
679,C12,Impact of insurance type on outcomes after radical cystectomy for bladder cancer.,"Chirag Doshi , Mazyar Zahir , Anosh Dadabhoy , Domenique Escobar , Gus Miranda , Jie Cai , Hooman Djaladat , Anne Schuckman , Siamak Daneshmand","Department of Urology, USC/Norris Comprehensive Cancer Center, Department of Urology, University of Southern California Norris Comprehensive Cancer Center, USC Institute of Urology, USC Norris Comprehensive Cancer Center, University of Southern California, USC Institute of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Institute of Urology, Keck School of Medicine, University of Southern California, USC Norris Comprehensive Cancer Center, University of Southern California"
750,E12,Evaluating the survival benefits of adjuvant immunotherapy in muscle-invasive urothelial carcinoma: A real-world experience.,"Mazyar Zahir , Chirag Doshi , Domenique Escobar , Leilei Xia , Gus Miranda , Jie Cai , Anne Schuckman , Hooman Djaladat , Siamak Daneshmand","Department of Urology, USC/Norris Comprehensive Cancer Center, Department of Urology, University of Southern California Norris Comprehensive Cancer Center, USC Institute of Urology, USC Norris Comprehensive Cancer Center, University of Southern California, USC Institute of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, USC Norris Comprehensive Cancer Center, University of Southern California, Institute of Urology, USC Norris Cancer Center, USC/Norris Comprehensive Cancer Center, University of Southern California"
831,G27,A non-coding RNA based classifier for favorable outcomes in clinically organ confined bladder cancer.,"Yair Lotan , Joep de Jong , James Proudfoot , Siamak Daneshmand , Robert Svatek , Vikram Narayan , Ewan Gibb , Elai Davicioni , Shreyas Joshi , Roger Li , Brant Inman , Paras Shah , Jonathan Wright","Department of Urology, UT Southwestern Medical Center, Erasmus MC Cancer Institute, Veracyte, Inc., USC Institute of Urology, USC Norris Comprehensive Cancer Center, University of Southern California, UT Health San Antonio, Department of Urology, Emory University School of Medicine, Department of Urology, Emory University, Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Duke University Medical Center, Mayo Clinic in Rochester, University of Washington"
391,K21,"An open-label phase 1, window-of-opportunity study of ultrasound-guided long acting periprostatic neuraxial block with ethanol in patients with high-risk prostate cancer.","Ali Zahalka , George Haines III , Vitaly Margulis , Ashutosh Tewari","Department of Urology, UT Southwestern Medical Center, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai"
394,K24,Final oncological outcomes of the randomized phase II trial ARNEO: Neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer.,"Alexander Giesen , Gaëtan Devos , Lorenzo Tosco , Marcella Baldewijns , Thomas Gevaert , Karolien Goffin , Niloefar Ahmadi Bidakhvidi , Annouschka Laenen , Yannic Raskin , Carl Van Haute , Lieven Goeman , Gert de Meerleer , Charlien Berghen , Wout Devlies , Frank Claessens , Hendrik Van Poppel , Wouter Everaerts , Steven Joniau","Department of Urology, UZ Leuven, Department of Urology, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Erasme Hospital, Department of Pathology, UZ Leuven, Department of Nuclear Medicine, Division of Nuclear Medicine and Molecular Imaging, University Hospital Leuven, KU Leuven, Department of Nuclear Medicine, UZ Leuven, Leuven Biostatistics and Statistical Bioinformatics Center, KU Leuven, Department of Development and Regeneration, KU Leuven, Department of Radiation Oncology, UZ Leuven, Laboratory of Molecular Endocrinology, KU Leuven"
492,E25,Clinicopathological features and prognosis of MED15-TFE3 rearrangement renal cell carcinoma: An updated report.,"Sike He , Haoyang Liu , Xu Hu , Junru Chen , Zhenhua Liu , Pengfei Shen , Hao Zeng","Department of Urology, West China Hospital, Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Department of Urology, West China Hospital, Sichuan Univertity, West China Hospital of Sichuan University"
423,L19,Assessment of the proficiency of ChatGPT-4o in an image-based robot-assisted radical prostatectomy scenario.,"Jiakun Li , Jing Zhao , Zeqi Wang , Le Tong , Bairong Shen , Qiang Wei","Department of Urology, West China Hospital, Sichuan University, West China Hospital, West China Hospital, Sichuan University"
726,D23,Efficacy and safety of disitamab vedotin combined with toripalimab as neoadjuvant treatment for patients with locally advanced muscle-invasive bladder cancer: A mono-institutional retrospective study.,"Geng Zhang , Qiang Fu , Fuxun Zhang , Fan Yang , Haozhong Hou","Department of Urology, Xijing Hospital, Fourth Military Medical Universit, Tangdu Hospital of Air Force Medical University, Department of Urology, Xijing Hospital, Air Force Military Medical University"
504,F2,Clinicopathological characteristics and prognosis of metastatic non-clear cell renal cell carcinoma.,"Jie Wu , Hong-Lei Cui , Hongzhe Shi , Youyan Guan , Xin-Gang Bi , Aiping Zhou , Jianzhong Shou","Department of Urology, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College"
744,E6,The impact of micropapillary histology and clinical staging on overall survival in bladder cancer: A retrospective analysis.,"Muhammad Alkazemi , Syed Alam , Ao Zhang , Eugene Pietzak , S. Donat , Harry Herr , Bernard Bochner , Jie-Fu Chen , Hikmat Al-Ahmadie","Dept. of Surgery, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center"
230,G3,Adrenal androgens and overall survival (OS) in men with castration-resistant prostate cancer (CRPC) treated with enzalutamide without (ENZ) or with abiraterone and prednisone (ENZ/AAP) (Alliance).,"Nima Sharifi , Hyotae Kim , Mohammad Alyamani , Robert Diaz , Himisha Beltran , Andrew Armstrong , Michael Morris , Susan Halabi , Charles Ryan","Desai Sethi Urology Institute at the University of Miami Sylvester Comprehensive Cancer Center, Department of Biostatistics & Bioinformatics, Duke University, Dana-Farber Cancer Institute, Duke Cancer Institute at Duke University, Memorial Sloan Kettering Cancer Center, Duke University School of Medicine"
234,G7,HSD3B1 and overall survival (OS) in high-risk non-metastatic (M0) and metastatic (M1) prostate cancer starting androgen deprivation therapy (ADT) in the enzalutamide (ENZ) and abiraterone acetate plus prednisolone (AAP) STAMPEDE phase 3 trial.,"Nima Sharifi , Mahaz Kayani , Laura Murphy , Robert Diaz , Emily Grist , Zsofia Kote-Jarai , Ros Eeles , Gianmarco Leone , Noel Clarke , Mahesh Parmar , Louise Brown , Nicholas James , Gerhardt Attard","Desai Sethi Urology Institute at the University of Miami Sylvester Comprehensive Cancer Center, University College London Cancer Institute, Medical Research Council Clinical Trials Unit, University College London, Oncogenetics, Institute of Cancer Research, Institute of Cancer Research, The Christie and Salford Royal NHS Foundation Trusts, Medical Research Council Clinical Trials Unit at University College London, The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust"
TPS904,J32,"A multicenter, open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations (SURF301).","Aaron Hansen , Alison Zhang , Valentina Boni , Charlene Mantia , Evan Yu , Andrew Weickhardt , Marie Robert , Shilpa Gupta , Rafael Morales-Barrera , Christopher Hoimes , Jordan Berlin , Gopa Iyer , Michael Millward , Christine Lihou , Yohan Loriot , Damien Pouessel , Kriti Mittal , Andrew Hill , Fabricio Racca , Ben Tran","Division of Cancer Services, Princess Alexandra Hospital, Macquarie University, NEXT Madrid Universitary Hospital Quirosalud Madrid, Dana-Farber Cancer Institute, Fred Hutchinson Cancer Center, University of Washington, Austin Health, Institut de Cancérologie de l’Ouest & ARPEGO Network, Cleveland Clinic Taussig Cancer Institute, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Universitat Autònoma de Barcelona, Duke Cancer Institute, Vanderbilt-Ingram Cancer Center, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, Linear Clinical Research & University of Western Australia, Tyra Biosciences, Université Paris-Sud, Université Paris-Saclay, Oncopole Claudius Régaud–IUCT Oncopole, University of Massachusetts Chan Medical School, Tasman Oncology Research, Vall d'Hebron University Hospital; NEXT Oncology, Peter MacCallum Cancer Centre"
TPS275,L28,Phase Ib/IIa dose escalation and expansion study of [212Pb]Pb-ADVC001 in metastatic castration-resistant prostate cancer: TheraPb–phase I/II study.,"Aaron Hansen , David Pattison , Stanley Ngai , Anna Karmann , Amanda Walker , Louise Campbell , Alyssa Vito , Jasmine Brady , Loren Katchel , Ingrid Holmes , Stephen Rose , Meghan Baronet , Thomas Kryza , Alyssa Vito , William Tieu , Kevin Kuan , Matthew Griffiths , Eoin O’Mahoney , Melissa Latter , Chun Loo Gan , David Wyld","Division of Cancer Services, Princess Alexandra Hospital, Royal Brisbane and Women's Hospital, Princess Alexandra Hospital, Queensland University of Technology, Translational Research Institute, AdvanCell Pty Limited, Princess Alexandra Hospital, Royal Brisbane and Women’s Hospital"
315,H15,Socioeconomic position as a social determinant of health and its effect on cardiovascular outcomes and mortality in patients with prostate cancer: A SEER-Medicare based study.,"Tarek Nahle , Omar Elsayed , Viraj Shah , Harikrishnan Hyma Kunhiraman , Sami Abi Farraj , Priyanshu Nain , Nickolas Stabellini , Sadeer Al-Kindi , Umang Swami , Jordan Ciuro , Jigarkumar Parikh , Ashanda Esdaille , Zachary Klaassen , Martha Terris , Jennifer Cullen , Neal Weintraub , Neeraj Agarwal , Avirup Guha","Division of Cardiology, Department of Medicine, Medical College of Georgia at Augusta University, Department of Medicine, Medical College of Georgia at Augusta University, Department of Radiation Oncology, Hotel Dieu de France Hospital, Faculdade Israelita de Ciências da Saúde Albert Einstein, Hospital Israelita Albert Einstein, Houston Methodist DeBakey Heart & Vascular Center, Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute at the University of Utah, Winship Cancer Institute of Emory University, Augusta University, Department of Urology, Medical College of Georgia at Augusta University, Houston Methodist Neal Cancer Center, Huntsman Cancer Institute (NCI-CCC) at the University of Utah, Department of Medicine, Division of Cardiology, Medical College of Georgia at Augusta University"
132,D6,Sociodemographic predictors of the late-stage diagnosis in patients with prostate cancer: A retrospective cohort study.,"Muhammad Ali Khan , Muhammad Umar Afzal , Ammad Raina , Zaryab Bin Riaz , Kainat Warraich , Alton Sartor , Alan Bryce , Parminder Singh , Daniel Childs , Jacob Orme , Haidar Abdul-Muhsin , Adam Kase , Cassandra Moore , Neeraj Agarwal , Yousef Zakharia , Ewan Cobran , Irbaz Riaz","Division of Hematology and Medical Oncology, Mayo Clinic in Arizona, Mayo Clinic in Arizona, Midwestern University, AZCOM, Rashid Latif Medical College, Mayo Clinic, City of Hope, Department of Oncology, Mayo Clinic in Arizona, Department of Medical Oncology, Mayo Clinic in Rochester, Mayo Clinic in Florida, Huntsman Cancer Institute at the University of Utah, Mayo Clinic College of Medicine and Science"
134,D8,Survival in advanced prostate cancer (PCa) patients with visceral metastasis: A population-based SEER study.,"Salman Ayub Jajja , Syed Arsalan Ahmed Naqvi , Muhammad Ali Khan , Muhammad Umar Afzal , Muhammad Umair Anjum , Ammad Raina , Prateek Jain , Fnu Swati , Zaryab Bin Riaz , Daniel Childs , Ewan Cobran , Alan Bryce , Yousef Zakharia , Parminder Singh , Irbaz Riaz","Division of Hematology and Medical Oncology, Mayo Clinic, Mayo Clinic in Arizona, Division of Hematology and Medical Oncology, Mayo Clinic in Arizona, Canyon Vista Medical Center, Mayo Clinic, Rashid Latif Medical College, Department of Medical Oncology, Mayo Clinic in Rochester, Mayo Clinic College of Medicine and Science, City of Hope"
270,H11,Heterogeneity in subgroup reporting across clinical trials assessing systemic therapies in metastatic castration resistant prostate cancer: A report from a living systematic review.,"Muhammad Umair Anjum , Syed Arsalan Ahmed Naqvi , Kaneez Khakwani , Ammad Raina , Salman Ayub Jajja , Muhammad Ali Khan , Bryan Rumble , Rohan Garje , Yousef Zakharia , Parminder Singh , Rahul Parikh , Alan Bryce , Irbaz Riaz","Division of Hematology and Medical Oncology, Mayo Clinic, University of Arizona, Canyon Vista Medical Center, Division of Hematology and Medical Oncology, Mayo Clinic in Arizona, American Society of Clinical Oncology, Miami Cancer Institute, Baptist Health South Florida, Mayo Clinic in Arizona, Department of Oncology, Mayo Clinic in Arizona, University of Kansas Medical Center, City of Hope"
172,E11,"Updated follow up of a randomized, double-blinded phase II study of ketoconazole (keto), hydrocortisone (HC), and anti-PSMA antibody J591 labeled with 177Lu or 111In in patients (pts) with high-risk non-metastatic (met) castration-resistant prostate cancer (M0 CRPC).","Abdul Baseet Arham , Charlene Thomas , Issa Castaneda , Samuel Ruder , Yousef Zakharia , Leonard Appleman , Joseph Osborne , George Philips , Luke Nordquist , Anishka D'souza , Elizabeth Wulff-Burchfield , Edwin Posadas , Neeraj Agarwal , Paul Christos , Nabil Adra , David Nanus , Scott Tagawa","Division of Hematology and Medical Oncology, Weill Cornell Medical College, Weill Cornell Medicine, Division of Hematology & Medical Oncology, Weill Cornell Medicine, NewYork-Presbyterian Hospital, University of Iowa, Division of Hematology, Oncology, Blood & Marrow Transplantation, Department of Internal Medicine, University of Pittsburgh, Molecular Imaging & Therapeutics, Department of Radiology, Weill Cornell Medicine, Georgetown University Hospital, XCancer/Urology Cancer Center, USC Norris Comprehensive Cancer Center, University of Kansas Medical Center, Cedars-Sinai Medical Center, Huntsman Cancer Institute (NCI-CCC), University of Utah, Department of Biostatistics and Epidemiology, Weill Cornell Medical College, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Weill Cornell Medical Center, NewYork-Presbyterian Hospital"
222,F26,Characterizing the clinical and genomic features of androgen indifferent prostate cancer.,"Jack Masur , Krzysztof Wierbilowicz , Aakrosh Ratan , Adanma Ayanambakkam , Michelle Churchman , Saum Ghodoussipour , Laura Graham , George Grass , Sumati Gupta , Sean Kern , Jennifer King , Zin Myint , Seyi Oderinde , Robert Rounbehler , Bodour Salhia , Eric Singer , Yousef Zakharia , Bryce Paschal , Paul Viscuse","Division of Hematology and Oncology, University of Virginia, University of Virginia School of Medicine, Center for Public Health Genomics, University of Virginia, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Aster Insights, Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, University of Colorado Cancer Center Anschutz Medical Campus, H. Lee Moffitt Cancer Center, Department of Radiation Oncology, Huntsman Cancer Institute at the University of Utah, Uniformed Services University/Murtha Cancer Center, Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center, University of Kentucky, Indiana University School of Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, The Ohio State University Comprehensive Cancer Center, University of Iowa Holden Comprehensive Cancer Center, Division of Hematology/Oncology, University of Virginia"
475,E8,A single-institution experience of pneumonitis in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors.,"Jack Masur , Soham Ali , Kathryn Fortune , Juliana Bueno , Thomas Battey , Abhishek Mullapudi , Ariaz Goudarzi , Hitesh Patel , Jeffrey Sturek , Michael Devitt , William Skelton IV, Robert Dreicer , Paul Viscuse","Division of Hematology and Oncology, University of Virginia, University of Virginia, Department of Internal Medicine, University of Virginia, Department of Radiology and Medical Imaging, University of Virginia School of Medicine, University of Virginia, Division of Pulmonary and Critical Care Medicine, University of Virginia, Division of Hematology/Oncology, Division of Hematology/Oncology, University of Virginia"
TPS434,M32,"A phase 1b, open-label, multicenter study of xaluritamig in patients with newly diagnosed localized intermediate- or high-risk prostate cancer in the neoadjuvant setting.","David Oh , Deepak Kilari , Christopher Darr , Kevin Zarrabi , Jessica Hawley , Russell Pachynski , Scott Tagawa , Yuanquan Yang , Simon Buetikofer , Qing Xia , Gunhild Von Amsberg","Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Department of Urology, University Hospital Essen, Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, Division of Hematology & Oncology, Department of Medicine, University of Washington; Clinical Research Division, Fred Hutch Cancer Center, Siteman Cancer Center; Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, Weill Cornell Medicine, Division of Medical Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University, The Ohio State University Comprehensive Cancer Center, Amgen, Inc, Amgen Inc., Department of Oncology and Hematology, University Cancer Center Hamburg Eppendorf and Martini-Klinik, Prostate Cancer Center, University Hospital Hamburg-Eppendorf"
637,J22,Management of relapsed primary retroperitoneal (RP) germ-cell tumor (GCT) after front-line chemotherapy.,"Kirsten Lewis , Rebecca Hassoun , Sandra Althouse , Tareq Salous , Nasser Hanna , Lawrence Einhorn , Nabil Adra , Jennifer King","Division of Hematology/Oncology, Indiana University School of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center"
125,C35,Assessment of cardiovascular (CV) toxicity by providers in advanced prostate cancer (PCa) patients (pts) on novel hormonal therapy (NHT).,"Dalia Kaakour , Eunah Cho , Aya Ozaki , Ali Raad , Amanda Macaraeg , Jeanah Go , Steven Seyedin , Ali Naqvi , Nataliya Mar","Division of Hematology/Oncology, University of California, Irvine, University of California, Irvine, Stern Center for Cancer Clinical Trials and Research, Chao Comprehensive Cancer Center, University of California, San Francisco, University of California Irvine"
199,F3,"Circulating tumor cell expression analysis from the phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in first-line metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects (BRCAAway).","Zachery Reichert , Maha Hussain , Jennie Lovett , Masha Kocherginsky , Channing Paller , Neeraj Agarwal , Nabil Adra , Jingsong Zhang , Joel Picus , Russell Szmulewitz , Timothy Kuzel , Scott Tagawa , Latifa Bazzi , Young Whang , Ryan Stephenson , Robert Dreicer , Daniel Shevrin , Matthew Rettig , Emmanuel Antonarakis , Todd Morgan","Division of Hematology/Oncology, University of Michigan, Northwestern University, Feinberg School of Medicine, Rogel Comprehensive Cancer Center, University of Michigan, Division of Biostatistics, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Huntsman Cancer Institute at the University of Utah, Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center, H. Lee Moffitt Cancer Center and Research Institute, Division of Oncology, Siteman Cancer Center, Washington University, The University of Chicago, Rush University Medical Center, Weill Cornell Medical College of Cornell University, Northwestern University, The University of North Carolina at Chapel Hill, Rutgers Cancer Institute of New Jersey, University of Virginia School of Medicine, NorthShore University Health System, Department of Medical Oncology, University of California, Los Angeles, University of Minnesota, Masonic Cancer Center"
770,E32,Survey-based study of treatment sequencing after first-line (1L) enfortumab vedotin/pembrolizumab (EVP) in the evolving landscape of locally advanced/metastatic (la/m) urothelial cancer (UC).,"Priyanka Chablani , Ali Khaki , Karine Tawagi , Petros Grivas , Jeannie Hoffman-Censits , Matthew Galsky , Shilpa Gupta , Vadim Koshkin , Elizabeth Plimack , Jonathan Rosenberg , Peter O'Donnell","Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Division of Oncology, Stanford University School of Medicine, University of Illinois Chicago, University of Washington and Fred Hutchinson Cancer Center, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Department of Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, Fox Chase Cancer Center, Memorial Sloan Kettering Cancer Center, University of Chicago Comprehensive Cancer Center"
489,E22,Efficacy and safety of lenvatinib plus everolimus in metastatic renal cell carcinoma after immune checkpoint and VEGFR tyrosine kinase inhibitors.,"So Heun Lee , Inkeun Park , Shinkyo Yoon , Jae Lyun Lee","Division of Hematology-Oncology, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine"
TPS276,L29,"A randomized phase 3 trial of docetaxel added to ADT plus ARTA in patients with metastatic hormone-sensitive prostate cancer (Adding Docetaxel, KCSG- GU22-24).","Kwonoh Park , Inkeun Park , Jae Lyun Lee","Division of Hematology-Oncology, Department of Internal Medicine, Hanyang University Seoul Hospital, Hanyang University College of Medicine, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine"
785,F12,"Second-line platinum-based chemotherapy (PBT) in patients with metastatic urothelial carcinoma (mUC) treated with first-line pembrolizumab plus enfortumab vedotin (P/EV): A single-center, retrospective study.","Junkyu Kim , Se Hoon Park , Changgon Kim , Jiyeon Hyeon , Sung Hee Lim , Minsuk Kwon","Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Samsung Medical Center, Sungkyunkwan Univ Cheil Hosp, Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center"
588,H23,Use of integrated multi-omics profiling in renal cell carcinoma to identify molecular subtypes and associated clinical outcomes and therapeutic vulnerabilities.,"Chang Gon Kim , Harim Koo , Woo Sun Kwon , Woo Kyun Bae , Eu Chang Hwang , Won Sik Ham , Nam Hoon Cho , Jason Sa , Jong Bae Park , Sun Young Rha","Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Songdang Institute for Cancer Research, Yonsei University College of Medicine, Division of Hematology-Oncology, Department of Internal Medicine, Chonnam National University Medical School, Department of urology, Chonnam National University Medical School, Department of Urology, Yonsei Cancer Center, Yonesi University College of Medicine, Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Department of Biomedical Sciences, Korea University College of Medicine, Yonsei Cancer Center"
174,E13,Efficacy and safety of ifosfamide and mesna in metastatic castration-resistant prostate cancer after taxane-based chemotherapy and novel hormonal therapy failure.,"Chang Gon Kim , Yeo Gyeong Ko , Jongjin Yoon , Chung Lee , Seung-Hoon Beom , Young Deuk Choi , Woong Kyu Han , Won Sik Ham , Hyunho Han , Jongsoo Lee , Ji Eun Heo , Daeseong Kim , Eunsil Baek , Sang Woo Kim , Minsun Jung , Sang Joon Shin","Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Department of Radiology, Yonsei Cancer Center, Yonesi University College of Medicine, Department of Pathology, Yonsei University College of Medicine, Department of Urology, Yonsei Cancer Center, Yonesi University College of Medicine, Songdang Institute for Cancer Research, Yonesi University College of Medicine, Department of Biomedical Systems Informatics and Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine"
473,E6,Prognostic and predictive genomic biomarkers in metastatic clear cell renal cell carcinoma (mccRCC): A large retrospective analysis of real-world data from a US-based clinico-genomic database (CGDB).,"Mimma Rizzo , Gaetano Pezzicoli , Camilla Porta , Massimiliano Povero , Lorenzo Pradelli , Emilia Sicari , Valentina Sara Barbiero , Camillo Porta","Division of Medical Oncology, Policlinico di Bari, Interdisciplinary Department of Medicine, University of Bari ‘Aldo Moro’, AdRes Health Economics and Outcome Research, Roche, Roche SpA, University of Bari ‘Aldo Moro’ and Policlinico di Bari"
597,H32,Concordance of circulating tumor DNA and imaging surveillance in patients with urothelial carcinoma and renal cell carcinoma post-immunotherapy.,"Lingbin Meng , Katharine Collier , Elshad Hasanov , Amir Mortazavi , Steven Clinton , Peng Wang , Danielle Zimmerman , Fuat Bicer , Timothy Gauntner , Edmund Folefac , Paul Monk III, Yuanquan Yang","Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, Division of Medical Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University"
748,E10,Impact of adding immunotherapy to chemotherapy for metastatic neuroendocrine bladder cancer in the National Cancer Database.,"Lingbin Meng , Peng Wang , Shihua Wang , Yuanquan Yang , Feng Hong , Katharine Collier , Elshad Hasanov , Shang-Jui Wang , Debasish Sundi , Akshay Sood , Danielle Zimmerman , Fuat Bicer , Timothy Gauntner , Edmund Folefac , Paul Monk III, Amir Mortazavi , Steven Clinton","Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, The Ohio State University Comprehensive Cancer Center, The Ohio State University, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Department of Urology, The Ohio State University Comprehensive Cancer Center, Department of Urology, College of Medicine, The Ohio State University, Division of Medical Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University"
TPS899,J27,A phase 2 trial of neoadjuvant futibatinib plus durvalumab for cisplatin-ineligible patients with FGFR overexpressing muscle-invasive bladder cancer.,"Yuanquan Yang , Rohit Jain , Shilpa Gupta , Irene Tsung , Dharmesh Gopalakrishnan , Jinesh Gheeya , Lai Wei , Swati Satturwar , Anil Parwani , Katharine Collier , Kamal Pohar , Debasish Sundi , Cheryl Lee , Zihai Li , Sameek Roychowdhury , Amir Mortazavi","Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Weill Cornell Medicine, Cleveland Clinic Taussig Cancer Institute, Division of Hematology/Oncology, University of Michigan, Roswell Park Comprehensive Cancer Center, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Department of Pathology, The Ohio State University Comprehensive Cancer Center, Department of Urology, The Ohio State University Comprehensive Cancer Center, The Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center"
TPS287,M6,"Mevrometostat (PF-06821497) in combination with enzalutamide for androgen receptor pathway inhibitor (ARPI)-naïve patients with metastatic castration-resistant prostate cancer (mCRPC): The phase 3, randomized MEVPRO-2 trial.","Michael Schweizer , Jayeta Chakrabarti , Sujata Narayanan , Stella Lin","Division of Medical Oncology, University of Washington, and Clinical Research Division, Fred Hutchinson Cancer Cancer, Oncology, Pfizer Inc."
LBA138,,"Mevrometostat (PF-06821497), an enhancer of zeste homolog 2 (EZH2) inhibitor, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC): A randomized dose-expansion study.","Michael Schweizer , Mariona Calvo , Victor Moreno , Begoña Mellado , Daniel Castellano , Alexander Spira , Qiang Wei , Joan Carles , Benjamin Garmezy , Cheol Kwak , Iwona Lugowska , Konstantin Penkov , Neal Shore , Li Liu , Rajendar Mittapalli , Jessica Tougias , Claudia Andreu-Vieyra , Neelesh Soman , Teresa Alonso Gordoa","Division of Medical Oncology, University of Washington; Clinical Research Division, Fred Hutchinson Cancer Center, Medical Oncology Department, Catalan Institute of Oncology, L’Hospitalet del Llobregat, START-Madrid-FJD, Hospital Fundación Jiménez Díaz, Hospital Clínic i Provincial de Barcelona, Hospital 12 de Octubre, Virginia Cancer Specialists PC, Department of Urology, West China Hospital, Sichuan University, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Sarah Cannon Research Institute, Department of Urology, Seoul National University Hospital, Early Phase Clinical Trials Department, Maria Skłodowska Curie National Research Institute of Oncology, General Department, Private Medical Institution ""Euromedservice"", Carolina Urologic Research Center, Pfizer Inc., Medical Oncology Department, Hospital Universitario Ramón y Cajal"
146,D20,Modulation of enhancer of zeste homolog 2 (EZH2) pharmacodynamic markers and tumor gene expression by mevrometostat (PF-06821497) in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC).,"Michael Schweizer , Li Liu , Szu-Yu Tang , Whijae Roh , Vinicius Bonato , Joan Carles , Benjamin Garmezy , Curtis Dunshee , Guillermo de Velasco , Konstantin Penkov , Claudia Andreu-Vieyra , Neelesh Soman , Begoña Mellado","Division of Medical Oncology, University of Washington; Clinical Research Division, Fred Hutchinson Cancer Center, Pfizer Inc., Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Sarah Cannon Research Institute, Arizona Urology Specialists, Hospital Universitario 12 de Octubre, General Department, Private Medical Institution ""Euromedservice"", Hospital Clínic i Provincial de Barcelona"
697,C30,Early findings from a national quality improvement (QI) program to address disparities in bladder cancer (BLCA) care.,"Ali Khaki , Fionna Sun , Patrick Hensley , Mary Dunn , Rebecca Peebles , Stephanie Chisolm , Karen Johnson , Manish Vira , Bradley Carthon , Allison Harvey , Christina Mangir , Caroline Offit , Molly Kisiel , Elana Plotkin , Samuel Washington III, Heather Goltz","Division of Oncology, Stanford University School of Medicine, University of California, San Francisco, University of Kentucky, University of North Carolina at Chapel Hill, St. Jude Medical Center, Bladder Cancer Advocacy Network (BCAN), American Urological Association, Northwell Health, Winship Cancer Institute of Emory University, Rhizome, LLC, Association of Community Cancer Centers, Association of Cancer Care Centers, Department of Urology, University of California, San Francisco, University of Houston-Downtown"
739,D36,Real-world analysis of 2IR immune response score in urothelial carcinoma (UC).,"Jason Brown , Tolulope Adeyelu , Andrew Elliott , Arnab Basu , Mehmet Bilen , Roger Li , Tyler Stewart , Rana McKay , Elisabeth Heath , Daniel Geynisman , Norm Smith , Pedro Barata","Division of Solid Tumor Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Caris Life Sciences, University of Alabama at Birmingham, Winship Cancer Institute of Emory University, Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, University of California, San Diego Health, Moores Cancer Center, University of California San Diego, Karmanos Cancer Institute, Wayne State University, Fox Chase Cancer Center"
96,C6,Association between sociodemographic marginalization and receipt of intensified treatment for metastatic castrate-sensitive prostate cancer.,"Christopher Wallis , David-Dan Nguyen , Raj Satkunasivam , Khatereh Aminoltejari , Amanda Hird , Soumyajit Roy , Scott Morgan , Shawn Malone , Bobby Shayegan , Girish Kulkarni , Quoc-Dien Trinh , Laura Rosella , Rodney Breau , Aly-Khan Lalani","Division of Urology and Surgical Oncology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, University of Toronto, Department of Urology, Houston Methodist Hospital, Sunnybrook Health Sciencies, Rush University Medical Center, The Ottawa Hospital, University of Ottawa, St. Josephs Healthcare, McMaster University, Princess Margaret Cancer Center, University Health Network, Brigham and Women's Hospital, Ottawa Hospital Research Institute, Department of Oncology, Juravinski Cancer Centre, McMaster University"
349,J13,Population-based assessment of treatment patterns for high-risk localized prostate cancer.,"Christopher Wallis , Shawn Malone , Ilias Cagiannos , Robert Hamilton , Naveen Basappa , Cristiano Ferrario , Geoffrey Gotto , Ricardo Fernandes , Tamim Niazi , Chris Morash , Ricardo Rendon , Fred Saad , Sebastien Hotte , Brendan Osborne , Anousheh Zardan , Bobby Shayegan","Division of Urology, Department of Surgery, University of Toronto, and Mount Sinai Hospital and University Health Network, The Ottawa Hospital Cancer Centre, The Ottawa Hospital, University of Ottawa, Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Segal Cancer Centre, Jewish General Hospital, Southern Alberta Institute of Urology, University of Calgary, Division of Medical Oncology, London Regional Cancer Program, London Health Sciences Centre, University of Western Ontario, Jewish General Hospital, McGill University, Queen Elizabeth II Health Sciences Centre, Dalhousie University, Centre Hospitalier de l’Université de Montréal/CRCHUM, Université de Montreal, Department of Oncology, Juravinski Cancer Centre, McMaster University, Johnson & Johnson Innovative Medicine, Department of Surgery, McMaster University"
316,H16,Racial differences in active surveillance intensity and overtreatment in men with prostate cancer.,"Dawson Hill , Samuel Kaufman , Paula Guro , Sarah Leick , Preeti Chachlani , Addison Shay , Mary Oerline , Christopher Dall , Brent Hollenbeck , Vahakn Shahinian , Arnav Srivastava","Dow Division of Health Services Research, Department of Urology, University of Michigan, Department of Urology, Massachusetts General Hospital"
352,J16,Clinical outcomes for radiographic node-positive prostate cancer following definitive radiotherapy.,"Jade Dodge , Lillian Boe , Kevin Boehm , David Guttmann , Zachary Moore , Dhwani Parikh , Andrew Barsky , Marisa Kollmeier , Sean McBride , Victoria Brennan , Jeremy Setton , Daniel Gorovets , Himanshu Nagar , Michael Bernstein , James Janopaul-Naylor","Drexel University College of Medicine, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Cente, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center"
65,B11,"Relationship between undetectable PSA nadir and outcomes for patients with metastatic hormone-sensitive prostate cancer (mHSPC) in IRONMAN, the International Registry for Men with Advanced Prostate Cancer.","Hannah McManus , Lauren Howard , Kerri-Anne Crowell , Terry Hyslop , Karen Autio , Dana Rathkopf , Robert Dreicer , Kim Chi , Michael Ong , Joaquin Mateo , Deborah Enting , Emilio Esteban , Vincent Khoo , Amanda McMannis , Rebecca Green , Shannon Pileggi , Jake Vinson , Philip Kantoff , Lorelei Mucci , Daniel George","Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Duke University, Sidney Kimmel Cancer Center, Thomas Jefferson University, Memorial Sloan Kettering Cancer Center, University of Virginia School of Medicine, University of British Columbia, BC Cancer, Vancouver Cancer Centre, The Ottawa Hospital Cancer Centre, Medical Oncology, Vall d'Hebron University Hospital and Vall d'Hebron Institute, Guy's and St Thomas' NHS Foundation Trust, Central University Hospital of Asturias, The Royal Marsden NHS Foundation Trust, Prostate Cancer Clinical Trials Consortium, LLC, Convergent Therapeutics, Harvard T.H. Chan School of Public Health, Department of Medicine, Duke Cancer Institute, Duke University School of Medicine"
158,D32,"Real-world use and outcomes of darolutamide (DARO), enzalutamide (ENZA), and apalutamide (APA) for nonmetastatic castration-resistant prostate cancer (nmCRPC): Race subgroup analysis.","Daniel George , Alicia Morgans , Nasreen Khan , Niculae Constantinovici , Guifang Chen , Mercedeh Ghadessi , Vlasta Hlebec , Neal Shore","Duke Cancer Institute, Department of Medical Oncology, Dana-Farber Cancer Institute, Bayer HealthCare Pharmaceuticals, Inc., Bayer Consumer Care AG, Carolina Urologic Research Center"
686,C19,Upstaging and risk migration with blue light cystoscopy for non–muscle-invasive bladder cancer: Results from a prospective multi-center registry.,"Alireza Ghoreifi , Badrinath Konety , Kamal Pohar , Jeffrey Holzbeierlein , John Taylor III, Max Kates , Brian Willard , Jennifer Taylor , Joseph Liao , Hristos Kaimakliotis , Sima Porten , Gary Steinberg , Mark Tyson , Yair Lotan , Siamak Daneshmand","Duke University Medical Center, Allina Health Cancer Institute, Department of Urology, The Ohio State University Comprehensive Cancer Center, University of Kansas Hospital, University of Kansas Medical Center, The Johns Hopkins University School of Medicine, Lexington Medical Center, Baylor College of Medicine, Stanford University, Indiana University Simon Cancer Center, University of California, San Francisco, Department of Urology, Rush University, Mayo Clinic in Arizona, Department of Urology, UT Southwestern Medical Center, Department of Urology, University of Southern California Norris Comprehensive Cancer Center"
410,L6,Characterizing the activity of inflammasome genes and their association with oncological outcomes in prostate cancer.,"Alireza Ghoreifi , Mohammed Alshalalfa , Elai Davicioni , Yangyang Hao , Daniel Spratt , R. Jeffrey Karnes , J. Todd Purves , Francis Hughes Jr. , Judd Moul , Michael Abern","Duke University Medical Center, Veracyte, Inc., University Hospitals Seidman Cancer Center, Case Western Reserve University, Department of Urology, Mayo Clinic in Rochester"
768,E30,Influence of gut microbiome composition on treatment efficacy and toxicity in bladder cancer: A comprehensive meta-analysis.,"Atif Hussain Sarwar , Hashim Talib Hashim , Ahmed Qasim Mohammed Alhatemi , Muhammad Nabeel Saddique , Sheena Shamoon","Duke University, Durham, University of Warith Al-Anbiyaa, College of Medicine, Al Nasiriyah Teaching Hospital, King Edward Medical University, Rawalpindi Medical University"
782,F9,Safety and efficacy of FGFR inhibitors in urothelial carcinoma: A systematic review and meta-analysis.,"Oguz Kagan Sahin , Ayesha Ayesha , Paweł Łajczak , Sriharsha Koduru , Rafae Ali Khan , Giulia Almirón , Hussam Akram","Edremit State Hospital, Shifa College of Medicine, Medical University of Silesia, Jawaharlal Institute of Postgraduate Medical Education and Research, Riphah International University, Universidade Metropolitana de Santos (UNIMES)"
97,C7,Real world outcomes of 177Lu-PSMA-617 PSMA in a racially diverse cohort of patients with metastatic castration resistant prostate cancer (mCRPC).,"Margo Gerke , Angelo Marra , Yuan Liu , Saima Muzahir , Jacqueline Brown , Bassel Nazha , Jacob Berchuck , Ravi Parikh , Jordan Ciuro , Caitlin Hartman , Greta McClintock , Sarah Caulfield , Omer Kucuk , Bradley Carthon , David Schuster , Mehmet Bilen","Emory University School of Medicine, Winship Cancer Institute of Emory University, Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Department of Radiology and Imaging Sciences, Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Department of Radiology and Imaging Sciences, Division of Nuclear Medicine and Molecular Imaging, Emory University, Emory University School of Medicine, Winship Cancer Institute of Emory University"
370,J34,"Utilization, healthcare expenditures, and patient costs of definitive treatment modalities for localized prostate cancer in the United States.","Nikhil Sebastian , Dattatraya Patil , Pretesh Patel , Ashesh Jani , Bruce Hershatter , Vishal Dhere , Karen Godette , Aaron Weiss , Charles Lorentz , Shreyas Joshi , Martin Sanda , Sagar Patel","Emory University, Department of Urology, Emory University School of Medicine, Winship Cancer Institute of Emory University, Department of Urology, Emory University, Department of Radiation Oncology, Emory University"
216,F20,Clinical outcomes from a prospective study of comprehensive genomic testing in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).,"Daniel Shevrin , Mathew Yang , Linda Sabatini , Nicklas Pfanzelter , Michael Akroush , Hussein Alnajar , Henry Wittich , Larry Helseth",Endeavor Health
164,E3,Low-dose abiraterone in metastatic castration-resistant prostate cancer.,"Julia Lopes , Ana Sanches , Beatriz De Menezes Dobbert , Fabio Fernandez , João Guedes , João Netto , Luiza Ferreira , Lorena Forner , Daniel Araujo","Faculdade de Medicina de São José do Rio Preto, Hospital De Base São José do Rio Preto, Hospital De Base Sao Jose Do Rio Preto, Hospital de Base de São José do Rio Preto, Hospital de Base Faculdade de Medicina de São José do Rio Preto, BC Cancer"
856,H20,"PPARG protein expression in advanced urothelial carcinoma and selection for response to FX-909, a first-in-class PPARG-targeting agent.","Evisa Gjini , William Motley , Adarsh Joshi , Bijal Kakrecha , Jennifer Mertz , Kaylyn Williamson , Stefan Kirov , Michaela Bowden",Flare Therapeutics
743,E5,Optimizing treatment approaches in nested bladder tumors: A multicenter retrospective study.,"Patrizia Giannatempo , Paolo Ambrosini , Marco Maruzzo , Francesco Mistretta , Luigi Da Pozzo , Francesco Soria , Marco Barella , Alessandro Rametta , Alberto Quistini , Giovanni La Croce , David D'Andrea , Andrea Di Marco , Rodolfo Hurle , Roberto Contieri , Paolo Gontero , Gennaro Musi , Giuseppe Procopio , Rosalba Miceli , Alessio Polymeropoulos , Nicola Nicolai","Fondazione IRCCS Istituto Nazionale dei Tumori, Istituto Nazionale dei Tumori Milano, Oncology 3 Unit, Veneto Institute of Oncology IOV - IRCCS, European Institute of Oncology, ASST Papa Giovanni XIII, AOU Città della Salute e della Scienza di Torino, Division of Pathology, Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Genitourinary Oncology Unit, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, IEO Istituto Europeo di Oncologia, ASST Papa Giovanni XXIII, Medizinische Universität Wien, Oncology Unit 1, Istituto Oncologico Veneto, IOV - IRCCS, IRCCS - Humanitas Research Hospital, Humanitas University, Dipartimento di Discipline Medico Chirurgiche, Clinica Urologica, University of Torino, Genitourinary Medical Oncology, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Unit of Biostatistics for Clinical Research, Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Biostatistics for Clinical Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Urology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori"
TPS284,M3,"Global, phase 3, open-label, single arm studies to evaluate the efficacy, safety, and pharmacokinetics of FP‑014, 11.25 mg (triptorelin mesylate injection, 11.25 mg) and FP-014, 22.5 mg (triptorelin mesylate injection, 22.5 mg) in patients with advanced prostate cancer.","Bassem Elmankabadi , Yisheng Lee , Yuhua Li , Andrew Guarino , Wiliam Miller , Mathieu Boudreau , Benjamin Chien , Connor Peterson",Foresee Pharmaceuticals
201,F5,Evaluation of a variant origin prediction (VOP) algorithm to distinguish clonal hematopoiesis (CH) variants from tumor-derived variants and to predict metastatic castrate resistant prostate cancer (mCRPC) clinical responses.,"Daokun Sun , Shai He , Derek Brown , Hanna Tukachinsky , Jason Hughes , Eliana Polisecki , Russell Madison , Lincoln Pasquina , Alexander Fine , Brennan Decker , David Fabrizio , Jie He , Kalpit Shah , Zoe June Assaf , Thomas Powles , Christopher Sweeney , Lee Albacker , Jared White , Lucas Dennis , Chang Xu","Foundation Medicine, Inc., Foundation Medicine, Foundation Medicine Inc, Genentech, Inc., Barts Cancer Institute, Queen Mary University of London, South Australian Immunogenomics Cancer Institute, University of Adelaide"
480,E13,Real-world analysis of pembrolizumab utilization and characteristics of patients being prescribed treatment in early stage RCC.,"Robert Uzzo , Rituparna Bhattacharya , Manojkumar Bupathi , Aymen Elfiky , Alisha Monnette , Karen Todoroff , Paul Conkling , Murali Sundaram","Fox Chase Cancer Center, Merck & Co., Inc., Rocky Mountain Cancer Centers, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Ontada"
548,G15,Results from the prior treatment cohort of a phase I/II study of nivolumab and axitinib in patients with advanced renal cell carcinoma.,"Matthew Zibelman , Yasser Ged , Michael Carducci , Ana Molina , Rahul Ravilla , Rachel Basiura , Courtney Lambert , Madeline Wargins , Erika Jerome , Eli Mikkelsen , Karthik Devarajan , Karen Ruth , Rutika Kokate , Fern Anari , Pooja Ghatalia , Daniel Geynisman , Elizabeth Plimack","Fox Chase Cancer Center, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Weill Cornell Medical College, NewYork-Presbyterian Hospital, US Oncology Network/New York Oncology Hematology, Fox Chase Cancer Center - Office of Clinical Research, Biostatistics and Bioinformatics Core, Fox Chase Cancer Center, Fox Chase Cancer Center, Temple Health"
815,,A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2).,"Pooja Ghatalia , Eric Ross , Matthew Zibelman , Fern Anari , Philip Abbosh , William Tester , Tracy Rose , Suzanne Cole , James Mark , Rosalia Viterbo , Erika Jerome , Eric Horwitz , Mark Hallman , Andres Correa , Marc Smaldone , Robert Uzzo , David Chen , Alexander Kutikov , Elizabeth Plimack , Daniel Geynisman","Fox Chase Cancer Center, Thomas Jefferson University, The University of North Carolina at Chapel Hill, Department of Internal Medicine, Division of Hematology and Oncology, UT Southwestern, Fox Chase Cancer Center, Temple Health"
817,G13,Concurrent pembrozulimab and radiation treatments in the management of locally advanced bladder cancer in cisplatin-ineligible patients.,"Niraj Gupta , Robert Liebross , Jainie Clark , Aneesh Gupta , Christopher Leagre , Scott Pike , Thomas Dugan , Kenneth Ney , Markus Fitzik , Vasu Tumati","Franciscan Health, Cancer Care Group, Park Tudor high school, Urology of Indiana"
TPS286,M5,OMAHA-003: A phase 3 study of CYP11A1 inhibitor opevesostat versus next-generation hormonal agent (NHA) switch in metastatic castration-resistant prostate cancer (mCRPC) after NHA and taxane-based chemotherapy.,"Evan Yu , Yue Song , Chris Garratt , Christian Poehlein , Charles Schloss , Emmanuel Antonarakis","Fred Hutchinson Cancer Center, University of Washington, Merck & Co., Inc., Orion Corporation, Masonic Cancer Center, University of Minnesota"
789,F16,Efficacy and safety of fexagratinib (Fexa) in combination with tislelizumab (T) in a phase II study of patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC) harboring FGFR alterations (FGFRa).,"Xiaojie Bian , Dingwei Ye , Lijun Chen , Changlu Hu , Shusuan Jiang , Nianzeng Xing , Qingyun Zhang , Shuang Zhang , Jimin Chen , Fan Cheng , Guiling Li , Bin Hu , Gongxian Wang , Haitao Niu , Hui Chen , Jinjian Yang , Peng Zhang , Quan Yuan , Xi Gu , Yichao Chen","Fudan University Cancer Hospital, Department of Oncology Shanghai Medical College, Fudan University, Fifth Medical Center of Chinese People's Liberation Army General Hospital, Anhui Provincial Cancer Hospital, Hunan Cancer Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Guangxi Medical University Cancer Hospital, West China Medical Center, Sichuan University, Second Hospital of Zhejiang Uni, Renmin Hospital of Wuhan University Hubei General Hospital, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Liaoning Cancer Hospital & Institute, The First Affiliated Hospital of Nanchang University, The Affiliated Hospital of Qingdao University, Harbin Medical University Cancer Hospital;, The First Affiliated Hospital of Zhengzhou University, Abbisko Therapeutics Co.,Ltd"
796,F23,Efficacy and safety of sacituzumab tirumotecan monotherapy in patients with advanced urothelial carcinoma who progressed on or after prior anti-cancer therapies: Report from the phase 1/2 MK-2870-001 study.,"Dingwei Ye , Shusuan Jiang , Fang Yuan , Fangjian Zhou , Kui Jiang , Xiaoping Zhang , XingYa Li , Lasika Seneviratne , Guohua Yu , Mingjun Zhang , Shuang Zhang , Mei Chen , Gideon Blumenthal , Omobolaji Akala , Yaling Li , Dian Jing , Junyou Ge , Yanxia Shi","Fudan University Cancer Hospital, Department of Urology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital, Changsha, Department of Urologic Oncology Surgery, Chongqing University Cancer Hospital (Chongqing Cancer Institute and Chongqing Cancer Hospital), Department of Urology Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Department of Gynecological and Genitourinary Medical Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Union Hospital, Tongji Medical College of Huazhong University of Science & Technology, The First Affiliated Hospital of Zhengzhou University, Department of Hematology/Oncology, Los Angeles Hematology Oncology Medical Group, Weifang People's Hospital, Department of Oncology, The Second Hospital of Anhui Medical University, West China Medical Center, Sichuan University, Merck & Co., Inc., Oncology, Merck & Co., Inc., Clinical Research Center, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd, Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China"
790,F17,Efficacy and safety of fexagratinib (Fexa) in Chinese patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) harboring FGF receptor (FGFR) genetic alterations.,"Xiaojie Bian , Shanshan Wang , Dingwei Ye , Shaoxing Zhu , Xin Gou , Benkang Shi , Jun Xiao , Bin Hu , Xianling Liu , Shusuan Jiang , Haitao Liu , Chaohong He , Xiaoping Zhang , Zhiwen Chen , Xinli Kang , Changfu Li , Ning Xu , Yong Yang , Kun Li , Qilin Wang","Fudan University Cancer Hospital, Fudan University Shanghai Cancer Center, Fujian Medical University Union Hospital, First Affiliated Hospital of Chongqing Medical University, Department of Urology, Qilu Hospital of Shandong University, Anhui Provincial Hospital, Liaoning Cancer Hospital & Institute, Oncology, Second Xiangya Hospital of Central South University, Department of Urology Surgery, Hunan Cancer Hospital, Shanghai General Hospital;, Henan Cancer Hospital, Union Hospital, Tongji Medical College of Huazhong University Of Science And Technology, The First Affiliated Hospital of the Army Medical University, Hainan General Hospital, Harbin Medical University Cancer Hospital, The First Affiliated Hospital of Fujian Medical University, Beijing Cancer Hospital, Shijiazhuang People’s Hospital, Yunnan Cancer Hospital"
8,D7,Apatinib monotherapy for pretreated advanced squamous cell carcinoma of the penis: A phase II trial.,"Sheng Zhang , Xiaoying Zhao , Juan Zhou , Mingjuan Sun","Fudan University Shanghai Cancer Center, Department of Medical Oncology, Fudan University Shanghai Cancer Center, Naval Medical University"
703,C36,Intravesical gemcitabine and docetaxel combined with intravenous tislelizumab as a durable strategy for high-risk non–muscle-invasive bladder cancer.,"Xiaobao Chen , Jiang Wei , Ruoyun Xie , Huaiying Zheng",Fujian Medical University Union Hospital
TPS895,J23,A clinical trial evaluating the efficacy and safety of disitamab vedotin plus tislelizumab combined with re-TURBT in the treatment of HER-2-high expression (2+-3+) non-muscle invasive bladder cancer at high-risk and very high-risk.,"Jianhui Chen , Yiming Su , Rong Liu , Ru Chen , Shaoxing Zhu , Qianyi Qiu","Fujian Medical University Union Hospital, Fujian Medical University  Union Hospital"
177,E16,"CUPID (64Cu-TLX592 phase I PK, biodistribution and dosimetry): A proof-of-concept study of TLX592-targeted alpha therapy in prostate cancer.","Nat Lenzo , Anne Capp , Aviral Singh , Giuseppe Cardaci , Neel Patel , Michael Wheatcroft , David Cade","Genesis Care, GenesisCare Australia. St John of God Hospital Murdoch. Radiation Oncology and Theranostics Centre, Telix Pharmaceuticals"
780,F7,Preferred treatment regimens for rare genitourinary (GU) malignancies.,"Nicholas Simon , Stephanie Berg , Alan Tan , Elias Chandran , Saad Atiq , Andre Kydd , Lisa Cordes , Amir Mortazavi , Melissa Reimers , Matthew Milowsky , Cora Sternberg , Jonathan Rosenberg , Matthew Galsky , Andrea Apolo","Genitourinary Malignancies Branch, CCR, NCI, NIH, Dana-Farber Cancer Institute, Vanderbilt-Ingram Cancer Center, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Department of Medicine, Division of Oncology, Washington University School of Medicine, UNC Lineberger Comprehensive Cancer Center, Englander Institute for Precision Medicine, Weill Cornell Medicine, NewYork-Presbyterian Hospital, Memorial Sloan Kettering Cancer Center, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute"
45,A23,Prospective monitoring of prostate specific membrane antigen (PSMA) –positive recurrent prostate cancer: Preliminary data from 6 months PSMA follow-up.,"Ravi Madan , Melissa Abel , Esther Mena , Liza Lindenberg , Megan Hausler , Monique Williams , Amy Hankin , Jeanny Aragon-Ching , Laura Sena , Russell Pachynski , Edwin Posadas , Helen Moon , Marijo Bilusic , Philip Arlen , Krishnan Patel , Deborah Jolissaint , Gregory Chesnut , William Figg , Fatima Karzai , Peter Choyke","Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health, Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Inova Schar Cancer Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Department of Medicine, Division of Oncology, Washington University School of Medicine, Cedars-Sinai Medical Center, SCPMG, Kaiser Permanente, University of Miami Sylvester Comprehensive Cancer Center, Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, The Center for Prostate Disease Research/Walter Reed, Molecular Imaging Program, National Cancer Institute, National Institutes of Health"
TPS306,M25,WITHDRAWN: Evaluating PSA and PSMA responses of enzalutamide with or without a tumor targeting immunocytokine (PDS01ADC) in patients with PSMA-positive recurrent prostate cancer without testosterone-lowering therapy.,"Monique Williams , Melissa Abel , Amy Hankin , Lisa Cordes , Ruchi Patel , Katherine Lee-Wisdom , Megan Hausler , Jeanny Aragon-Ching , Philip Arlen , Renee Donahue , Yo-Ting Tsai , Jeffrey Schlom , James Gulley , William Figg , Fatima Karzai , Ravi Madan","Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health, Inova Schar Cancer Institute, Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health"
587,H22,Nectin-4 and Trop-2 expression as potential therapeutic target in collecting duct carcinoma: Preliminary results from the CICERONE trial (NCT05372302).,"Giuseppe Procopio , Alessandro Rametta , Marco Stellato , Filippo Guglielmo Maria de Braud , Katia Todoerti , Luca Agnelli , Veronica Huber , Licia Rivoltini , Luisa Rollo , Chiara Vela , Melanie Claps , Valentina Guadalupi , Eleonora Gusmaroli , Simone Rota , Anna Caliò , Guido Martignoni , Elena Verzoni , Matteo Brunelli","Genitourinary Medical Oncology, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Genitourinary Oncology Unit, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Genitourinary Oncology Unit, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Unit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy, Genitourinary Oncology Unit, Medical Oncology Department, Fondaione IRCCS Istituto Nazionale Tumori, Genitourinary Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Department of Diagnostic and Public Health, Section of Pathology, University of Verona, Department of Diagnostic and Public Health, Section of Pathology, University of Verona, Verona; Department of Pathology, Pederzoli Hospital, Genitourinary Medical Oncology, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori"
858,H22,Prevalence of FGFR3 p.Arg248Cys mutation in lynch syndrome associated urothelial carcinoma: A single institution dataset.,"Alessandro Rametta , Marco Vitellaro , Marco Barella , Marco Stellato , Paolo Ambrosini , Valentina Guadalupi , Sebastiano Nazzani , Davide Biasoni , Mario Catanzaro , Andrea Scardino , Biagio Paolini , Andrea Vingiani , Federica Perrone , Elena Tamborini , Francesca Barbetta , Nicola Nicolai , Giancarlo Pruneri , Massimo Milione , Giuseppe Procopio , Patrizia Giannatempo","Genitourinary Oncology Unit, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Unit of Hereditary Digestive Tract Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Division of Pathology, Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Genitourinary Medical Oncology, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Urology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Urology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Department of Pathology and Laboratory Medicine - Fondazione IRCCS Istituto Nazionale dei Tumori, Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Diagnostic Pathology and Laboratory, Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, First Division of Pathology, Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Genitourinary Medical Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori"
586,H21,Association of myeloid-derived suppressor cell (MDSC) dynamics with clinical response to nivolumab in metastatic clear cell renal carcinoma patients (mRCC): Results from the I-RENE Meet-URO 8 study.,"Elena Verzoni , Monica Rodolfo , Viviana Vallacchi , Katia Todoerti , Paolo Andrea Zucali , Bruno Perrucci , Sebastiano Buti , Marco Maruzzo , Isabella Vittimberga , Giuseppe Fornarini , Eleonora Gusmaroli , Agata Cova , Simona Frigerio , Francesca Rini , Paola Squarcina , Luca Lalli , Giuseppe Procopio , Licia Rivoltini , Veronica Huber","Genitourinary Oncology Unit, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Unit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Department of Oncology, IRCCS Humanitas Research Hospital, Ospedale di Cremona, Medical Oncology Unit, University Hospital of Parma, Oncology 3 Unit, Veneto Institute of Oncology IOV - IRCCS, Oncologia Medica Ospedale A Manzoni, IRCCS Ospedale Policlinico San Martino, Genitourinary Medical Oncology, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori"
501,E34,Real-world treatment pattern and clinical outcomes among patients with metastatic renal cell (mRCC) carcinoma post PD-1/PD-L1 immuno-oncology (IO) therapies.,"Neil Shah , Rahul Ravilla , Andrew Osterland , Karen Todoroff , Ching-Yu Wang , Pratik Rane , Hakim Saal , Ding Wang , Robert Motzer","Genitourinary Oncology, Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College, US Oncology Network/New York Oncology Hematology, Ontada, Merck & Co., Inc., Eisai Inc."
623,J8,Impact of bleomycin shortage in patients with advanced testicular non-seminoma germ-cell tumors: A middle-income country cancer center experience.,"Nora Sobrevilla-Moreno , Josette Staufert-Gutiérrez , Ruben Rodriguez-Bautista , Diego Lopez , Jorge Chamorro-Chamorro , Carlos Arturo Gonzalez Nuñez , Maritza Ramos-Ramirez , Paula Anel Cabrera Galeana , Miguel Jimenez Rios , Anna Scavuzzo","Genitourinary Tumors Clinic - Instituto Nacional de Cancerologia, Instituto Nacional de Cancerologia, Instituto Nacional de Cancerología"
170,E9,Use and clinical outcomes of androgen receptor inhibitors (ARIs) for non-metastatic castration resistant prostate cancer (nmCRPC) at labeled doses in Japan.,"Kazuhiro Suzuki , Nasreen Khan , Tomoyuki Taguchi , Kana Hattori , Guifang Chen , Mercedeh Ghadessi , Niculae Constantinovici , Vanessa Quintero , Hiroyoshi Suzuki","Gunma University Graduate School of Medicine, Bayer HealthCare Pharmaceuticals, Inc., Bayer Yakuhin Ltd., Bayer Consumer Care AG, Toho University Sakura Medical Center"
TPS898,J26,A phase 2/3 study of bicycle toxin conjugate zelenectide pevedotin (BT8009) targeting Nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC) (Duravelo-2).,"Yohann Loriot , Arlene Siefker-Radtke , Terence Friedlander , Andrea Necchi , Alexander Wei , Srikala Sridhar , Benjamin Garmezy , Santiago Arroyo , Emma Gartside , Jie Liu , Carly Campbell , Justin Bader , Daniel Petrylak","Gustave Roussy Institute, University Paris-Saclay, The University of Texas MD Anderson Cancer Center, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Department of Medicine, Columbia University Medical Center, Princess Margaret Cancer Centre, Sarah Cannon Research Institute, Bicycle Therapeutics, Yale School of Medicine"
440,,KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and targeted therapy combinations for advanced clear cell renal cell carcinoma (ccRCC).,"Laurence Albiges , Cristina Suárez , Thomas Powles , Robert Motzer , Walter Stadler , Wilson Miller Jr., Carlos Rojas , Avivit Peer , Jeffrey Goh , Se Hoon Park , Tom Waddell , Philippe Barthelemy , Pablo Gajate , Andrew Weickhardt , Guy Faust , Rodolfo Perini , Lockman Bousserouel , Ding Wang , Hans Hammers , Katy Beckermann","Gustave Roussy, Paris-Saclay University, Vall d’Hebron Institute of Oncology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barts Health NHS Trust and the Royal Free NHS Foundation Trust, Barts Cancer Institute and Queen Mary University of London, Memorial Sloan Kettering Cancer Center, The University of Chicago, Jewish General Hospital, Bradford Hill, Rambam Health Care Campus, Royal Brisbane & Women’s Hospital, Sungkyunkwan University Samsung Medical Center, Christie Hospital, Institut de cancérologie Strasbourg Europe, Strasbourg University Hospital, Ramón y Cajal University Hospital, Olivia Newton John Cancer Research Institute, University Hospitals of Leicester NHS Trust, Merck & Co., Inc., UT Southwestern Medical Center, Vanderbilt University Medical Center"
23,A1,Late onset of apalutamide-related skin toxicity in Black men with advanced prostate cancer: A diverse real-world analysis.,"Chen Yong , Alaa Ahmed Genidy Aly , Debra Josephs , Deborah Enting , Kate Smith , Danielle Crawley , Nabil Mahmoud Abdelfattah , Elias Pintus","Guy's and St Thomas' NHS Foundation Trust, Bahrain Oncology Center, Guy's and St Thomas' NHS Foundation Trust, Guy's Cancer Centre"
118,C28,Implementation and preliminary validity of the Functional Assessment of Cancer Therapy – Radionuclide Therapy (FACT-RNT) in patients receiving radionuclide therapy for prostate cancer.,"Lisa Gudenkauf , Tugce Telli , Astrid Delker , Danielle Simon , Heather Jim , Laura Oswald , Xiaoyin Li , Aasha Hoogland , Adam Dicker , Scott Tagawa , David Cella , Michael Hofman , Johannes Czernin , Jeremie Calais , Lena Unterrainer , Wolfgang Fendler , Ken Herrmann , Ghassan El-Haddad , Brian Gonzalez","H. Lee Moffitt Cancer Center and Research Institute, Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Department of Health Outcomes and Behavior, H. Lee Moffitt Cancer Center and Research Institute, Kimmel Cancer Center, Thomas Jefferson University, Weill Cornell Medical College of Cornell University, Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Peter MacCallum Cancer Centre, Ahmanson Translational Theranostics Division, University of California, Los Angeles, Department of Nuclear Medicine, University Hospital, LMU Munich, Department of Nuclear Medicine, University of Duisburg-Essen, and German Cancer Consortium (DKTK), University Hospital Essen, Clinic for Nuclear Medicine and German Cancer Consortium, University Hospital Essen"
3,D2,Application of radiomics as a risk stratification tool in node positive penile cancer.,"Adnan Fazili , Brian Morse , Abraham Ahmed , Jongphil Kim , Daniel Jeong , Philippe Spiess , Jad Chahoud","H. Lee Moffitt Cancer Center and Research Institute, H. Lee Moffitt Cancer Center & Research Institute, Moffitt Cancer Center, Department of Genitourinary Medical Oncology, H. Lee Moffitt Cancer Center and Research Institute"
12,D11,Use of geospatial analysis with multiplex immunofluorescence to analyze tumor immune microenvironment patterns and prognosis in penile cancer.,"Adnan Fazili , Keerthi Gullapalli , Jasreman Dhillon , Carlos Segura , Jonathan Nguyen , Youngchul Kim , Junmin Whiting , Justin Miller , Christopher Guske , Hiroko Miyagi , Jeffrey Johnson , Logan Zemp , Philippe Spiess , Jad Chahoud","H. Lee Moffitt Cancer Center and Research Institute, H. Lee Moffitt Cancer Center and Research Institute/University of South Florida Morsani, University of South Florida Morsani College of Medicine, H. Lee Moffitt Cancer Center, Department of Hematology/Oncology, Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Department of Genitourinary Medical Oncology, H. Lee Moffitt Cancer Center and Research Institute"
824,G20,Frequency and impact of a genome-wide homologous recombination deficiency signature (HRDsig+) on the genomic landscape of clinically advanced penile squamous cell carcinoma (CAPSCC).,"Philippe Spiess , Andrea Necchi , Roger Li , Ashish Kamat , Petros Grivas , Shilpa Gupta , Neeraj Agarwal , Liang Cheng , Dean Pavlick , Ethan Sokol , Ryon Graf , Douglas Lin , Jeffrey Ross , Alexa Schrock , Julia Quintanilha , Gerald Li , Jerry Mitchell , Joseph Jacob , Alina Basnet , Gennady Bratslavsky","H. Lee Moffitt Cancer Center and Research Institute, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, The University of Texas MD Anderson Cancer Center, University of Washington and Fred Hutchinson Cancer Center, Cleveland Clinic Taussig Cancer Institute, Huntsman Cancer Institute (NCI-CCC), University of Utah, Warren Alpert Medical School of Brown University, Foundation Medicine, Inc., Department of Pathology, SUNY Upstate Medical University, Department of Urology, Upstate Medical University, SUNY Upstate Medical University"
11,D10,Progressive T cell exhaustion and predominance of aging tissue associated macrophages with advancing disease stage in penile squamous cell carcinoma.,"Hiroko Miyagi , Xiaoqing Yu , Taylor Peak , Jasreman Dhillon , Xuefeng Wang , Sean Yoder , Douglas Marchion , Xin Lu , Curtis Pettaway , Carlos Segura , Gabriel Roman Souza , Alice Yu , Chaomei Zhang , Logan Zemp , Philippe Spiess , Jad Chahoud , Casey Le","H. Lee Moffitt Cancer Center and Research Institute, Molecular Genomics Core Facility, H. Lee Moffitt Cancer Center and Research Institute, University of Notre Dame, Division of Surgery, Department of Urology, The University of Texas MD Anderson Cancer Center, H. Lee Moffitt Cancer Center and Research Institute/University of South Florida Morsani, Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center & Research Institute, H. Lee Moffitt Cancer Center, Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Department of Genitourinary Medical Oncology, H. Lee Moffitt Cancer Center and Research Institute"
117,C27,Comparing quality of life in prostate cancer patients: Continuous vs. intermittent androgen deprivation therapy—A systematic review and meta-analysis.,"Moazzam Shahzad , Ahmad Basharat , Ghulam Mujtaba , Muhammad Fareed Khalid , Prashil Dave , Ammad Naeem , Sarmad Warraich , Michael Jaglal","H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Marshfield Clinic, LSU Health, Danbury Hospital, SUNY Downstate, CAMC Institute for Academic Medicine, Internal Medicine, Medical University of Verna, H. Lee Moffitt Cancer Center and Research Institute"
TPS14,K5,A phase II trial of dostarlimab and niraparib combination therapy in patients with stage III-IV recurrent or refractory penile cancer.,"Gabriel Roman Souza , Curtis Pettaway , Matthew Campbell , Robin Neubauer , Andrew Johns , Sarah Mizelle , Youngchul Kim , Jus Chadha , Jingsong Zhang , Ghazal Jameel , Erika Oschmann , Jasreman Dhillon , Anay Moscu , Ryan Janeway , David Harris , Xin Lu , Philippe Spiess , Jad Chahoud","H. Lee Moffitt Cancer Center and Research Institute/University of South Florida Morsani, Division of Surgery, Department of Urology, The University of Texas MD Anderson Cancer Center, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, H. Lee Moffitt Cancer Center and Research Institute, Investigational Drug Services, H. Lee Moffitt Cancer Center and Research Institute, University of Notre Dame, Department of Genitourinary Medical Oncology, H. Lee Moffitt Cancer Center and Research Institute"
863,H27,Spatial transcriptomic analysis of tumor tissue from patients with metastatic urothelial carcinoma (mUC) receiving ipilimumab (IPI) plus nivolumab (Nivo) combined with sacituzumab govitecan (SG).,"Faustine Ong , Jin Xu , Yonghong Zhang , Monica Chatwal , Jus Chadha , Carlos Segura , Sean Yoder , Gabriela Villeta-Astacio , Douglas Marchion , Jasreman Dhillon , Jingsong Zhang , Jose Alejandro Guevara , Xuefeng Wang , Guru Sonpavde , Rohit Jain , Youngchul Kim","H. Lee Moffitt Cancer Center and Research Institute/University of South Florida Morsani, H. Lee Moffitt Cancer Center and Research Institute, H. Lee Moffitt Cancer Center, Molecular Genomics Core Facility, H. Lee Moffitt Cancer Center and Research Institute, H. Lee Moffitt Cancer Center & Research Institute, Department of Immuno-Oncology, H. Lee Moffitt Cancer Center and Research Institute, AdventHealth Cancer Institute, Weill Cornell Medicine"
13,D12,Spatial analysis of the immune microenvironment and identification of phenotypes of prognostic significance in penile squamous cell carcinoma (PSCC).,"Keerthi Gullapalli , Justin Miller , Adnan Fazili , Jeffrey Johnson , Christopher Guske , Junmin Whiting , Youngchul Kim , Hiroko Miyagi , Niki Zacharias , Andrew Johns , Carlos Segura , Jonathan Nguyen , Priya Rao , Philippe Spiess , Curtis Pettaway , Jad Chahoud","H. Lee Moffitt Cancer Center and Research Institute/University of South Florida Morsani, USF Health Morsani College of Medicine, H. Lee Moffitt Cancer Center and Research Institute, H. Lee Moffitt Cancer Center, Department of Hematology/Oncology, University of South Florida Morsani College of Medicine, Department of Urology, The University of Texas MD Anderson Cancer Center, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Division of Surgery, Department of Urology, The University of Texas MD Anderson Cancer Center, Department of Genitourinary Medical Oncology, H. Lee Moffitt Cancer Center and Research Institute"
554,G21,"Updated efficacy, safety, and correlative analysis of a phase II trial in metastatic renal cell carcinoma with coordinated pembrolizumab and high dose IL-2.","Jeffrey Johnson , Mayer Fishman , Michael Schell , Xiaoqing Yu , Xuefeng Wang , Gabriel Roman Souza , Justin Miller , Sarah Mizelle , Keerthi Gullapalli , Adnan Fazili , Christopher Guske , Gowtam Mannam , Ghazal Jameel , Ling Cen , Jiqiang Yao , Junmin Whiting , Jennifer Swank , Jingsong Zhang , Philippe Spiess , Jad Chahoud","H. Lee Moffitt Cancer Center, Department of Hematology/Oncology, Tampa, General Hospital Cancer Institute, H. Lee Moffitt Cancer Center and Research Institute, H. Lee Moffitt Cancer Center and Research Institute/University of South Florida Morsani, University of South Florida Morsani College of Medicine, USF Health Morsani College of Medicine, Moffitt Cancer Center, Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Department of Genitourinary Medical Oncology, H. Lee Moffitt Cancer Center and Research Institute"
472,E5,"OCTOPUS: A retrospective, multicenter study of real-world cabozantinib treatment of patients with advanced renal cell carcinoma in France—Subgroup analyses of treatment sequences and optimization.","Constance Thibault , Loic Mourey , David Pasquier , Jean-Christophe Bernhard , Mostefa Bennamoun , Pierre Bigot , Bertrand Billemont , Loïc Jaffrelot , Bérengère Narciso , Thomas Ryckewaert , Christophe Sajous , Delphine Topart , Armelle Vinceneux , Marion Boissier , Valérie Perrot , Laurence Albiges","Hôpital Européen Georges Pompidou, Institut Claudius Regaud/IUCT-Oncopole, Academic Radiation Oncology Department, Centre Oscar Lambret, CHU Bordeaux, Department of Medical Oncology; Institut Mutualiste Montsouris, CHU Angers, Department of Medical Oncology, Sainte Catherine Institut du Cancer, City Hopital, CHU Bretonneau, Centre Oscar Lambret, Hospices Civils de Lyon, Medical Oncology, CHU Montpellier, Department of Medical Oncology, Centre Léon Bérard, University of Lyon, Ipsen, Gustave Roussy, Paris Saclay University"
TPS615,K16,Phase III randomized trial of stereotactic ablative radiotherapy (SAbR) for oligometastatic advanced renal carcinoma (EA8211-SOAR).,"Suzanne Cole , Se Kim , Andrew Wentland , Mu-Han Lin , Payal Kapur , Elizabeth Wulff-Burchfield , Daniel Shevrin , Tami Gurley , John Lin , Lynne Wagner , Rana McKay , James Brugarolas , Qian Qin , Tyler Gunter , Christos Kyriakopoulos , Seema Harichand-Herdt , Glenn Sykes , Naomi Haas , Michael Carducci , Raquibul Hannan","Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, DFCI/PCC Fellowship Program - Attendings, University of Wisconsin-Madison, UT Southwestern Medical Center, Department of Pathology, University of Texas Southwestern Medical Center, University of Kansas Medical Center, Endeavor Health, University Of Pennsylvania, Wake Forest University School of Medicine, UC San Diego School of Medicine, Department of Internal Medicine, Division of Hematology and Oncology, UT Southwestern, Stephenson Cancer Center, University of Wisconsin Carbone Cancer Center, Mid Florida Cancer Center, ECOG-ACRIN Patient Advocate for Kidney Cancer, Abramson Cancer Center, University of Pennsylvania, Johns Hopkins"
224,F28,Whole-slide multiplexed tissue imaging of prostate adenocarcinoma to investigate  immune niches in high- versus low-grade tumors.,"Ali Amiryousefi , Jeremiah Wala , Brian Labadie , Aishwarya Atmakuri , Kiranj Chaudagar , Eamon Toye , Andréanne Gagné , Jia-Ren Lin , Eliezer Van Allen , Akash Patnaik , Peter Sorger","Harvard Medical School, Dana-Farber Cancer Institute, Columbia University Medical Center, Pritzker School of Medicine, The University of Chicago, University of Chicago, University of Minnesota, Quebec Heart and Lung Institute Research Center, The University of Chicago Medicine, Harvard University"
46,A24,Impact of baseline PSMA PET in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) starting first-line (1L) androgen receptor signaling inhibitor (ARSI) therapy.,"Ivan de Kouchkovsky , Moein Moradpour , Li Zhang , Abuzar Moradi Tuchayi , Xiaolin Zhu , Roxanna Juarez , Daniel Kwon , Vadim Koshkin , Jonathan Chou , Terence Friedlander , Eric Small , Rahul Aggarwal , Thomas Hope","Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, University of California, San Francisco Medical Center, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, University of California, San Francisco, Department of Radiology and Biomedical Imaging. University of California, San Francisco, Department of Radiology and Biomedical Imaging, University of California, San Francisco"
867,H31,Outcomes of enfortumab vedotin and pembrolizumab for patients previously treated with immune checkpoint inhibitors in the UNITE study.,"Tanya Jindal , Cindy Jiang , Omar Alhalabi , Fady Sidhom , Albert Jang , Dimitra Rafailia Bakaloudi , Ishita Narula , Salvador Jaime-Casas , Michael Glover , Amanda Nizam , Shilpa Gupta , Mehmet Bilen , Sumit Shah , Abhishek Tripathi , Petros Grivas , Jason Brown , Arnab Basu , Matthew Campbell , Ajjai Alva , Vadim Koshkin","Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, The University of Texas MD Anderson, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, University of Alabama at Birmingham, University Hospitals Seidman Cancer Center, Division of Oncology, Department of Medicine, University of Washington, University of Michigan Rogel Comprehensive Cancer Center, City of Hope Comprehensive Cancer Center, Stanford University Medical Center, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland Clinic Taussig Cancer Institute, Winship Cancer Institute of Emory University, Division of Oncology, Stanford University School of Medicine, University of Washington and Fred Hutchinson Cancer Center, Division of Solid Tumor Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, The University of Texas MD Anderson Cancer Center, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco"
119,C29,Impact of pre-existing diabetes mellitus on acute care use in older patients with metastatic prostate cancer on androgen receptor signaling inhibitors.,"Michael Liu , Rohit Raghunathan , Karie Runcie , Shikun Wang , Jason Wright , Alexander Wei , Mark Stein , Dawn Hershman","Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, Division of Gynecologic Oncology, Columbia University Irving Medical Center, Columbia University Irving Medical Center"
446,D14,"State of the genitourinary medical oncology workforce in the United States, 2024.","David Benjamin , Arash Rezazadeh","Hoag Family Cancer Institute, Division of Hematology/Oncology, University of California Irvine"
872,H36,"Characterization of genitourinary drug approvals by the FDA, 2020-2024.","David Benjamin , Arash Rezazadeh","Hoag Family Cancer Institute, Division of Hematology/Oncology, University of California Irvine"
783,F10,Checkpoint blockade as neoadjuvant strategy: A single-arm meta-analysis of dual PD-1/PD-L1 and CTLA-4 inhibition in urothelial cancer.,"Gabriela Gazzoni , Isadora Mamede , Guilherme Lopes , Carlos Stecca","Hospital do Servidor Público Estadual, Federal University of São João del-Rei, University Centre FMABC, Oncology Parana Center"
761,E23,Enfortumab vedotin-related skin toxicities in patients with urothelial carcinoma: A systematic review and meta-analysis.,"Gabriela Gazzoni , Maysa Vilbert , João Pedro Oliveira , Maria Dacoregio Sr., Isabella Michelon , Pedro Reis , Marcelo Braga , Clara Aleixo Simões , Lilia Oliveira , Ana Paula Cardoso","Hospital do Servidor Público Estadual, Mass General Cancer Center, Massachusetts General Hospital, Federal Univerity of Rio de Janeiro, Universidade Estadual do Centro Oeste, Catholic University of Pelotas, RS, Brazil, Universidade Federal do Rio de Janeiro, Multivix College, Harvard T. H. Can School of Public Health, Hospital Israelita Albert Einstein"
178,E17,Extreme bipolar androgen therapy: Alternating darolutamide and testosterone cypionate in patients with metastatic castration-resistant prostate cancer (mCRPC; ExBAT trial/LACOG 0620).,"Pedro Isaacsson , Andrey Soares , Denis Fontes Jardim , Fernando Maluf , Igor Alexandre Morbeck , Daniel Girardi , Mariane Dias , Vinicius Souza , Adriano Silva , Rafaela de Jesus , Gustavo Werutsky , Taiane Rebelatto , Diogo Bastos","Hospital Moinhos de Vento (HMV), Hospital Albert Einstein, Hospital Sírio-Libanês, BP - A Beneficência Portuguesa de São Paulo, Oncoclínicas & Co, Medica Scientia Innovation Research (MEDSIR), Centro de Tratamento de Tumores Botafogo (CTTB) - Oncoclinicas & Co, Hospital São Rafael - Oncologia D'Or, Instituto do Câncer e Transplante de Curitiba (ICTr), Latin American Cooperative Oncology Group (LACOG)"
250,G23,Prospective analysis of AR-V7 expression in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) sequentially treated with docetaxel and enzalutamide.,"Diogo Bastos , Luiza Primo , Jamile Silva , Nathália Crusoé , Jose Mauricio Mota , Vivian Horita , Guilherme Fialho de Freitas , David Muniz , João Resende Martins , Lilian Inoue , Elisangela Coser , Ernande dos Santos , Anamaria Camargo","Hospital Sírio-Libanês, Instituto do Câncer do Estado de São Paulo, University of São Paulo"
638,J23,Immune checkpoint inhibitors in patients with testicular cancer: A systematic review.,"Carlos Eduardo Salazar-Mejía , Estefanía Guadarrama-Rendón , Andrea Sarahi Guerra-Garza , Karina Alicia Salazar-Salazar , Carlos de la Cruz-de la Cruz , Sofia Alejandra Alvarado-Ruiz , Ramiro Quiroz-Huerta , Neri Alejandro Alvarez-Villalobos , Oscar Vidal-Gutiérrez , Rosalaura Villarreal-Gonzalez","Hospital Universitario ""Dr. José Eleuterio González"", Centro universitario contra el cancer, Oncology Service, Hospital Universitario ""Dr. José Eleuterio González"""
106,C16,Health-related quality of life in patients with metastatic prostate cancer: Results from an international real-world survey.,"Elena Castro , Suvina Amin , Alexander Niyazov , Melissa Kirker , Amanda Ribbands , Jake Butcher , Maria Walley , Maryam Munir , Pedro Barata","Hospital Universitario 12 de Octubre, Pfizer Inc., Adelphi Real World, University Hospitals Seidman Cancer Center"
TPS884,J12,Phase 2 study of perioperative sacituzumab govitecan in combination with zimberelimab and domvanalimab for patients with muscle invasive bladder cancer ineligible or who refuse cisplatin-based chemotherapy: The PRISMA-1 study.,"Ignacio Duran , Miguel Climent Duran , Iciar García Carbonero , Angela Villares , Ricardo Sánchez-Escribano , Jesus Calleja , Naiara Sagastibelza , Ainara Villafruela , Isabel Galante , Jose Dominguez , Albert Font Pous , Pol Servian , Nuria Lainez , Vicente Grasa , Urbano Anido , Anton Cimadevila , Mario Dominguez , Xavier Garcia del Muro , Oscar Buisan , Javier Puente","Hospital Universitario Marqués de Valdecilla, IDIVAL Santander, Fundación Instituto Valenciano de Oncología, Medical Oncology Department, Hospital General Universitario de Toledo, Hospital Universitario de Toledo, Valladolid University Clinical Hospital, Hospital Clinico Universitario de Valladolid, Universitary Hospital Donostia, Hospital Donostia, Hospital Clínico San Carlos, Fundación Instituto Valenciano de Oncologia, Institut Català d’Oncologia, Hospital Universitari Germans Trias i Pujol (HUGTiP), ICO - Institut Català d'Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Hospital Universitario de Navarra, Medical Oncology, University Clinical Hospital of Santiago de Compostela, Complejo Hospitalario Universitario de Santiago de Compostela SERGAS, Hospital Universitario Marques de Valdecilla, Medical Oncology Department, Institut Català d'Oncologia IDIBELL Research Institute, University of Barcelona, Hospital Germans Trias i Pujol, Urology Department, Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC)"
74,B20,"Real-world treatment patterns in patients diagnosed with metastatic castration-resistant prostate cancer in the US, 2018-2023.","Eleni Efstathiou , Weiyan Li , James Roose , Brendan Kerr , Chinelo Orji , Nina Yeh , Stephen Corson , Kumar Mukherjee","Houston Methodist Cancer Center, AstraZeneca, Flatiron Health, Merck & Co., Inc., AstraZeneca UK Ltd."
849,H13,Germline DNA repair gene variants in patients under active surveillance for low-grade bladder cancer: Implications for risk stratification.,"Roberto Contieri , Hurle Rodolfo , Giovanni Lughezzani , Pier Paolo Avolio , Vittorio Fasulo , Marco Paciotti , Giuseppe Chiarelli , Giuseppe Garofano , Giulia Soldà , Rosanna Asselta , Anita Capalbo , Piergiuseppe Colombo , Pietro Cavalli , NicolòMaria Buffi , Alberto Saita , Paolo Casale , Massimo Lazzeri","Humanitas University, IRCCS - Humanitas Research Hospital"
337,J1,Absence of prostate cancer events after 3 years of tailored screening in high-risk individuals with germline pathogenic variants in DNA repair genes.,"Vittorio Fasulo , Giuseppe Chiarelli , NicolòMaria Buffi , Pier Paolo Avolio , Giuseppe Garofano , Muhannad Aljoulani , Rosanna Asselta , Giulia Soldà , Ilaria De Simone , Piergiuseppe Colombo , Miriam Cieri , Rodolfo Hurle , Marco Paciotti , Paolo Casale , Federica Maura , Pietro Cavalli , Giovanni Lughezzani , Massimo Lazzeri","Humanitas University, IRCCS - Humanitas Research Hospital"
803,F30,Evaluating neoadjuvant intravesical mitomycin C in NMIBC: A phase III randomized clinical trial.,"Roberto Contieri , Alberto Saita , Marco Paciotti , Alessandro Uleri , Pier Paolo Avolio , Vittorio Fasulo , Ludovica Cella , Stefano Mancon , Federica Sordelli , Giuseppe Garofano , Paola Arena , Chiara Pozzi , Miriam Cieri , Piergiuseppe Colombo , NicolòMaria Buffi , Giovanni Lughezzani , Paolo Casale , Maria Rescigno , Massimo Lazzeri , Rodolfo Hurle","Humanitas University, IRCCS - Humanitas Research Hospital, Humanitas University, Department of Biomedical Sciences, Istituto Clinico Humanitas"
842,H6,Immune profiling at the single-cell level to evaluate the immune microenvironment in bladder cancer: Insights from non-muscle invasive and muscle-invasive disease.,"Pier Paolo Avolio , Anna Garbin , Marta Pandini , Roberta Carriero , Paolo Kunderfranco , Maria Elefante , Piergiuseppe Colombo , Paolo Casale , Giovanni Lughezzani , NicolòMaria Buffi , Roberto Contieri , Gianluca Basso , Diletta Di Mitri , Massimo Lazzeri","Humanitas University, IRCCS - Humanitas Research Hospital, IRCCS - Humanitas Clinical and Research Center"
421,L17,Prevalence of germline variants of uncertain significance in DNA repair genes and their potential impact on prostate cancer outcomes following radical prostatectomy.,"Giuseppe Chiarelli , Vittorio Fasulo , NicolòMaria Buffi , Giuseppe Garofano , Alessio Finocchiaro , Marco Paciotti , Pier Paolo Avolio , Miriam Cieri , Giulia Soldà , Piergiuseppe Colombo , Alberto Saita , Rodolfo Hurle , Federica Maura , Pietro Cavalli , Rosanna Asselta , Paolo Casale , Giovanni Lughezzani , Massimo Lazzeri","Humanitas University, IRCCS - Humanitas Research Hospital, Istituto Clinico Humanitas"
579,H14,Leveraging tumor organoids to model drug response in clear cell renal cell carcinoma.,"NicolòMaria Buffi , Pier Paolo Avolio , Paolo Casale , Giovanni Lughezzani , Alberto Saita , Rodolfo Hurle , Marco Paciotti , Vittorio Fasulo , Roberto Contieri , Edoardo Beatrici , Karina Koczberska , Salvatore Piscuoglio , Massimo Lazzeri","Humanitas University, IRCCS - Humanitas Research Hospital, Istituto Clinico Humanitas"
108,C18,Receipt of poly(ADP) ribose polymerase inhibitors (PARPi) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring BRCA1/2 alterations.,"Micah Ostrowski , Yeonjung Jo , Chadi Hage Chehade , Zeynep Ozay , Georges Gebrael , Nicolas Sayegh , Edwin Lin , Ayana Srivastava , Richard Ji , Haoran Li , Vinay Mathew Thomas , Sumati Gupta , Irbaz Riaz , Benjamin Maughan , Soumyajit Roy , Umang Swami , Neeraj Agarwal","Hunstman Cancer Institute at the University of Utah, Huntsman Cancer Institute at the University of Utah, Huntsman Cancer Insititute at the University of Utah, University of Kansas Cancer Center, Mayo Clinic in Arizona, Rush University Medical Center, Department of Medicine, Huntsman Cancer Institute at the University of Utah"
90,B36,First next-generation sequencing (NGS) testing at the end of life in patients with metastatic prostate cancer.,"Zeynep Ozay , Yeonjung Jo , Chadi Hage Chehade , Nicolas Sayegh , Georges Gebrael , Micah Ostrowski , Edwin Lin , Gliceida Galarza Fortuna , Blake Nordblad , Haoran Li , Vinay Mathew Thomas , Ryon Graf , Irbaz Riaz , Avirup Guha , Benjamin Maughan , Soumyajit Roy , Rana McKay , Emmanuel Antonarakis , Umang Swami , Neeraj Agarwal","Huntsman Cancer Insititute at the University of Utah, Huntsman Cancer Institute at the University of Utah, Hunstman Cancer Institute at the University of Utah, University of Kansas Cancer Center, Foundation Medicine, Inc., Mayo Clinic in Arizona, Department of Medicine, Division of Cardiology, Medical College of Georgia at Augusta University, Rush University Medical Center, University of California San Diego, Moores Cancer Center, University of Minnesota, Masonic Cancer Center, Department of Medicine, Huntsman Cancer Institute at the University of Utah"
137,D11,Association of statin use with overall survival and cardiac adverse events in patients with advanced prostate cancer treated with apalutamide: A pooled analysis of TITAN and SPARTAN.,"Zeynep Ozay , Scott Morgan , Kim Chi , Eric Small , Shawn Malone , Christopher Wallis , Michael Ong , Amar Kishan , Angela Jia , Nicholas Zaorsky , Umang Swami , Yilun Sun , Daniel Spratt , Simon Chowdhury , Neeraj Agarwal , Fred Saad , Soumyajit Roy","Huntsman Cancer Insititute at the University of Utah, The Ottawa Hospital, University of Ottawa, BC Cancer Agency, University of British Columbia, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, The Ottawa Hospital Cancer Centre, Division of Urology, Department of Surgery, University of Toronto and Mount Sinai Hospital and University Health Network, Department of Radiation Oncology, University of California, Los Angeles, University Hospitals Seidman Cancer Center, Case Western Reserve University, Department of Medicine, Huntsman Cancer Institute at the University of Utah, Case Western Reserve University, Guy's, King's, and St. Thomas' Hospitals, and Sarah Cannon Research Institute, Huntsman Cancer Institute at the University of Utah, University of Montreal Hospital Centre, Rush University Medical Center"
TPS288,M7,"Mevrometostat (PF-06821497) in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate: The phase 3, randomized MEVPRO-1 study.","Neeraj Agarwal , Michael Schweizer , Elena Castro , Arun Azad , Daniel George , Jayeta Chakrabarti , Sujata Narayanan , Yiyun Tang , Karim Fizazi","Huntsman Cancer Institute (NCI-CCC), University of Utah, Division of Medical Oncology, University of Washington, and Clinical Research Division, Fred Hutchinson Cancer Cancer, Medical Oncology, Hospital 12 de Octubre, Department of Medical Oncology, Peter MacCallum Cancer Centre, Duke Cancer Institute, Duke University School of Medicine, Oncology, Pfizer Inc., Biostatistics Oncology, Global Biometrics and Data Management, Pfizer Inc., Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Saclay"
48,A26,Barriers to and facilitators of first-line treatment intensification (TI) in metastatic castration-sensitive prostate cancer (mCSPC) by practice setting and intensification frequency: A sub-analysis of IMPLEMENT.,"Neeraj Agarwal , Stacy Loeb , Nader El-Chaar , Laura de Ruiter , Janet Kim , Jessica Mack , Betty Thompson , Sarah Rich-Zendel , Jay Sheldon , Jin Su Joo , Judith Dyson","Huntsman Cancer Institute (NCI-CCC), University of Utah, NYU Langone Health, Astellas Pharma Inc., Pfizer Inc., Throughline Strategy, Birmingham City University"
38,A16,Phase II trial of image-guided oligometastatectomy and radiation therapy in recurrent prostate cancer (SOAR).,"Alejandro Sanchez , Umang Swami , Bogdana Schmidt , Christopher Dechet , Kenneth Boucher , Lisa Chapman , Hillary Davis , Jeff Linton , Erica Farr , Samuel Leonhart , Josiah Hawks , Skyler Johnson , Jonathan Tward , Bismarck Odei , Sumati Gupta , Neeraj Agarwal , Brock ONeil , Benjamin Maughan","Huntsman Cancer Institute at the University of Utah, Department of Medicine, Huntsman Cancer Institute at the University of Utah, Hunstman Cancer Institute at the University of Utah"
173,E12,Time to metastasis after prostatectomy (TTM) and survival outcomes in patients (pts) with metachronous metastatic hormone-sensitive prostate cancer (mHSPC): A secondary analysis of the SWOG 1216 phase 3 trial.,"Nicolas Sayegh , Yeonjung Jo , Umang Swami , Chadi Hage Chehade , Zeynep Ozay , Georges Gebrael , Benjamin Maughan , Melissa Plets , Maha Hussain , Tanya Dorff , Primo Lara Jr., Amir Goldkorn , Seth Lerner , Neeraj Agarwal","Huntsman Cancer Institute at the University of Utah, Department of Medicine, Huntsman Cancer Institute at the University of Utah, SWOG Statistics and Data Management Center, Northwestern University, Feinberg School of Medicine, City of Hope Comprehensive Cancer Center, University of California, Davis Comprehensive Cancer Center, USC Norris Comprehensive Cancer Center, Baylor College of Medicine, Huntsman Cancer Institute (NCI-CCC), University of Utah"
205,F9,Impact of homologous recombination repair alterations (HRRalt) on survival outcomes of patients (Pts) with metastatic hormone-sensitive prostate cancer (mHSPC).,"Chadi Hage Chehade , Ryon Graf , Georges Gebrael , Zeynep Ozay , Nicolas Sayegh , Gerald Li , Benjamin Maughan , Emmanuel Antonarakis , Rana McKay , Neeraj Agarwal , Umang Swami","Huntsman Cancer Institute at the University of Utah, Foundation Medicine, Inc., University of Minnesota, Masonic Cancer Center, University of California, San Diego, Huntsman Cancer Institute (NCI-CCC), University of Utah, Department of Medicine, Huntsman Cancer Institute at the University of Utah"
42,A20,Utilizing ChatGPT for assessing disease volume in patients (pts) with metastatic prostate cancer (mPC).,"Diya Garg , Micah Ostrowski , Ayana Srivastava , Beverly Chigarira , Yeonjung Jo , Zeynep Ozay , Chadi Hage Chehade , Georges Gebrael , Nicolas Sayegh , Gliceida Fortuna , Vinay Mathew Thomas , Benjamin Maughan , Umang Swami , Neeraj Agarwal , Haoran Li","Huntsman Cancer Institute at the University of Utah, Hunstman Cancer Institute at the University of Utah, Department of Medicine, Huntsman Cancer Institute at the University of Utah"
120,C30,A prospective trial of a structured exercise program to lessen fatigue in patients with advanced prostate cancer (aPC) undergoing androgen deprivation therapy (ADT).,"Benjamin Maughan , Neeraj Agarwal , Darren Walker , Adriana Coletta , Blake Nordblad , Umang Swami , Sumati Gupta , Saundra Buys , Manish Kohli , Pamela Hansen , Kenneth Boucher , Norah Henry","Huntsman Cancer Institute at the University of Utah, Hunstman Cancer Institute at the University of Utah, Department of Medicine, Huntsman Cancer Institute at the University of Utah, University of Michigan Medical School"
100,C10,Evaluation of time to metastasis (TTM) from prostatectomy and survival in patients (pts) with metachronous metastatic hormone-sensitive prostate cancer (mHSPC) receiving androgen deprivation therapy (ADT) intensification: A real-world study.,"Nicolas Sayegh , Yeonjung Jo , Zeynep Ozay , Chadi Hage Chehade , Georges Gebrael , Micah Ostrowski , Patrick Campbell , Siqi HU , Nishita Tripathi , Blake Nordblad , Beverly Chigarira , Richard Ji , Gliceida Galarza Fortuna , Vinay Mathew Thomas , Benjamin Maughan , Umang Swami , Neeraj Agarwal","Huntsman Cancer Institute at the University of Utah, Hunstman Cancer Institute at the University of Utah, Huntsman Cancer Insititute at the University of Utah, Weill Medical College, Cornell University, NewYork-Presbyterian Hospital, Department of Medicine, Huntsman Cancer Institute at the University of Utah, Huntsman Cancer Institute (NCI-CCC), University of Utah"
75,B21,Treatment (Rx) patterns and attrition rates in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).,"Georges Gebrael , Yeonjung Jo , Chadi Hage Chehade , Zeynep Ozay , Nicolas Sayegh , Micah Ostrowski , Patrick Campbell , Ethan Anderson , Blake Nordblad , Gliceida Galarza Fortuna , Vinay Mathew Thomas , Irbaz Riaz , Ryon Graf , Avirup Guha , Benjamin Maughan , Soumyajit Roy , Emmanuel Antonarakis , Neeraj Agarwal , Umang Swami","Huntsman Cancer Institute at the University of Utah, Hunstman Cancer Institute at the University of Utah, University of Utah Health, Mayo Clinic in Arizona, Foundation Medicine, Inc., Department of Medicine, Division of Cardiology, Medical College of Georgia at Augusta University, Rush University Medical Center, University of Minnesota, Masonic Cancer Center, Huntsman Cancer Institute (NCI-CCC), University of Utah, Department of Medicine, Huntsman Cancer Institute at the University of Utah"
82,B28,Survival outcomes of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving lutetium-177-PSMA-617 (Lu) based on line of therapy.,"Nicolas Sayegh , Yeonjung Jo , Zeynep Ozay , Chadi Hage Chehade , Georges Gebrael , Micah Ostrowski , Patrick Campbell , Nishita Tripathi , Siqi HU , Beverly Chigarira , Ethan Anderson , Richard Ji , Gliceida Fortuna , Vinay Mathew Thomas , Haoran Li , Sumati Gupta , Benjamin Maughan , Neeraj Agarwal , Umang Swami","Huntsman Cancer Institute at the University of Utah, Hunstman Cancer Institute at the University of Utah, University of Utah Health, University of Kansas Cancer Center, Huntsman Cancer Institute (NCI-CCC), University of Utah, Department of Medicine, Huntsman Cancer Institute at the University of Utah"
162,D36,Survival outcomes based on line of therapy and treatment trends with cabazitaxel in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).,"Ayana Srivastava , Yeonjung Jo , Zeynep Ozay , Chadi Hage Chehade , Georges Gebrael , Nicolas Sayegh , Micah Ostrowski , Patrick Campbell , Gliceida Fortuna , Beverly Chigarira , Siqi HU , Diya Garg , Richard Ji , Blake Nordblad , Ethan Anderson , Vinay Mathew Thomas , Sumati Gupta , Benjamin Maughan , Umang Swami , Neeraj Agarwal","Huntsman Cancer Institute at the University of Utah, Hunstman Cancer Institute at the University of Utah, University of Utah Health, Weill Medical College, Cornell University, NewYork-Presbyterian Hospital, Department of Medicine, Huntsman Cancer Institute at the University of Utah, Huntsman Cancer Institute (NCI-CCC), University of Utah"
109,C19,Time from medication order to administration of cabazitaxel (C) vs. lutetium Lu-177 vipivotide tetraxetan (Lu) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).,"Yeonjung Jo , Chadi Hage Chehade , Zeynep Ozay , Georges Gebrael , Nicolas Sayegh , Richard Hardy , Siqi HU , Nishita Tripathi , Beverly Chigarira , Blake Nordblad , Richard Ji , Diya Garg , Gliceida Galarza Fortuna , Vinay Mathew Thomas , Haoran Li , Soumyajit Roy , Benjamin Maughan , Irbaz Riaz , Neeraj Agarwal , Umang Swami","Huntsman Cancer Institute at the University of Utah, Huntsman Cancer Insititute at the University of Utah, Univeristy of Utah, Weill Medical College, Cornell University, NewYork-Presbyterian Hospital, University of Kansas Cancer Center, Rush University Medical Center, Mayo Clinic in Arizona, Huntsman Cancer Institute (NCI-CCC), University of Utah, Department of Medicine, Huntsman Cancer Institute at the University of Utah"
86,B32,In-field progression following radiation therapy as a prognostic biomarker for lutetium-177-PSMA-617 response in metastatic castration-resistant prostate cancer.,"Jackson Howell , Jacob Wilkes , Nichole Maughan , Kathryn Morton , Eric Hu , David Gill , Scott Samuelson , Dustin Boothe","Huntsman Cancer Institute at the University of Utah, Intermountain Health, Department of Radiology, Intermountain Health, Utah Cancer Specialists, Department of Radiation Oncology, Intermountain Health"
LBA18,,Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial.,"Neeraj Agarwal , Arun Azad , Joan Carles , Andre Fay , Nobuaki Matsubara , Cezary Szczylik , Ugo De Giorgi , Jae Young Joung , Peter Fong , Eric Voog , Robert Jones , Neal Shore , Curtis Dunshee , Stefanie Zschaebitz , Jan Oldenburg , Xun Lin , Cynthia Healy , Matko Kalac , Dana Kennedy , Karim Fizazi","Huntsman Cancer Institute at the University of Utah, Peter MacCallum Cancer Centre, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), PUCRS School of Medicine, National Cancer Center Hospital East, European Health Center, Otwock, and Postgraduate Medical Education Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, National Cancer Center, Auckland City Hospital and University of Auckland, Clinique Victor Hugo Centre Jean Bernard, School of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Carolina Urologic Research Center, Arizona Urology Specialists, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Akershus University Hospital (Ahus), Pfizer Inc., Institut Gustave Roussy, University of Paris-Saclay"
727,D24,Rates of first next-generation sequencing (NGS) testing at the end of life in patients (pts) with advanced urothelial carcinoma (aUC).,"Chadi Hage Chehade , Yeonjung Jo , Zeynep Ozay , Georges Gebrael , Nicolas Sayegh , Richard Hardy , Ethan Anderson , Blake Nordblad , Vinay Mathew Thomas , Haoran Li , Sumati Gupta , Ryon Graf , Soumyajit Roy , Benjamin Maughan , Irbaz Riaz , Rana McKay , Umang Swami , Neeraj Agarwal","Huntsman Cancer Institute at the University of Utah, Univeristy of Utah, University of Kansas Cancer Center, Foundation Medicine, Inc., Rush University Medical Center, Mayo Clinic in Arizona, UC San Diego School of Medicine, Department of Medicine, Huntsman Cancer Institute at the University of Utah, Huntsman Cancer Institute (NCI-CCC), University of Utah"
225,F29,Plasma proteome-based integrative prognostic nomogram in metastatic castrate-resistant prostate cancer (mCRPC).,"Manish Kohli , Joseph Finklestein , Xingyue Huo , Claire Hanson , Matt Larsen , Enos Ampaw , Bogdana Schmidt , Benjamin Maughan , Umang Swami , Jonathan Tward , Skyler Johnson , Brock ONeil , Christopher Dechet , Liang Wang , Aikchoon Tan , Muhammad Hidayatullah Fadlullah","Huntsman Cancer Institute at the University of Utah, University of Utah, Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute at the University of Utah, Hunstman Cancer Institute at the University of Utah, H. Lee Moffitt Cancer Center and Research Institute"
204,F8,Association of a novel AI-based digital pathology (CHAI) biomarker with progression free survival (PFS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC).,"Georges Gebrael , Vrishab Krishna , Nicolas Sayegh , Chadi Hage Chehade , Zeynep Ozay , Snehal Sonawane , Viswesh Krishna , Daniel Miller , Waleed Abuzeid , Siddhant Shingi , Louis Vaickus , Damir Vrabac , Anirudh Joshi , Vivek Nimgaonkar , Umang Swami , Deepika Sirohi , Neeraj Agarwal","Huntsman Cancer Institute at the University of Utah, Valar Labs, Inc, Valar Labs, Dartmouth Hitchcock Medical Center, Department of Medicine, Huntsman Cancer Institute at the University of Utah, University of California, San Francisco, Huntsman Cancer Institute (NCI-CCC), University of Utah"
659,,Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA.,"Matthew Galsky , Michiel Van Der Heijden , James Catto , Hikmat Al-Ahmadie , Joshua Meeks , Hiroyuki Nishiyama , Alexandra Drakaki , Toan Vu , Lorenzo Antonuzzo , Vagif Atduev , Ariel Kann , Albert Font Pous , Chao-Hsiang Chang , Ronald De Wit , Marek Wojtukiewicz , Wenjing Xin , Sarah Donegan , Stephan Hois , Thomas Powles","Icahn School of Medicine at Mount Sinai, Department of Medical Oncology, Netherlands Cancer Institute, Division of Clinical Medicine, University of Sheffield, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, Departments of Urology, Biochemistry and Molecular Genetics, Northwestern University, Feinberg School of Medicine, Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Department of Internal Medicine 3, Vietnam National Cancer Hospital, Department of Experimental and Clinical Medicine, University of Florence, and the Medical Oncology Unit, Careggi University Hospital, Volga District Medical Center, Federal Medical-Biological Agency, Clinical Oncology, Hospital Alemão Oswaldo Cruz, Medical Oncology Department, Institut Català d’Oncologia, Badalona Applied Research Group in Oncology (BARGO), Hospital Universitari Germans Trias i Pujol, Department of Urology and School of Medicine, China Medical University and Hospital, Department Medical Oncology, Division Lead Genito-Urinary Clinical Research, Erasmus Medical Center, Maria Skłodowska-Curie Białystok Oncology Center, AstraZeneca, Barts Cancer Centre, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London"
416,L12,Molecular insights of low-PSA–expressing high-risk prostate cancer.,"Goutam Chakraborty , Nabila Zaman , Adriana Pedraza , Natasha Kyprianou , Ashutosh Tewari","Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai"
722,D19,Real world effectiveness of systemic treatment in patients (pts) with advanced upper tract urothelial carcinoma (UTUC) with histological variants.,"Fabien Moinard-Butot , Karim Amrane , Luca Campedel Sr., Damien Pouessel , Mostefa Bennamoun , Aude Flechon , Matthieu Roulleaux Dugage , Pierre-Etienne Gabriel Jr., Constance Thibault , Baptiste Abbar , Jean-Baptiste Barbe-Richaud , Clement Dumont , Philippe Barthelemy","ICANS - Institut de Cancérologie Strasbourg, CH Pays de Morlaix, CHU Clermont-Ferrand, Department of Medical Oncology, Institut Claudius Régaud-IUCT-Oncopole, Department of Medical Oncology; Institut Mutualiste Montsouris, Centre Léon Bérard, Hôpital Européen Georges Pompidou, Hôpital Saint-Louis, Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP Centre, Université de Paris Cité, AP-HP Pitié Salpêtrière Hospital, Institut de Cancérologie Strasbourg Europe, Department of Oncology, Saint-Louis Hospital, AP-HP"
80,B26,Frailty and adverse clinical outcomes in prostate cancer patients: An analysis from the RADICAL-PC cohort.,"Rocio Baro Vila , Jehonathan Pinthus , Sarah Karampatos , Cristina Cano Garcia , Rajibul Mian , Jose Lopez-Lopez , Ariel Kann , Philippe Violette , surya Prakash V , Vincent Fradet , Patrick Anderson , Nicolas Villareal Trujillo , Li Ling Tan , Robert Sabbagh , Luke Lavallee , Lívia Oliveira , Darryl Leong","ICBA, Department of Surgery, Division of Urology, McMaster University, McMaster University, University Hospital Frankfurt, Goethe University Frankfurt, Department of Health Research, Evidence, and Impact, McMaster University, Population Health Research Institute, McMaster University and Hamilton Health Sciences, Clinical Oncology, Hospital Alemão Oswaldo Cruz, Woodstock General Hospital, Yashoda Hospital, CHU de Québec-Université Laval Research Center, Niagara Health, FOSCAL, National University Heart Centre, CIUSSE-CHUS, Universite de Sherbrooke, The Ottawa Hospital Cancer Centre, University of Ottawa, Centro De Pesquisa Clínica Do HC/UFTM/EBSERH"
98,C8,"Detection of mutations in homologous recombination repair (HRR) pathway genes using liquid biopsy in metastatic, castration-resistant prostate cancer (mCRPC) patients without tumor tissue availability.","Yoojoo Lim , Dong Soo Kyung , Won Yeong Ko , Hwang-Phill Kim , Tae-You Kim","IMBdx Inc., IMBdx, Seoul National University Hospital"
TPS905,J33,Phase 2 trial of immuno-ablation with intrabladder injection of N-803 or intravesical N-803 plus BCG for intermediate-risk non-muscle invasive papillary bladder cancer.,"Sandeep Bobby Reddy , Max Kates , Megan Huang , Bhavya Ravi , Paul Bhar , Bruce Brown , Leonard Sender , Patrick Soon-Shiong , Patricia Spilman","ImmunityBio, Inc., Johns Hopkins Medicine, ImmunityBio, Inc, ImmunityBio"
TPS883,J11,"A phase 1, first-in-human, open label, dose escalating study of B440, an oral cancer vaccine using a WT1-expressing Bifidobacterium, in patients with advanced urothelial cancer.","Toshiro Shirakawa , Junya Furukawa , Yasumasa Kakei , Hideto Ueki , Takuto Hara , Jun Teishima , Nobuyuki Hinata , Hideaki Miyake , Masato Fujisawa","Immunorock, Co., Ltd., Tokushima Unoversity, Kobe University, Hiroshima University, Kobe University School of Medicine"
771,E33,"Neuropathy, skin rash, and hyperglycemia as predictors of response to enfortumab vedotin in locally advanced and metastatic bladder and upper tract urothelial carcinoma.","Tareq Salous , Rebecca Hassoun , Sandra Althouse , Stephanie Schneck , Jennifer King , Nabil Adra",Indiana University Melvin and Bren Simon Comprehensive Cancer Center
68,B14,Utility of extended interval dosing of denosumab in patients with metastatic prostate cancer.,"Stephanie Schneck , Rebecca Hassoun , Sandra Althouse , Jennifer King , Tareq Salous , Nabil Adra",Indiana University Melvin and Bren Simon Comprehensive Cancer Center
127,D1,PSA response to Lu177-PSMA-617 in patients experiencing xerostomia and ocular dryness in metastatic castration resistant prostate cancer.,"Rebecca Hassoun , Mark Tann , Justin Sims , Ashleigh Auxier , Sandra Althouse , Tareq Salous , Jennifer King , Nabil Adra","Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center"
634,J19,Stage II embryonal predominant NSGCT: Minimizing treatment burden.,"Jiping Zeng , Parth Thakker , Timothy Masterson , Tareq Salous , Jennifer King , Nabil Adra , Lawrence Einhorn , Clint Cary","Indiana University School of Medicine, Department of Urology, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University, Division of Hematology & Medical Oncology, Department of Medicine, Indiana University School of Medicine, Indiana University Simon Comprehensive Cancer Center"
646,J31,Circulating tumor DNA as a prognostic biomarker to predict retroperitoneal histology in patients undergoing retroperitoneal lymph node dissection.,"Parth Thakker , Connor Drake , Jiping Zeng , Timothy Masterson , Clint Cary","Indiana University School of Medicine, Department of Urology, Indiana University Simon Comprehensive Cancer Center"
630,J15,Management of relapsed stage I seminomatous germ cell tumor with retroperitoneal or pelvic only relapse.,"Ahmed Bilal Khalid , Sandra Althouse , Tareq Salous , Clint Cary , Timothy Masterson , Lawrence Einhorn , Nabil Adra , Jennifer King , Rebecca Hassoun","Indiana University School of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University Simon Comprehensive Cancer Center, Indiana University School of Medicine, Department of Urology"
622,J7,Survival outcomes of testicular cancer (TC) in Hispanic men based on analyses from the National Cancer Database (NCDB).,"Eun-mi Yu , Hongkun Wang , Jeanny Aragon-Ching","Inova Schar Cancer Institute, Department of Biostatistics, Bioinformatics and Biomathematics, Georgetown University"
685,C18,Role of circulating tumor DNA (ctDNA) in locally advanced (LA) and metastatic urothelial cancer (mUC).,"Minira Aslanova , Arianna Lawrence , Hongkun Wang , Jeanny Aragon-Ching","Inova Schar Cancer Institute, Inova Fairfax Hospital, University of Virginia School of Medicine, Department of Biostatistics, Bioinformatics and Biomathematics, Georgetown University, Inova Schar Cancer Institute"
471,E4,Real-world assessment of clinical outcomes of first-line treatment in metastatic papillary renal cell carcinoma.,"Manon De Vries , Zineb Hamilou , Sunita Ghosh , Daniel Heng , Lori Wood , Naveen Basappa , Christian Kollmannsberger , Jeffrey Graham , Bimal Bhindi , Antonio Finelli , Georg Bjarnason , Dominick Bosse , Frederic Pouliot , Vincent Castonguay , Rodney Breau , Ramy Saleh , Eric Winquist , Aly-Khan Lalani , Denis Soulieres","Institut de Cancérologie de l'Ouest, Centre Hospitalier de l’Université de Montréal, Department of Oncology, University of Alberta, Tom Baker Cancer Centre, University of Calgary, Queen Elizabeth II Health Sciences Centre, Dalhousie University, Cross Cancer Institute, University of Alberta, British Columbia Cancer Agency, CancerCare Manitoba, University of Manitoba, Southern Alberta Institute of Urology, University of Toronto, Sunnybrook Odette Cancer Centre, University of Ottawa, CHU de Québec-Université Laval Research Center, Hotel Dieu de Quebec, Ottawa Hospital Research Institute, Department of Medical Oncology, McGill University Health Centre, Division of Medical Oncology, London Health Sciences Centre & Western University, McMaster University"
825,G21,Gut microbiota as a biomarker for the efficacy of pembrolizumab in patients with advanced urothelial carcinoma treated in a prospective multicenter study.,"Soufyan Annakib , Lucia Grenga , Catherine Dunyach-Remy , Guilhem Roubaud , Pierre Fournel , Aline Guillot , Delphine Borchiellini , Damien Pouessel , Elouen Boughalem , Remy Delva , Philippe Barthelemy , Stephane Oudard , Constance Thibault , Diego Tosi , Jean Armengaud , Nadine Houede","Institut de Cancérologie du Gard (ICG), CHU de Nîmes, Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SPI, VBIC, INSERM U1047, Service de Microbiologie et Hygiène Hospitalière, Université de Montpellier, CHU Nîmes, Department of Medical Oncology, Institut Bergonié, Pneumology Department, Institut de Cancérologie de la Loire Lucien Neuwirth, Hôpital Privé de la Loire, Department of Medical Oncology, Centre Antoine Lacassagne, Université Côte d'Azur, Department of Medical Oncology, Institut Claudius Régaud-IUCT-Oncopole, Paul Papin Centre, Institut De Cancerologie D'Ouest Centre Paul Papin, Department of Medical Oncology, Institut de Cancérologie Strasbourg Europe, Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP.Centre – Université Paris Cité, Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP Centre, Université de Paris Cité, Medical Oncology Departement, Institut du Cancer de Montpellier Inserm U1194, Montpellier University, Medical Oncology Department, Institut de Cancérologie du Gard - CHU Caremeau"
661,,Safety and efficacy of neoadjuvant immunotherapy with durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (gemcitabine/cisplatin or carboplatin) in patients with operable high-risk upper tract urothelial carcinoma.,"Nadine Houede , Thierry Chevallier , Jaffrelot Loic , Constance Thibault , Neuzillet Yann , Christine Abraham Jaillon , Alexandra Masson-Lecomte , Gwenaelle Gravis , Sophie Tartas , Damien Pouessel , Brigitte Laguerre , Francois Audenet , Evanguelos Xylinas , Luquiens Guillaume , Morgan Roupret","Institut de Cancérologie du Gard, Oncology Department, Montpellier University, Department of Biostatistics, Epidemiology, Public Health and Innovation In Methodology (BESPIM), CHU de Nîmes, Univ Montpellier, Pitie-Salpetriere Hospital, Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP Centre, Université de Paris Cité, Foch Hospital, Department of Urology, University of Paris-Saclay – UVSQ, Foch Hospital, Service d’Oncologie Médicale, Service d'Urologie Hôpital Saint Louis, Université Paris Cité, Service de Recherche en Hémato-Immunologie CEA - INSERM U976 HIPI, Immunity and Cancer Team, Department of Medical Oncology, Institut Paoli-Calmettes, INSERM, CNRS, CRCM, Aix-Marseille University, Hopital Jules Courmont, Institut Universitaire du Cancer de Toulouse - Oncopole, Oncopole Claudius Regaud, Department of Medical Oncology, Eugène Marquis Cancer Center, Hopital Européen Georges Pompidou, Bichat-Claude Bernard Hospital, Assistance Publique–Hôpitaux de Paris, Université Paris Cité, Department of Biostatistics, Epidemiology, Public Health and Innovation in Methodology, Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitie-Salpetriere Hospital"
724,D21,"Treatment sequence (TS) and overall survival (OS) in patients with metastatic urothelial cancer (mUC): An observational, multicenter, real-life STATES-Bladder study.","Fabien Moinard-Butot , Jean-Baptiste Barbe-Richaud , Edwige Baudry , Karim Amrane , Denis Maillet , Philippe Barthelemy","Institut de Cancérologie Strasbourg Europe, Institut de Cancérologie de Lorraine, CH Pays de Morlaix, Hospital Lyon SUD"
442,,Racial disparities in renal cell carcinoma histology and outcomes: Insights from the French Kidney Cancer Research Network (UroCCR-191).,"Xiaofan Lu , Jean-Christophe Bernhard , Francois Audenet , Nicolas Doumerc , Pierre Merlin , Morgan Roupret , Thibaut Waeckel , Cécile Champy , Louis Surlemont , Jonathan Olivier , Nicolas Branger , Bastien Parier , Victor Gaillard , Franck Bruyere , Alexis Fontenil , Constance Michel , Louis Vignot , Jean Luc Descotes , Pierre Bigot , Gabriel Malouf","Institut de génétique, biologie moléculaire et cellulaire (IGBMC), CHU Bordeaux, Hopital Européen Georges Pompidou, CHU Rangueil, Lyon Sud - Hospices Civils de Lyon, CHU La Pitié Salpêtrière, CHU Caen, Henri Mondor University Hospital, CHU Rouen, Lille University Hospital, Institut Paoli Calmettes, Hôpital Bicêtre, CHRU Strasbourg, CHRU Tours, CHU Nîmes, Hospital Paris Saint-Joseph, CHU Nice, CHU Grenoble, CHU Angers, Institut de Cancérologie de Strasbourg (ICANS)"
438,,Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313.,"Laurence Albiges , Robert Motzer , Sergio Trevino , Ravindran Kanesvaran , Piotr Centkowski , Melissa Reimers , Juan Pablo Sade , Damien Pouessel , Elisa Biscaldi , Emilio Esteban , Jose Angel Arranz Arija , Scott Tykodi , Haijun Ma , Lei Zhou , Maximiliano Van Kooten Losio , Andrew Simmons , Fatima Rangwala , David Braun , Toni Choueiri , Thomas Powles","Institut Gustave Roussy, Université Paris Saclay, Memorial Sloan Kettering Cancer Center, iCan Oncology Center SA De CV, National Cancer Centre, KO-MED Centra Kliniczne, Department of Medicine, Division of Oncology, Washington University School of Medicine, Instituto Alexander Fleming, IUCT Oncopole - Institut Claudius Régaud, Istituti Clinici Scientifici Maugeri–IRCCS Pavia, Central Hospital Universitario Central de Asturias, Hospital General Universitario Gregorio Marañon, University of Washington and Fred Hutchinson Cancer Center, Exelixis, Inc., Bristol Myers Squibb, Boudry, Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School, Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free National Health Service Trust"
252,G25,Circulating tumor DNA levels and related kinetics as prognostic biomarkers for clinical outcomes in mCRPC: A post hoc analysis of CM 7DX.,"Karim Fizazi , Fred Saad , Teresa Alonso Gordoa , Philippe Barthelemy , Jeffrey Goh , Tomáš Büchler , Daniel Castellano , Chung-Wei Lee , Ding Jiang , Pradipta Ray , David Paulucci , Ana Lako , Saurabh Gupta , Aranzazu Campos , Sumit Subudhi , Maximiliano Van Kooten Losio , Hernán Cutuli","Institut Gustave Roussy, University of Montréal Hospital Centre, Medical Oncology, Hospital Universitario Ramón y Cajal, Institut de Cancérologie Strasbourg Europe (ICANS), Department of Oncology, Royal Brisbane and Women’s Hospital, Charles University and Thomayer University Hospital, Medical Oncology Service, Hospital Universitario 12 de Octubre, Bristol Myers Squibb, Bristol Myers Squibb Research, Bristol Meyers Sqibb, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Sirio Libanes Hospital"
LBA141,D15,Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line (1L) treatment in patients (pts) with homologous recombination repair (HRR)-deficient metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial.,"Karim Fizazi , Arun Azad , Nobuaki Matsubara , Joan Carles , Andre Fay , Ugo De Giorgi , Jae Young Joung , Peter Fong , Eric Voog , Robert Jones , Neal Shore , Curtis Dunshee , Stefanie Zschaebitz , Jan Oldenburg , Dingwei Ye , Xun Lin , Matko Kalac , Douglas Laird , Dana Kennedy , Neeraj Agarwal","Institut Gustave Roussy, University of Paris-Saclay, Department of Medical Oncology, Peter MacCallum Cancer Centre, National Cancer Center Hospital East, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), PUCRS School of Medicine, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, National Cancer Center, Auckland City Hospital and University of Auckland, Clinique Victor Hugo Centre Jean Bernard, School of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Carolina Urologic Research Center, Arizona Urology Specialists, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Akershus University Hospital (Ahus), Fudan University Cancer Hospital, Pfizer Inc., Huntsman Cancer Institute at the University of Utah"
386,K16,Results of AFU-GETUG-20: A randomised phase 3 trial of adjuvant androgen deprivation therapy with leuprorelin acetate after radical prostatectomy in patients with high-risk localized prostate cancer.,"Francois Rozet , Alain Ruffion , Michel Soulie , Gregoire Robert Sr., Jochen Walz , Alexandre de la Taille , Christian Pfister , Romain Mathieu , Aurelien Descazeaud , Igor Latorzeff , Laurent Brureau , Marc Colombel , Morgan Roupret , Lise Roca , Pablo Lemercier , Karim Fizazi , Stephane Culine","Institut Montsouris, Department of Urology, Centre Hospitalier Lyon Sud, Hôpital Rangueil, Urology Department, University Hospital of Bordeaux, Institut Paoli-Calmettes, Hopital Henri Mondor, Urology Department, University of Rennes Hospital Centre, CHU Limoges, Groupe Oncorad Garonne, GH Pointe a Pitre, Hopital Edouard Herriot, CHU La Pitié Salpêtrière, Montpellier Cancer Institute, Institut Gustave Roussy, University of Paris-Saclay, Hopital Saint Louis"
37,A15,PET imaging for metastatic castration sensitive prostate cancer (mCSPC) for patients with PSA response after systemic therapy: A multicentric ambispective analysis.,"Mathilde Beaufils , Lucie Meynard , Alice Bernard-Tessier , Isabelle Brenot-Rossi , Mathilde Guerin , Alban Tauty , Lorene Seguin , Naji Salem , Geraldine Pignot , Cecile Vicier , Jochen Walz , Guilhem Roubaud , Boughalem Elouen , Gwenaelle Gravis","Institut Paoli-Calmettes, Institut Bergonié, Institut Gustave Roussy, University of Paris-Saclay, Department of Medical Oncology, Institut-Paoli-Calmettes, INSERM, CNRS, CRCM, Aix-Marseille Université, Department of Radiotherapy, Institut Paoli-Calmettes, Department of Surgical Oncology, Institut Paoli-Calmettes, Department of Medical Oncology, Institut Bergonié, Institut de Cancérologie de l'Ouest, Immunity and Cancer Team, Department of Medical Oncology, Institut Paoli-Calmettes, INSERM, CNRS, CRCM, Aix-Marseille University"
756,E18,Phase I trial of hypofractionated radiotherapy and pembrolizumab in the treatment of muscle invasive/metastatic bladder cancer: Results of the PLUMMB trial.,"Robert Huddart , Shaista Hafeez , Emilia Nuzzaci , Kelly Jones , Alison Tree , Emily Greenlay","Institute of Cancer Research and Royal Marsden NHS Foundation Trust, The Royal Marsden NHS Foundation Trust"
575,H10,Association between vascular patterns of clear cell renal cell carcinoma and immune cell infiltration and therapeutic response.,"Marieta Toma , Tim Kempchen , Yangping Li , Katharina Baschun , Fabian Hörst , Melina Kehl , Niklas Klümper , Joerg Ellinger , Manuel Ritter , Kati Erdmann , Arndt Hartmann , Glen Kristiansen , Thomas Pinetz , Viktor Grünwald , Alexander Effland , Michael Hölzel","Institute of Pathology, University Hospital Bonn, Institute of Experimental Oncology, University Hospital Essen, Department of Urology and Paediatric Urology, University Hospital, Department of Urology, University Hospital Bonn (UKB), Venusberg-Campus 1, Department of Urology and Pediatric Urology, University Hospital Bonn, Department of Urology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, University Bonn, Institute of Applied Mathematics, Essen University Hospital, Institute of Experimental Oncology, University Hospital Bonn"
828,G24,"Molecular subtypes, NECTIN4/HER2 expression, and clinical outcomes in patients (pts) with advanced urothelial carcinoma (aUC) or muscle invasive bladder cancer (MIBC): Exploratory analyses from JAVELIN Bladder 100 and the Tempus database.","Markus Eckstein , Niklas Klümper , Petros Grivas , Enrique Grande , Johannes Brägelmann , Jason Hoffman , Johanna Mazur , Olga Bogatyrova , Viktor Grünwald","Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Department of Urology and Paediatric Urology, University Hospital, University of Washington and Fred Hutchinson Cancer Center, Department of Medical Oncology, MD Anderson Cancer Center Madrid, University of Cologne and University Hospital Cologne, EMD Serono, Inc., The Healthcare Business of Merck KGaA, Essen University Hospital"
338,J2,"Head-to-head comparison of micro-ultrasound, mpMRI, and PSMA PET/CT with a wholemount histopathology as gold standard in the detection and T staging of prostate cancer.","Wayne Brisbane , Qi Miao , Ida Sonni , Kyla Grunden , Steven Raman , Anthony Sisk , Robert Reiter , Kyung Sung","Institute of Urologic Oncology, David Geffen School of Medicine, University of California, Los Angeles, Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Department of Pathology, University of California, Los Angeles"
497,E30,Metastasis-directed treatment (MDT) for patients (pts) with non-clear cell renal cell carcinoma (nccRCC): Results from a matched 15-year retrospective cohort.,"Rogerio Almeida Moreno Santos , Gabriel Polho , Vinicius Parrela , Matheus Arneiro , Matheus Andrade , Gustavo Alves Contado , Douglas Tozzo Machado Ferreira , Vitor Felix , Letícia Murazawa , Luisa Costa , Nathália Crusoé , Jose Mauricio Mota","Instituto do Câncer do Estado de São Paulo (ICESP), Universidade de São Paulo, Instituto do Câncer do Estado de São Paulo (ICESP), Faculdade de Medicina da Universidade de São Paulo (FMUSP), Instituto do Câncer do Estado de São Paulo, Instituto do Câncer do Estado de São Paulo, University of São Paulo"
34,A12,[99mTc]Tc-iPSMA SPECT/CT as an alternative to PET imaging for decision making in prostate cancer patients.,"Francisco Osvaldo Garcia-Perez , Anna Scavuzzo , Irma Soldevilla-Gallardo , Miguel Jimenez Rios , Nora Sobrevilla , Joel E. Vargas Ahumada , Maritza Ramos-Ramirez , Josette Staufert-Gutiérrez , Roberto Pedrero , Edgar Gómez Argumosa , Mauricio Cantellano","Instituto Nacional de Cancerologia, Instituto Nacional de Cancerología, Instituto Nacional De Cancerologia, Hospital Manuel Gea Gonzalez"
508,F6,Efficacy of targeted therapies (TT) after HIF-2⍺ inhibitor-based treatment in advanced renal cell carcinoma (aRCC).,"Patricia Rioja , Macarena Rey , Jorge Esteban Villarrubia , David Plata , Ileana Sparagna , Fabio Schutz , Ray Manneh , Roberto Iacovelli , Ronan Flippot , Daniel Castellano , Guillermo de Velasco","Instituto Nacional de Enfermedades Neoplásicas (INEN), Department of Medical Oncology, Gustave Roussy, Paris Saclay University, Hospital Universitario 12 de Octubre, Sociedad de Oncología y Hematología del Cesar, Universita' Cattolica del Sacro Cuore - Fondazione Policlinico Universitario A. Gemelli IRCCS, Real Benemérita Associação Portuguesa de Beneficência, Comprehensive Cancer Center, Oncology Unit, Fondazione Policlinico Universitario ""A. Gemelli"" IRCCS, Department of Medical Oncology, Gustave Roussy, Medical Oncology Department, Hospital 12 de Octubre"
502,E35,Impact of deferred cytoreductive nephrectomy in the era of the immunotherapy in metastatic renal cell carcinoma: A multicenter retrospective study.,"Patricia Rioja , Carolina Passarella , Martin Angel , Wbeimar Valderrama , Freya Bosma , Georgia Anguera , Victoria Gomez , Álvaro Ruiz-Granados , David Plata , Martin Zapata Laguado , Alberto Orta-Ruiz , Maria Gandur-Quiroga , Maria Bourlon , Enrique Grande , Ray Manneh , Javier Molina-Cerrillo , Pablo Maroto-Rey , Juan Pablo Sade , Daniel Castellano","Instituto Nacional de Enfermedades Neoplásicas (INEN), Hospital Universitario Austral, Instituto Alexander Fleming, Hospital de la Santa Creu i Sant Pau, Hospital Universitario de Ramon y Cajal, Medical Oncology Department, Hospital Universitario Ramón y Cajal, Sociedad de Oncología y Hematología del Cesar, Instituto Nacional De Cancerologia (Colombia), Department of Medical Oncology, MD Anderson Cancer Center Madrid, Department of Medical Oncology, Genitourinary Tumors, Institute of Oncology Angel H Roffo, Urologic Oncology Clinic, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, 12 de Octubre University Hospital Medical Oncology Deparment"
523,F21,A phase III study testing the role of proactive coaching on patient reported outcome in advanced or metastatic renal cell carcinoma treated with sunitinib or a combination of axitinib + pembrolizumab or avelumab in first line therapy (PREPARE; AIO-NZK-0115/ass).,"Viktor Grünwald , Lutz Jacobasch , Maike de Wit , Severine Banek , Guenter Niegisch , Mark-Oliver Zahn , Andreas Neisius , Phillip Marks , Mirko Müller , Ludwig von Weikersthal , Andreas Huebner , Marinela Augustin , Eyck von der Heyde , Christian Thomas , Nils Gilbert , Alexander Fehr , Heribert Stauder , Ursula Vehling-Kaiser , Ralf Eckert , Philipp Ivanyi","Interdisciplinary Genitourinary Oncology at the West-German Cancer Center, Clinic for Medical Oncology, Clinic for Urology, Essen University Hospital, Onkologische Schwerpunktpraxis, Department of Hematology, Oncology and Palliative Care, Vivantes Klinikum Neukölln, University Hospital Frankfurt, Department of Urology, University Hospital and Medical Faculty, Heinrich-Heine-University, MVZ Onkologische Kooperation Harz, Hospital Barmherzige Brüder, Department for Urology, University Hospital Hamburg-Eppendorf, Department for Urology, Knappschaftskrankenhaus Bottrop, Klinik für Urologie, MVZ Mariahilfbergweg Praxis für Hämatologie und Internistische Onkologie, Wissenschaftskontor Nord, Klinikum Nürnberg, Klinik für Innere Medizin 5, Onkologie am Raschplatz, University Hospital Dresden, University Hospital Lübeck, Department of Urology, Otto von Guericke University Medical School, Krankenhaus Barmherzige Brüder, Department for hematology and oncology, Medical Care Center-Dr. Vehling-Kaiser GmbH, Urologische Arztpraxis Dr. Ralf Eckert, Department of Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School"
186,E25,"A phase 1b study of cabozantinib and nivolumab with abiraterone (CABIOS) in metastatic castration-sensitive prostate cancer (mCSPC): Updated safety, efficacy, and immunologic findings.","Parker Mathews , Muhammad Saeed , Jesse Zaretsky , Dhruv Bansal , Bo Peng , Jingqin Luo , Jessica Klette , Melissa Reimers , Russell Pachynski","Internal Medicine Residency Program, Washington University in St. Louis, Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Luke's Hospital of Kansas City"
683,C16,Variants of unknown significance (VUS) in DNA repair genes in Caucasian men with muscle invasive bladder cancer (MIBC): A case of “serendipity” pushing for a BC screening program.,"Massimo Lazzeri , Giovanni Lughezzani , Roberto Contieri , Pier Paolo Avolio , Vittorio Fasulo , Marco Paciotti , Giuseppe Chiarelli , Giuseppe Garofano , Giulia Soldà , Rosanna Asselta , Anita Capalbo , Piergiuseppe Colombo , Pietro Cavalli , NicolòMaria Buffi , Alberto Saita , Paolo Casale , Hurle Rodolfo","IRCCS - Humanitas Research Hospital, Humanitas University"
190,E29,Serum biomarkers in metastatic castration-resistant prostate cancer (mCRPC) patients receiving [177Lu]Lu-PSMA-617 therapy: Post hoc analysis of a phase II clinical trial.,"Emilio Giunta , Irene Marini , Anna Sarnelli , Nicole Brighi , Flavia Foca , Giuseppe Schepisi , Cristian Lolli , Manuela Monti , Silvia Nicolini , Maria Concetta Cursano , Giovanni Rosti , Ilaria Grassi , Giovanni Paganelli , Stefano Severi , Federica Matteucci , Maddalena Sansovini , Ugo De Giorgi","IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) ""Dino Amadori"", Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) ""Dino Amadori"", IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori"
527,F25,Paraneoplastic and symptomatic score for prediction of overall and cancer-specific survival in patients with renal cell carcinoma.,"Giacomo Musso , Margaret Meagher , Kit Yuen , Aaron Ahdoot , Dhruv Puri , Mai Dabbas , Melis Guer , Natalie Birouty , Dattatraya Patil , Hajime Tanaka , Masaki Kobayashi , Shohei Fukuda , Francesco Montorsi , Alberto Briganti , Andrea Salonia , Umberto Capitanio , Alessandro Larcher , Yasuhisa Fujii , Viraj Master , Ithaar Derweesh","IRCCS San Raffaele Scientific Institute, Urological Research Institute (URI), Department of Urology, University of California San Diego School of Medicine, Department of Urology, Emory University School of Medicine, Department of Urology, Tokyo Medical and Dental University, Department of Urology, Institute of Science Tokyo, Emory University School of Medicine"
515,F13,Comparative survival outcomes of non-clear cell and clear cell renal cell carcinomas with indications for adjuvant pembrolizumab.,"Giacomo Musso , Margaret Meagher , Kit Yuen , Aaron Ahdoot , Dhruv Puri , Mai Dabbas , Melis Guer , Natalie Birouty , Dattatraya Patil , Hajime Tanaka , Masaki Kobayashi , Shohei Fukuda , Francesco Montorsi , Alberto Briganti , Andrea Salonia , Umberto Capitanio , Alessandro Larcher , Yasuhisa Fujii , Viraj Master , Ithaar Derweesh","IRCCS San Raffaele Scientific Institute, Urological Research Institute (URI), Department of Urology, University of California San Diego School of Medicine, Department of Urology, Emory University School of Medicine, Department of Urology, Tokyo Medical and Dental University, Department of Urology, Institute of Science Tokyo, Emory University School of Medicine"
862,H26,Estimation of overall survival in immunotherapy-treated bladder cancer using computer vision.,"Brandon Ginley , Bolan Linghu , Chaitanya Parmar , Neil Beeharry , Shibu Thomas , Patricia Raciti , Joel Greshock , Kristopher Standish , Albert Ramon","J&J Innovative Medicine, Research & Development, J&J Innovative Medicine, Janssen Research & Development, LLC, Johnson & Johnson Innovative Medicine, Johnson & Johnson"
TPS885,J13,A phase III single-arm study to evaluate the efficacy and safety of paclitaxel-hyaluronic acid conjugate administered intravesically to patients with BCG-unresponsive carcinoma in situ of the bladder with or without Ta-T1 papillary disease (Orion-BC study).,"Max Kates , Stephen Bardot , Félix Guerrero-Ramos , Laurent Guy , Rodolfo Hurle , Gautier Marcq , Marco Moschini , Geraldine Pignot , Angelo Porreca , Francesco Soria , Alberto Macchi , Gregoire Robert Sr., Stephen Savage , Rafal Walczak","James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Ochsner Health System, University Hospital 12 de Octubre, Centre Hospitalo Universitaire Gabriel Montpied, Istituto Clinico Humanitas, Lille University Hospital, IRCCS San Raffaele Hospital, Institut Paoli-Calmettes, Department of Oncological Urology, Veneto Institute of Oncology IOV-IRCCS, AOU Città della Salute e della Scienza di Torino, Fondazione IRCCS Istituto Nazionale dei Tumori, Urology Department, University Hospital of Bordeaux, Medical University of South Carolina, Wojewodzki Szpital im Sw. Ojca Pio w Przemyslu"
229,G2,Biomarker testing patterns among patients newly diagnosed with prostate cancer in a community oncology network.,"Lisa Dwyer Orr , Siraje Mahmud , Vivian Jean Cline , Ayda Mirsalehi , Monica Lisi , Laura Ensley , Lorraine Brisbin , Roy Paulson","Janssen Scientific Affairs, a Johnson & Johnson company, Precision Health Informatics, Texas Oncology PA, Precision Health Informatics, LLC"
87,B33,Prospective observational study in Japanese patients with metastatic castration-sensitive prostate cancer (mCSPC) with or without intraductal carcinoma of the prostate (IDC-P).,"Masashi Kato , Toyonori Tsuzuki","Japanese Red Cross Aichi Medical Center, Nagoya Daiichi Hospital, Aichi Medical University"
674,C7,Trends in inpatient outcomes of bladder cancer: 2008-2021.,"Ayobami Olafimihan , Inimfon Jackson , Olanipekun Lanny Ntukidem , Oboseh Ogedegbe , Hafeez Shaka","John H. Stroger Hospital, Cook County, The University of Texas MD Anderson Cancer Center, Trinity Health Ann Arbor"
620,J5,Characteristics and clinical outcomes of metastatic testicular cancer in a distinct demographic.,"Ayobami Olafimihan , Olanipekun Lanny Ntukidem , Inimfon Jackson , Youjin Oh , Oboseh Ogedegbe , Hafeez Shaka","John H. Stroger Hospital, Cook County, Trinity Health Ann Arbor, The University of Texas MD Anderson Cancer Center, John H. Stroger, Jr. Hospital of Cook County"
31,A9,"Novel urine-enriched RNA panel (EPCAM, TTC3, H4C5) to detect prostate cancer and differentiate it from benign prostatic disease.","Ranjan Perera , Menglang Yuan , Marcio Moschovas , Roshane Perera , Ernest Amankwah , Bongyong Lee , Guru Sonpavde , Vipul Patel , Christian Pavlovich , Kandarp Joshi","Johns Hopkins All Children's Hospital, AdventHealth Global Robotics Institute, Johns Hopkins, AdventHealth Cancer Institute, Florida Hospital - Global Robotics Institute, Johns Hopkins University School of Medicine"
684,C17,Primary tumor response to enfortumab vedotin with/without pembrolizumab in patients with upper tract urothelial cancer.,"Evangelia Vlachou , Jeannie Hoffman-Censits , Nirmish Singla , Noah Hahn , Burles Johnson III, Max Kates , Sunil Patel , Stephanie Russell , Armine Smith , Kelli Rourke , Farzad Sedaghat , Timothy McMahon","Johns Hopkins, Departments of Medical Oncology and Urology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Greenberg Bladder Cancer Institute, Johns Hopkins Brady Urological Institute, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Johns Hopkins School of Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Johns Hopkins Hospital"
740,E2,Treatment patterns and clinical outcomes in patients with metastatic urothelial carcinoma in England: A retrospective observational study.,"Tinevimbo Shiri , Max Nievaart , Simran Gill , William Perkin",Johnson & Johnson Innovative Medicine
213,F17,­Radiographic progression without PSA progression in advanced prostate cancer patients.,"Ruchi Chaudhary , Amitabha Bhaumik , Neeraj Agarwal , Kristin Shotts , Angela Lopez-Gitlitz , Sharon McCarthy , Suneel Dinkar Mundle , Kim Chi , Eric Small","Johnson & Johnson Innovative Medicine, Janssen Research & Development, LLC, Huntsman Cancer Institute (NCI-CCC), University of Utah, Johnson & Johnson, Vancouver Prostate Centre, University of British Columbia, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco"
198,F2,NSD2 inhibition as a therapeutic approach for treatment-induced neuroendocrine prostate cancer.,"Lan Xu , J Flynt , Sanjana Miskin , Luis Soares , Eva Corey , Terry Connolly , Benjamin Winograd","K36 Therapeutics, Consultant, University of Washington"
358,J22,"S2,3PSA% as a predictor of reclassification of 1st protocol biopsy on active surveillance for early-stage prostate cancer patients: From the PRIAS-JAPAN study.","Takuma Kato , Tohru Yoneyama , Shingo Hatakeyama , Yoichiro Tohi , Ryuji Matsumoto , Takuma Sato , Katsuyoshi Hashine , Takahiro Kimura , Toshiki Tanikawa , Takayuki Goto , Masaharu Inoue , Kohei Hashimoto , Chikara Ohyama , Mikio Sugimoto","Kagawa University, Department of Urology, Hirosaki University Graduate School of Medicine, Hokkaido University, Tohoku University, National Hospital Organization Shikoku Cancer Center, Jikei University School of Medicine, Niigata Cancer Center Hospital, Department of Urology, Graduate School of Medicine, Kyoto University, Saitama Cancer Center, Sapporo Medical University School of Medicine"
351,J15,The analysis of active surveillance for Japanese young early-stage prostate cancer patients: From the PRIAS-JAPAN study.,"Takuma Kato , Takahiro Kimura , Ryuji Matsumoto , Akira Yokomizo , Takuma Sato , Yoichiro Tohi , Haruki Kume , Koji Inoue , Hidefumi Kinoshita , Shinichi Sakamoto , Isao Hara , Hiroshi Fukuhara , Mikio Sugimoto","Kagawa University, Jikei University School of Medicine, Hokkaido University, Department of Urology, Harasanshin Hospital, Tohoku University, Department of Urology, Graduate School of Medicine, The University of Tokyo, Kurashiki Central Hospital, Department of Urology, Kansai Medical University, Department of Urology, Chiba University Graudate School of Medicine, Second Department of  Surgery, Wakayama Medical University, Kyorin University Hospital"
774,E36,Boosting survival in advanced urothelial carcinoma: The power of CBM588 probiotic and pembrolizumab combination.,"Hirofumi Yoshino , Hideki Enokida",Kagoshima University Hospital
388,K18,Fifteen-year outcomes of external radiation with or without 6 months of neoadjuvant deprivation therapy for intermediate risk prostate cancer.,"Barry Goy , Janis Yao",Kaiser Permanente
359,J23,Impact of the 2012 and 2018 USPSTF statements on prostate cancer screening and metastatic rates in Kaiser Permanente Northern California.,"Joseph Presti Jr., Brandon Horton , Stacey Alexeeff , Stephanie Prausnitz , Andrew Avins","Kaiser Permanente, Division of Research, Kaiser Permanente Northern California"
764,E26,Impact of tumor burden on treatment patterns and outcomes in patients with locally advanced or metastatic urothelial carcinoma (la/mUC) treated with avelumab first-line maintenance (1LM).,"Helen Moon , Mairead Kearney , Seyed Hamidreza Mahmoudpour , Chiemeka Ike , Valerie Morris , Andrew Rava , Sonia Kim , Haiyan Sun , Allison Dillon , Marty Masek , Jocelyn Sun","Kaiser Permanente, The Healthcare Business of Merck KGaA, the healthcare business of Merck KGaA, EMD Serono, Inc., EMD Serono, Genesis Research Group"
59,B5,Real-world treatment patterns and outcomes in advanced prostate cancer: A cohort study using the prostate cancer disease observation (PRECISION) data platform.,"Elisabeth Heath , Alton Sartor , Neal Shore , Daniel George , Jennifer Nguyen , Jeetvan Patel , Vamsi Bollu , Amrita Sawhney , Barinder Kang , Mark Fallick , Kyle Runeckles , Jackson Tang , Xiao Wei","Karmanos Cancer Center, Mayo Clinic, Carolina Urologic Research Center, Department of Medicine, Duke Cancer Institute, Duke University School of Medicine, Novartis Pharmaceuticals Corporation, Asclepius Analytics, Department of Medical Oncology, Dana-Farber Cancer Institute"
467,D35,Burden of cancer in metastatic renal cell carcinoma (mRCC).,"Dena Battle , Meghan Griffith , Pavlos Msaouel , Sarah Psutka , Ulka Vaishampayan , Tian Zhang , Michael Staehler","KCCure, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Department of Urology, University of Washington, Division of Hematology/Oncology, University of Michigan, Department of Internal Medicine, Division of Hematology and Oncology, UT Southwestern, University of Munich"
868,H32,A prognostic model for survival of patients with metastatic upper tract urothelial carcinoma with first-line systemic therapy.,"Jinchang Wei , Siming Li , Huayan Xu , Xiaowen Wu , Juan Li , Li Zhou , Xieqiao Yan , Bixia Tang , Lu Si , Chuanliang Cui , Zhihong Chi , Jun Guo , Xinan Sheng","Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute"
585,H20,Use of integrated multi-omics analysis to analyze prognostic molecular subtype in collecting duct carcinoma.,"Xiaowen Wu , Yiqiang Liu , Yu Fan , Zhisong He , Jin Zhang , Hongqian Guo , Jiaju Lyu , Hao Zeng , Fuli Wang , Xiongjun Ye , Gang Guo , Tiejun Yang , Xieqiao Yan , Jun Guo , Xinan Sheng","Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Pathology, Peking University Cancer Hospital & Institute, Collaborative Innovation Center of Cancer Medicine, Department of Urology, Peking University First Hospital; The Institution of Urology, Peking University; Beijing Key Laboratory of Urogenital Diseases (Male) Mol, Peking University First Hospital, Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Department of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University; Institute of Urology, Nanjing University, Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, West China Hospital of Sichuan University, Department of Urology, Xijing Hospital, Fourth Military Medical University, Department of Urology, National Cancer Center & National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Medical Ethics Committee of Chinese PLA General Hospital, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital"
665,,Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: Updated efficacy and safety results from the phase II RC48-C017 trial.,"Xinan Sheng , Cuijian Zhang , Yongpeng Ji , Li Zhou , Benkui Zou , Hang Huang , Yonghua Wang , Kaiwei Yang , Xue Bai , Dan Feng , Yong Yang , Jiasheng Bian , Zhixian Yu , Haitao Niu , Peng Du , Jianmin Fang , Zhisong He , Jun Guo","Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Peking University First Hospital, Department of Urology, Peking University Cancer Hospital, Shandong Cancer Hospital and Institute, Shandong First Medical University, The First Affiliated Hospital of Wenzhou Medical University, The Affiliated Hospital of Qingdao University, Department of Urology, Peking University First Hospital, Medical Department of Oncology, RemeGen Co., Ltd., RemeGen Co., Ltd., Beijing Cancer Hospital, Haidian, Shandong Cancer Hospital, School of Life Science and Technology, Tongji Univesity"
32,A10,"Impact of liquid biopsies on early detection, monitoring, and prognostication in prostate cancer: A meta-analysis of emerging evidence.","Muhammad Nabeel Saddique , Atif Hussain Sarwar , Hashim Talib Hashim , Ahmed Qasim Mohammed Alhatemi , Sheena Shamoon","King Edward Medical University, Duke University, Durham, University of Warith Al-Anbiyaa, College of Medicine, Al Nasiriyah Teaching Hospital, Rawalpindi Medical University"
535,G2,Evaluating the efficacy of cabozantinib in patients with advanced renal cell carcinoma with bone metastasis: An open-label phase 2 study.,"Fumiya Hongo , Yasutomo Nakai , Masahiro Nozawa , Taigo Kato , Sadanori Kamikawa , Satoshi Tamada , Kaori Yamada , Junpei Soeda , Ryoichi Tsubouchi , Tsuyoshi Osaka , Hirotsugu Uemura","Kyoto Prefectural University of Medicine, Department of Urology, Osaka International Cancer Institute, NHO Osaka Minami Medical Center, Department of Urology, Osaka University Graduate School of Medicine, Department of Urology, Osaka City General Hospital, Bell-Land General Hospital, Department of Diagnostic Radiology, Japanese Red Cross Society Kyoto Daiichi Hospital, Japan Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Company Ltd, Japan Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Company Ltd., Japan Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Company Limited, Department of Urology, Kindai University Faculty of Medicine"
861,H25,Immune and inflammatory profiling in bladder cancer: Insights into biomarkers and therapeutic strategies.,"Andre Zambrana , André Santos , Gabriela Camargo , Gabriela Oliveira , Leandro Freitas , Jörg Kobarg , Adriano Cintra , Jean Lestingi , Martin Bottene , Fabio Guimaraes , João Alonso , Wagner Fávaro","Laboratory of Urogenital Carcinogenesis and Immunotherapy (LCURGIN), Universidade Estadual de Campinas (UNICAMP), Centro de Oncologia Integrativa e Prevenção - COIP, Laboratory of Urogenital Carcinogenesis and Immunotherapy (LCURGIM) – Departament of Structural and Functional Biology, Institute of Biology - University of Cam, Laboratory of Urogenital Carcinogenesis and Immunotherapy (LCURGIM) - School of Medicine, University of Campinas (UNICAMP), Department of Pathology, School of Medicine, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil, Laboratory of Signal Mechanisms, School of Pharmaceutical Sciences (FCF), Universidade Estadual de Campinas (UNICAMP), Paulínia Municipal Hospital, São Paulo, Brazil, Sao Paulo Cancer Institute, Hospital São Vicente de Paulo, Paulínia Municipal Hospital, Paulínia City, São Paulo State, Laboratory of Urogenital Carcinogenesis and Immunotherapy, School of Medicine, University of Campinas (UNICAMP), Laboratory of Urogenital Carcinogenesis and Immunotherapy (LCURGIM), Department of Structural and Functional Biology, Institute of Biology, University of Campinas (UNICAMP)"
682,C15,Missed opportunity: PROMs as primary endpoints in bladder cancer trials.,"Avi Harisingani , Mahnoor Sukaina , Sameer Deshmukh , Mahnoor Keen , Zain Ahmad , Annu Zerin , Madhan Srinivasan Kumar , Gagandeep Singh , Sadia Ansar , Hritik Madan , Maria Naveed , Karan Jatwani","Loyola Medicine MacNeal Hospital, Karachi Medical and Dental College, Department of Medicine, Division of Hematology & Oncology, University of Alabama at Birmingham, Birmingham, AL, Northwest School of Medicine, Buckinghamshire Healthcare, NHS Trust, All India Institute of Medical Sciences, Saint Vincent Hospital, Goa Medical College, Rawal Institute of Health Sciences, Adesh Medical College, George Washington University, The George Washington University Hospital"
419,L15,Decipher risk stratification of radiorecurrent prostate cancer: Correlative analysis of the F-SHARP trial of salvage reirradiation.,"Abhishek Solanki , James Proudfoot , William Adams , Eileen Kelly , Kristin Baldea , Alec Block , Elizabeth Farkas , Ahmer Farooq , Alex Gorbonos , Gopal Gupta , Rebecca Joel , Marcus Quek , Carly Quick , James Welsh , Michael Woods , Ryan Yoo , William Small Jr., Matthew Harkenrider , Elai Davicioni , Guliz Barkan","Loyola University Chicago, Veracyte, Inc., Loyola University Medical Center, Loyola University Chicago College of Arts and Sciences, Loyola University, Cardinal Bernardin Cancer Center"
486,E19,Clinical utility of measuring steady-state plasma level of lenvatinib in advanced renal cell carcinoma.,"Sang Yoon Kim , James Checkley , Mirjana Radovanovic , Peter Galettis , Alison Zhang , Howard Gurney","Macquarie University, The University of Newcastle, Department of Clinical Medicine, Macquarie University"
675,C8,Current impact of ureteral carcinoma amongst racial minorities: Analysis of the National Cancer Database.,"Christopher Edwards , Navid Leelani , Katiana Vazquez Rivera , Michael West , Benjamin Shpeen , Ariel Schulman","Maimonides Medical Center, Department of Urology"
79,B25,Lutetium-177 PSMA radioligand therapy in taxan-naive first- and second-line metastatic castration resistant prostate cancer after first-line ARPI therapy.,"Philipp Mandel , Benedikt Hoeh , Carolin Siech , Florestan Koll , Clara Humke , Daniel Groener , Thomas Steuber , Markus Graefen , Tobias Maurer , Severine Banek , Felix Chun , Mike Wenzel","Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Department of Urology, University Hospital Frankfurt, Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Department of Nuclear Medicine, Goethe University Frankfurt, Martini-Klinik, University Medical Center Hamburg-Eppendorf, Department of Urology, Goethe University Frankfurt"
202,F6,"Assessment of PARP1 mRNA expression as prognostic of aggressive pathology and adverse outcomes, and as predictor of response to PARP inhibition in castration-sensitive prostate cancer.","Emmanuel Antonarakis , Mohammed Alshalalfa , Benjamin Teply , Yangyang Hao , James Proudfoot , Elai Davicioni , Edward Schaeffer , R. Jeffrey Karnes , Daniel Spratt , Justin Hwang , Tamara Lotan , Catherine Marshall","Masonic Cancer Center, University of Minnesota, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, University of Nebraska Medical Center, Veracyte, Inc., Department of Urology, Northwestern University Feinberg School of Medicine, Department of Urology, Mayo Clinic in Rochester, University Hospitals Seidman Cancer Center, Case Western Reserve University, University of Minnesota, Masonic Cancer Center, Johns Hopkins University School of Medicine"
215,F19,Combined analysis of circulating tumor cells and PSMA imaging metrics to predict efficacy of 177Lu-PSMA-617 in metastatic prostate cancer.,"Yoshiyuki Miyazawa , Arda Könik , Zoe Guan , Ibrahim Chamseddine , Keisuke Otani , Yukako Otani , Rea Pittie , Ella Chung , Daniel Rodden , Linda Nieman , Katherine Xu , Mythreayi Shan , Richard Lee , Xin Gao , Pedram Heidari , Dejan Juric , Miles Miller , Thomas Ng , David Miyamoto","Massachusetts General Hospital Cancer Center, Department of Imaging, Dana-Farber Cancer Institute, Massachusetts General Hospital, Department of Radiation Oncology, Massachusetts General Hospital, Massachusetts General Hospital, Harvard Medical School, Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital; Department of Radiology, Harvard Medical School, Henri and Belinda Termeer Center for Targeted Therapies, Massachusetts General Hospital, Center of Systems Biology, Massachusetts General Hospital, Department of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital"
TPS900,J28,"NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors.","Xin Gao , Amita Patnaik , Nehal Lakhani , Justin Call , Matthew Galsky , Benjamin Garmezy , Alexander Wei , Louise Carter , Thomas Powles , Arlene Siefker-Radtke , Peter O'Donnell , Shigehisa Kitano , Daniel Castellano , Rajiv Shinde , Anthony Joshua , Minna Balbas , Hongmei Han , Amy Chang , Capucine Baldini , Gopa Iyer","Massachusetts General Hospital Cancer Center, The START Center for Cancer Research, Genitourinary Medical Oncology, Division of Hematology and Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Sarah Cannon Research Institute, Department of Medicine, Columbia University Medical Center, Division of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Barts Cancer Institute, Queen Mary University of London, Department of Medicine, The University of Texas MD Anderson Cancer Center, Department of Medicine, Section of Hematology/Oncology, University of Chicago, Department of Advanced Medical Development, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Medical Oncology Service, Hospital Universitario 12 de Octubre, Linear Clinical Research and Sir Charles Gairdner Hospital, Nedlands, St Vincent’s Hospital Melbourne, Eli Lilly and Company, Drug Development Department, Gustave Roussy, Department of Medicine, Memorial Sloan Kettering Cancer Center"
235,G8,Circulating tumor cell RNA biomarker for bavdegalutamide (ARV-110) in metastatic castration-resistant prostate cancer without AR T878/H875 mutations.,"Keisuke Otani , Xin Gao , Erika Kusaka , Priscilla Badusi , Yukako Otani , Megan Carney , Douglas Kauff , Kara Olivier , Erika Meneely , Rojer Ranjit , Matthew Smith , M. Dror Michaelson , Philip Saylor , Richard Lee , David Miyamoto","Massachusetts General Hospital, Harvard Medical School, Massachusetts General Hospital"
235,G8,Circulating tumor cell RNA biomarker for bavdegalutamide (ARV-110) in metastatic castration-resistant prostate cancer without AR T878/H875 mutations.,"Keisuke Otani , Xin Gao , Erika Kusaka , Priscilla Badusi , Yukako Otani , Megan Carney , Douglas Kauff , Kara Olivier , Erika Meneely , Rojer Ranjit , Matthew Smith , M. Dror Michaelson , Philip Saylor , Richard Lee , David Miyamoto","Massachusetts General Hospital, Harvard Medical School, Massachusetts General Hospital"
113,C23,"Evaluation of de novo oligometastatic prostate cancer patients managed with radiation therapy: A multi-institution, real-world dataset.","Sophia Kamran , Adetolani Odogiyon , Madison Baxter , Giana Grigsby , Derek Lamb , Alexander Lukez , Abigail Pepin , Cole Friedes , Dominic LaBella , Sean Parker , Tyler Seibert , Jessica Wong , Eric Horwitz , Ryan Fecteau , Christina Huang , Rahul Tendulkar , Leslie Ballas , Jason Efstathiou , Neha Vapiwala","Massachusetts General Hospital, Harvard Medical School, Massachusetts General Hospital, University of California, San Diego, Cedars-Sinai, Duke University, Fox Chase Cancer Center, Department of Radiation Oncology, Hospital of University of Pennsylvania, University of Pennsylvania, Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Department of Radiation Oncology, Duke University Medical Center, Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cedars-Sinai Medical Center, Abramson Cancer Center"
418,L14,Germline correlates of clinical outcomes in aggressive prostate cancer subtypes treated with radiation therapy.,"Grace Cerrato , Rishab Sanjeev , Isabella Pompa , David Kozono , Anthony DAmico , Paul Nguyen , David Miyamoto , Jason Efstathiou , Sophia Kamran","Massachusetts General Hospital, Massachusetts General Brigham, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Harvard Medical School"
356,J20,A natural language processing algorithm to extract MRI and biopsy-related phenotypes for prostate cancer patients.,"John Culnan , Sergey Goryachev , Daniel Chen , Oleg Soloviev , Grace Lee , John Bihn , June Corrigan , Karlynn Dulberger , Jennifer La , Kaitlin Swinnerton , Tanya Dorff , Isla Garraway , Susan Halabi , Stacy Loeb , Nicholas Nickols , Matthew Rettig , Martin Schoen , Channing Paller , Nathanael Fillmore , Matthew Cooperberg","Massachusetts Veterans Epidemiology Research and Information Center, Department of Veterans Affairs Healthcare System, VA Boston Healthcare System, Boston University Medical School, University of California, San Fransisco, City of Hope Comprehensive Cancer Center, UCLA David Geffen School of Medicine, Duke University School of Medicine, NYU Langone Health, VA Greater Los Angeles Healthcare System, Department of Medical Oncology, University of California, Los Angeles, Saint Louis University School of Medicine, Department of Medical Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, University of California, San Francisco"
428,L24,Domain-specific large language model for predicting prostate cancer treatment plan.,"Umar Ghaffar , Amara Tariq , Mouneeb Choudry , Logan Briggs , Aneeta Channar , Imon Banerjee , Man Luo , Irbaz Riaz , Haidar Abdul-Muhsin",Mayo Clinic in Arizona
458,D26,Clinical and radiographic trends in patients with renal angiomyolipomas (AML).,Mouneeb Choudry,Mayo Clinic in Arizona
745,E7,Clinical efficacy of enfortumab vedotin-pembrolizumab (EV-P) in locally advanced (LA) or metastatic urothelial carcinoma (mUC): A real-world retrospective study.,"Prateek Jain , Syed Arsalan Ahmed Naqvi , Muhammad Umair Anjum , Muhammad Ali Khan , Muhammad Umar Afzal , Ji-Eun Yum , Kainat Warraich , Salman Ayub Jajja , Fnu Swati , Nikita Tripathi , Daniel Childs , Jacob Orme , Yousef Zakharia , Mark Tyson , Nathan Yu , Irbaz Riaz , Parminder Singh","Mayo Clinic in Arizona, Division of Hematology and Medical Oncology, Mayo Clinic in Arizona, Mayo Clinic Alix School of Medicine, Division of Hematology and Medical Oncology, Mayo Clinic, Department of Medical Oncology, Mayo Clinic in Rochester"
341,J5,Automated risk stratification in localized prostate cancer using an AI-assisted framework.,"Umair Ayub , Syed Arsalan Ahmed Naqvi , Salman Ayub Jajja , Muhammad Umar Afzal , Kaneez Khakwani , Jack Andrews , Alan Bryce , Alton Sartor , Haidar Abdul-Muhsin , Daniel Childs , Jacob Orme , Chitta Baral , Neeraj Agarwal , Sumanta Pal , Abhishek Tripathi , Parminder Singh , Yousef Zakharia , Irbaz Riaz","Mayo Clinic in Arizona, Division of Hematology and Medical Oncology, Mayo Clinic, University of Arizona, City of Hope, Mayo Clinic, Department of Medical Oncology, Mayo Clinic in Rochester, Arizona State Univeristy (ASU), Huntsman Cancer Institute (NCI-CCC), University of Utah, Department of Medical Oncology, City of Hope Comprehensive Cancer Center, University of Okahoma Health Sciences Center"
866,H30,Assessment of pathologic responses from unstructured pathology reports using large language models.,"Swati Popli , Muhammad Umair Anjum , Syed Arsalan Ahmed Naqvi , Prateek Jain , Parminder Singh , Yousef Zakharia , Irbaz Riaz","Mayo Clinic in Arizona, Mayo Clinic"
716,D13,Real-world outcomes of nadofaragene firadenovec in BCG-unresponsive non-muscle invasive bladder cancer.,"Jacob Moyer , Adri Durant , Mimi Nguyen , Lanyu Mi , Andrew Zganjar , Timothy Lyon , Paras Shah , Stephen Boorjian , Mark Tyson","Mayo Clinic in Arizona, Mayo Clinic in Florida, Mayo Clinic in Rochester"
261,H2,Large language models (LLMs) for inferring genomic characteristics and facilitating genomic literacy in prostate cancer (PCa) patients.,"Syed Arsalan Ahmed Naqvi , Umair Ayub , Muhammad Ali Khan , Peter R. Khoury , Deepak B Ravichandar , Owen H. Witte , Daniel Childs , Jacob Orme , Yousef Zakharia , Parminder Singh , Alan Bryce , Irbaz Riaz","Mayo Clinic in Arizona, Mayo Clinic in Rochester, Department of Medical Oncology, Mayo Clinic in Rochester, City of Hope"
155,D29,Rucaparib vs docetaxel (DTX) or second-generation androgen pathway inhibitor (ARPI) therapy for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 final overall survival (OS) and safety.,"Alan Bryce , Raymond McDermott , Josep Piulats , M. Reaume , Peter Ostler , Joel Gingerich , Elias Pintus , Srikala Sridhar , Richard Bambury , Urban Emmenegger , Henriette Lindberg , David Morris , Franco Nole , John Staffurth , Wassim Abida , Lisa Caunt , Darrin Despain , Charles Ryan , Karim Fizazi , Simon Chowdhury","Mayo Clinic in Arizona, St. Vincent’s University Hospital and University College Dublin, Fundacio Institut D'Investigacio Biomedica de Bellvitge, L'Hospitalet del Llobregat, The Ottawa Hospital Cancer Centre and University of Ottawa, Mount Vernon Cancer Centre, CancerCare Manitoba, Guy's and St. Thomas' NHS Foundation Trust, Princess Margaret Cancer Centre and University of Toronto, Cork University Hospital, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Herlev Hospital, Urology Associates, P.C., European Institute of Oncology IRCCS, Cardiff University School of Medicine, Memorial Sloan Kettering Cancer Center, pharma&, University of Minnesota, Institut Gustave Roussy, University of Paris-Saclay"
TPS272,L25,Intra-patient comparison of urinary radioactivity after 18F-piflufolastat and 18F‑flotufolastat PET in men with low PSA biochemical recurrence of prostate cancer who have had radical prostatectomy.,"Jack Andrews , David Josephson , Daniel Saltzstein , Andrei Purysko , Neal Shore , Benjamin Gartrell , Ram Pathak , Phillip Kuo , James Sykes , Phillip Davis , Brian Helfand","Mayo Clinic in Arizona, Tower Urology, Urology San Antonio, Cleveland Clinic, Carolina Urologic Research Center, LLC, Montefiore Medical Center, Mayo Clinic in Florida, City of Hope Comprehensive Cancer Center, Blue Earth Diagnostics Ltd., Blue Earth Diagnostics Inc., Endeavor Health"
184,E23,Choice of androgen receptor pathway inhibitors (ARPi) by disease volume and timing of metastases in metastatic hormone sensitive prostate cancer (mHSPC).,"Syed Arsalan Ahmed Naqvi , Kunwer Sufyan Faisal , Kaneez Khakwani , Daniel Childs , Jacob Orme , Jack Andrews , Praful Ravi , Syed Hussain , Neeraj Agarwal , Parminder Singh , Yousef Zakharia , Alton Sartor , Irbaz Riaz , Alan Bryce","Mayo Clinic in Arizona, Ziauddin Medical University, University of Arizona, Department of Medical Oncology, Mayo Clinic in Rochester, Dana-Farber Cancer Institute, University of Sheffield, Huntsman Cancer Institute (NCI-CCC), University of Utah, Mayo Clinic, City of Hope"
537,G4,Individualized neoantigen vaccine with nivolumab plus cabozantinib for translocation renal cell carcinoma: Single patient investigational new drug.,"Adam Kase , Winston Tan , John Copland III, Michael Gustafson , Yan Asmann , Brian Necela , Keith Knutson","Mayo Clinic in Florida, Mayo Clinic, Mayo Clinic in Arizona"
524,F22,Olanzapine for managing side effects from tyrosine-kinase inhibitors.,"Regina Koch , Miguel Muniz , Candy Peskey , Aminah Jatoi , Kathryn Ruddy , Jacob Orme , Lance Pagliaro , Fernando Quevedo , Brian Costello , Spychalla Megan , Elisabeth Heath , Yousef Zakharia , Parminder Singh , Irbaz Riaz , Elizabeth Cathcart-Rake , Stacy D'Andre , Charles Loprinzi , Daniel Childs","Mayo Clinic in Rochester, Department of Medical Oncology, Mayo Clinic in Rochester, Mayo Clinic, Department of Oncology, Mayo Clinic Department of Medical Oncology, Karmanos Cancer Institute, Wayne State University, Mayo Clinic in Arizona, Mayo Clinic"
382,K12,Quantifying the benefit of salvage radiation versus surveillance for biochemically recurrent prostate cancer after radical prostatectomy.,"Spyridon Basourakos , Stephen Boorjian , Phillip Schulte , Grant Henning , Jamie O'Byrne , Matthew Tollefson , Igor Frank , Abhinav Khanna , Ryan Phillips , Brad Stish , R. Jeffrey Karnes , Vidit Sharma","Mayo Clinic in Rochester, Department of Urology, Mayo Clinic in Rochester, Department of Quantitative Health Sciences, Mayo Clinic in Rochester, Department of Radiation Oncology, Mayo Clinic in Rochester"
TPS294,M13,Long-term safety outcomes of 177Lu‑PSMA-617 in patients with prostate cancer.,"Alton Sartor , Shilpa Gupta , Alicia Morgans , Luke Nordquist , Michael Crosby , Jeff Michalski , Fred Saad , Neal Shore , Hyun Kim , Natalie Carnahan , Shaheen Alanee , Arijana Jobst , Sanjay Samantray , Diego Ospina Gonzalez , Ken Herrmann","Mayo Clinic, Cleveland Clinic Taussig Cancer Institute, Department of Medical Oncology, Dana-Farber Cancer Institute, XCancer/Urology Cancer Center, Veterans Prostate Cancer Awareness, Washington University School of Medicine in St. Louis, University of Montreal Hospital Center, Carolina Urologic Research Center, Novartis Pharmaceuticals Corporation, Novartis Farmacéutica, Universitätsmedizin Essen"
56,B2,Clinical outcomes of prompt versus deferred 177Lu-PSMA-617 initiation for metastatic castration-resistant prostate cancer (mCRPC) based on prior androgen receptor pathway inhibitor (ARPI) and taxane chemotherapy exposure: A real-world prostate cancer disease observation (PRECISION) data platform analysis.,"Alton Sartor , Xiao Wei , Neal Shore , Elisabeth Heath , Jennifer Nguyen , Jeetvan Patel , Amrita Sawhney , Barinder Kang , Clare Byrne , Jackson Tang , Daniel George","Mayo Clinic, Department of Medical Oncology, Dana-Farber Cancer Institute, Carolina Urologic Research Center, Karmanos Cancer Center, Novartis Pharmaceuticals Corporation, Asclepius Analytics, Department of Medicine, Duke Cancer Institute, Duke University School of Medicine"
520,F18,Difference in renal cell carcinoma (RCC) prevalence between kidney transplant versus other solid organ transplant patients.,"Kainat Warraich , Logan Briggs , Mouneeb Choudry , Jaxson Jeffery , Umar Ghaffar , Alex Nica , Declan Carr , Aneeta Channar , Muhammad Ali Khan , Parminder Singh , Yousef Zakharia , Irbaz Riaz , Haidar Abdul-Muhsin","Mayo Clinic, Mayo Clinic in Arizona"
TPS303,M22,ProstACT GLOBAL: A phase 3 study of 177Lu-rosopatamab (TLX591) with and without the best standard of care for patients with PSMA expressing metastatic castration-resistant prostate cancer progressing despite prior treatment with a novel androgen axis drug.,"Alton Sartor , Scott Tagawa , Nat Lenzo , David Cade , Neeraj Agarwal","Mayo Clinic, Weill Cornell Medical College of Cornell University, Genesis Care, Telix Pharmaceuticals, Huntsman Cancer Institute (NCI-CCC), University of Utah"
TPS282,M1,"ACCEL: [Ac-225]-PSMA-62 phase Ia/Ib/II clinical trial to characterize efficacy, safety, tolerability, and dosimetry in oligometastatic hormone-sensitive and metastatic castration-resistant prostate cancer.","Ramy Saleh , Kim Chi , Di Maria Jiang , Vincent Castonguay , Farzad Abbaspour , Ur Metser , Don Wilson , Junsheng Ma , Richard Cioci , Karim Nacerddine , Jean-Mathieu Beauregard","McGill University Health Centre, BC Cancer, Princess Margaret Hospital, University Health Network, CHU de Quebec, Université Laval, POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company, Eli Lilly and Company"
22,,Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration resistant prostate cancer: A randomized phase II trial (GROUQ-PCS 9).,"Tamim Niazi , Fred Saad , Rashmi Koul , Isabelle Thibault , Peter Chung , George Wakil , Michael Lock , Guila Delouya , Boris Bahoric , Andrew Feifer , Venkata Ramana Agnihotram , Theodoros Tsakiridis , Fabio Cury , Rafika Dahmane , Steven Tisseverasinghe , Nikhilesh Patil , Scott Tyldesley","McGill University, University of Montreal Hospital Centre, CancerCare Manitoba, CHU de Quebec, Université Laval, Princess Margaret Hospital, University Health Network, Charles-Lemoyne Hospital, London Regional Cancer Centre, Centre Hospitalier de l'Université de Montréal (CHUM), Hôpital Général Juif de Montréal, Trillium Health Partners, Credit Valley Hospital, McGill University and the Research Institute of the McGill University Health Centre, McMaster University and Juravinski Cancer Centre, CIUSSS MCQ CHAUR, Dalhousie University, Nova Scotia Cancer Centre, British Columbia Cancer Agency"
TPS305,M24,OCOG-RATIONAL: A phase II randomized trial of optimal recurrence-directed therapy (RDT) without or with androgen-deprivation therapy (ADT) in radio-recurrent oligo-metastatic castrate sensitive prostate cancer (romCSPC).,"Theodoros Tsakiridis , Andre Gouveia , Aruz Mesci , Peter Vavassis , Alejandro Berlin , Scott Morgan , Nathan Perlis , Tamim Niazi , John Thoms , Sebastien Hotte , Jim Wright","McMaster University and Juravinski Cancer Centre, Radiation Oncology, Juravinski Cancer Centre, Hamilton Health Science, University of Toronto and Princess Margaret Cancer Centre, Hôpital Maisonneuve-Rosemont de Montréal, Cancer Digital Intelligence, Princess Margaret Cancer Centre, University Health Network, The Ottawa Hospital, University of Ottawa, Department of Surgical Oncology, Division of Urology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, McGill University, Memorial University, Juravinski Cancer Institute, McMaster University, Ontario Clinical Oncology Group, McMaster University"
511,F9,Impact of initial local therapy (LT) in the combination treatment era for metastatic renal cell carcinoma (mRCC): Subgroup analysis from ProPaxi study.,"Annalisa Guida , Alessio Gili , Claudia Mosillo , Marco Maruzzo , Eleonora Lai , Francesco Pierantoni , Davide Bimbatti , Umberto Basso , Giuseppe Fornarini , Sara Elena Rebuzzi , Fabio Calabrò , Linda Cerbone , Grazia Sirgiovanni , Alex Mammarella , Debora Serafin , Orazio Caffo , Sarah Scagliarini , Sergio Bracarda","Medical and Translational Oncology Unit, Department of Oncology, Azienda Ospedaliera Santa Maria, Department of Life Sciences, Health and Health Professions, Link Campus University, Medical Oncology Unit 1, Department of Oncology, Istituto Oncologico Veneto IOV-IRCCS, Oncology 3 Unit, Istituto Oncologico Veneto IOV - IRCCS, Castelfranco Veneto, Oncology Unit 3, Istituto Oncologico Veneto, IOV-IRCCS, Medical Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Medical Oncology Unit, Ospedale San Paolo, IFO Istituto Regina Elena, Azienda Ospedaliera San Camillo Forlanini, Medical and Translational Oncology, Azienda Ospedaliera Santa Maria Terni, Scuola di Specializzazione di Oncologia Medica, Università Politecnica delle Marche, Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Santa Chiara Hospital, Medical Oncology Department, APSS Santa Chiara Hospital, Department of Medical Oncology, AORN ""A. Cardarelli"""
5,D4,"Characterization, treatment and survival outcomes of penile cancer: Over a decade in a tertiary Mexican center.","Cristhel Cervin , Aaron Saenz , Mariana Perez Rosado , Maria Guadalupe Diaz Alvarado , Perla Perez , Jorge Aguirre , Mariana Madrid Morales","Medical Oncology Department, Centro Medico Nacional 20 Noviembre ISSSTE, Centro Médico Nacional 20 de Noviembre ISSSTE, Centro Médico Nacional ""20 de Noviembre"" ISSSTE, Hospital Regional de Alta Especialidad ""Bicentenario de la Independencia"" ISSSTE"
720,D17,Effectiveness and safety of first-line atezolizumab in locally advanced or metastatic urothelial cancer: The IMFLAME study.,"Alfonso Gomez De Liaño Lista , Nuria Romero-Laorden , Pablo Gajate , Alberto Orta-Ruiz , Jesús García-Donas Jiménez , Maria Jose Miranda , Sergio Vázquez Estévez , Carmen Molins , Cristina Pernaut , Marta González Cordero , Ovidio Fernández , José García Sánchez , Iria González Maeso , Patricia Rodríguez Blázquez , Òscar Reig , Pablo Maroto-Rey , Almudena Martín , Ignacio Ramírez Gallegos , Javier Puente","Medical Oncology Department, Complejo Hospitalario Universitario Insular-Materno Infantil, Medical Oncology Department, University Hospital de La Princesa. Cátedra UAM-Fundación Instituto Roche de Medicina Personalizada de Precisión, Medical Oncology Department, Hospital Universitario Ramón y Cajal, Department of Medical Oncology, MD Anderson Cancer Center Madrid, Medical Oncology Department, Centro Integral Oncológico Clara Campal (CIOCC), Medical Oncology Department, Institut d’Oncologia de la Catalunya Sud (IOCS). Hospital Universitari Sant Joan de Reus. IISPV. URV, Medical Oncology Department, University Hospital Lucus Augusti, Medical Oncology Department, University Hospital Dr. Peset, Medical Oncology Department, University Hospital Severo Ochoa, Medical Oncology Department, University Hospital Badajoz, Medical Oncology Department, Complexo Hospitalario Universitario de Ourense, Medical Oncology Department, University Hospital Arnau de Vilanova, Fundación para el Fomento de la Investigación Sanitaria i Biomédica de la Comunidad Valenciana (FISABIO), Medical Oncology Department, University Hospital Son Llàtzer, Medical Oncology Department, University Hospital Lluis Alcañiz de Xàtiva, Medical Oncology Department, Hospital Clínic, Translational Genomics and Targeted Therapeutics in Solid Tumors Group (IDIBAPS), Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Medical Department, Roche Farma S.A., Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC"
538,G5,Efficacy outcomes with belzutifan versus everolimus by baseline disease characteristics and burden subgroups in the phase 3 LITESPARK-005 study.,"Guillermo de Velasco , Laurence Albiges , Thomas Powles , Cristina Suárez , Katriina Jalkanen , Mauricio Burotto , Pooja Ghatalia , Roberto Iacovelli , Elaine Lam , Elena Verzoni , Mahmut Gumus , Walter Stadler , Christian Kollmannsberger , Bohuslav Melichar , Balaji Venugopal , Jingyi Lin , Rodolfo Perini , Donna Vickery , Brian Rini , Toni Choueiri","Medical Oncology Department, Hospital 12 de Octubre, Gustave Roussy, Paris Saclay University, St Bartholomew's Hospital, Barts Health NHS Trust, Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Helsinki University Hospital, Comprehensive Cancer Center, Bradford Hill Clinical Research Center, Fox Chase Cancer Center, Comprehensive Cancer Center, Oncology Unit, Fondazione Policlinico Universitario ""A. Gemelli"" IRCCS, University of Colorado Cancer Center, Genitourinary Medical Oncology, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Istanbul Medeniyet University, Prof. Dr. Suleyman Yalcin City Hospital, University of Chicago, British Columbia Cancer Agency, Palacký University Medical School and Teaching Hospital, Beatson West of Scotland Cancer Centre, University of Glasgow, Merck & Co., Inc., Vanderbilt-Ingram Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute"
142,D16,Treatment patterns in prostate cancer patients who received darolutamide in the ARAMIS trial in Spain: PARASEC study.,"Javier Puente , José García Sánchez , Joan Folqué , Javier Casas","Medical Oncology Department, Hospital Clínico San Carlos, Hospital Arnau Vilanova Valencia, Bayer Hispania SL, Hospital Universitario Lucus Augusti"
702,C35,Real-world epidemiology and clinical outcomes of bladder cancer patients in Spain: BLARWE multicenter study.,"Javier Puente , Alberto Sánchez-Camacho , Cristina Caballero , Victoria Gonzalo , Ricardo Fernandez-Rodriguez , Félix Guerrero-Ramos , Saray Galvan Ruiz , Eva Fernández Parra , Eduardo Pujol , Sara Martinez Breijo , Alfonso Gomez De Liaño Lista , Alejo Rodriguez-Vida , Marta González Cordero , Alvaro Pinto , Carlos Alvarez-Fernandez , Miguel Climent Duran , Ariela Baliera , Jose Rubio-Briones","Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Medical Oncology Department, University Hospital Virgen Macarena, Hospital General Universitario de Valencia, Hospital Universitario de Burgos, Hospital Universitario de Cruces, University Hospital 12 de Octubre, Hospital Universitario de Gran Canaria Dr. Negrín, Hospital Universitario Virgen de Valme, Medical Oncology Department, Hospital Clínico Universitario Lozano Blesa, Complexo Hospitalario Universitario A Coruña, Medical Oncology Department. Complejo Hospitalario Universitario Insular - Materno Infantil (CHUIMI), Medical Oncology Department, Hospital del Mar, Medical Oncology Department, University Hospital Badajoz, Oncology Department, Hospital La Paz Institute for Health Research-IdiPAZ, Hospital Universitario La Paz, Medical Oncology Department, Hospital Universitario Central de Asturias, Fundación Instituto Valenciano de Oncología, Medical Department. AstraZeneca Farmacéutica Spain, Hospital VITHAS 9 de Octubre"
798,F25,Evaluating the contribution of circulating tumor DNA (ctDNA) towards magnetic resonance imaging (MRI) in clinical staging and response assessment of patients with muscle-invasive bladder cancer (MIBC).,"Valentina Tateo , Giorgio Brembilla , Brigida Anna Maiorano , Antonio Cigliola , Chiara Mercinelli , Michele Cosenza , Francesco De Cobelli , Gaia Latini , Miriam Borella , Roberta Lacava , Maurizio Colecchia , Marco Moschini , Alberto Briganti , Francesco Montorsi , Andrea Necchi","Medical Oncology Department, IRCCS San Raffaele Hospital, Department of Radiology, IRCCS San Raffaele Hospital, Medical Oncology Department, IRCCS San Raffaele Hospital; Vita-Salute San Raffaele University, Department of Radiology, IRCCS Ospedale San Raffaele, IRCCS San Raffaele Hospital, Department of Pathology and Laboratory Medicine, IRCCS San Raffaele Hospital, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, IRCCS San Raffaele Scientific Institute, Urological Research Institute (URI), Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute"
843,H7,The estrogen response pathway as a putative predictive biomarker of neoadjuvant pembrolizumab benefit in patients with muscle-invasive bladder carcinoma (MIBC).,"Valentina Tateo , Joep de Jong , Antonio Cigliola , Brigida Anna Maiorano , Chiara Mercinelli , Emanuele Crupi , Daniele Raggi , Patrizia Giannatempo , Maurizio Colecchia , Marco Moschini , Elai Davicioni , Alberto Briganti , Francesco Montorsi , Daniele Santini , Andrea Necchi","Medical Oncology Department, IRCCS San Raffaele Hospital, Erasmus MC Cancer Institute, Medical Oncology Department, IRCCS San Raffaele Hospital; Vita-Salute San Raffaele University, Vita-Salute San Raffaele University, The Royal Marsden Hospital Foundation Trust, Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Pathology and Laboratory Medicine, IRCCS San Raffaele Hospital, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Veracyte, Inc., IRCCS San Raffaele Scientific Institute, Urological Research Institute (URI), Divisione di Oncologia Medica A, Policlinico Umberto I, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute"
196,E35,Homologous recombination deficiency signature (HRDsig+) and the genomic landscape of clinically advanced prostate carcinoma (CAPC).,"Chiara Mercinelli , Philippe Spiess , Roger Li , Ashish Kamat , Petros Grivas , Shilpa Gupta , Neeraj Agarwal , Liang Cheng , Dean Pavlick , Ethan Sokol , Ryon Graf , Jeffrey Ross , Alexa Schrock , Julia Quintanilha , Gerald Li , Douglas Lin , Joseph Jacob , Gennady Bratslavsky , Alina Basnet , Andrea Necchi","Medical Oncology Department, IRCCS San Raffaele Hospital, H. Lee Moffitt Cancer Center and Research Institute, Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, University of Washington and Fred Hutchinson Cancer Center, Cleveland Clinic Taussig Cancer Institute, Huntsman Cancer Institute at the University of Utah, Indiana University, Foundation Medicine, Inc., Department of Pathology, SUNY Upstate Medical University, Upstate Medical University, Department of Urology, Department of Urology, SUNY Upstate Medical University, Department of Hematology/Oncology, SUNY Upstate Medical University, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute"
244,G17,Genomic characteristics of patients with metastatic hormone-sensitive prostate cancer treated with ARPI-based therapy: A single-center analysis.,"Brigida Anna Maiorano , Antonio Cigliola , Chiara Mercinelli , Valentina Tateo , Giovanni Luigi Pastorino , Maurizio Colecchia , Dean Pavlick , Jeffrey Ross , Andrea Necchi","Medical Oncology Department, IRCCS San Raffaele Hospital, Medical Oncology Department, IRCCS San Raffaele Hospital; Vita-Salute San Raffaele University, Università Vita e Salute San Raffaele, Department of Pathology and Laboratory Medicine, IRCCS San Raffaele Hospital, Foundation Medicine, Inc., Foundation Medicine Inc., Vita-Salute San Raffaele University and Department of Medical Oncology, IRCCS San Raffaele Hospital"
732,D29,Outcomes of immune-checkpoint inhibitor rechallenge in urothelial carcinoma: Results from a global real-world evidence study.,"Brigida Anna Maiorano , Antonio Cigliola , Valentina Tateo , Chiara Mercinelli , Giovanni Luigi Pastorino , Nazli Dizman , Hedyeh Ebrahimi , Sumanta Pal , Shilpa Gupta , Petros Grivas , Ashish Kamat , Philippe Spiess , Neeraj Agarwal , Andrea Necchi","Medical Oncology Department, IRCCS San Raffaele Hospital, Medical Oncology Department, IRCCS San Raffaele Hospital; Vita-Salute San Raffaele University, Università Vita e Salute San Raffaele, The University of Texas MD Anderson Cancer Center, City of Hope Comprehensive Cancer Center, Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Cleveland Clinic Taussig Cancer Institute, University of Washington and Fred Hutchinson Cancer Center, H. Lee Moffitt Cancer Center and Research Institute, Huntsman Cancer Institute (NCI-CCC), University of Utah, Vita-Salute San Raffaele University and Department of Medical Oncology, IRCCS San Raffaele Hospital"
553,G20,Outcomes of different therapeutic modalities for patients with metachronous oligometastatic renal-cell carcinoma (RCC): Analyses of a single-institution database.,"Antonio Cigliola , Chiara Re , Brigida Anna Maiorano , Valentina Tateo , Antonio Nuccio , Chiara Mercinelli , Chiara Deantoni , Giovanni Luigi Pastorino , Giorgio Brembilla , Maurizio Colecchia , Francesco De Cobelli , Nadia Di Muzio , Alessandro Larcher , Giuseppe Rosiello , Alberto Briganti , Francesco Montorsi , Umberto Capitanio , Andrea Necchi","Medical Oncology Department, IRCCS San Raffaele Hospital; Vita-Salute San Raffaele University, Urology Unit, IRCCS San Raffaele Hospital, Medical Oncology Department, IRCCS San Raffaele Hospital, IRCCS San Raffaele Hospital, Università Vita-Salute San Raffaele, Department of Radiation Oncology, San Raffaele Scientific Institute, Department of Radiology, IRCCS San Raffaele Hospital, Department of Pathology and Laboratory Medicine, IRCCS San Raffaele Hospital, Department of Radiation Oncology, IRCCS Ospedale San Raffaele, IRCCS San Raffaele Scientific Institute, Urological Research Institute (URI), Department of Urology, IRCCS Ospedale San Raffaele, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University"
495,E28,Comparison of IO-TKI vs IO-IO combinations in IMDC poor-risk metastatic renal cell carcinoma (mRCC) patients (Meet-URO 33 analysis).,"Sara Elena Rebuzzi , Alessio Signori , Sebastiano Buti , Alberto Dalla Volta , Martina Fanelli , Valeria Sardaro , Marilena Di Napoli , Cristina Masini , Annalisa Guida , Roberto Filippi , Silvia Chiellino , Carlo Messina , Sarah Scagliarini , Emanuela Fantinel , Lucia Bonomi , Vincenza Conteduca , Filippo Maria Deppieri , Mariella Sorarù , Giuseppe Fornarini , Davide Bimbatti","Medical Oncology, Ospedale San Paolo, Department of Health Sciences (DISSAL), Section of Biostatistics, University of Genova, Medical Oncology Unit, University Hospital of Parma; Department of Medicine and Surgery, University of Parma, Unit of Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, ASST Spedali Civili di Brescia, University of Brescia, Department of Oncology, Azienda Sanitaria Universitaria Friuli Centrale Santa Maria Della Misericordia, Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Medical Oncology Unit, AUSL-IRCCS of Reggio Emilia, Oncologia Medica e Traslazionale, Azienda Ospedaliera Santa Maria di Terni, Department of Oncology, University of Turin, Medical Oncology Unit, IRCCS Policlinico San Matteo, Clinical Oncology Unit, Ospedale A.R.N.A.S. Civico, Department of Medical Oncology, AORN ""A. Cardarelli"", Section of Oncology, University of Verona - School of Medicine, Unit of Oncology, ASST Papa Giovanni XXIII Hospital, Unit of Medical Oncology and Biomolecular Therapy, Department of Medical and Surgical Sciences, University of Foggia, Policlinico Riuniti, Medical Oncology Unit, AULSS 3 Serenissima, UOC Oncologia, AULSS 6 Euganea, Ospedale di Camposampiero, Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Oncology Unit 1, Veneto Institute of Oncology IOV - IRCCS"
552,G19,KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and novel immunotherapy agents for advanced clear cell renal cell carcinoma (ccRCC).,"Cristina Suárez , Laurence Albiges , Katy Beckermann , Hans Hammers , Walter Stadler , Wilson Miller Jr., Carlos Rojas , Avivit Peer , Jeffrey Goh , Se Hoon Park , Tom Waddell , Philippe Barthelemy , Pablo Gajate , Andrew Weickhardt , Guy Faust , Rodolfo Perini , Lockman Bousserouel , Ding Wang , Robert Motzer , Thomas Powles","Medical Oncology, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Gustave Roussy, Paris Saclay University, Vanderbilt University Medical Center, UT Southwestern Medical Center, The University of Chicago, Jewish General Hospital, Bradford Hill, Rambam Medical Center, Royal Brisbane & Women’s Hospital, Sungkyunkwan University, Samsung Medical Center, The Christie Hospital NHS Foundation Trust, Department of Medical Oncology, Institut de Cancérologie Strasbourg Europe (ICANS), Medical Oncology Department, Hospital Universitario Ramón y Cajal, Olivia Newton-John Cancer Wellness & Research Centre, University Hospitals of Leicester NHS Trust, Merck & Co., Inc., Memorial Sloan Kettering Cancer Center, Barts Health NHS Trust and the Royal Free NHS Foundation Trust, Barts Cancer Institute, and Queen Mary University of London"
149,D23,Safety and efficacy of salvage lymph node dissection in prostate cancer patients with nodal recurrence after radical prostatectomy: A prospective single center phase I/II study.,"Nicolai Huebner , Bernhard Grubmueller , David D'Andrea , Eva Comperat , Pascal Baltzer , Sazan Rasul , Shahrokh Shariat","Medical University of Vienna, Department of Urology and Andrology, University Hospital Krems, Karl Landsteiner University of Health Sciences, Medical University of Vienna, Department of Urology, Medical University of Vienna, Vienna General Hospital"
365,J29,Real-world U.S. county-level analysis of erectile dysfunction diagnosis following radiation therapy for localized prostate cancer: The impact of rectal spacer utilization.,"Ryan Hankins , Ryoko Sato , Parthiv Mehta , Samir Bhattacharyya , Emmanuel Ezekekwu , Sean Collins","MedStar Georgetown University Hospital, Boston Scientific Corp, Uropartners, Boston Scientific, USF Health Morsani College of Medicine"
589,H24,Association between clonal hematopoiesis and survival after nephrectomy in patients with renal cell carcinoma.,"Yash Khandwala , Neil Ruthen , Ritesh Kotecha , Paul Russo , Jonathan Coleman , Eduard Reznik , A. Hakimi",Memorial Sloan Kettering Cancer Center
833,G29,Characterizing the immune effects of enfortumab vedotin (EV) on peripheral blood mononuclear cells (PBMCs) in metastatic urothelial cancer patients (mUC).,"Aditi Gupta , Carlo Sevilla , Nicole Pihlstrom , Stanley Liang , Ashley Regazzi , Asia McCoy , Colleen Maher , Phillip Wong , Firas Ahmed , Samuel Funt , Gopa Iyer , Dean Bajorin , Min Yuen Teo , Jonathan Rosenberg , Juan Osorio , David Aggen","Memorial Sloan Kettering Cancer Center - Fellowship (GME Office), Rockefeller University, Memorial Sloan Kettering Cancer Center, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College"
628,J13,Time to real-world progression (TTrwP) among patients (pts) with relapsed/refractory (R/R) testicular germ cell tumors (GCT) undergoing palliative chemotherapy (CT) in the United States (US).,"Darren Feldman , Patrick Gagnon-Sanschagrin , Jessica Maitland , Philippe Boileau , Kana Yokoji , Annie Guérin , Victoria Guan , George Joseph","Memorial Sloan Kettering Cancer Center, Analysis Group, Inc., BioNTech US"
TPS610,K11,"INTerpath-004: A phase 2, randomized, double-blind study of adjuvant pembrolizumab (pembro) with V940 (mRNA-4157) or placebo for renal cell carcinoma (RCC).","Robert Motzer , David Braun , Thomas Powles , Howard Gurney , Lawrence Fong , Daniel George , Naomi Haas , David McDermott , Brian Shuch , Robert Meehan , Tracey Posadas , Sterling Wu , Aymen Elfiky , Toni Choueiri","Memorial Sloan Kettering Cancer Center, Center of Molecular and Cellular Oncology, Yale University, Barts Health NHS Trust and the Royal Free NHS Foundation Trust, Barts Cancer Institute and Queen Mary University of London, MQ Health, Macquarie University, Division of Hematology and Oncology, University of California, San Francisco, Duke University, Abramson Cancer Center, Penn Medicine, Beth Israel Deaconess Medical Center, University of California, Los Angeles, Moderna, Inc., Merck & Co., Inc., Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute"
246,G19,Racial differences in organic anion transport proteins (OATP) and outcome in castration resistant prostate cancer treated with AR pathway inhibitors in Alliance A031201: A phase III trial.,"Charles Ryan , Hyotae Kim , Michael Morris , Mohammad Alyamani , Roberto Diaz , Himisha Beltran , Andrew Armstrong , Nima Sharifi , Susan Halabi","Memorial Sloan Kettering Cancer Center, Department of Biostatistics & Bioinformatics, Duke University, Desai Sethi Urology Institute at the University of Miami Sylvester Comprehensive Cancer Center, University of Miami Sylvester Comprehensive Cancer Center, Dana-Farber Cancer Institute, Duke University Cancer Institute, Duke University School of Medicine"
124,C34,Digital physiological monitoring for personalized prediction of physical function and fatigue in men with castration sensitive prostate cancer.,"Ian Wax , Anneliese Markus , Adele Carlson , Jessica Scott , Lee Jones , Andrew Laccetti","Memorial Sloan Kettering Cancer Center, Department of Medicine, Roswell Park Comprehensive Cancer Center"
264,H5,A novel predictive model using changes in clinical and serum biomarkers and automated quantitative imaging for mCRPC patients treated with AR-directed therapy.,"Michael Morris , Jessica Flynn , Binsheng Zhao , Aseem Anand , Karl Sjöstrand , Steven Larson , Howard Scher , Ashley Regazzi , Gary Borzillo , Autumn Park , Lawrence Schwartz , Glenn Heller","Memorial Sloan Kettering Cancer Center, Exini Diagnostics AB, Janssen Research & Development, LLC"
811,G7,Updated long-term follow-up from a phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy for patients with high-grade upper tract urothelial carcinoma.,"Viranda Jayalath , Min Yuen Teo , Melissa Assel , Daniel Rodriguez , Abraham Meyerson , Bernard Bochner , Guido Dalbagni , S. Donat , Harry Herr , Eugene Cha , Timothy Donahue , Eugene Pietzak , A. Hakimi , Kwanghee Kim , Hikmat Al-Ahmadie , Hebert Vargas , Jonathan Rosenberg , Gopa Iyer , Dean Bajorin , Jonathan Coleman","Memorial Sloan Kettering Cancer Center, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center"
540,G7,Outcomes with first-line ipilimumab and nivolumab for patients with metastatic renal cell carcinoma by number of doses.,"Sahil Doshi , Andrea Lopez Sanmiguel , Andrea Knezevic , Ritesh Kotecha , Neil Shah , Marie Carlo , Darren Feldman , Robert Motzer , Martin Voss","Memorial Sloan Kettering Cancer Center, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center and Weill Medical College"
439,,Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial.,"Robert Motzer , Bernard Escudier , Mauricio Burotto , Thomas Powles , Andrea Apolo , Maria Bourlon , Amishi Shah , Camillo Porta , Cristina Suárez , Carlos Barrios , Martin Richardet , Howard Gurney , Elizabeth Kessler , Yoshihiko Tomita , Jens Bedke , Fatima Rangwala , Margarita Askelson , Julie Panzica , Viktor Fedorov , Toni Choueiri","Memorial Sloan Kettering Cancer Center, Gustave Roussy, Bradford Hill Clinical Research Center, Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free National Health Service Trust, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Urologic Oncology Clinic, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, The University of Texas MD Anderson Cancer Center, University of Bari Aldo Moro, Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Centro de Pesquisa em Oncologia, Hospital São Lucas, PUCRS, Latin American Cooperative Oncology Group, Fundación Richardet Longo, Instituto Oncológico de Córdoba, Westmead Hospital and Macquarie University, University of Colorado School of Medicine, Niigata University Graduate School of Medical and Dental Sciences, Eva Mayr-Stihl Cancer Center, Klinikum Stuttgart, Exelixis, Inc., Bristol Myers Squibb, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School"
150,D24,Darolutamide monotherapy in patients with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR): ARAMON lead-in phase results.,"Andrew Laccetti , Matthew Smith , Howard Scher , Sepehr Nowfar , David Einstein , Benjamin Martin , Patrick Adorjan , Manjari Dissanayake , Frank Verholen , Xin Gao","Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital Cancer Center and Harvard Medical School, Genesis Healthcare Partners, Beth Israel Deaconess Medical Center, Central Ohio Urology Group, Bayer Consumer Health AG, Bayer HealthCare Pharmaceuticals, Inc., Massachusetts General Hospital, Harvard Medical School"
TPS608,K9,STARLITE 2: Phase 2 study of nivolumab plus 177lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab (177Lu-girentuximab) in patients with advanced clear cell renal cell carcinoma (ccRCC).,"Darren Feldman , Robert Motzer , Andrea Knezevic , Martin Voss , Serge Lyashchenko , Hijin Park , Steven Larson , Neeta Pandit-Taskar","Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center - Fellowship (GME Office), Memorial Sloan Kettering Cancer Center and Weill Medical College"
TPS609,K10,"A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan in patients with advanced or metastatic renal cell carcinoma (NCT06234605).","Neil Shah , Manojkumar Bupathi , Benjamin Garmezy , Rana McKay , Moshe Ornstein , Robert Figlin , Joel Picus , Brian Rank , Pedro Barata , Hans Hammers , Thomas Hutson , Elaine Lam , Scott Tykodi , Song Zhao , Hamid Emamekhoo , Michael Chisamore , Paulette Mattson , Megan Holm , Jose Iglesias , Robert Motzer","Memorial Sloan Kettering Cancer Center, Rocky Mountain Cancer Centers, Sarah Cannon Research Institute, University of California, San Diego, Cleveland Clinic, Cedars-Sinai Medical Center, Washington University in St. Louis, HealthPartners, University Hospitals Seidman Cancer Center, UT Southwestern Medical Center, Texas Tech University Health Science Center, University of Colorado Cancer Center, University of Washington, Fred Hutchinson Cancer Center, Swedish Cancer Institute, University of Wisconsin Carbone Cancer Center, Merck & Co., Inc., HiberCell, Inc., APEX Oncology Consulting, Inc. (Consultant Chief Medical Officer)"
853,H17,DNA damage repair alterations as predictive biomarker for platinum-based chemotherapy in metastatic urothelial cancer.,"Michal Sternschuss , Alexander Paynter , Wenxin Xu , Chelsea Nichols , Jennifer Hoppe , Nancy Davis , Di Maria Jiang , Neil Shah","Memorial Sloan Kettering Cancer Center, Sage Bionetworks, Dana-Farber Cancer Institute, Harvard Medical School, American Association for Cancer Research, Merck Sharp & Dohme LLC, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College"
TPS289,M8,"CONVERGE-01: Dosimetry, randomized dose optimization, dose escalation, and efficacy of ac-225 rosopatamab tetraxetan in participants with PSMA-positive castration-resistant prostate cancer.","Michael Morris , Ana Kiess , Luke Nordquist , Shilpa Gupta , Daniel George , Richard Messmann , Philip Kantoff , Jones Nauseef , Neil Bander , Emmanuel Antonarakis","Memorial Sloan Kettering Cancer Center, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, XCancer Omaha/Urology Cancer Center, Cleveland Clinic Taussig Cancer Institute, Department of Medicine, Duke Cancer Institute, Duke University School of Medicine, Convergent Therapeutics, University of Minnesota Masonic Cancer Center"
857,H21,"The Oncopig bladder cancer model, an innovative large animal platform for evaluating treatment effects.","Viranda Jayalath , Andreas Autlitzky , Natalia Kudinova , Jonathan Coleman , Lawrence Schook , Kyle Schachtschneider","Memorial Sloan Kettering Cancer Center, Sus Clinicals Inc"
92,C2,Real-world evidence for factors associated with development of castration-resistant prostate cancer (CRPC).,"Charles Ryan , Kristine Lacuna , Lena Yoo , Zuzanna Szmukier , Deborah Boldt-Houle","Memorial Sloan Kettering Cancer Center, Tolmar, Inc., Tolmar Pharmaceuticals Canada Inc."
TPS290,M9,A phase 1b/2 study evaluating the activity of tinengotinib in combination with androgen receptor pathway inhibitors (ARPIs) in patients with metastatic castration resistant prostate cancer (mCRPC).,"Wassim Abida , Yu Chen , Deaglan McHugh , Michael Morris , Frank Wu , Peng Peng , Katie Hennessy , Hui Wang , Jean Fan , Samir Zaidi","Memorial Sloan Kettering Cancer Center, TransThera Sciences (Nanjing), Inc., TransThera Sciences (US), Inc."
209,F13,"Analysis of distinct genomic, transcriptomic, and immune landscapes driven by alterations in androgen production, uptake, and conversion (APUC) genes in metastatic prostate cancers.","Kristine Lacuna , Khalid Ishani , Ella Boytim , Wassim Abida , Michael Morris , Emmanuel Antonarakis , Justin Hwang , Charles Ryan","Memorial Sloan Kettering Cancer Center, University of Minnesota, Masonic Cancer Center, University of Minnesota"
714,D11,Disease management costs and healthcare resource utilization by progression health state among patients with previously untreated locally advanced or metastatic urothelial cancer.,"Aram Babcock , Wei Gao , Reshma Shinde , Yipeng Gao , Travis Wang , Qi Hua , Yan Song , James Signorovitch , Shujing Zhang","Merck & Co., Inc., Analysis Group, Inc."
705,D2,Recurrence and its association with overall survival (OS) in muscle-invasive bladder cancer (MIBC) patients undergoing radical cystectomy (RC): A real-world analysis.,"Patrick Squires , Jon Tepsick , Francesca Coutinho , Aljosja Rogiers , Chethan Ramamurthy , Haojie Li , Todd Morgan","Merck & Co., Inc., ConcertAI, LLC, University of Michigan"
69,B15,Characterization of circulating tumor DNA (ctDNA) burden and its association with real-world overall survival among prostate cancer (PC) patients.,"Ping Du , Jiemin Liao , Angela Watkins , Razvan Cristescu , Nicole Barkley , Julia Markensohn","Merck & Co., Inc., Guardant Health"
93,C3,Real-world prevalence and outcomes of androgen receptor ligand-binding domain mutations in prostate cancer.,"Ping Du , Jiemin Liao , Angela Watkins , Razvan Cristescu , Nicole Barkley , Julia Markensohn","Merck & Co., Inc., Guardant Health, Merck & Co, Inc."
704,D1,Peri-operative treatment patterns in real-world muscle-invasive bladder cancer patients undergoing radical cystectomy in the era of adjuvant immunotherapy.,"Patrick Squires , Ke Meng , Xiaohan Hu , Vladimir Turzhitsky , Yu-Han Kao , Zara Wermers , Jennifer Stuart , Chethan Ramamurthy , Connor Sweetnam , Haojie Li , Ronac Mamtani","Merck & Co., Inc., Harvard T.H. Chan School of Public Health, Syapse Holdings, Inc., Abramson Cancer Center"
347,J11,Prognostic significance of PSA in the outcomes of patients with high risk localized prostate cancer.,"Mohammad Arfat Ganiyani , Atulya Khosla , Pushan Prabhakar , Arjun Pon Avudaiappan , Karan Jatwani , Manmeet Ahluwalia , Murugesan Manoharan , Rohan Garje","Miami Cancer Institute, Baptist Health South Florida, Corewell Health William Beaumont University Hospital, The George Washington University Hospital"
380,K10,Rates of acute GI and GU toxicities with dose-escalated intensity modulated proton therapy (IMPT) for the treatment of node-positive prostate cancer.,"Mehmet Murat Zerey , Omer Gal , Maria-Amelia Rodrigues , Adeel Kaiser , Alonso Gutierrez , Minesh Mehta , Jessica Wohl , Marcio Fagundes","Miami Cancer Institute, Baptist Health South Florida, Miami Cancer Institute"
654,K2,Clinical outcomes of invasive primary urethral cancer: A real world multi-institutional study.,"Rohan Garje , Mohammad Arfat Ganiyani , Pedro Barata , Vinay Mathew Thomas , Neeraj Agarwal , Nabil Adra , Ravindran Kanesvaran , Alexandra Drakaki , Marsenne Cabral , Jorge Esteban Villarrubia , Daniel Castellano , Andrea Necchi , Philippe Spiess , Andrea Apolo , Guru Sonpavde","Miami Cancer Institute, Baptist Health South Florida, University Hospitals Seidman Cancer Center, Huntsman Cancer Institute at the University of Utah, Huntsman Cancer Institute (NCI-CCC) at the University of Utah, Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center, Division of Medical Oncology, National Cancer Centre Singapore, University of California, Los Angeles, Division of Hematology/Oncology, David Geffen School of Medicine, University of California, Los Angeles, Hospital Universitario 12 de Octubre, IRCCS San Raffaele Hospital and Scientific Institute, H. Lee Moffitt Cancer Center and Research Institute, National Cancer Institute, National Institutes of Health, AdventHealth Cancer Institute"
864,H28,Surveillance with plasma ctDNA in non-muscle invasive bladder cancer.,"Santosh Kagathur , Shaniza Haniff , Joshua Christy , Dan Isaac","Michigan State University, University at Buffalo"
136,D10,Inferring ECOG performance status (PS) using large language models in patients with advanced prostate cancer.,"Ammad Raina , Miguel Muniz , Muhammad Umair Anjum , Umair Ayub , Syed Arsalan Ahmed Naqvi , Salman Ayub Jajja , Ji-Eun Yum , Ben Zhou , Nathan Yu , Haidar Abdul-Muhsin , Alton Sartor , Jacob Orme , Parminder Singh , Yousef Zakharia , Daniel Childs , Irbaz Riaz","Midwestern University, AZCOM, Department of Medical Oncology, Mayo Clinic in Rochester, Mayo Clinic in Arizona, Division of Hematology and Medical Oncology, Mayo Clinic, Mayo Clinic Alix School of Medicine, Arizona State University, Mayo Clinic"
847,H11,Determining an immunohistochemical profile to predict response to intravesical bacillus Calmette–Guérin (BCG) in patients with high-grade non-muscle invasive bladder cancer.,"Darren Lam , Gavin Wei , Mitchell Lawrence , Nicholas Choo , Renea Taylor , Nicholas Huntington , Beena Kumar , Steuart Rorke , Piero Nelva , Shivakumar Keerthikumar , Matthew Harper , Scott Donnellan , Weranja Ranasinghe","Monash Health, Department of Urology, Monash Health, Department of Anatomy and Developmental Biology, Biomedical Discovery Centre, Monash University, Monash University, Department of Anatomical Pathology, Monash Health, Peter MacCallum Cancer Centre"
420,L16,Targeting highly aggressive ductal prostate tumours with poly ADP ribose polymerase inhibitor (PARPi) and androgen receptor signaling inhibitor (ARSi) combination therapy.,"Weranja Ranasinghe , Mahsa Delavar , Mitchell Lawrence , Nicholas Choo , Birunthi Niranjan , Melissa Papagiris , Jenna Kraska , Hong Wang , Shivakumar Keerthikumar , Ganiraju Manyam , Patricia Troncoso , Peter Shephard , Timothy Thompson , Renea Taylor , Brian Chapin , Gail Risbridger","Monash University, Department of Anatomy and Developmental Biology, Biomedical Discovery Centre, Monash University, Peter MacCallum Cancer Centre, The University of Texas MD Anderson Cancer Center, Prostate Cancer Research Group, Monash University"
217,F21,Lewis Y antigen as a novel target for CAR (chimeric antigen receptor) T-cell therapy in patients with neuroendocrine prostate cancer.,"Weronika Kulakowska , Renea Taylor , Weranja Ranasinghe , Phillip Darcy , Joseph Trapani , Gail Risbridger","Monash University, Peter MacCallum Cancer Centre, Prostate Cancer Research Group, Monash University"
TPS652,K20,"A phase 1, first-in-human, dose escalation and expansion study to evaluate the safety and tolerability of XmAb541 (claudin-6 x CD3) T-cell engaging bispecific antibody in subjects with germ cell tumors and other advanced solid tumors.","David Levitz , Martin Gutierrez , Ira Winer , Matthew Reilley , Linda Duska , Vivek Subbiah , Debra Richardson , Chet Bohac , Michael Chiarella , Carlos Naranjo , Jitendra Kanodia , Jacky Woo , Nicole Nevadunsky","Montefiore Einstein Comprehensive Cancer Center, Hackensack University Medical Center, Wayne State University, Barbara Ann Karmanos Cancer Center, University of Virginia Cancer Center, University of Virginia Comprehensive Cancer Center, University of Texas MD Anderson Cancer Center and Sarah Cannon Research Institute, University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Xencor, Inc, Xencor, Inc., Department of Obstetrics, Gynecology, and Women’s Health, Montefiore Medical Center"
454,D22,Prognosis in metastatic renal cell cancer (mRCC) with major venous involvement (MVI): A population-based study.,"Ahsan Ayaz , Manahil Khan , Syed Arsalan Ahmed Naqvi , Muhammad Umar Afzal , Ewan Cobran , Sajid Mir , Haidar Abdul-Muhsin , Parminder Singh , Irbaz Riaz , Yousef Zakharia","Montefiore St. Luke's Cornwall Hospital, Aga Khan University Hospital, Mayo Clinic in Arizona, Mayo Clinic College of Medicine and Science"
687,C20,Detection of early-stage urothelial cancers using methylation patterns in urine cell-free DNA.,"Tyler Stewart , Archana Shenoy , Rojin Safavi , Sarah Stuart , Kelly McClintock , Amani Alchaar , Aditya Bagrodia , Karim Kader , Rana McKay , Neil Recio , Heidi Wagner , Neil Fleshner , Matthew Larson , Amirali Salmasi","Moores Cancer Center, University of California San Diego, GRAIL, Inc, UC San Diego Moores Cancer Center, Princess Margaret Cancer Centre, University Health Network"
25,A3,Ethnic disparities in clinical trials for FDA-approved drugs in prostate cancer: A post–COVID-19 era analysis (2020-2024).,"Bruno Bastos , Michael Schwartz , Oleg Gligich , Jacqueline Barrientos , Antonio Ramirez-Ridelli , Leonardo Borregales , Alan Nieder , Akshay Bhandari , Debra Linzer , Nicolas Kuritzky , Mike Cusnir",Mount Sinai Medical Center
452,D20,Ethnic disparities in clinical trials for FDA-approved drugs in renal cell carcinoma: An analysis in the post-COVID-19-era (2020-2024).,"Bruno Bastos , Michael Schwartz , Oleg Gligich , Jacqueline Barrientos , Antonio Ramirez-Ridelli , Leonardo Borregales , Akshay Bhandari , Alan Nieder , Nicolas Kuritzky , Debra Linzer , Mike Cusnir","Mount Sinai Medical Center, Mount Sinai Comprehensive Cancer Center"
677,C10,Ethnic disparities in clinical trials for FDA-approved drugs in urothelial cancer: An analysis in the post-COVID-19 era (2020-2024).,"Bruno Bastos , Michael Schwartz , Oleg Gligich , Akshay Bhandari , Nicolas Kuritzky , Leonardo Borregales , Jacqueline Barrientos , Alan Nieder , Debra Linzer , Antonio Ramirez-Ridelli , Mike Cusnir","Mount Sinai Medical Center, Mount Sinai Comprehensive Cancer Center"
TPS429,M27,CLARIFY: Positron emission tomography using 64Cu-SAR-bisPSMA in patients with high-risk prostate cancer prior to radical prostatectomy—A phase 3 diagnostic performance study.,"Michael Gorin , Eva Lengyelova , Luke Nordquist , Glynn Morrish , Othon Gervasio , Robert Miller , Neal Shore","Mount Sinai, Clarity Pharmaceuticals, XCancer, Carolina Urologic Research Center and Atlantic Urology Clinics"
20,,Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD).,"David Fisher , Claire Vale , Larysa Rydzewska , Peter Godolphin , Neeraj Agarwal , Gerhardt Attard , Kim Chi , Noel Clarke , Ian Davis , Karim Fizazi , Silke Gillessen , Nicholas James , David Matheson , Robert Oldroyd , Mahesh Parmar , Christopher Sweeney , Bertrand Tombal , Ian White , Jayne Tierney","MRC Clinical Trials Unit at UCL, Huntsman Cancer Institute (NCI-CCC), University of Utah, University College London Cancer Institute, University of British Columbia, BC Cancer, Vancouver Cancer Centre, The Christie and Salford Royal NHS Foundation Trusts, Monash University and Eastern Health, Institut Gustave Roussy, University of Paris-Saclay, Oncology Institute of Southern Switzerland (IOSI), The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, University of Wolverhampton, Medical Research Council Clinical Trials Unit at University College London, South Australian Immunogenomics Cancer Institute, University of Adelaide, Cliniques Universitaires Saint-Luc"
406,L2,Chimeric RNA landscape in the Chinese population and the role of SFT2D2-TBX19 in prostate cancer progression.,Qiong Wang,"Nanfang Hospital, Southern Medical University"
673,C6,Postoperative adjuvant treatment of HER2 overexpression in upper urinary tract urothelial carcinoma with the combination of disitamab vedotin and toripalimab: A real-world retrospective study.,"Shun Zhang , Shiwei Zhang , Yongming Deng II, Hongqian Guo , Hao Wu","Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing University of Chinese Medicine"
556,G23,The evaluation of therapeutic outcomes of percutaneous US/CT-guided bipolar radiofrequency ablation for small renal masses under local anesthesia.,"Yifan Sun , Wang Wei , HongQian Guo","Nanjing Drum Tower Hospital, Drum Tower Hospital, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School"
TPS296,M15,CHAPTER-Platform-201: Phase 2 trial of pimitespib plus enzalutamide for patients with metastatic castration-resistant prostate cancer.,"Nobuaki Matsubara , Masaki Shiota , Hiroji Uemura","National Cancer Center Hospital Japan East, Kyushu University, Yokohama City University Medical Center"
332,H32,WITHDRAWN: It’s in the genes: A study of men at high genetic risk of developing prostate cancer (PCa).,"Anna Couvillon , Nikhil Pramod , Baris Turkbey , Peter Choyke , Shisi He , Sonja Berndt , Inger Rosner , Robert Sidlow , Michael Mullane , Veda Giri , Todd Morgan , Heather Cheng , Sandeep Gurram , Yi Liu , Kathleen Calzone , James Gulley , William Figg , Peter Pinto , William Dahut , Fatima Karzai","National Cancer Institute, National Institutes of Health, Cleveland Clinic Lerner College of Medicine, Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Walter Reed National Military Medical Center, Memorial Sloan Kettering Cancer Center, Aurora Cancer Care, Yale Cancer Center, Yale School of Medicine, University of Michigan, University of Washington, Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, American Cancer Society"
401,K31,Association of localized high-risk prostate cancer (PC) and an androgen receptor low subpopulation susceptible to HER2 inhibition.,"Adam Sowalsky , Scott Wilkinson , Anson Ku , Rosina Lis , Isaiah King , Daniel Low , Shana Trostel , Anna Baj , Sumeyra Kartal , Kayla Heyward , Baohan Vo , Caroline Jansen , Huihui Ye , Stephanie Harmon , Haydn Kissick , Peter Pinto , Peter Choyke , Baris Turkbey , William Dahut , Fatima Karzai","National Cancer Institute, National Institutes of Health, Emory University, Cedars-Sinai Medical Center"
715,D12,Enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma: First results on outcomes and safety in a German multicenter real-world patient cohort (GUARDIANS).,"Stefanie Zschaebitz , Jozefina Casuscelli , Thomas Büttner , Christopher Darr , Anna-Lisa Volk , Martin Hennig , Friedemann Zengerling , Muammar Dib , Katrin Schlack , Pia Paffenholz , Julia Heinzelbecker , Subhajit Mandal , Frederik Wessels , Daniel Seidl , Eva Erne , Susan Foller , Alexander Höllein , Viktor Grünwald , Marco Julius Schnabel , Nina Holzwarth","National Center for Tumor Diseases (NCT), Department of Urology, LMU University Hospital, LMU Munich, Department of Urology, University Hospital Bonn (UKB), Department of Urology, University Hospital Essen, and German Cancer Consortium (DKTK), University Hospital Magdeburg, Dept. of Urology, Hospital Am Urban, Department of Urology und Paediatric Urology, Hospital University of Ulm, University Hospital Düsseldorf, Dept. of Urology, Department of Urology, University Hospital Muenster, Department of Urology, Uro-Oncology, Robot Assisted and Reconstructive Urologic Surgery, University of Cologne Faculty of Medicine and University Hospital Cologne, Department of Urology and Pediatric Urology, Saarland University Medical Center and Saarland University, Department of Urology, University of Marburg, University Medicine Mannheim, Dept. of Urology, Department of Urology, Diakonie-Klinikum Stuttgart, Department of Urology, Hospital University of Tübingen, Urology Department, Jena University Hospital, Red Cross Hospital, Dept. of Oncology, Department of Medical Oncology and Clinic for Urology, West-German Cancer Center Essen, University Hospital Essen and German Cancer Consortium (DKTK), Klinik für Urologie der Universität Regensburg am Caritas-Krankenhaus St. Josef, Department of Urology and Pediatric Urology, University Hospital Würzburg"
180,E19,Radium 223 without androgen deprivation therapy (ADT) in patients (Pts) with biochemically recurrent prostate cancer (BCR) and PET findings in the bones.,"Melissa Abel , Fatima Karzai , Philip Arlen , Clara Chen , Esther Mena , Liza Lindenberg , Jeanny Aragon-Ching , Lisa Cordes , Katherine Lee-Wisdom , Amy Hankin , Monique Williams , Yolanda McKinney , James Gulley , William Figg , Peter Choyke , Ravi Madan","National Institutes of Health, National Cancer Institute, National Institutes of Health, Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health, Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Walter Reed Army Medical Center, Inova Schar Cancer Institute, Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health"
50,A28,Prostate-specific antigen (PSA) response in Black patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) versus abiraterone acetate (ABI): A real-world comparison.,"Gordon Brown , Shawn Du , Ibrahim Khilfeh , Carmine Rossi , Sabree Burbage , Frédéric Kinkead , Lilian Diaz , Dominic Pilon , Benjamin Lowentritt","New Jersey Urology, A Summit Health Company, and Rowan University School of Osteopathic Medicine, Johnson & Johnson Innovative Medicine, Analysis Group, Inc., Chesapeake Urology"
599,H34,Renal cell carcinoma in kidney transplant recipients receiving immunosuppression: A 55-year retrospective single-center study.,"Annalisa Zeppellini , Giorgio Patelli , Fabio Ferla , Martino Pedrani , Silvia Pierri , Gabriele Calvanese , Gabriele Ciarlo , Giuseppe Sala , Nicole Gri , Valentina Falcone , Francesco Spina , Andrea Sartore-Bianchi , Luciano De Carlis , Salvatore Siena","Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Università degli Studi di Milano (La Statale) and Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Department of General and Transplant Surgery, Grande Ospedale Metropolitano Niguarda"
566,H1,Association between site of metastases and survival stratification of the IMDC classification in metastatic renal cell carcinoma (mRCC).,"Annalisa Zeppellini , Giorgio Patelli , Martino Pedrani , Caterina Vaghi , Rebecca Romanò , Laura Roazzi , Francesca Martinelli , Silvia Pierri , Gabriele Calvanese , Gabriele Ciarlo , Andrea Sartore-Bianchi , Francesco Spina , Salvatore Siena","Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Università degli Studi di Milano (La Statale) and Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Università degli Studi di Milano"
604,J3,Surgical variables and risk factors associated with urinary leak following partial nephrectomy: Insights from a high-risk population.,"Milan Patel , Lauren Loebach , Ruben Blachman-Braun , Braden Millan , Jaskirat Saini , Sandeep Gurram , W Linehan , Mark Ball","NIH, National Institutes of Health, Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, National Cancer Institute, National Institutes of Health"
381,K11,Differences in incidence and clinicopathologic features of secondary bladder cancer after long-term follow-up of brachytherapy and radical prostatectomy for localized prostate cancer.,"Kotaro Obayashi , Go Kimura , Hiroya Hasegawa , Hikaru Mikami , Jun Akatsuka , Hayato Takeda , Yuki Endo , Yuka Toyama , Hiroyuki Muramatsu , Katsuya Maebayashi , Shinichiro Kumita , Yukihiro Kondo","Nippon Medical School Hospital, Department of Urology, Nippon Medical School Hospital"
690,C23,Association between combination of VI-RADS based on T2WI and morphological features and pathological outcome and prognosis in bladder cancer.,"Shunsuke Ikuma , Jun Akatsuka , Hikaru Mikami , Kotaro Obayashi , Yuki Endo , Hayato Takeda , Go Kimura , Yukihiro Kondo","Nippon Medical School Hospital, Department of Urology, Nippon Medical School Hospital"
728,D25,Impact of relative dose intensity on efficacy of enfortumab vedotin monotherapy in platinum and ICI resistant metastatic urothelial carcinoma: A multi-institutional real-world analysis.,"Yuki Endo , Yukihiro Kondo , Yuma Sakura , Go Kaneko , Nozomi Hayakawa , Daiki Ikarashi , Ryo Yamashita , Suguru Shirotake , Wataru Obara , Eiji Kikuchi","Nippon Medical School Hospital, Department of Urology, Nippon Medical School Hospital, Shizuoka Cancer Center Department of Urology, Saitama Medical University International Medical Center, Keio University School of Medicine, Department of Urology, Iwate Medical University School of Medicine, Shizuoka Cancer Center, Saiatama Medical University International Medical Center, Iwate Medical University, Department of Urology, St Marianna University School of Medicine"
415,L11,"Tumor necrosis factor alpha signaling activity and NCCN risk, adverse pathology, and progression during active surveillance in prostate cancer.","Conor Driscoll , Nicole Handa , Yangyang Hao , Mohammed Alshalalfa , Alexander Hakansson , James Proudfoot , Elai Davicioni , Ashley Ross , William Catalona , Matthew Cooperberg , Edward Schaeffer , Shilajit Kundu","Northwestern University Feinberg School of Medicine, Department of Urology, Northwestern University, Feinberg School of Medicine, Veracyte, Inc., University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, University of California, San Francisco, Department of Urology, Northwestern University Feinberg School of Medicine"
376,K6,Racial and ethnic disparities in urinary continence recovery post-prostatectomy.,"Austin Drysch , Conor Driscoll , Adam Murphy , Shilajit Kundu , David Victorson","Northwestern University Feinberg School of Medicine, Northwestern University, Northwestern University Robert H. Lurie Comprehensive Cancer Center"
725,D22,Prognostic impact of first-line (1L) chemotherapy cycles in patients with metastatic urothelial carcinoma receiving avelumab 1L maintenance.,"Satoshi Katayama , Tatsuhi Kawada , Keita Kobayashi , Ryuta Watanabe , Yoichiro Tohi , Shinkuro Yamamoto , Atsushi Takamoto , Ryutaro Shimizu , Kei Daizumoto , Taichi Nagami , Koichiro Wada , Junya Furukawa , Noriyoshi Miura , Shuichi Morizane , Keiji Inoue , Mikio Sugimoto , Koji Shiraishi , Motoo Araki","Okayama University Graduate School of Medicine, Okayama University Hospital, Yamaguchi University, Department of Urology, Ehime University Graduate School, Kagawa University, Kochi Medical School, Fukuyama City Hospital, Tottori University Faculty of Medicine, Department of Urology, Tokushima University Graduate School of Biomedical Sciences, Shimane University Faculty of Medicine School, Tokushima University Faculty of Medicine, Ehime University, Department of Urology, Kochi Medical School, Okayama university Graduate School of Medicine"
130,D4,Impact of adherence to a remote exercise program on health-related quality of life in prostate cancer patients undergoing treatment: A prospective study in Brazil.,"Paulo Bergerot , Cristiane Bergerot , Jonas Silva , Marcos Franca , Dr. Paulo Lages , William Fuzita , Enrique Soto Pérez de Celis , Narjust Florez , Kathryn Schmitz , Sumanta Pal","Oncoclinicas & Co, Medica Scientia Innovation Research (MEDSIR), Oncoclinicas & Co, University of Colorado Anschutz Medical Campus, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Penn State College of Medicine, Department of Medical Oncology, City of Hope Comprehensive Cancer Center"
526,F24,Development of a FKSI-23: A new bespoke health-related quality of life (HRQOL) questionnaire for the advanced and adjuvant setting in renal cell carcinoma (RCC).,"Cristiane Bergerot , Paulo Bergerot , Daniela Castro , Benjamin Mercier , Elizabeth Nally , Adil Ali , Thomas Hutson , Axel Bex , Sarah Psutka , Brian Rini , Elizabeth Plimack , Viraj Master , Viktor Grünwald , Laurence Albiges , Toni Choueiri , Sumanta Pal , David Cella , Thomas Powles","Oncoclinicas & Co, Oncoclinicas & Co, Medica Scientia Innovation Research (MEDSIR), City of Hope Comprehensive Cancer Center, Barts Cancer Institute, Department of Urology, Emory University School of Medicine, Texas Oncology, Netherlands Cancer Institute, Department of Urology, University of Washington, Department of Medicine, Vanderbilt University Medical Center, Fox Chase Cancer Center, Temple Health, Emory University School of Medicine, Essen University Hospital, Gustave Roussy, Paris Saclay University, Department of Medical Oncology, Dana-Farber Cancer Institute, Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Barts Cancer Centre, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London"
243,G16,Integrating aggressive variant prostate cancer–associated tumor suppressor genes (AVPC-TSG) status to refine prognosis and predict androgen-receptor pathway inhibitors (ARPI) response in metastatic hormone-sensitive prostate cancer (mHSPC).,"Martino Pedrani , Giuseppe Salfi , Sara Merler , Irene Testi , Chiara Agrippina Clerici , Luis Castelo-Branco , Luigi Tortola , Fabio Turco , Ursula Vogl , Jean-Philippe Theurillat , Silke Gillessen , Ricardo Pereira Mestre","Oncology Institute of Southern Switzerland (IOSI), Institute of Oncology Research (IOR)"
169,E8,"EMETPRO: A multicenter, international, retrospective analysis evaluating patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) with early progression (EP).","Fabio Turco , Martino Pedrani , Giuseppe Salfi , Niven Mehra , Peter Slootbeek , Matthew Labriola , Amanda Broderick , Anna Patrikidou , Hortense Patry , Consuelo Buttigliero , Hirotsugu Uemura , Takanobu Utsumi , Daniele Raggi , Rafael Morales-Barrera , Daniela Guevara , Orazio Caffo , Andrea Zivi , Pedro Barata , Silke Gillessen , Ricardo Pereira Mestre","Oncology Institute of Southern Switzerland (IOSI), Radboud University Medical Center, Department of Medical Oncology, Radboud University Medical Center, Division of Medical Oncology, Duke University Medical Center, Duke Cancer Institute, Duke University, Gustave Roussy Cancer Centre, Gustave Roussy Cancer Centre, Villejuif, France, Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Kindai University, Department of Urology, Toho University Sakura Medical Center, Department of Medical Oncology, IRCCS San Raffaele Hospital, Medical Oncology Department, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Weill Cornell Medical Center, Presidio Ospedaliero Santa Chiara di Trento, APSS Trento, Oncology Unit, Azienda Ospedaliera Universitaria Integrata di Verona, University Hospitals Seidman Cancer Center"
TPS280,L33,Addition of darolutamide to first line treatment of metastatic castration-resistant prostate cancer (mCRPC): A randomized open label phase II trial (SAKK 08/23).,"Ursula Vogl , Katrin Eckhardt , Katrin Gobat , Silke Gillessen , Richard Cathomas","Oncology Institute of Southern Switzerland (IOSI), Swiss Group for Clinical Cancer Research (SAKK), Division of Oncology/Hematology, Cantonal Hospital Grisons"
499,E32,Metastatic renal cell carcinoma (mRCC) primary refractory patients to first-line IO-TKI and IO-IO combinations (Meet-URO 33 analysis).,"Davide Bimbatti , Alessio Signori , Sebastiano Buti , Francesca Vignani , Federico Paolieri , Cinzia Ortega , Lucia Fratino , Emilia Cocorocchio , Cristian Lolli , Claudia Mucciarini , Martina Buffoni , Diego Zara , Valeria Sardaro , Debora D'Ausilio , Stefania Di Girolamo , Claudia Mosillo , Letizia Galeasso , Anna Tortorella , Michele Maffezzoli , Sara Rebuzzi","Oncology Unit 1, Veneto Institute of Oncology IOV - IRCCS, Department of Health Sciences (DISSAL), Section of Biostatistics, University of Genova, Medical Oncology Unit, University Hospital of Parma, Medical Oncology, Ordine Mauriziano Hospital, Department of Oncology, Hospital of Prato, Azienda USL Toscana Centro, Department of Medical Oncology, Michele e Pietro Ferrero Hospital, Verduno-Azienda Sanitaria Locale CN2, Department of Medical Oncology, Centro di Riferimento Oncologico (CRO)-IRCCS, Division of Medical Oncology, Humanitas Gavazzeni, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) ""Dino Amadori"", Medical Oncology Unit, AUSL Modena, Ramazzini Hospital, Unit of Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, ASST Spedali Civili di Brescia, University of Brescia, University Hospital of Udine, Department of Oncology, Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Medical Oncology Unit, AUSL-IRCCS di Reggio Emilia, Medical and Translational Oncology Unit, Department of Oncology, Azienda Ospedaliera Santa Maria, Department of Oncology, University of Turin, Medical Oncology Unit, IRCCS Policlinico San Matteo, Department of Medicine and Surgery, University of Parma, Medical Oncology, Ospedale San Paolo"
584,H19,"The role of circulating kidney injury molecule-1 (KIM-1) in metastatic renal cell carcinoma (mRCC): A biomarker analysis of Tide-A, a phase 2 study of first-line avelumab (ave) plus intermittent axitinib (axi).","Chiara Ciccarese , Antonio Agostini , Martina Panebianco , Sebastiano Buti , Paolo Andrea Zucali , Davide Bimbatti , Emanuela Fantinel , Elena Verzoni , Caterina Accettura , Lucia Bonomi , Consuelo Buttigliero , Giuseppe Fornarini , Maria Giuseppa Vitale , Romina Pedone , Geny Piro , Giulia Claire Giudice , Matteo Perrino , Giampaolo Tortora , Carmine Carbone , Roberto Iacovelli","Oncology Unit, Fondazione Policlinico Universitario ""A. Gemelli"" IRCCS, Catholic University of Rome, Medical Oncology, Fondazione Policlinico A. Gemelli IRCCS, Medical Oncology, Ospedale San Paolo Civitavecchia, Medical Oncology Unit, University Hospital of Parma, Department of Oncology, IRCCS Humanitas Research Hospital, Oncology Unit 1, Veneto Institute of Oncology IOV - IRCCS, Oncology Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Genitourinary Medical Oncology, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Medical Oncology, Vito Fazzi Hospital, Unit of Oncology, ASST Papa Giovanni XXIII Hospital, University of Turin, San Luigi Gonzaga Hospital, IRCCS Ospedale Policlinico San Martino, Oncology Unit, Azienda Policlinico-Universitaria di Modena, Fondazione Policlinico Universitario ""Agostino Gemelli"" IRCCS, University of Parma, Medical Oncology, Humanitas Research Hospital, Humanitas Cancer Center, Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Comprehensive Cancer Center, Oncology Unit, Fondazione Policlinico Universitario ""A. Gemelli"" IRCCS"
470,E3,Real-world (RW) treatment (tx) patterns and clinical outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) in the US community setting.,"Cherrishe Brown-Bickerstaff , Paul Conkling , Rosa Banuelos , Jose Perez-Torrealba , Tasha Hall , Navendu Samant , Yue Zhang","Ontada, Exelixis, Inc., Virginia Oncology Associates"
268,H9,"Evaluating survival post-7 mo PSA response, stratified by response, disease extent, and intermittent vs. continuous ADT in mHSPC: The S9346 trial.","Alexandra Sokolova , Catherine Tangen , Maha Hussain , Christopher Sweeney , Tanya Dorff , Ian Thompson Jr., Seth Lerner","Oregon Health & Science University, Knight Cancer Institute, Fred Hutchinson Cancer Research Center, Northwestern University, Feinberg School of Medicine, Dana-Farber Cancer Institute, City of Hope Comprehensive Cancer Center, UT Health San Antonio, Baylor College of Medicine"
263,H4,"Approach to treatment of metastatic hormone-sensitive prostate (mHSPC) cancer among cooperative oncology groups (CCTG, SWOG, and Alliance) in North America.","Cameron Chalker , Michael Ong , Rana McKay , Catherine Tangen , Shuchi Gulati , Megan Keim , Seth Lerner , Tanya Dorff , Alexandra Sokolova","Oregon Health & Science University, Knight Cancer Institute, The Ottawa Hospital Cancer Centre, University of California, San Diego, SWOG Statistics and Data Management Center, UC Davis Comprehensive Cancer Center, SWOG, Baylor College of Medicine, City of Hope Comprehensive Cancer Center"
405,L1,Associations between protein biomarkers and adverse pathologic features in MRI-mapped prostate cancers: An interim analysis.,"Wesley Chou , Solange Bassale , Tao Liu , Tai-Tu Lin , Yuqian Gao , Yi-Ting Wang , Lorenz Nierves , Athena Schepmoes , Brianna Gonzalez , Thomas Fillmore , Tujin Shi , Patricia Miller , Andrew Cowan , Karin Rodland , Fergus Coakley , Travis Rice-Stitt , Jen-Jane Liu , Sudhir Isharwal , Christopher Amling , Ryan Kopp","Oregon Health & Science University, Pacific Northwest National Laboratory, Kymera Therapeutics"
339,J3,Interim analysis of the “shutter speed” MRI model to detect clinically significant prostate cancer.,"Andrew Cowan , Solange Bassale , Fergus Coakley , Travis Rice-Stitt , Xin Li , Wesley Chou , Sudhir Isharwal , Jen-Jane Liu , Mark Garzotto , Christopher Amling , Ryan Kopp","Oregon Health & Science University, Portland VA Medical Center, VA Portland Healthcare System and Oregon Health & Science University"
212,F16,Analysis of gut microbiota profiles in patients with prostate cancer: The PROMISE-JAPAN study.,"Koji Hatano , Toshiki Oka , Takuji Yamada , Makoto Matsushita , Saizo Fujimoto , Junya Hata , Akira Tsujimura , Wataru Obara , Tetsuya Takao , Shingo Takada , Shinichi Yachida , Norio Nonomura , Kazutoshi Fujita","Osaka University Graduate School of Medicine, Tokyo Institute of Technology, Osaka University, Graduate School of Medicine, Kindai University, Faculty of Medicine, Fukushima Medical University, Juntendo University Urayasu Hospital, Department of Urology, Iwate Medical University, Osaka General Medical Center, Osaka Police Hospital, Department of Cancer Genome Informatics, Graduate School of Medicine, Osaka University, Department of Urology, Osaka University Graduate School of Medicine, Department of Urology, Kindai University Faculty of Medicine"
693,C26,Avelumab first-line (1L) maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma (la/mUC) in the Czech Republic: Updated real-world results from a national reimbursement registry.,"Hana Studentova , Anežka Zemánková , Bohuslav Melichar , Michal Eid , Alexandr Poprach , Jindřich Kopecký , Tomáš Büchler , Darja Šustrová , Šárka Stuhlová , Jan Dvořák , Zuzana Donátová , Pavel Vlček , Kateřina Zycháčková , Jana Katolicka , Tomáš Blažek , David Vrána , Ondřej Fiala , Petra Májková , Adam Čepa","Palacký University and University Hospital, Department of Oncology, Faculty of Medicine and Dentistry, Palacký University and University Hospital, University Hospital, Palacký University, Masaryk University, Department of Clinical Oncology and Radiotherapy, University Hospital in Hradec Králové, Department of Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Oncology Department, Jihlava Hospital, Department of Radiotherapy and Oncology, University Hospital Kralovske Vinohorady & Third Faculty of Medicine, Charles University, Clinic of Oncology 1st Faculty of Medicine Charles University and Thomayer University Hospital, Department of Oncology, Ceske Budejovice Hospital, Oncology Department, T. Bata Regional Hospital, Department of Oncology, St. Anne's University Hospital Brno, Department of Oncology, Ostrava University Hospital & Faculty of Medicine, University of Ostrava, Comprehensive Cancer Center Novy Jicin, Hospital Novy Jicin, Department of Oncology and Radiotherapeutics, Faculty of Medicine, University Hospital in Pilsen, Charles University, Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Merck spol. s r.o., an affiliate of Merck KGaA, Darmstadt, Germany"
837,H1,Changes in circulating tumor cells (CTCs) and HER2 expression in evaluating the efficacy of neoadjuvant disitamab vedotin plus toripalimab treatment in patients with muscle-invasive bladder cancer (MIBC).,"Yudong Cao , Ruojing Li , Shuo Wang , Jinchao Ma , Yongpeng Ji , Chen Lin , Peng Du","Peking University Cancer Hospital & Institute, Department of Urology, Peking University Cancer Hospital"
TPS279,L32,"Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with androgen receptor pathway inhibitors in patients with metastatic hormone-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01).","Arun Azad , Neeraj Agarwal , Andrew Armstrong , Eva Hellmis , Friederike Schlürmann , Mikio Sugimoto , Yüksel Ürün , Nianzeng Xing , Mehreteab Aregay , Julianne Lima , Didier Meulendijks , Kim Chi","Peter MacCallum Cancer Centre, Huntsman Cancer Institute at the University of Utah, Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University, Urologicum Duisburg, Centre Hospitalier de Quimper, Institut de Cancérologie de Cornouaille (ICC), Kagawa University, Ankara University School of Medicine, Department of Medical Oncology, Ankara, Turkey; Ankara University Cancer Institute, Ankara, Turkey, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, AstraZeneca, University of British Columbia, BC Cancer, Vancouver Cancer Centre"
572,H7,Vasculo-immune modulatory effects of anti-VEGF therapy in metastatic clear cell renal cell carcinoma: The A-PREDICT trial.,"Lewis Au , Zayd Tippu , Husayn Pallikonda , Anne-Laure Cattin , Georgia Whitton , Andrew Rowan , Annika Fendler , Jahangeer Malik , Ekaterini Boleti , Naveen Vasudev , Martin Highley , Agnieszka Michael , Tim Eisen , Steven Penegar , Rebecca Lewis , Lucy Kilburn , Judith Bliss , Charles Swanton , James Larkin , Samra Turajlic","Peter MacCallum Cancer Centre, Royal Marsden Hospital, The Francis Crick Institute, Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, Western General, Royal Free London NHS Foundation Trust, St. James's Hospital, Derriford Hospital, University of Surrey, University of Cambridge, Institute of Cancer Research, The Institute of Cancer Research, Clinical Trials and Statistics Unit, The Institute of Cancer Research, Clinical Trials and Statistics Unit, The Institute of Cancer Research, University College London Cancer Institute"
730,D27,Bacillus Calmette-Guérin (BCG) treatment patterns and real-world outcomes in high-risk (HR) non-muscle-invasive bladder cancer (NMIBC): A systematic literature review (SLR).,"Anthony Eccleston , Abin Koshy , Mihaela Musat , Cristiana Tzonev , Julia Brinkmann , Jane Chang","Pfizer Ltd, Pfizer Inc., Cytel, Pfizer Pharma GmbH"
738,D35,Treatment patterns of MIBC patients not receiving radical cystectomy: Results from a real-world survey in Europe.,"Anthony Eccleston , Abin Koshy , Julia Brinkmann , Neil Milloy , Laure Manuel , Jacob Skilling , Emilia Biondi , Elliott Brown , Jane Chang","Pfizer Ltd, Pfizer Inc., Pfizer Pharma GmbH, Adelphi Real World"
110,C20,Real-world outcomes in metastatic prostate cancer patients with ctDNA-detected SPOP mutations.,"Windy Dean-Colomb , Jayati Saha , Courtney Lewis , Leslie Bucheit , Clayton Yates","Piedmont Oncology Institute, Guardant Health, Johns Hopkins School of Medicine"
859,H23,Biomarker analysis in localized urothelial cancer DUART patients post-treatment.,"Adriana Ramos Medero , Junjia Zhu , Monika Joshi , Todd Schell","Ponce Health Sciences University School of Medicine, Penn State Cancer Institute, Department of Microbiology and Immunology, Penn State Health Milton S. Hershey Medical Center"
373,K3,"Impact of COVID-19 pandemic on the treatment of prostate cancer in Brazilian public health system, comparing pre and post pandemic data.","Gustavo Carvalhal , Guilherme Zulli , Igor Alexandre Morbeck , Daniel Herchenhorn , Andre Sasse , Rana McKay , Brent Rose , Fernando Maluf , Fernando Monteiro , Vinicius Souza , Andrey Soares , Denis Jardim , Diogo Bastos , Dr. Paulo Lages , Elcio Firminiano , Douglas Valverde , Nicholas James","Pontifical Catholic University of Rio Grande do Sul, Instituto do Câncer Brasil de Ensino e Pesquisa, Oncoclínicas & Co, Oncologia D'OR/Instituto D'OR de Ensino e Pesquisa and Latin American Cooperative Oncology Group (LACOG), Grupo SOnHe, Moores Cancer Center, University of California, San Diego, University of California, San Diego, Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil and Hospital Israelita Albert Einstein, Latin American Cooperative Oncology Group (LACOG), Porto Alegre, and Oncology and Hematology Department, Hospital Sírio Libanês, Latin American Oncology Group (LACOG), Hospital Albert Einstein, Oncoclínicas & Co, Medica Scientia Innovation Research (MEDSIR), Hospital Sírio-Libanês; LACOG (Latin American Cooperative Oncology Group), Oncoclinicas & Co, Medica Scientia Innovation Research (MEDSIR), Techtrials, The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust"
633,J18,Outcomes of patients with stage I testicular cancer following orchidectomy with borderline retroperitoneal lymph node enlargement at diagnosis.,"Deepro Chowdhury , Eshetu Atenafu , Di Maria Jiang , Esmail Al-Ezzi , Rachel Glicksman , Peter Chung , Susan Prendeville , Martin O'Malley , Padraig Warde , Robert Hamilton , Philippe Bedard","Princess Margaret Cancer Centre, Department of Biostatistics, Princess Margaret Cancer Centre, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Princess Margaret Hospital, University Health Network, Department of Medical Imaging, Princess Margaret Cancer Centre, University Health Network, Princess Margaret - University Health Network, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Department of Medicine, University of Toronto"
765,E27,Patient perceptions about their treatment for muscle-invasive bladder cancer (MIBC) over the last decade.,"Deepro Chowdhury , Andrea Apolo , Di Maria Jiang , Eila Skinner , Stephanie Chisolm , Rick Bangs , Manjula Maganti , Gary Steinberg , Matthew Kaag , Jason Efstathiou , Srikala Sridhar","Princess Margaret Cancer Centre, National Cancer Institute, National Institutes of Health, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, GU Surgical Oncology, Stanford Cancer Center, Bladder Cancer Advocacy Network (BCAN), Bladder Cancer Advocacy Network, Inc., Department of Urology, Rush University, Penn State Milton S. Hershey Medical Center, Massachusetts General Hospital"
629,J14,Clinical outcomes of stage IIA/IIB seminoma treated with radiotherapy and chemotherapy: Should regional therapy be considered the preferred treatment approach?,"Rachel Glicksman , Di Maria Jiang , Philippe Bedard , Xiang Ye , Lynn Anson-Cartwright , Astrid Billfalk-Kelly , Satheesh Krishna , Martin O'Malley , Carol Cheung , Abigail Shin , Robert Hamilton , Padraig Warde , Peter Chung","Princess Margaret Cancer Centre, University Health Network, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Department of Medicine, University of Toronto, Department of Biostatistics, Princess Margaret Cancer Centre, Departments of Surgery (Urology) and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Department of Radiation Oncology, Dr. H. Bliss Murphy Cancer Centre, Department of Medical Imaging, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Department of Medical Imaging, Princess Margaret Cancer Centre, University Health Network, Department of Pathology, University Health Network; Department of Laboratory Medicine and Pathobiology, University of Toronto, Radiation Medicine Department, Princess Margaret Cancer Centre, University Health Network, Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Radiation Medicine Department, Princess Margaret Cancer Centre, University Health Network; Department of Radiation Oncology, University of Toronto"
699,C32,Patterns of split-dose gemcitabine and cisplatin (GC) use in patients with locally advanced or metastatic urothelial carcinoma (la/mUC): Results of a 10-country physician survey.,"Richard O'Dwyer , Sophia Junker , Robert Szulkin , Scarlette Kienzle , Mairead Kearney , Srikala Sridhar","Princess Margaret Cancer Centre, University Health Network, Real-World Evidence Department, Cytel Inc., The Healthcare Business of Merck KGaA"
194,E33,Assessing genomic instability (GI) by shallow whole-genome sequencing (sWGS) to predict PARP inhibitor (PARPi) response in metastatic castration-resistant prostate cancer (mCRPC).,"Peter Slootbeek , Yarah Quint , Julian Kokke , Samhita Pamidimarri Naga , Iris Kloots , Maria Luna-Velez , Marjolijn Ligtenberg , Richarda de Voer , Niven Mehra",Radboud University Medical Center
183,E22,Re-treatment of metastatic castration-resistant prostate cancer patients with radium-223 therapy in daily practice.,"Maarten van der Doelen , Joost van Riel , Maarten Donswijk , Christel Brouwer , Winald Gerritsen , Ha Tan-Phan , Willie Thimister , Walter Noordzij , Erik te Beek , Laurence van Warmerdam , Andre Bergman , Inge van Oort , Dirk Wyndaele","Radboud University Medical Center, Netherlands Cancer Institute, Catharina hospital, Department of Medical Oncology, Radboud University Medical Center, Leeuwarden Medical Center, Admiraal de Ruyter Hospital, UMC Groningen, Reinier de Graaf Gasthuis, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Catharina Hospital"
160,D34,"PERSIAN trial: Early results from a randomized phase II trial testing apalutamide and stereotactic body radiation therapy for low-burden, metastatic, hormone-sensitive prostate cancer.","Giulio Francolini , Vanessa Di Cataldo , Pietro Garlatti , Saverio Caini , Alessio Bruni , Nicola Simoni , Matteo Augugliaro , Roberto Iacovelli , Luca Tagliaferri , Nicola Battelli , Gianluca Ingrosso , Angelo Porreca , Marco Trovò , Giuseppe Fornarini , Giuseppe Iorio , Alessia Guarneri , Michele Sisani , Lorenzo Antonuzzo , Alfio Di Grazia , Lorenzo Livi","Radiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence, Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPO), Radiation Oncology Unit, Department of Oncology and Hematology, University Hospital of Modena, Radiotherapy Unit, Azienda Ospedaliera Universitaria, Unit of Radiotherapy, Azienda USL, IRCCS di Reggio Emilia, Comprehensive Cancer Center, Medical Oncology Department, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Oncology Unit, Macerata Hospital, Radiation Oncology Section, Department of Medicine and Surgery, University of Perugia, Department of Oncological Urology, Veneto Institute of Oncology IOV-IRCCS, Department of Radiation Oncology, University General Hospital, IRCCS Ospedale Policlinico San Martino, Department of Oncology, Radiation Oncology, University of Turin, Radiation Oncology, Department of Medical and Surgical Sciences, University of Turin, Medical Oncology Unit, San Donato Hospital, Clinical Oncology Unit, Careggi University Hospital, Florence, Italy, and Department of Experimental and Clinical Medicine, University of Florence, Radioterapia Humanitas, Istituto Clinico Catanese, Azienda Ospedaliero Universitaria Careggi, University of Florence"
47,A25,The comparison of clinical utility between pan-cancer panel and PCa-specific panel for mCRPC.,Baijun Dong,Renji Hospital
710,D7,Effectiveness and safety of RC48-ADC in combination with toripalimab as neoadjuvant treatment in HER2-positive muscular invasive urothelial bladder cancer patients.,"Chenglong Li , Jiefu Zhu , Fan Cheng , Weimin Yu , Zhiyuan Chen , Chao Song , Hengcheng Zhu , Haoyong Li","Renmin Hospital of Wuhan University Hubei General Hospital, Rennin Hospital Wuhan University"
835,G31,Clinical outcomes in metastatic bladder cancer associated with mutations in Trithorax-group protein genes.,"Mark Sikov , Galina Lagos , Sheldon Holder , Benedito Carneiro , Anthony Mega , Sari Khaleel , Dragan Golijanin , Liang Cheng , Andre De Souza","Rhode Island Hospital, Lifespan Cancer Institute, Department of Hematology and Oncology, The Miriam Hospital, Warren Alpert Medical School of Brown University, Cancer Center at Brown University, Brown University, Legorreta Cancer Center, Memorial Sloan-Kettering Cancer Center - Fellowship (GME Office), The Minimally Invasive Urology Institute, Division of Urology, The Miriam Hospital, Warren Alpert Medical School of Brown University, Warren Alpert Medical School of Brown University, Center for Cancer Research, National Cancer Institute, National Institutes of Health"
TPS283,M2,Phase 2 randomized study of high-risk metachronous oligometastatic prostate cancer with high-risk mutations treated with metastasis-directed therapy and niraparib/abiraterone acetate plus prednisone (KNIGHTS) trial.,"Matthew Deek , Xiaolei Shi , Noura Radwan , Caitlin Eggleston , Kaysee Baker , Zaker Rana , Matthew Ferris , Young Kwok , Soren Bentzen , Ronald Ennis , Lara Hathout , Biren Saraiya , Tina Mayer , Heather Mannuel , Arif Hussain , Matthew Abramowitz , Alejandro Berlin , Mark Mishra , Phuoc Tran , Jason Molitoris","Robert Wood Johnson Medical School, Rutgers University, University of Maryland School of Medicine, University of Maryland Upper Chesapeake Health, University of Maryland Medical Center, Rutgers Cancer Institute of New Jersey, Rutgers Health, Rutgers Cancer Institue of New Jersey, Rutgers Cancer Institute of New Jersey, University of Maryland, University of Maryland Medical Center, Greenebaum Comprehensive Cancer Center, University of Miami Miller School of Medicine, Cancer Digital Intelligence, Princess Margaret Cancer Centre, University Health Network"
128,D2,Prevalence of adverse events following T-cell engaging bispecific antibodies (bsAbs) and chimeric antigen receptor (CAR) T-cell therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC): A meta-analysis.,"Abhiraj Saxena , Nicholas Zorko , Vivek Narayan , Biren Saraiya , William Tester , Grace Lu-Yao , William Kelly , Kevin Zarrabi","Robert Wood Johnson University Hospital, University of Minnesota, Hospital of the University of Pennsylvania, Rutgers Cancer Institute of New Jersey, Thomas Jefferson University, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, Thomas Jefferson University"
810,G6,A novel CD28 x Nectin-4 costimulatory bispecific antibody for advanced bladder cancer.,"Thomas Manley , Starlynn Clarke , Manpreet Kaur , Sebastian Moreno Arteaga , Soumili Chattopadhyay , Elaine Chen , Ruth Chu , Jacqueline Morgan , Cynthia Nguyen , Udaya Rangaswamy , Mathias Rickert , Katja Rueger , Imani Smith , Gizelle Taleno , Laura Davison , Katherine Harris , Shelley Force Aldred , Nathan Trinklein",Rondo Therapeutics
374,K4,GLP-1 analogues and prostate cancer incidence: A systematic review and meta-analysis.,"Selena Gong , Eric Yu , Tanvir Chakkal , Tahmina Shamsheri , Yousef Abumustafa , Declan Lavoie , Darryl Leong , Filipe Cirne , Rocio Baro Vila , Germano Dallegrave Cavalli , Ahmed Aldarraji","Royal College of Surgeons of Ireland, Michael G. DeGroote School of Medicine, Faculty of Medicine University of Ottawa, McMaster University, ICBA, Population Health Research Institute, McMaster University, Michael G. DeGroote School of Medicine, McMaster University"
317,H17,The Man Van phase 2 results: Mobile targeted case finding for prostate cancer.,"Masood Moghul , Fionnuala Croft , Fiona Mutch , Elisabeth Westaway , Kathyrn Bradshaw , Patrick Kierkegaard , Netty Kinsella , Declan Cahill , Nicholas James","Royal Marsden Hospital NHS Trust, Institute of Cancer Research, Royal Marsden Hospital NHS Trust, Royal Marsden Hospital, Cancer Research UK Convergence Science Centre Imperial College London and The Institute of Cancer Research, Royal Marsden NHS Foundation Trust, The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust"
484,E17,A multi-centre review of the use of adjuvant pembrolizumab for renal cell carcinoma.,"Eleanor McCarthy , Alice Chadwick , Juan Jose Soto-Castillo , Lisa Pickering , Ricky Frazer , Manon Pillai , Tom Waddell , Duncan Lindsay , Ansh Agarwal , Diana Matthews , Mahrukh Khalid , Simon Grumett , Ellis Adamson , John McGrane , Helen Dearden , Naveen Vasudev , Natalie Charnley","Royal Preston Hospital, Lancashire Teaching Hospitals NHS Foundation Trust, Manchester Medical School, The Royal Marsden Hospital, Royal Marsden Hospital NHS Trust, Velindre Cancer Centre, Velindre University NHS Trust, Christie NHS Foundation Trust, The Christie NHS Foundation Trust, Velindre Cancer Centre, University Hospital Birmingham, University Hospitals Birmingham NHS Trust, Royal Cornwall Hospitals NHS Trust, Royal Cornwall Hospital NHS Trust, Leeds Teaching Hospitals NHS trust, St James's University Hospital, Royal Preston Hospital"
392,K22,"LEEP: A randomised, window of opportunity, neoadjuvant trial examining the pharmacodynamic effects of ribociclib prior to radical prostatectomy for high-risk, localised prostate cancer.","Tahlia Scheinberg , James Kench , Peter Ferguson , Sarah Sutherland , Martin Stockler , Kate Mahon , Phillip Stricker , Anthony Joshua , Henry Woo , Ruban Thanigasalam , Nariman Ahmadi , Gavin Marx , Ian Davis , Shomik Sengupta , Scott Leslie , Margaret Centenera , Lisa Butler , Lisa Horvath","Royal Prince Alfred Hospital, Chris O'Brien Lifehouse, The University of Sydney, Department of Urology, St. Vincent’s Hospital; St Vincent’s Prostate Cancer Centre, Kinghorn Cancer Centre, Northern Hematology and Oncology Group, Monash University and Eastern Health, Monash University Eastern Health Clinical School, South Australian Health and Medical Research Institute"
81,B27,Effectiveness and safety of radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC): A systematic literature review of 48 real-world studies.,"Michaela Lunan , Amit Raval , Nguyen Thi Nhan Phan , Matthew Korn , Vanessa Quintero , Rana McKay","RTI Health Solutions, Bayer HealthCare Pharmaceuticals, Inc., Department of Medicine, University of California San Diego"
309,,Radical prostatectomy (RP) versus radiotherapy (RT) in high-risk prostate cancer (HR-PCa): Emulated randomized comparison with individual patient data (IPD) from two phase III randomized trials (RCTs).,"Soumyajit Roy , Yilun Sun , James Eastham , Martin Gleave , Himisha Beltran , Amar Kishan , Angela Jia , Nicholas Zaorsky , Jorge Garcia , Eric Small , Paul Nguyen , Gerhardt Attard , Rana McKay , Alton Sartor , Seth Rosenthal , Susan Halabi , Felix Feng , Michael Morris , Howard Sandler , Daniel Spratt","Rush University Medical Center, Case Western Reserve University, Memorial Sloan Kettering Cancer Center, Vancouver Prostate Centre, University of British Columbia, Dana-Farber Cancer Institute, Department of Radiation Oncology, University of California, Los Angeles, University Hospitals Seidman Cancer Center, Case Western Reserve University, Division of Solid Tumor Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, University of California San Francisco, Brigham and Women's Hospital, Institute of Cancer Research, University College, Moores Cancer Center at UC San Diego Health, Mayo Clinic, Department of Radiation Oncology, Sutter Medical Group, Department of Biostatistics and Bioinformatics, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Radiology School of Medicine, University of California, San Francisco, Cedars-Sinai Medical Center"
192,E31,"Individual patient data (IPD) analysis of early PSA nadir in ARASENS, LATITUDE, and TITAN: Training and validation of a novel model.","Soumyajit Roy , Yilun Sun , Maha Hussain , Kim Chi , Simon Chowdhury , Pedro Barata , Christopher Wallis , Bertrand Tombal , Neeraj Agarwal , Amar Kishan , Shawn Malone , Scott Morgan , Umang Swami , Angela Jia , Nicholas Zaorsky , Michael Ong , Karim Fizazi , Fred Saad , Neal Shore , Daniel Spratt","Rush University Medical Center, Department of Population Quantitative Health Sciences, Case Western Reserve University School of Medicine, Northwestern University, Feinberg School of Medicine, University of British Columbia, BC Cancer, Vancouver Cancer Centre, Guy's, King's, and St. Thomas' Hospitals, and Sarah Cannon Research Institute, University Hospitals Seidman Cancer Center, Division of Urology and Surgical Oncology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Cliniques Universitaires Saint-Luc, Huntsman Cancer Institute (NCI-CCC), University of Utah, Department of Radiation Oncology, University of California, Los Angeles, The Ottawa Hospital, University of Ottawa, Department of Medicine, Huntsman Cancer Institute at the University of Utah, University Hospitals Seidman Cancer Center, Case Western Reserve University, The Ottawa Hospital Cancer Centre, Institut Gustave Roussy, University of Paris-Saclay, University of Montreal Hospital Centre, Carolina Urologic Research Center"
TPS297,M16,Study of JAK inhibition in stem-like prostate cancer (JASPER): A phase 1/2 multicenter study of ruxolitinib and enzalutamide in castration resistant prostate cancer undergoing lineage plasticity.,"Thomas Westbrook , Frank Cackowski , Joshi Alumkal , Anbarasu Kumaraswamy , Megan Caram , Sarah Yentz , Ulka Vaishampayan , Manjunath Pai , Thomas Braun , Zachery Reichert","Rush University Medical Center, Karmanos Cancer Institute, Wayne State University, Rogel Cancer Center, University of Michigan, University of Michigan College of Pharmacy"
832,G28,Impact of gene expression signatures of immune infiltration on response to sequential intravesical gemcitabine and docetaxel versus bacillus Calmette-Guerin in high-risk non-muscle-invasive bladder cancer.,"Vignesh Packiam , Joep de Jong , Saum Ghodoussipour , James Proudfoot , Elai Davicioni , Ian McElree , Michael O'Donnell","Rutgers RWJ Barnabas Health, Erasmus MC Cancer Institute, Rutgers Cancer Institute of New Jersey, Veracyte, Inc., Carver College of Medicine, University of Iowa, University of Iowa and Clinic Holden Cancer Center"
139,D13,Survival outcomes of de novo mHSPC based on hemoglobin A1C and ARPI therapy.,"Rohan Agarwal , Luke Rohde , Jason Doherty , Martin Schoen","Saint Louis University School of Medicine, Department of Health and Clinical Outcomes Research, Saint Louis University, Division of Hematology and Medical Oncology, Department of Internal Medicine, Saint Louis University School of Medicine"
269,H10,Androgen receptor alterations and survival in veterans who develop metastatic castrate resistant prostate cancer.,"Carley Pickett , Krishny Karunanandaa , Jason Doherty , Isla Garraway , Matthew Rettig , Kara Maxwell , Martin Schoen","Saint Louis University School of Medicine, Department of Health and Clinical Outcomes Research, Saint Louis University, Greater Los Angeles Department of Veterans Affairs Healthcare System, Department of Medical Oncology, University of California, Los Angeles, University of Pennsylvania, Division of Hematology and Medical Oncology, Department of Internal Medicine, Saint Louis University School of Medicine"
76,B22,Overall survival between veterans with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone with kidney disease.,"Robert Wilson , Jason Doherty , Suhong Luo , Danielle Candelieri-Surette , Daniel Eaton Jr., Martin Schoen","Saint Louis University School of Medicine, Department of Health and Clinical Outcomes Research, Saint Louis University, Saint Louis VA Medical Center, University of Massachusetts Lowell, Veterans Affairs St. Louis Health Care System, St. Louis Veterans Affairs Medical Center"
72,B18,Hospitalizations in veterans treated with monotherapy vs combination therapy for metastatic hormone sensitive prostate cancer.,"Kara Ingram , Robert Wilson , Jason Doherty , Daniel Eaton Jr., Martin Schoen","Saint Louis University School of Medicine, Department of Health and Clinical Outcomes Research, Saint Louis University, Veterans Affairs St. Louis Health Care System, Division of Hematology and Medical Oncology, Department of Internal Medicine, Saint Louis University School of Medicine"
187,E26,Evaluating the impact of single vs. combination therapy on survival outcomes in mHSPC patients stratified by BMI.,"Luke Rohde , Rohan Agarwal , Martin Schoen","Saint Louis University School of Medicine, Research Service, St. Louis Veterans Affairs Medical Center"
680,C13,Inclusion of patients with reduced performance status (ECOG 2 or higher) in FDA registrational trials for urothelial cancer.,"Panah Parab , Ronit Juthani , Kala Seetharaman","Saint Vincent Hospital, St. Vincent Hospital, Saint Vincent Cancer and Wellness Center"
559,G26,Systemic therapies in renal cell carcinoma with brain metastases: A comparative meta-analysis of immunotherapy and tyrosine kinase inhibitors.,"Abdur Jamil , Zaheer Qureshi , Roshmita Bardhan , Mohsin Ahmad , Insija Selene","Samaritan Medical Centre, The Frank H. Netter M.D. School of Medicine at Quinnipiac University, The Jewish Hospital, Mercy Health, Christus Southeast Texas- St.Elizabeth, University of Kentucky"
807,G3,Phase I dose-escalation study of the next-generation nectin-4 targeting antibody–drug conjugate CRB-701 (SYS6002) in US and UK patients with urothelial cancer and other solid tumors.,"Cesar Perez , Neel Gandhi , Kailash Mosalpuria , C. Cowey , Ian Hodgson , Dominic Smethurst , David Pinato","Sarah Cannon Research Institute at Florida Cancer Specialists, Carolina BioOncology Institute, Nebraska Hematology-Oncology P.C., Texas Oncology-Baylor Charles A. Sammons Cancer Center, The US Oncology Network, Corbus Pharmaceuticals, Department of Surgery and Cancer, Imperial College"
73,B19,A real-world clinicogenomic study of androgen receptor mutations and co-mutations in prostate cancer: Clinical implications.,"Emma Sturgill , Daniel Luckett , Tarun Agrawal , Jordan Best , Rikki Williams , Manojkumar Bupathi , Mark Fleming , Ian Schnadig , Vivek Subbiah , David Spigel , Howard Burris III, Andrew McKenzie , Benjamin Garmezy","Sarah Cannon Research Institute, Genospace, TriStar Centennial Medical Center, Rocky Mountain Cancer Centers, Virginia Oncology Associates, Compass Oncology, Sarah Cannon Research Institute Oncology Partners"
723,D20,Avelumab first-line (1L) maintenance therapy in advanced urothelial carcinoma: Final analysis from a real-world study in the UK.,"Robert Jones , Yatri Shah , Alison Birtle , Amarnath Challapalli , Joachim Chan , Deborah Enting , Andrew Hudson , Mark Linch , Sophie Otter , Andrew Protheroe , Anand Sharma , Rufus Turner , Bhagyalakshmi Chengat Prakashbabu , Wendy Rice , Elima Jedy-Agba","School of Cancer Sciences, University of Glasgow, Merck Serono, Rosemere Cancer Centre, Lancs Teaching Hospitals, & University of Manchester, University of Central Lancashire, Bristol Haematology and Oncology Centre, University Hospitals Bristol and Weston NHS Foundation Trust, The Clatterbridge Cancer Centre NHS Foundation Trust, Guy's and St Thomas' NHS Foundation Trust, The Christie NHS Foundation Trust, University College London Cancer Institute, Royal Surrey County Hospital NHS Foundation Trust, Oxford University Hospitals NHS Foundation Trust, Mount Vernon Cancer Centre, The Beatson West of Scotland Cancer Centre, IQVIA, IQVIA Ltd"
TPS617,K18,"Implementing precision oncology in renal cell carcinoma (RCC): Prospective identification of clinical, tissue-based, and circulating factors to refine outcome prediction and support therapeutic choices (SIGNS-RCC TRIAL).","Ilaria Zampiva , Emanuela Fantinel , Veronica Mollica , Sara Elena Rebuzzi , Davide Bimbatti , Francesca Bertolotti , Matteo Brunelli , Stefano Manduca , Pierpaolo Marchetti , Andrea Marchetti , Jessica Menis , Guido Martignoni , Cecilia Nasso , Michela Piacentini , Francesco Pierantoni , Matteo Rosellini , Giuseppe Verlato , Roberta Vesentini , Michele Milella , Anna Caliò","Section of Innovation Biomedicine-Oncology Area, Department of Engineering for Innovation Medicine (DIMI) Verona, Italy; Oncology Unit 1, Istituto Oncologico Veneto, IOV-IRCCS, Medical Oncology Department, University and Hospital Trust of Verona, Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genoa, Genoa; Medical Oncology Unit, Ospedale San Paolo, Oncology Unit 1, Veneto Institute of Oncology IOV - IRCCS, Oncologia Medica, Ospedale San Paolo, Department of Diagnostic and Public Health, Section of Pathology, University of Verona, Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust (AOUI) of Verona, Department of Diagnostics and Public Health, Section of Epidemiology and Medical Statistics, University of Verona, Department of Diagnostic and Public Health, Section of Pathology, University of Verona, Verona; Department of Pathology, Pederzoli Hospital, Division of Oncology, S. Corona Hospital, Oncology Unit 3, Istituto Oncologico Veneto, IOV-IRCCS"
751,E13,A comparative analysis of complication rates in urinary diversions: Exploring the impact of contemporary surgical trends.,"John Pfail , Melinda Fu , Rachel Passarelli , Alain Kaldany , Benjamin Lichtbroun , David Golombos , Thomas Jang , Vignesh Packiam , Saum Ghodoussipour","Section of Urologic Oncology, Rutgers Robert Wood Johnson Medical School, Section of Urologic Oncology, Rutgers Cancer Institute and Rutgers Robert Wood Johnson Medical School, Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School"
51,A29,Role of liquid biopsy in the detection of homologous recombination repair gene mutations (HRRm) in metastatic prostate cancer (mPC).,"Soumaya Labidi , Parvaneh Fallah , Aida Salehi , Raghu Rajan , Mona Alameldine , Fadi Brimo , William Foulkes , Andreas Papadakis , Alan Spatz , Cristiano Ferrario , Ramy Saleh , April Rose","Segal Cancer Centre, Jewish General Hospital, McGill University Health Centre, Pathology Department, Jewish General Hospital, Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Lady Davis Institute, Lady Davis Institute, McGill University, Jewish General Hospital, Segal Cancer Centre, Jewish General Hospital, McGill University"
801,F28,A heterologous prime-boost strategy using RUTI vaccine to improve the BCG response in non–muscle-invasive bladder cancer patients (RUTIVAC-1 trial).,"Oscar Buisan , Pol Servian , Sonia Pedreño-Lopez , Joan Pagès , Victor Urrea , Roberto Martinez , Elisabet Garcia , Mercè Amat , Joan Areal , Joaquim Bellmunt , Bonaventura Clotet , Cecilia Cabrera","Servicio de Urología, Hospital Universitario de Bellvitge, ICO - Institut Català d'Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), IrsiCaixa, Institute for Health Science Research Germans Trias i Pujol (IGTP), Department of Urology, Archivel Farma, Bladder Cancer Center, Dana Farber Cancer Institute, Harvard Medical School, Irsicaixa. Institute for Health Science Research Germans Trias i Pujol (IGTP)"
829,G25,Comprehensive investigation of CPSF3's role in the progression of bladder cancer.,"Zhiyang Ma , Danfeng Xu , Chenghe Wang","Shanghai Ruijin Hospital, Ruijin Hospital Affliated to Shanghai Jiaotong Medical School"
2,D1,"Prevention, diagnosis, and management of penile cancer in the LGBTQ+ community: A systematic review and meta-analysis.","Akshit Chitkara , Fnu Anamika , Atulya Khosla , Sakshi Bai , Arshia Adib , Rushin Patel , Rohit Singh","Sidney Kimmel Comprehensive Cancer Institute, Thomas Jefferson University, Lenox Hill Hospital, Department of Internal Medicine, William Beaumont University Hospital, Henry Ford Jackson Hospital, NDMC Medical College, Washington University in St. Louis, University of Vermont Medical Center"
TPS295,M14,Phase 1/2 study of REGN4336 alone or in combination with cemiplimab or nezastomig in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).,"William Kelly , Sandy Srinivas , Joseph Maly , Deepak Kilari , Arif Hussain , Biren Saraiya , Bilal Siddiqui , Paul Monk III, Gurkamal Chatta , Vivek Narayan , Divya Rana , Pradeep Thanigaimani , Fang Fang , Dimitris Skokos , Jessica Kirshner , Frank Seebach , Israel Lowy , Matthew Ingham , Sabina Sandigursky , Elizabeth Miller","Sidney Kimmel Medical College, Thomas Jefferson University, Stanford School of Medicine, Norton Cancer Institute, Froedtert & Medical College of Wisconsin, University of Maryland Medical Center, Rutgers Cancer Institute, The State University of New Jersey, Robert Wood Johnson Medical School, The Cancer Institute of New Jersey, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, The Ohio State University Comprehensive Cancer Center, Roswell Park Comprehensive Cancer Center, Hospital of the University of Pennsylvania, Regeneron Pharmaceuticals, Inc."
644,J29,The prognostic value of LDH in patients with good risk metastatic seminoma treated with single agent carboplatin AUC10.,"Nasreen Abdul Aziz , Kenrick Ng , Sushila Ganguli , Prabhakar Rajan , Anand Sharma , Jonathan Shamash","St Bartholomew’s Hospital, Barts Health NHS Trust, Mount Vernon Cancer Centre, The Royal London Hospital, Barts Health NHS Trust"
TPS651,K19,THERATEST: A multi-centre observational cohort feasibility study of de-escalation therapies for stage II seminoma.,"Nasreen Abdul Aziz , Kenrick Ng , Constantine Alifrangis , Ben Tran , Ciara Conduit , Elizabeth Liow , Charlotte Ackerman , Ramona Georgescu , Tanim Jamal , Clare Relton , Erik Mayer , David Nicol , Walter Cazzaniga , Robert Huddart , Alison Reid , Jonathan Shamash , Prabhakar Rajan","St Bartholomew’s Hospital, Barts Health NHS Trust, University College London Hospitals NHS Foundation Trust, Peter MacCallum Cancer Centre, Royal Hobart Hospital, Division of Personalised Oncology, Walter and Eliza Hall Institute of Medical Research, Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, Wolfson Institute of Population Health, Queen Mary University of London, The Royal Marsden Hospital NHS Foundation Trust, Department of Oncology, Royal Marsden NHS Foundation Trust, Centre for Cancer Cell and Molecular Biology, Barts Cancer Institute, Queen Mary University of London"
453,D21,Inclusion of patients with reduced performance status (ECOG 2 or higher) in FDA registrational trials for renal cell carcinoma (RCC).,"Ronit Juthani , Panah Parab , Kala Seetharaman","St. Vincent Hospital, Saint Vincent Hospital, Saint Vincent Cancer and Wellness Center"
632,J17,Outcomes with tandem or triplet autologous stem cell transplant for refractory germ cell tumors.,"Michael Glover , Sumit Shah , Alice Fan , Sandy Srinivas , Ali Khaki , Laura Johnston","Stanford University Medical Center, Stanford Cancer Center, Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford University"
107,C17,PSA response and survival based on metastatic site in patients with metastatic castration resistant prostate cancer (mCRPC) treated with lutetium-177-PSMA-vipivotide tetraxetan (Lu177-PVT).,"Joseph Allen , Colin Bergstrom , Hong Song , Catiussi Hoffmann , Shann Ruiz , Joanne Chien , Kaidi Moore , Divya Parikh , Sumit Shah , Alice Fan , Sandy Srinivas , Andrei Iagaru , Ali Khaki","Stanford University School of Medicine, Stanford University Medical Center, Stanford University, Stanford Health Care, Division of Oncology, Stanford University School of Medicine, Stanford Hospitals and Clinics, Department of Medicine, Division of Oncology, Stanford University School of Medicine, Division of Nuclear Medicine and Molecular Imaging, Stanford University"
746,E8,Assess the journey: Characterizing muscle-invasive bladder cancer patients who receive neoadjuvant therapy and do not proceed with cystectomy.,"Jay Ogunkeye , Ruth Belay , Eila Skinner","Stanford University, GU Surgical Oncology, Stanford Cancer Center"
691,C24,Pathological complete response and potential for bladder preservation by theranostic instillation therapy targeting CXCR4 in combination with systemic chemotherapy: The Bladder BRIDGister experience.,"Ralph Wirtz , Enno Storz , Melanie von Brandenstein , Frank Friedersdorff , Dimitri Barski , Thomas Otto , Michael Waldner , Johannes Graff , Elke Veltrup , Roland Hake , Sebastian Eidt , Jenny Roggisch , Constantin Rieger , Stefan Koch , Thorsten Ecke , Lukas Greifenstein , Axel Heidenreich , Richard Baum","STRATIFYER Molecular Pathology GmbH, Dpt. of Urology, University Clinic Cologne, Department of Urology, University Hospital Cologne, Department of Urology, Charité - Universitätsmedizin Berlin, Department of Urology, Rheinlandklinikum, Department of Urology, St. Elisabeth Hospital, St. Elisabeth Hospital Köln-Hohenlind, Institute of Pathology at the St. Elisabeth Hospital Koeln-Hohenlind, Department of Pathology, Helios Hospital, HELIOS Hospital, Curanosticum Wiesbaden-Frankfurt, Department of Urology, Uro-Oncology, Robot Assisted and Reconstructive Urologic Surgery, University of Cologne Faculty of Medicine and University Hospital Cologne"
393,K23,Defining subgroups of patients with intermediate risk prostate cancer for whom active surveillance is safe.,"Ruben Del Castillo , Danny Vesprini , Stanley Liu , Hon Leong , Mona Beera , Zeeba Sadiq , Liying Zhang , Alexandre Mamedov , Meghan Kulasingham-Poon , Laurence Klotz , Andrew Loblaw","Sunnybrook Health Sciences Centre, Sunnybrook-Odette Cancer Centre, Sunnybrook Research Institute, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Sunnybrook Health Sciences Centre, University of Toronto"
564,G31,MTAP loss in primary kidney tumors: A comprehensive genomic profiling study.,"Alexandra Goodman , Devashish Desai , Philippe Spiess , Roger Li , Petros Grivas , Ashish Kamat , Shilpa Gupta , Neeraj Agarwal , Adam Singer , Liang Cheng , Andrea Necchi , Joseph Jacob , Mehdi Mollapour , Gennady Bratslavsky , Douglas Lin , Dean Pavlick , Ole Gjoerup , Tamara Jamaspishvili , Jeffrey Ross , Alina Basnet","SUNY Upstate Medical University, H. Lee Moffitt Cancer Center and Research Institute, Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Division of Oncology, Department of Medicine, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, The University of Texas MD Anderson Cancer Center, Cleveland Clinic Taussig Cancer Institute, Huntsman Cancer Institute (NCI-CCC) at the University of Utah, University of California, Los Angeles, Indiana University, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Upstate Medical University, Department of Urology, Department of Urology, SUNY Upstate Medical University, Foundation Medicine, Inc., Department of Pathology, SUNY Upstate Medical University, Department of Hematology/Oncology, SUNY Upstate Medical University"
210,F14,Clinically advanced prostate cancer (CAPC) in extremely young men: A genomic landscape study.,"Rebecca Sager , Andrea Necchi , Roger Li , Philippe Spiess , Ashish Kamat , Petros Grivas , Shilpa Gupta , Neeraj Agarwal , Liang Cheng , Dean Pavlick , Ethan Sokol , Douglas Lin , Ole Gjoerup , Jeffrey Ross , Joseph Jacob , Alina Basnet , Gennady Bratslavsky","SUNY Upstate Medical University, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, H. Lee Moffitt Cancer Center and Research Institute, The University of Texas MD Anderson Cancer Center, University of Washington and Fred Hutchinson Cancer Center, Cleveland Clinic Taussig Cancer Institute, Huntsman Cancer Institute (NCI-CCC) at the University of Utah, Warren Alpert Medical School of Brown University, Foundation Medicine, Inc., Department of Pathology, SUNY Upstate Medical University, Department of Urology, Upstate Medical University"
845,H9,Frequency and impact of a genome-wide homologous recombination deficiency signature (HRDsig+) on the genomic landscape of clinically advanced urothelial bladder carcinoma (CAUBC).,"Michael Basin , Andrea Necchi , Roger Li , Philippe Spiess , Ashish Kamat , Petros Grivas , Shilpa Gupta , Neeraj Agarwal , Liang Cheng , Dean Pavlick , Ethan Sokol , Ryon Graf , Douglas Lin , Jeffrey Ross , Alexa Schrock , Julia Quintanilha , Gerald Li , Joseph Jacob , Alina Basnet , Gennady Bratslavsky","SUNY Upstate Medical University, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, H. Lee Moffitt Cancer Center and Research Institute, The University of Texas MD Anderson Cancer Center, University of Washington and Fred Hutchinson Cancer Center, Cleveland Clinic Taussig Cancer Institute, Huntsman Cancer Institute (NCI-CCC), University of Utah, Warren Alpert Medical School of Brown University, Foundation Medicine, Inc., Department of Pathology, SUNY Upstate Medical University, Department of Urology, Upstate Medical University"
414,L10,"Decipher genomic classifier (DGC) of early prostate cancer (EPC), and underlying transcriptomic profile (TP): American (Am) versus non-American (NA).","Daniel Keizman , Elai Davicioni , Avivit Peer , David Sarid , Keren Rouvinov , Avishay Sella , Hadas Dresler , Yoav Manaster","Tel-Aviv Sourasky Medical Center, Veracyte, Inc., Rambam Health Care Campus, Sourasky Medical Center, Soroka Medical Center, Shaare Zedek Medical Center, Progenetics IL"
115,C25,Relationship between androgen deprivation therapy and kidney function in patients with prostate cancer: An analysis of the RADICAL-PC study.,"Geethan Baskaran , Jehonathan Pinthus , Celestia Higano , Cristina Cano Garcia , Rajibul Mian , Germano Dallegrave Cavalli , Guila Delouya , Cesar Dusilek , Bobby Shayegan , Rafaela Piccoli , Tamim Niazi , Margot Davis , Avirup Guha , Joseph Selvanayagam , Jose Pardo , Patrick Luke , Darryl Leong","Temerty Faculty of Medicine, University of Toronto, Department of Surgery, Division of Urology, McMaster University, University of British Columbia, University Hospital Frankfurt, Goethe University Frankfurt, Department of Health Research, Evidence, and Impact, McMaster University, Population Health Research Institute, McMaster University, Centre Hospitalier de l'Université de Montréal (CHUM), Hospital do Rocio, Hospital de Clínicas Ijuí, McGill University, Department of Medicine, Division of Cardiology, Medical College of Georgia at Augusta University, Flinders Medical Centre, Hospital Universitario San Ignacio, London Health Science Centre, McMaster University"
747,E9,Trends and demographic disparities in the preferred place of death for bladder cancer patients in the United States (2000–2020): An analysis from the CDC database.,"Manas Pustake , Mohammad Arfat Ganiyani , Atulya Khosla , Avi Harisingani , Mostafa Eysha","Texas Tech University Health Science Center, Miami Cancer Institute, Baptist Health South Florida, Department of Internal Medicine, William Beaumont University Hospital, Loyola Medicine MacNeal Hospital"
223,F27,Developing a deep learning algorithm for automated p53 immunohistochemistry digital image analysis in prostate cancer.,"Rithika Rajendran , Joshua Rodriguez , Shanshan Liu , Guoqing Diao , Justin Major , Maneesh Jain , James Meabon , Victor Nava","The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, Northwest Mental Illness Research, Education and Clinical Center, VA Puget Sound Health Care System, George Washington University Milken Institute School of Public Health, Visiopharm A/S"
481,E14,Observational study of tislelizumab (Tisle) combined with pazopanib in reducing venous tumor thrombus in clear cell renal cell carcinoma with venous invasion.,Baihetiya Azhati,The First Affiliated Hospital Of Xinjiang Medical University
328,H28,An online clustering algorithm predicting model for prostate cancer based on PHI-related variables and PI-RADS in different PSA populations.,"Gejun Zhang , Jiyuan Hu","The First Hospital of China Medical University, The First Affiliated Hospital of China Medical Univeristy"
28,A6,Beyond survival: Understanding the social dimensions of prostate cancer.,"Karan Jatwani , Philip Ma , Seyedeh Miran , Atulya Khosla , Michael Whalen , Maneesh Jain","The George Washington University Hospital, The George Washington University, Department of Internal Medicine, William Beaumont University Hospital, George Washington University School of Medicine, Washington DC VA Medical Center"
678,C11,The impact of social vulnerability on perceived health in individuals with bladder cancer.,"Karan Jatwani , Seyedeh Miran , Philip Ma , Michael Whalen , Maneesh Jain , Atulya Khosla","The George Washington University Hospital, The George Washington University, George Washington University School of Medicine, Washington DC VA Medical Center, Department of Internal Medicine, William Beaumont University Hospital"
757,E19,Patient-reported outcome (PRO) assessment and reporting in first-line (1L) locally advanced or metastatic urothelial cancer (la/mUC) clinical trials: Results of a systematic literature review (SLR).,"Mairead Kearney , Tom Macmillan , Julia Poritz , Sherrie Schreiber-Gosche , Mihaela Musat","The Healthcare Business of Merck KGaA, Cytel"
491,E24,Avelumab in combination with axitinib (Ave + Axi) for first-line (1L) treatment of advanced renal cell carcinoma (aRCC): A systematic literature review (SLR) of real-world effectiveness and safety.,"Mairead Kearney , Ankush Taneja , Aniket Sharma , Ahmed Elsada , Anna-Maria Fontrier , Stamatia Alexopoulos , Neil Roskell","The Healthcare Business of Merck KGaA, Lumanity, Merck Serono Ltd., Feltham, UK, an affiliate of Merck KGaA"
755,E17,Patient and caregiver preferences for the treatment of locally advanced or metastatic urothelial carcinoma (la/mUC): Results of a targeted literature review (TLR).,"Mairead Kearney , Rosanne Janssens , Matt Quaife , Myrto Trapali , Caitlin Thomas","The Healthcare Business of Merck KGaA, Patient-Centered Research, Evidera"
21,,Transdermal oestradiol (tE2) patches as androgen deprivation therapy (ADT): Efficacy and safety of combining with androgen receptor pathway inhibitors (ARPIs) in metastatic (M1) prostate cancer—Randomised comparison from the STAMPEDE trial platform.,"Nicholas James , Hannah Rush , Matthew Nankivell , Jyoti Sehjal , Stephen Mangar , Neil McPhail , Simon Brown , Jacob Tanguay , Joanna Gale , Wael Mohamed , Simon Crabb , Omar Khan , John Russell , William Cross , Claire Murphy , John Deighan , Noel Clarke , Mahesh Parmar , Duncan Gilbert , Ruth Langley","The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, MRC Clinical Trials Unit at UCL, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oncology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, Raigmore Hospital, NHS Highlands, Department of Oncology at Bradford Royal Infirmary, Velindre Cancer Centre, Portsmouth Hospitals NHS Trust, Singleton Hospital, School of Cancer Sciences at University Hospital Southampton NHS Foundation Trust, Great Western Hospitals NHS Foundation Trust, Forth Valley Royal Hospital, St James's University Hospital, Leeds, UK, The Christie and Salford Royal Hospital NHS Foundation Trusts and University of Manchester, Medical Research Council Clinical Trials Unit at University College London"
778,F5,Feasibility and safety results from RAD-IO: A multi-stage trial of durvalumab (Medi4736) with chemoradiotherapy with 5-fluorouracil and mitomycin C in patients with muscle-invasive bladder cancer.,"Nicholas James , Joseph van de Wiel , Ana Hughes , Anne-Marie Hodgkins , Shaista Hafeez , Anjali Zarkar , Maria De Santis , Omar Din , Romaana Mir , James Iddenden , Catalina Vassallo - Bonner , Sarah Pirrie , Sophia Magwaro , Syed Hussain","The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, University of Birmingham, The Royal Marsden NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, Department of Urology, Charité Universitaetsmedizin Berlin and Department of Urology, Medical University of Vienna, Weston Park Cancer Centre, Mount Vernon Cancer Center, Clatterbridge Cancer Centre NHS Foundation Trust, Patient Representative, Department of Oncology and Metabolism, University of Sheffield"
667,,A phase 1/2 trial of durvalumab plus intravesical gemcitabine and docetaxel in BCG-unresponsive non-muscle invasive bladder cancer patients (HCRN GU16-243: ADAPT-BLADDER Cohort 4).,"Noah Hahn , Marianna Zahurak , Hristos Kaimakliotis , Timothy Masterson , Nabil Adra , David Chen , Alexander Kutikov , Daniel Geynisman , Woodson Smelser , Melissa Reimers , Christopher Anderson , Mark Stein , Alexander Baras , Gabriela Colocho , Deborah Schwartz , David McConkey , Sunil Patel , Bilal Rahim , Michael O'Donnell , Max Kates","The Johns Hopkins University School of Medicine, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Indiana University School of Medicine, Indiana University School of Medicine, Department of Urology, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Fox Chase Cancer Center, Washington University School of Medicine in St. Louis, Department of Medicine, Division of Oncology, Washington University School of Medicine, Department of Urology, Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, University of Iowa Holden Comprehensive Cancer Center, Department of Urology, University of Iowa, Johns Hopkins Medicine"
84,B30,Clinical outcomes of lutetium-177-vipivotide tetraxetan in men with metastatic castration-resistant prostate cancer at a single academic center.,"Adam Khorasanchi , Jinesh Gheeya , Timothy Gauntner , Menglin Xu , Elshad Hasanov , Katharine Collier , Lingbin Meng , Danielle Zimmerman , Peng Wang , Edmund Folefac , Paul Monk III, Amir Mortazavi , Steven Clinton , Yuanquan Yang","The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, Pelotonia Institute for Immuno-Oncology and Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Pelotonia Institute for Immuno-Oncology and Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center"
870,H34,Germline genetic variants in cancers of the urothelial tract and association with outcomes.,"Kent Kamau , Lindsey Byrne , Debasish Sundi , Akshay Sood , Shang-Jui Wang , Yuanquan Yang , Lingbin Meng , Peng Wang , Danielle Zimmerman , Elshad Hasanov , Fuat Bicer , Timothy Gauntner , Edmund Folefac , Paul Monk III, Steven Clinton , Amir Mortazavi , Katharine Collier","The Ohio State University Comprehensive Cancer Center, Division of Human Genetics, Department of Internal Medicine, The Ohio State University, Department of Urology, College of Medicine, The Ohio State University, Department of Radiation Oncology, College of Medicine, The Ohio State University, Division of Medical Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University, The Ohio State University Comprehensive Cancer Center, Division of Medical Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University"
493,E26,Who undergoes cytoreductive nephrectomy now? An analysis of perioperative risk characteristics in contemporary patients.,"Shawn Dason , Rajvi Goradia , Akshay Sood , Elshad Hasanov , Yuanquan Yang , Shang-Jui Wang , Matthew Lee , Eric Singer","The Ohio State University Comprehensive Cancer Center, The Ohio State University, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Ohio State University"
152,D26,"Concomitant G-CSF use in maintaining an efficacious dose and safe delivery of docetaxel in combination with darolutamide in patients with metastatic hormone sensitive prostate cancer (mHSPC): ARASENS, a phase 3 study.","Michael Ong , Hiroyoshi Suzuki , Matthew Smith , Bertrand Tombal , Maha Hussain , Fred Saad , Karim Fizazi , Frank Verholen , Ha Pham , Shankar Srinivasan , Aly-Khan Lalani","The Ottawa Hospital Cancer Centre, Sakura Medical Center, Massachusetts General Hospital, Harvard Medical School, Division of Urology, IREC, Cliniques Universitaires Saint Luc, UCLouvain, Northwestern University, Feinberg School of Medicine, University of Montreal Hospital Center, Institut Gustave Roussy, University of Paris-Saclay, Bayer Consumer Care AG, Bayer HealthCare Pharmaceuticals, Inc., Juravinski Cancer Centre, McMaster University"
353,J17,Management strategies and patient outcomes among LPC patients with persistently positive PSA after RP.,"Shawn Malone , Christopher Wallis , Ilias Cagiannos , Robert Hamilton , Naveen Basappa , Cristiano Ferrario , Geoffrey Gotto , Ricardo Fernandes , Tamim Niazi , Chris Morash , Ricardo Rendon , Fred Saad , Sebastien Hotte , Brendan Osborne , Katherine Chan , Anousheh Zardan , Bobby Shayegan","The Ottawa Hospital, University of Ottawa, Division of Urology and Surgical Oncology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Cross Cancer Institute, University of Alberta, Jewish General Hospital, McGill University, University of Calgary, Southern Alberta Institute of Urology, Division of Medical Oncology, London Regional Cancer Program, London Health Sciences Centre, University of Western Ontario, Queen Elizabeth II Health Sciences Centre, Dalhousie University, University of Montreal Hospital Centre, Department of Oncology, Juravinski Cancer Centre, McMaster University, Johnson & Johnson Innovative Medicine, St. Josephs Healthcare, McMaster University"
636,J21,Therapeutic approaches and outcomes in patients aged 50+ with germ cell tumours.,"Marija Miletic , Razia Aslam , Catey Bunce , Clare Gilson , Teresa Mele , Deep Chakrabarti , Walter Cazzaniga , Daniele Raggi , Shraddha Adamame , Stephen Hazell , Erik Mayer , Syed Sohaib , David Nicol , Robert Huddart , Alison Reid","The Royal Marsden Hospital, Royal Marsden NHS Foundation Trust, Department of Medical Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, The Royal Marsden Hospital NHS Foundation Trust, The Royal Marsden NHS Foundation Trust, Section of Radiotherapy and Imaging, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Department of Oncology, Royal Marsden NHS Foundation Trust"
16,,Association of baseline and on-treatment ctDNA fraction with clinical outcomes in patients with mCRPC in the PSMAfore study of 177Lu-PSMA-617.,"Johann De Bono , Michael Morris , Alton Sartor , Xiao Wei , Karim Fizazi , Ken Herrmann , Josep Piulats , Hakim Mahammedi , Christopher Logothetis , Daniel George , Connie Wong , Louise Barys , Nisha Rajagopal , Shaheen Alanee , Kim Chi","The Royal Marsden NHS Foundation Trust, Memorial Sloan Kettering Cancer Center, Mayo Clinic, Dana-Farber Cancer Institute, Institut Gustave Roussy, University of Paris-Saclay, Clinic for Nuclear Medicine and German Cancer Consortium, University Hospital Essen, Catalan Institute of Oncology, Centre Jean Perrin, The University of Texas MD Anderson Cancer Center, Duke University Medical Center, Novartis Pharmaceuticals Corporation, Novartis Biomedical Research, University of British Columbia, BC Cancer, Vancouver Cancer Centre"
713,D10,First-line therapies analysis in advanced/metastatic urothelial carcinoma: Prognostic insights with propensity score analysis and RNA-seq.,"Jingjing Wang , Yupeng Jiang Sr., Wen Zou , Wei He , Minfeng Chen , Chao Xu","The Second Xiangya Hospital of Central South University, The Second Xiangya Hospital Of Central South University, Department of Oncology, The Second Xiangya Hospital, Central South University, The Xiangya Hospital of Central South University, Xiangya Hospital of Central South University"
445,D13,The impact of the Area Deprivation Index on immunotherapy outcomes in metastatic renal cell carcinoma (mRCC).,"Ardit Feinaj , Dena Rhinehart , Marianna Zahurak , Laura Linville , Nirmish Singla , Dina Lansey , Mark Markowski , Michael Carducci , Roy Elias , Yasser Ged","The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University"
TPS436,M34,Neoadjuvant androgen deprivation therapy with enzalutamide plus the glucocorticoid receptor modulator relacorilant versus placebo for patients with high-risk localized prostate cancer.,"Mohammad Atiq , Walter Stadler , Ashley Page , Meghan Catenacci , Akash Patnaik , Gladell Paner , Scott Eggener , Russell Szmulewitz","The University of Chicago Medicine, The University of Chicago"
265,H6,Feasibility of surgical orchiectomy in prostate cancer patients on long term luteinizing hormone-releasing hormone (LHRH) agonist therapy.,"Alon Lazarovich , Walter Stadler , Scott Eggener , Ashley Page , Brian Heiss , Daniel Geynisman , Natalie Reizine","The University of Chicago, The University of Chicago Medicine, U.S. Food and Drug Administration, Fox Chase Cancer Center, University of Illinois Chicago"
456,D24,Clinicopathological characteristics of cancer of unknown primary (CUP) with renal profile using gene expression profiling (GEP) based cancer classification.,"Joelle Allam , Li Ma , Jianping Zhao , Jeannelyn Estrella , Victoria Higbie , Anneleis Willett , Aurelio Matamoros , Elizabeth Lano , Kai Treuner , Kanwal Raghav , Ryan Huey","The University of Texas MD Anderson Cancer Center, Biotheranostics, A Hologic Company, Department of Pathology, The University of Texas MD Anderson Cancer Center"
195,E34,Sensitive tissue-based detection of AR-V7 and other androgen receptor alterations using combined DNA/RNA comprehensive genomic profiling.,"Amado Zurita , Shilpa Gupta , Ryon Graf , Jeffrey Ross , Andrej Savol , Eddie Grinman , Justin Allen , Lei Zhong , Abhishek Srivastava , Jue Wang , Elena Vagia , Josee Romann , Kara Cossis , Richard Huang , Rachel Keller-Evans","The University of Texas MD Anderson Cancer Center, Cleveland Clinic Taussig Cancer Institute, Foundation Medicine, Inc., Atlanta Urology Clinics, Department of Internal Medicine, Division of Hematology and Oncology, UT Southwestern, Jefferson Cary Cancer Center, Chesapeake Urology"
799,F26,Metastasis-directed radiotherapy in oligometastatic bladder and upper tract cancer: A single institution retrospective experience.,"Patrick Carriere , Omar Alhalabi , Jianjun Gao , Amishi Shah , Matthew Campbell , Lauren Mayo , Osama Mohamad , Karen Hoffman , Henry Mok , Charmaigne Lozano , Shalin Shah , Ryan Park , Sean Mcguire , Ashish Kamat , Neema Navai , Kelly Bree , Charles Guo , Chad Tang , Seungtaek Choi , Comron Hassanzadeh","The University of Texas MD Anderson Cancer Center, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Department of Pathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center"
624,J9,Regional and racial disparities in testicular cancer-related mortality among HIV/AIDS adults in the United States and Texas: A 21-year retrospective study (1999-2020).,"Sidra Naz , Hira Naz , Kashif Ali , Muhammad Hanif , Vikash Jaiswal , Nirmit Patel","The University of Texas MD Anderson Cancer Center, Fatima Jinnah Medical University, University of Texas Rio Grand Vallley, SUNY Upstate Medical University, Larkin Community Hospital, New York Medical College St. Mary and St. Clare Community Hospital"
30,A8,Evaluating disparities in prostate cancer-related mortality among diabetic adults in the United States and Texas: A 21-year observational study (1999-2020).,"Sidra Naz , Hira Naz , Kashif Ali , Muhammad Hanif , Nirmit Patel","The University of Texas MD Anderson Cancer Center, Fatima Jinnah Medical University, University of Texas Rio Grand Vallley, SUNY Upstate Medical University, New York Medical College St. Mary and St. Clare Community Hospital"
TPS293,M12,A phase 1/2 study of nezastomig (anti-PSMA×CD28) with or without cemiplimab (anti–PD-1) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and clear cell renal cell carcinoma (ccRCC).,"Bilal Siddiqui , Benedito Carneiro , Mark Stein , Jingsong Zhang , William Kelly , David Wise , Kai Tsao , Gerald Falchook , Przemyslaw Twardowski , Xin Gao , Joseph Kim , Edward Gelmann , Pradeep Thanigaimani , Fang Fang , Frank Seebach , Israel Lowy , Matthew Ingham , Michael Kinnaman , Sabina Sandigursky , Elizabeth Miller","The University of Texas MD Anderson Cancer Center, Legorreta Cancer Center at Brown University, Lifespan Cancer Institute, Columbia University Medical Center, Moffitt Cancer Center, Sidney Kimmel Medical College, Thomas Jefferson University, NYU Langone Perlmutter Cancer Center, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Sarah Cannon Research Institute at HealthONE, Providence Saint John’s Cancer Institute, Massachusetts General Hospital Cancer Center, Yale School of Medicine, Department of Medicine, University of Arizona, Regeneron Pharmaceuticals, Inc."
503,E36,Local definitive therapy (LDT) utilization patterns and outcomes in chromophobe renal cell carcinoma (chRCC) with metachronous metastasis: A multi-institution study.,"Nazli Dizman , Sahil Doshi , Andrea Knezevic , Ardit Feinaj , Nicolas Sayegh , Charbel Hobeika , Reza Alaghehbandan , Hal Rives , Zeynep Zengin , David Braun , Matthew Zibelman , Bradley McGregor , Hans Hammers , Yasser Ged , Moshe Ornstein , Pavlos Msaouel , Andrew Hahn , Martin Voss","The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Huntsman Cancer Institute at the University of Utah, St. Elizabeth's Medical Center, Cleveland Clinic, Fox Chase Cancer Center, Yale University School of Medicine, Center of Molecular and Cellular Oncology, Yale University, Dana-Farber Cancer Institute, Department of Internal Medicine, Division of Hematology and Oncology, UT Southwestern, Johns Hopkins University School of Medicine, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center and Weill Medical College"
140,D14,Metastasis-directed therapy (MDT) plus androgen deprivation therapy (ADT) for oligometastatic prostate cancer (omPC): Primary results of the EXTEND continuous ADT (cADT) basket plus combined analysis with the updated intermittent ADT (iADT) basket and immune correlatives.,"Alexander Sherry , Cara Haymaker , Bryan Fellman , Tharakeswara Bathala , Marina Medina-Rosales , Suyu Liu , Stephen Chun , Lauren Mayo , Seungtaek Choi , Ryan Phillips , Matthew Deek , Ana Aparicio , Amado Zurita , Patrick Pilié , Bilal Siddiqui , Sumit Subudhi , Alexandre Reuben , Paul Corn , Phuoc Tran , Chad Tang","The University of Texas MD Anderson Cancer Center, The University of Texas - MD Anderson Cancer Center, Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Department of Radiation Oncology, Mayo Clinic in Rochester, Robert Wood Johnson Medical School, Rutgers University, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, University of Maryland"
596,H31,A prognostic biomarker panel for chromophobe renal cell carcinoma using immunohistochemistry.,"Elizabeth Ellis , Ashley Li , Phillip Rappold , Patrick Hensley , Guan Wu , Edward Messing , Qi Yang , Hiroshi Miyamoto , William Tabayoyong","The University of Texas MD Anderson Cancer Center, University of Rochester Medical Center, University of Kentucky, University of Rochester"
400,K30,Impact of specimen type on digital histopathology-based multimodal artificial intelligence (MMAI) biomarker risk score: Whole slide image vs tissue microarray.,"Adam Dicker , Xiao Ma , Siyi Tang , Nitin Kumar Mittal , Gemma Migneco , Rajanikanth Vadigepalli , William Kelly , Leonard Gomella , Meghan Tierney , Danielle Croucher , Dibya Mukherjee , Stefany Hinojosa , Sujata Patil , Trevor Royce , Timothy Showalter , Andre Esteva , Felix Feng","Thomas Jefferson University, Artera, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco"
487,E20,"Real-world community oncology-based treatment patterns for first line axitinib plus pembrolizumab in advanced renal cell carcinoma: Initial dosing, dose reductions and clinical outcomes.","Kevin Zarrabi , Yaa Ababio , Anthony Eccleston , Dharanija Rao , Scott Kelly , Jane Chang , Kelechi Adejumo , Sarah Lucht , Caleb Paydar , Bryce Van Doren , Emily Bland , William John , Bruce Feinberg , Neil Shah","Thomas Jefferson University, Pfizer, Inc., Pfizer Ltd, Pfizer Inc., Cardinal Health, Memorial Sloan Kettering Cancer Center"
532,F30,Efficacy of selective renal tumor embolization combined with axitinib and reduced-dose toripalimab in oligometastatic clear cell renal carcinoma: A comparative analysis with axitinib combined with standard-dose toripalimab.,"Jun Du , Feiran Chen , Chao Zhang , Jie Tian , Li Zhang , Qing Yang , Xin Yao",Tianjin Medical University Cancer Institute Hospital National Clinical Research Center for Cancer
793,F20,Phase II study of oral APL-1202 plus tislelizumab or tislelizumab alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC).,"Matthew Galsky , John Sfakianos , Dingwei Ye , Badrinath Konety , Dalin He , Xiaodong Song , Hailong Hu , Hanzhong Li , Gongxian Wang , Xiaoliang Yuan","Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Department of Medical Oncology, Icahn School of Medicine at Mount Sinai, Fudan University Cancer Hospital, Allina Health Cancer Institute Minneapolis, MN and University of Minnesota, The First Affiliated Hospital of Xi'an Jiaotong University, Tongji Hospital, Second Affiliated Hospital of Tianjin Medical University, Peking Union Medical College Hospital, The First Affiliated Hospital of Nanchang University, Jiangsu Yahong Meditech Co., Ltd"
819,G15,Long-term outcomes of neoadjuvant chemotherapy (NAC) before bladder-sparing chemoradiotherapy (CRT) for patients with nonmetastatic muscle-invasive bladder cancer (MIBC).,"Meghan Mahoney , Nely Meija , Eshetu Atenafu , Peter Chung , Alex Zlotta , Nimira Alimohamed , Neil Fleshner , Gregory Lo , Girish Kulkarni , Alejandro Berlin , Robert Bristow , Maria Jiang , Srikala Sridhar","Tom Baker Cancer Centre, Princess Margaret Cancer Centre, Department of Biostatistics, Princess Margaret Cancer Centre, Princess Margaret Hospital, University Health Network, University of Calgary, University Health Network, Lakeridge Health, Princess Margaret Cancer Center, University Health Network, Cancer Digital Intelligence, Princess Margaret Cancer Centre, University Health Network, University of Manchester, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto"
477,E10,Real-world outcomes of first-line dual immunotherapy versus combination VEGF immunotherapy in intermediate-poor risk metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Data Consortium (IMDC).,"David Maj , Martin Zarba , Connor Wells , Razane El Hajj Chehade , Zeynep Ozay , Sumanta Pal , Benoit Beuselinck , Elizabeth Liow , Ajjai Alva , Thomas Powles , Georg Bjarnason , Lori Wood , Ravindran Kanesvaran , Guillermo de Velasco , Jae Lyun Lee , Arnoud Templeton , Rana McKay , Cristina Suárez , Toni Choueiri , Daniel Heng","Tom Baker Cancer Centre, University of Calgary, Barts Cancer Institute, Queen Mary University of London, Dana-Farber Cancer Institute, Harvard Medical School, Huntsman Cancer Insititute at the University of Utah, Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Leuven Cancer Institute, KU Leuven, Monash Health, University of Michigan Rogel Comprehensive Cancer Center, Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free National Health Service Trust, Sunnybrook Research Institute, Queen Elizabeth II Health Sciences Centre, Dalhousie University, National Cancer Centre, Hospital Universitario 12 de Octubre, Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Department of Medical Oncology, St. Claraspital Basel and Faculty of Medicine, University of Basel, Department of Medicine, University of California San Diego, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d´Hebron, Vall d´Hebron Barcelona Hospital Campus, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School"
479,E12,Cabozantinib real-world effectiveness in the second-line setting of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).,"Martin Zarba , Dylan O'Sullivan , Razane El Hajj Chehade , Rana McKay , Sumanta Pal , Benoit Beuselinck , Frede Donskov , Aly-Khan Lalani , Megan Crumbaker , Haoran Li , Ajjai Alva , Thomas Powles , Kosuke Takemura , Christian Kollmannsberger , Shirley Wong , Lori Wood , Guillermo de Velasco , Winson Cheung , Toni Choueiri , Daniel Heng","Tom Baker Cancer Centre, University of Calgary, University of Calgary, Dana-Farber Cancer Institute, Harvard Medical School, Department of Medicine, University of California San Diego, Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Leuven Cancer Institute, KU Leuven, University Hospital of Southern Denmark, McMaster University, Garvan Institute of Medical Research, University of Kansas Cancer Center, Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Barts Cancer Centre, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Department of Genitourinary Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, BC Cancer, Vancouver Cancer Centre, Western Health Hospital, University of Melbourne, Dalhousie University, Hospital Universitario 12 de Octubre, University of Calgary Tom Baker Cancer Centre"
735,D32,Feasibility and efficacy of cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer in older patients: A retrospective French GETUG study.,"Benjamin Combe , Clement Dumont , Guilhem Roubaud , Damien Pouessel , Elsa Lafitte , Manon De Vries , Brigitte Laguerre , Helen Boyle , Aymeric Guilbert , Bérengère Narciso , Hakim Mahammedi , Delphine Borchiellini , Baptiste Abbar , Marine Gross-Goupil , Mathieu Laramas , Franck Bruyere , Julie Biogeau , Mathilde Cancel","Tours University Hospital, Department of Oncology, Saint-Louis Hospital, AP-HP, Department of Medical Oncology, Institut Bergonié, Department of Medical Oncology, Institut Claudius Régaud-IUCT-Oncopole, Institut Paoli-Calmettes, Institut de Cancérologie de l'Ouest, Department of Medical Oncology, Eugène Marquis Cancer Center, Centre Leon Bérard, Department of Medical Oncology, HEGP, AP-PH, Department of Medical Oncology, CHU Bretonneau Centre, Tours University, Comprehensive Cancer Center, Department of Medical Oncology, Centre Antoine Lacassagne, Université Côte d'Azur, AP-HP Pitié Salpêtrière Hospital, Department of Medical Oncology, Bordeaux University Hospital, Grenoble University Hospital Centre, CHRU Tours, Department of Geriatrics, CHU Bretonneau Centre, Tours University, Department of Medical Oncology, University Hospital"
29,A7,Trends in cardiovascular mortality in older adults with malignant neoplasms of male genital organs in the United States from 1999 to 2020.,"Mohammad Abu-Tineh , Eeshal Fatima , Wajeeh Hassan , Zain Nadeem , Umar Akram , Muhammad Iftikhar","Tower Health, Reading Hospital, Services Institute of Medical Sciences, Allama Iqbal Medical College, Department of Medicine, Allama Iqbal Medical College, Lahore, Pakistan, King Edward Medical University"
650,K1,Racial disparities in incidence-based mortality and survival outcomes in testicular cancer in adolescent and young adults.,"Oboseh Ogedegbe , Olanipekun Lanny Ntukidem , Sakshi Bai , Ayobami Olafimihan , Asfand Yar Cheema","Trinity Health Ann Arbor, Henry Ford Jackson Hospital, John H. Stroger, Jr. Hospital of Cook County, Cleveland Clinic Foundation/Fairview Hospital"
450,D18,Chronic obstructive pulmonary disease mortality risk in renal cell carcinoma: A population-based study from 1992-2021.,"Oboseh Ogedegbe , Olanipekun Lanny Ntukidem , Sakshi Bai , Ayobami Olafimihan , Peter Egwom , Duresha Malik","Trinity Health Ann Arbor, Henry Ford Jackson Hospital, John H. Stroger, Jr. Hospital of Cook County, University of Missouri, Trinity Health"
676,C9,Second primary malignancy in bladder cancer: A retrospective population-based analysis.,"Oboseh Ogedegbe , Sakshi Bai , Olanipekun Lanny Ntukidem , Peter Egwom , Duresha Malik , Ayobami Olafimihan , Stanley Atencah","Trinity Health Ann Arbor, Henry Ford Jackson Hospital, University of Missouri, Trinity Health, John H. Stroger Hospital, Cook County, Athens Regional Pathology Associates"
247,G20,ctDNA characterization in mCRPC patients with pathogenic germline variants.,"Tivoli Nguyen , Nicholas Habibian , Opeoluwa Akerele , Olivia Pocha , Priya Bhandari , Courtney Johnson , Minqi Huang , Alexandra Lieberman , Jennifer Schwartz , Jodi Layton , Brian Lewis , Alton Sartor , Elisa Ledet","Tulane University School of Medicine, Tulane University, Mayo Clinic"
245,G18,Evaluation of ctDNA alterations in lethal mCRPC.,"Minqi Huang , Nicholas Habibian , Tivoli Nguyen , Opeoluwa Akerele , Olivia Pocha , Priya Bhandari , Courtney Johnson , Alexandra Lieberman , Jennifer Schwartz , Jodi Layton , Brian Lewis , Alton Sartor , Elisa Ledet","Tulane University, Tulane University School of Medicine, Mayo Clinic"
335,H35,"Comparison of digital pathology AI models, genomics classifier, and clinical variables in predicting progression free survival in TCGA prostate data set.","Aidan McLoughlin , Alboukadel Kassambara , Ho Yin Ho , Xin Zhao , James Proudfoot , Giovanni Bussotti , Ahmad Alzein , Alexander Hakansson , Mamoudou Sano , Alireza Moradi , Thomas Sbarrato , Jacques Fieschi , Elai Davicioni , Phil Febbo , Yang Liu","UC Berkeley, Veracyte, Inc."
592,H27,Development of an ex-vivo platform to model immunotherapy in kidney cancer.,"Shuchi Gulati , Wen-Hsin Chang , Aedric Lim , Mamta Parikh , Nicholas Mitsiades , Marc Dall'Era , Thenappan Chandrasekar , Philip Hsiao , Primo Lara Jr., Ching-Hsien Chen","UC Davis Comprehensive Cancer Center, University Of California, Davis, University of California, Davis, University of California, Davis Comprehensive Cancer Center, Department of Urology, University of California, Davis, UC Davis Health, Department of Internal Medicine, University of California, Davis"
66,B12,Clinical use and outcomes of androgen-receptor pathway inhibitors triplet therapy for metastatic hormone-sensitive prostate cancer (ARAAT).,"Rana McKay , Alicia Morgans , Nasreen Khan , Niculae Constantinovici , Guifang Chen , Mercedeh Ghadessi , Sreevalsa Appukkuttan , Jay Jhaveri , Daniel George","UC San Diego School of Medicine, Department of Medical Oncology, Dana-Farber Cancer Institute, Bayer HealthCare Pharmaceuticals, Inc., Bayer Consumer Care AG, Duke Cancer Institute, Duke University School of Medicine"
355,J19,Association of PSMA PET results at biochemical recurrence (BCR) with metastasis free survival (MFS) by conventional imaging (CI) in patients with locally advanced or high-risk localized prostate cancer initially treated with radical prostatectomy (RP): A retrospective multicenter study.,"Jesus Juarez Casillas , Thomas Hope , Jeremie Calais , Wolfgang Fendler , Matthias Eiber , Fei Jiang , Abuzar Moradi Tuchayi , Ken Herrmann , Vishnu Murthy , Luisa Willner , Andrew Nguyen , Madeleine Karpinski , Lela Theus , Türkay Hekimsoy , Alexander Kretschmer , Sharon McCarthy , Branko Miladinovic , Megan Price , Ariel Bourla , Jose Zamalloa","UCLA Radiation Oncology, Department of Radiology and Biomedical Imaging, University of California, San Francisco, Ahmanson Translational Theranostics Division, University of California, Los Angeles, Department of Nuclear Medicine, University of Duisburg-Essen, and German Cancer Consortium (DKTK), University Hospital Essen, Department of Nuclear Medicine, School of Medicine and Health, TUM University Hospital, Technical University of Munich, University of California, San Francisco, Clinic for Nuclear Medicine and German Cancer Consortium, University Hospital Essen, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, School of Medicine and Health, TUM, Department of Molecular and Medical Pharmacology Ahmanson Translational Theranostics Division David Geffen School of Medicine at UCLA, Department of Nuclear Medicine, University of Duisburg-Essen, and German Cancer Consortium (DKTK), NCT, University Hospital Essen, Technical University Munich, Janssen Research & Development, Janssen Research & Development, LLC, The Janssen Pharmaceutical Companies of Johnson & Johnson"
814,G10,Efficacy of neoadjuvant/induction (NAC) chemotherapy in nonmetastatic muscle-invasive bladder cancer treated with chemoradiotherapy (CRT): A systematic review and meta-analysis.,"Mariana Fauth Seibel , Letícia Dal Ri , Bruno Lins de Souza , Julia Lopes , Vitor Liutti , Daniel Araujo","Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Universidade Federal de Ciências da Saúde de Porto Alegre, Federal University of Ceara, Faculdade de Medicina de São José do Rio Preto, Hospital do Câncer de Londrina, BC Cancer"
567,H2,Association between abnormal IMDC laboratory criteria after surgery and cancer-specific and overall survival in non-metastatic renal cell carcinoma: Potential biomarkers for adjuvant therapy patient selection.,"Caio Vínicius Suartz , Rodney Breau , Kaleem Atchia , Camilla Tajzler , Ranjeeta Mallick , Daniel Heng , Georg Bjarnason , Aly-Khan Lalani , Bimal Bhindi , Lori Wood , Naveen Basappa , Simon Tanguay , Frederic Pouliot","Université Laval, Ottawa Hospital Research Institute, CT Consulting & Solutions, University of Calgary Tom Baker Cancer Centre, Sunnybrook Odette Cancer Centre, Juravinski Cancer Centre, McMaster University, University of Calgary, Queen Elizabeth II Health Sciences Centre, Dalhousie University, Cross Cancer Institute, University of Alberta, McGill University Health Center, CHU de Québec-Université Laval Research Center"
417,L13,Genomic alterations in intraductal prostate cancer: Insights from the Genomic Umbrella Neoadjuvant study (GUNS) in high-risk localized disease.,"Rui Bernardino , Joshua Scurll , Htoo Zarni Oo , Lucia Nappi , Alexander Wyatt , Amina Zoubeidi , Doron Berlin , Tiiu Sildva , Jessica Cockburn , Theodorus van der Kwast , Martin Gleave , Neil Fleshner","University Health Network, Vancouver Prostate Centre, British Columbia Cancer Agency, University of British Columbia, Princess Margaret Cancer Centre, University Health Network, Princess Margaret Cancer Centre"
TPS274,L27,Prostate Cancer Real World Evidence Registry (PROCARE): Recurrent and metastatic prostate cancer.,"Boris Hadaschik , Gunhild Von Amsberg , Ken Herrmann , Axel Merseburger , Peter Goebell , Erik Belleville , Peter Fasching , Lothar Haeberle , Andrea Roessler , Marc-Oliver Grimm","University Hospital Essen, Germany Cancer Consortium (DKTK), Department of Urology, Martini-Clinic, Prostate Cancer Center Hamburg and Department of Oncology, University Hospital Hamburg Eppendorf, Clinic for Nuclear Medicine and German Cancer Consortium, University Hospital Essen, Department of Urology, University Schleswig-Holstein, Campus Lübeck, Department of Urology and Pediatric Urology, University Hospital Erlangen, ClinSol GmbH & Co KG, Department of Gynaecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), bioMed Statistics GmbH, UroTrials GmbH, Department of Urology, Jena University Hospital, Friedrich-Schiller University Jena, Comprehensive Cancer Center Germany"
531,F29,Analyses on impact of tumor burden at progression and changes in IMDC from baseline in patients (pts) with advanced renal cell carcinoma (aRCC) treated with lenvatinib + pembrolizumab (L+P) in the phase 3 CLEAR trial.,"Viktor Grünwald , Daniel Keizman , Jens Bedke , Michael Staehler , Vsevolod Matveev , Saby George , Thomas Hutson , Ulka Vaishampayan , Jaime Merchan , Masatoshi Eto , Sun Young Rha , Tom Waddell , Roberto Sabbatini , Philippe Barthelemy , Joseph Burgents , Min Ren , Ian Brown , Hakim Saal , Toni Choueiri , Robert Motzer","University Hospital Essen, Tel-Aviv Sourasky Medical Center, Eva Mayr-Stihl Cancer Center, Klinikum Stuttgart, University Hospital of Munich, State Budgetary Institution “N.N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of the Russian Federation, Roswell Park Cancer Institute, Texas Oncology, Rogel Cancer Center, University of Michigan, University of Miami Sylvester Comprehensive Cancer Center, Kyushu University, Yonsei Cancer Center, Yonsei University College of Medicine, The Christie NHS Foundation Trust, University Hospital of Modena, Strasbourg European Cancer Institute, Merck & Co., Inc., Eisai Inc., Eisai Ltd., Dana-Farber Cancer Institute and Harvard Medical School, Memorial Sloan Kettering Cancer Center"
TPS301,M20,Phase 3 OMAHA-004 study of CYP11A1 inhibitor opevesostat versus next-generation hormonal agent (NHA) switch in patients with metastatic castration-resistant prostate cancer (mCRPC) after 1 prior NHA.,"Christian Gratzke , Donald Vile , Zheng Hong Chen , Chris Garratt , Christian Poehlein , Jelena Todoric , Karim Fizazi","University Hospital Freiburg, Blue Ridge Cancer Care, MSD China, Orion Corporation, Merck & Co., Inc., Institut Gustave Roussy, University of Paris-Saclay"
455,D23,18F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing first line tyrosine kinase or checkpoint inhibitor therapy.,"Michael Staehler , Sophie Kunte , Adrien Holzgreve , Marcus Unterrainer , Iulia Blajan , Christian Stief , Peter Bartenstein , Jozefina Casuscelli , Lena Unterrainer","University Hospital of Munich, University of Munich, Ahmanson Translational Theranostics Division, University of California, Los Angeles, Department of Radiology, Ludwig-Maximilians-University Munich, Department of Urology, University Hospital, Ludwig Maximilian University of Munich, Department of Nuclear Medicine, University Hospital, LMU Munich, Department of Urology, LMU University Hospital, LMU Munich"
33,A11,Prognostic value of quantitative PSMA-PET parameters during chemotherapy in prostate cancer.,"Stephan Beintner-Skawran , Andrei Gafita , Theo Lorenzini , Sebastian Hoberück , Francesco Mattana , Andrea Di Giorgio , Matthias Miederer , Channing Paller , Loic Djaileb , Lilja Solnes , Andrea Farolfi , Francesco Ceci , Matthias Eiber , Andrew Voter","University Hospital Zurich, Johns Hopkins University, Department of Nuclear Medicine, School of Medicine and Health, TUM University Hospital, Technical University of Munich, Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Technical University Dresden, Division of Nuclear Medicine and Theranostics, IEO European Institute of Oncology, IRCCS, Nuclear Medicine, Alma Mater Studiorum University of Bologna, Department of Medical Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Department of Nuclear Medicine, Grenoble Alpes University Hospital, Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University, Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Division of Nuclear Medicine, IEO European Institute of Oncology IRCCS, Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine"
464,D32,Understanding health inequalities based on socio-economic factors and geographical location in renal cell carcinoma: A large-scale national cohort study in England.,"Prantik Das , Joshua Owide , Rania Mohammed","University Hospitals of Derby and Burton NHS Foundation Trust, University of Nottingham, School of Medicine, HSJ Information Ltd, University Hospitals of Derby and Burton NHS Foundation Trust"
313,H13,Validation of navigator-assisted hypofractionation (NAVAH) program surveys in African-American prostate cancer patients.,"Erica Fleming Hall , Ursula Burnette , Tamika Smith , Abizairie Sanchez Feliciano , Maya Stephens , Louisa Onyewadume , Chesley Cheatham , Daniel Spratt , Angela Jia , Shearwood McClelland III","University Hospitals Seidman Cancer Center, Case Western Reserve University, Case Western Reserve University, Medical College of Georgia, University Hospital Seidman Cancer Center, Case Western Reserve University, University Hospitals Seidman Cancer Center, University Hospitals Seidman Cancer Center, Departments of Radiation Oncology and Neurological Surgery, Case Western Reserve University School of Medicine"
408,L4,"Risk stratification using the Decipher 22-gene genomic classifier (GC) and digital pathology artificial intelligence (DPAI) in nearly 10,000 localized prostate cancer patients.","Daniel Spratt , Soumyajit Roy , Ho Yin Ho , Xin Zhao , Alexander Hakansson , Ahmad Alzein , Alboukadel Kassambara , Atallah Baydoun , Angela Jia , Phuoc Tran , Mamoudou Sano , Jason Hughes , Thomas Sbarrato , Jacques Fieschi , Elai Davicioni , Gerhardt Attard , Michael Leapman , Ashley Ross , Yang Liu , Edward Schaeffer","University Hospitals Seidman Cancer Center, Case Western Reserve University, Rush University Medical Center, Veracyte, Inc., University Hospitals, Cleveland Medical Center, University of Maryland, Institute of Cancer Research, University College, Yale School of Medicine, Northwestern University Feinberg School of Medicine, Department of Urology, Northwestern University Feinberg School of Medicine"
67,B13,Optyx study: Clinical characteristics and preferences for initiating relugolix in a cohort of US patients in real-world care settings.,"Daniel Spratt , Rana McKay , Ashley Ross , Benjamin Lowentritt , Scott Flanders , Yi Zhong , Agnes Hong , Michael Ryan , Tanya Dorff","University Hospitals Seidman Cancer Center, Case Western Reserve University, University of California, San Diego, Northwestern University Feinberg School of Medicine, Chesapeake Urology, Sumitomo Pharma America, Inc., Pfizer Inc., Pfizer, Inc., City of Hope Comprehensive Cancer Center"
560,G27,Innovative diagnostic approaches: Serum protein markers in renal cell carcinoma.,"Laura Davis , Betty Wang , Eran Maina , Rebecca Campbell , Mohit Sindhani , Christopher Wee , Christopher Weight , Phillip Abbosh , Steven Campbell , Robert Abouassaly , Adam Calaway , Pedro Barata , Laura Bukavina","University Hospitals Seidman Cancer Center, Cleveland Clinic Glickman Urologic Institute, Cleveland Clinic Lerner College of Medicine, India Institute of Technology, Cleveland Clinic Glickman Urological and Kidney Institute, Fox Chase Cancer Center, Department of Urology, University Hospitals Cleveland Medical Center"
830,G26,Impact of variant allele frequency (VAF) of TP53 alterations and Signatera circulating tumor DNA (ctDNA) monitoring for patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV).,"Albert Jang , Hamsa Kumar , Chen-Han Wu , Ravi Kumar Kyasaram , Iris Sheng , Prateek Mendiratta , Jorge Garcia , Pedro Barata , Santosh Rao , Jason Brown","University Hospitals Seidman Cancer Center, Division of Solid Tumor Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Department of Genetics and Genomic Sciences, Department of Urology, Case Western Reserve University, University Hospitals, and Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center, Cancer Informatics"
102,C12,Homologous recombination repair mutation testing patterns in metastatic castration-resistant prostate cancer: Analysis of real-world data in the United States.,"Pedro Barata , Suvina Amin , Alexander Niyazov , Melissa Kirker , Amanda Ribbands , Jake Butcher , Jacob Skilling , Alex Busby , Alastair Hinds , Elena Castro","University Hospitals Seidman Cancer Center, Pfizer Inc., Adelphi Real World, Hospital Universitario 12 de Octubre"
154,D28,Docetaxel rechallenge versus cabazitaxel in patients previously treated with docetaxel for metastatic castrate-resistant prostate cancer (mCRPC).,"Pedro Barata , June Corrigan , John Culnan , Karlynn Dulberger , Jennifer La , Elliot Akama-Garren , Clark DuMontier , Jason Hansen , Rhonda Bitting , Heather Cheng , Matthew Cooperberg , Tanya Dorff , Susan Halabi , Stacy Loeb , David Nanus , Chong-xian Pan , Martin Schoen , Nathanael Fillmore , Channing Paller , Matthew Rettig","University Hospitals Seidman Cancer Center, VA Boston Healthcare System, Harvard Medical School, VA Boston Healthcare System and Brigham and Women's Hospital, University of New England, Durham Veterans Affairs Medical Center, University of Washington, University of California, San Francisco, City of Hope Comprehensive Cancer Center, Duke University School of Medicine, NYU Langone Health, Weill Cornell Medicine, NewYork-Presbyterian Hospital, Department of Medicine and Urology, Brigham and Women’s Hospital, Harvard Medical School, and VA Boston Healthcare System, Saint Louis University School of Medicine, VA Boston Healthcare System and Harvard Medical School, Department of Medical Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Department of Medical Oncology, University of California, Los Angeles"
193,E32,Image-based artificial intelligence algorithms for molecular diagnostics in prostate pathology: How far are we? A systematic review.,"Jacqueline van Hees , Michiel Vlaming , Nikolas Stathonikos , Britt Suelmann , Richard Meijer , Peter-Paul Willemse , Paul van Diest","University Medical Center Utrecht, Department of Oncological Urology, University Medical Center Utrecht"
781,F8,The role of salvage cystectomy after prior trimodality therapy.,"Nikolaos Pyrgidis , Gerald Schulz , Pietro Schilipoti , Francesco Pellegrino , Jozefina Casuscelli , Lazaros Tzelves , Davide Ciavarella , Maria del Carmen Mir , Tobias Klatte , Ramos Belinchon , Jorge Caño Velasco , Yasuhisa Fujii , Hajime Tanaka , Soichiro Yoshida , Paolo Umari , Jeremy Teoh , Chris Wong Ho Ming , Giuseppe Simone , Riccardo Mastroianni , Marco Moschini","University Munich, University of Munich, Department of Urology, San Raffaele Hospital and Scientific Institute, Milan, Italy, Department of Urology, LMU University Hospital, LMU Munich, 2nd Department of Urology, Sismanoglio General Hospital, National and Kapodistrian University of Athens, Athens, Greece, Department of Urology, IMED Hospital, Valencia, Spain, Fundacion Instituto Valenciano Oncologia, Department of Urology, Helios Klinikum Bad Saarow, Bad Saarow, Germany., Department of Urology, Hospital Universitario General Universitario Gregorio Marañón, Madrid, Spain, Department of Urology, Institute of Science Tokyo, Department of Urology, Tokyo Medical and Dental University, Institute of Science Tokyo, St. George's University Hospital, London, UK., SH Ho Urology Centre, Department of Surgery, S.H. Ho Urology Centre, The Chinese University of Hong Kong, Regina Elena Institute (IRE), Department of Urology, IRCCS ""Regina Elena"" National Cancer Institute, Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele"
460,D28,Adherence to clinical surveillance guidelines in von Hippel-Lindau (vHL) disease: Evaluating the impact of a coordinated care centre implementation in Canada.,"Dawson Born , Anna Pasco , Maryam Soleimani","University of British Columbia, BC Cancer, BC Cancer, Vancouver"
TPS890,J18,NEO-BLAST: Neoadjuvant therapy for bladder cancer followed by active surveillance vs treatment.,"Marie-Pier St-Laurent , Bernhard Eigl , Ren Yuan , Silvia Chang , Peter Black","University of British Columbia, British Columbia Cancer Agency"
346,J10,Prostate Cancer Supportive Care (PCSC) program: An alternative to consolidated framework for implementation research (CFIR) model.,"Celestia Higano , Rosalie Ho , Daniella Sare , Judy Shih , Angela Hwang , Monita Sundar","University of British Columbia, Prostate Cancer Supportive Care Program"
403,K33,Genomic alterations and their pathologic responses in high-risk localized prostate cancer (HRLPC) in subprotocol 1 of the Genomic Umbrella Neoadjuvant study (GUNS).,"Martin Gleave , Eric Belanger , Joshua Scurll , Htoo Zarni Oo , Lucia Nappi , Himisha Beltran , Alexander Wyatt , Miles Mannas , Peter Black , Amina Zoubeidi , Jonathan Ma , Doron Berlin , Tiiu Sildva , Theo Van Der Kwast , Neil Fleshner","University of British Columbia, University of British Columbia; Vancouver Coastal Health, Vancouver Prostate Centre, Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Dana-Farber Cancer Institute, The University of British Columbia, Vancouver Prostate Center, University of British Columbia, Princess Margaret Cancer Centre, University Health Network, Princess Margaret Cancer Centre, University Health Network"
TPS889,J17,A phase 2/3 multicenter trial evaluating safety and efficacy of a new mucoadhesive gemcitabine suspension for ablation of upper tract urothelial carcinoma.,"Marie-Pier St-Laurent , Veronika Schmitt , Martin Gleave , Peter Black","University of British Columbia, Vancouver Prostate Centre"
126,C36,Targeting the soluble epoxide hydrolase (sEH) enzyme to relieve painful docetaxel-induced peripheral neuropathy.,"Nicholas Mitsiades , Karen Wagner , Jun Yang , Bruce Hammock","University of California Davis Comprehensive Cancer Center, Department of Entomology and Nematology, University of California, Davis"
734,D31,Real world toxicity profile of enfortumab vedotin (EV) with or without pembrolizumab (P) in ultra elderly urothelial carcinoma (UC) patients (pts).,"Nataliya Mar , Jeanah Go , Marsenne Cabral , Dalia Kaakour , Sami Dwabe , Steven Seyedin , Alexandra Drakaki","University of California Irvine, University of California, Irvine, Division of Hematology/Oncology, David Geffen School of Medicine, University of California, Los Angeles, Division of Hematology/Oncology, University of California, Irvine, University of California, San Francisco, University of California, Los Angeles Medical Center"
TPS881,J9,Outcomes with multi parametric MRI (mpMRI) compared to diagnostic transurethral resection of bladder tumor (TURBT) in patients (pts) with suspected muscle-invasive bladder cancer (MIBC): A pilot study.,"Nataliya Mar , Amanda Macaraeg , Ali Raad , Dalia Kaakour , Arash Rezazadeh , Michael Daneshvar","University of California Irvine, University of California, Irvine, Stern Center for Cancer Clinical Trials and Research, Chao Comprehensive Cancer Center, Division of Hematology/Oncology, University of California, Irvine, Division of Hematology/Oncology, University of California Irvine, University of California, Irvine Health"
696,C29,Mental health monitoring in clinical trials for FDA-approved genitourinary cancer treatments: A decade review.,"Parnian Jabbari , Farzad Teymouri , Omid Yazdanpanah , Aditya Mahadevan , Arash Rezazadeh , David Benjamin","University of California Riverside, Eisenhower Medical Center, Division of Hematology/Oncology, University of California Irvine, Department of Medicine University of California, San Francisco, Hoag Family Cancer Institute"
88,B34,Real-world persistence and adherence to relugolix (REL) in US patients with nonmetastatic (nm) vs metastatic (m) prostate cancer (PC).,"Rana McKay , Agnes Hong , Juan Razo , Scott Flanders , Christine Ferro , Mila Shapoval , Benjamin Li , Stephen Freedland","University of California San Diego, Moores Cancer Center, Pfizer Inc., Sumitomo Pharma America, Inc., Milliman, Inc., Pfizer, Department of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles; Durham VA Medical Center"
121,C31,Efficacy of 177Lu-PSMA-617 with or without ARPIs for the treatment of mCRPC: VISION secondary analysis.,"Omid Yazdanpanah , Jeremie Calais , Kim Chi , Johann De Bono , Sheila Deymann , Ghassan El-Haddad , Ken Herrmann , Karim Fizazi , Diego Ospina Gonzalez , Ayse Kendi , Bernd Krause , Michael Morris , James Nagarajah , Luke Nordquist , Alton Sartor , Kambiz Rahbar , Scott Tagawa , Nitin Vaishampayan , Ye Yue , James Nagarajah , Arash Rezazadeh","University of California, Ahmanson Translational Theranostics Division, University of California, Los Angeles, University of British Columbia, BC Cancer, Vancouver Cancer Centre, The Royal Marsden NHS Foundation Trust, Novartis Pharmaceutical Corporation, Moffitt Cancer Center, Clinic for Nuclear Medicine and German Cancer Consortium, University Hospital Essen, Institut Gustave Roussy, University of Paris-Saclay, Novartis Pharmaceuticals Corporation, Mayo Clinic in Rochester, Rostock University Medical Center, Memorial Sloan Kettering Cancer Center, Radboud University Medical Center, GU Research Network-Urology Cancer Center, Tulane Cancer Center, Department of Nuclear Medicine, University Hospital Münster, Weill Cornell Medicine, Wayne State University"
709,D6,"Retrospective, observational analysis of real-world safety outcomes in sacituzumab govitecan (SG)-treated patients (pts) with locally advanced/metastatic urothelial cancer (la/mUC).","Mamta Parikh , Peter McMahon , Susan Eng , Freda Boateng , Youssef Ghazi , Kerstin Schmidt , Jane Michelle Brockman , Xinran Ma , Mitch Sierecki","University of California, Davis Comprehensive Cancer Center, Gilead Sciences Europe LTD, Gilead Sciences, Inc., Gilead Sciences, Inc, Flatiron Health"
336,H36,Five-year follow-up of prostate specific membrane antigen PET/CT-guided salvage radiotherapy following radical prostatectomy: A single center retrospective analysis.,"John Nikitas , Clayton Smith , Wesley Armstrong , Vishnu Murthy , Tristan Grogan , Kevyn Clark , Jonathan Moore , Makayla Roberts , Andrea Farolfi , Robert Reiter , Matthew Rettig , John Shen , Luca Valle , Nicholas Nickols , Michael Steinberg , Johannes Czernin , Amar Kishan , Jeremie Calais","University of California, Department of Radiation Oncology, Department of Radiation Oncology, University of California, Los Angeles, Ahmanson Translational Theranostics Division, University of California, Los Angeles, Department of Medicine Statistics Core, UCLA, Division of Nuclear Medicine, IRCCS Azienda Ospedaliero, Universitaria di Bologna, Department of Urology, University of California, Los Angeles, Department of Medical Oncology, University of California, Los Angeles"
344,J8,Early detection of recurrent prostate cancer using 18F-DCFPyL PET/CT PET/CT in patients with minimal PSA levels.,"Ida Sonni , Nicholas Nickols , Katelyn Niknam , Gholam Berenji , Derace Schaffer , Louis Montagut , Karl Sjöstrand , Aseem Anand , Matthew Rettig","University of California, Department of Radiation Oncology, University of California, Los Angeles, VA Greater Los Angeles Healthcare System, Lantheus Medical Imaging, Exini Diagnostic AB, Exini Diagnostics AB, Department of Medical Oncology, University of California, Los Angeles"
123,C33,Safety profile of lutetium-177 in patients with impaired renal function: A retrospective analysis of adverse events in mCRPC treatment.,"Allen Seylani , Peter Zang , Erasmus Poku , Phil Kuo , Dave Yamauchi , Tanya Dorff","University of California, Riverside, City of Hope Comprehensive Cancer Center, City of Hope Cancer Center / Beckman Research Institute, City of Hope, City of Hope National Medical Center"
26,A4,Impact of prior primary care utilization on limiting racial disparities for prostate cancer diagnosis and mortality.,"Sakshith Reddy Chintala , Kylie Morgan , Edmund Qiao , Daniel Sabater Minarim , Elizabeth Duran , Sharon Choi , Aditya Bagrodia , Rana McKay , James Murphy , Matthew Banegas , Brent Rose","University of California, San Diego Health, Department of Radiation Medicine and Applied Sciences, University of California, San Diego, University of California, San Diego, University of California San Diego Health, Moores Cancer Center, University of California San Diego"
TPS430,M28,A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune).,"Yu-Wei Chen , Lin Liu , Yuwei Cheng , Arlene Araneta , Neremiah Castano , Jennifer Gomez , Archana Ajmera , Huihui Ye , Karie Runcie , Deaglan McHugh , Kenneth Offit , Channing Paller , Naomi Haas , Robert Franklin , Roberto Pili , Juan Javier-Desloges , Christopher Kane , Tyler Seibert , Aditya Bagrodia , Rana McKay","University of California, San Diego Medical Center, University of California, San Diego, University of California, San Diego, Cedars-Sinai Medical Center, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, Memorial Sloan Kettering Cancer Center, Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Abramson Cancer Center, University of Pennsylvania, University of Cincinnati Medical Center, Division of Hematology-Oncology, Medicine, Jacobs School of Medicine, University at Buffalo, Department of Urology, University of California, San Diego, University of California San Diego Health, Moores Cancer Center, University of California, San Diego"
407,L3,Evaluating molecular alteration profiles to distinguish intraductal carcinoma of the prostate.,"Harshitha Dudipala , Shayan Nazari , Isabela Werneck da Cunha , Shuanzeng Wei , Andrew Elliott , Yasmine Baca , Norm Smith , Daniel Geynisman , Jacqueline Brown , Kevin Zarrabi , Neeraj Agarwal , Emmanuel Antonarakis , Daniel Herchenhorn , Rana McKay","University of California, San Diego, Caris Life Sciences, D’Or Institute for Research and Education (IDOR), Department of Pathology, Fox Chase Cancer Center, Fox Chase Cancer Center, Winship Cancer Institute of Emory University, Sidney Kimmel Cancer Center, Thomas Jefferson University, Huntsman Cancer Institute (NCI-CCC), University of Utah, University of Minnesota, Masonic Cancer Center, Oncologia D'Or, University of California San Diego, Moores Cancer Center"
257,G30,Downregulation of E-selectin and contributions to immune restraining in prostate cancer.,"Ida Deichaite , Andrew Elliott , Ahmed Shabaik , Leisa Sutton , Stephanie Weaver , Miki Haraguchi , Daniel Geynisman , Shuanzeng Wei , Napoleone Ferrara , Fotis Asimakopoulos , Pablo Tamayo","University of California, San Diego, Caris Life Sciences, Fred Hutchinson Cancer Center, Fox Chase Cancer Center, Department of Pathology, Fox Chase Cancer Center"
TPS281,L34,Precision diagnostics in prostate cancer treatment (PREDICT): A phase 2 multi-arm biomarker-based study (Alliance A032102).,"Rana McKay , Glenn Heller , Shuang Zhao , Elizabeth Wulff-Burchfield , Dhaval Shah , Alan Tan , Matthew Galsky , Jonathan Rosenberg , Himisha Beltran","University of California, San Diego, Memorial Sloan Kettering Cancer Center, University of Wisconsin Carbone Cancer Center, University of Kansas Medical Center, Medical Oncology Hematology Consultants, Vanderbilt-Ingram Cancer Center, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Department of Medical Oncology, Dana-Farber Cancer Institute"
321,H21,Results of a cross-sectional survey to explore determinants of health-promoting activities among Hispanic/Latino (H/L) patients (pts) with prostate cancer (PCa) on androgen deprivation therapy (ADT).,"Sharon Choi , Frances Ramos Diaz , Kristine Ly , Yu-Wei Chen , James Randall , Tyler Stewart , Fred Millard , James Murphy , Noe Crespo , Soo Park , Brent Rose , Aditya Bagrodia , Elena Martinez , Rana McKay","University of California, San Diego, Moores Cancer Center at UC San Diego Health, UC San Diego Moores Cancer Center, Moores Cancer Center, University of California San Diego, UC San Diego Health, UC San Diego School of Medicine, San Diego State University, Department of Medicine, Division of Hematology and Oncology, University of California San Diego, University of California San Diego Moores Cancer Center, Population Sciences, Disparities and Community Engagament, University of California San Diego, Moores Cancer Center"
TPS302,M21,A phase 2 study of cabozantinib and nivolumab in metastatic castration resistant prostate cancer (CANOPY).,"Justine Panian , Yu-Wei Chen , Sharon Choi , Lin Liu , Minya Pu , Emily Pittman , Samuel Pena , Qian Qin , Tian Zhang , Hamid Emamekhoo , Joshua Lang , Akash Patnaik , Rana McKay","University of California, San Diego, Moores Cancer Center at UC San Diego Health, University of California, San Diego, Department of Internal Medicine, Division of Hematology and Oncology, UT Southwestern, University of Wisconsin-Madison, University of Wisconsin Carbone Cancer Center, The University of Chicago Medicine"
237,G10,Evaluating an integrated germline polygenic and clinical risk model (P-CARE) specifically for aggressive prostate cancer.,"Anna Dornisch , George Xu , Roshan Karunamuni , Jason Vassy , Charles Brunette , Morgan Danowski , Kyung Min Lee , Craig Teerlink , Scott DuVall , J. Gaziano , Isla Garraway , Richard Hauger , Adam Kibel , Julie Lynch , Brent Rose , Kara Maxwell , Jenny Donovan , Freddie Hamdy , Tyler Seibert","University of California, San Diego, VA San Diego Healthcare System, VA Boston Healthcare System, VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, VA Salt Lake City Health Care System, Department of Veteran Affairs Salt Lake City Health Care System, VA Boston Healthcare System, Massachusetts Veterans Epidemiology Research and Information Center, Greater Los Angeles Department of Veterans Affairs Healthcare System, Brigham and Women's Hospital, Corporal Michael Crescenz VA Medical Center, University of Bristol, University of Oxford"
259,G32,Evaluating survival in aggressive variant prostate cancer patients undergoing PSMA radioligand therapy.,"Moein Moradpour , Abuzar Moradi Tuchayi , Irene Burger , Sabin George. Pop , Ana Aparicio , Ivan de Kouchkovsky , Thomas Hope","University of California, San Francisco Medical Center, University of California, San Francisco, Universita' degli Studi di Messina, Kantonsspital Baden, The University of Texas MD Anderson Cancer Center"
422,L18,Relationship of spatial transcriptomic analyses with distance-associated transcriptomic spectrum and morphology-specific signatures of localized prostate cancer.,"Brendan Raizenne , Hanbing Song , Nancy Greenland , Maggie Tsui , Jared Khan , Taiqi Li , Chih-Hao Chang , Matthew Cooperberg , Franklin Huang","University of California, San Francisco, Department of Pathology, University of California, San Francisco"
43,A21,Impact of PSMA-PET and conventional imaging on contemporary management in patients with biochemical recurrence after radical prostatectomy.,"Arielle Ilano , Lufan Wang , Janet Cowan , Samuel Washington III, Hao Nguyen , Matthew Cooperberg , Thomas Hope , Peter Carroll , Carissa Chu","University of California, San Francisco, Department of Urology, University of California, San Francisco"
364,J28,Predicting long term outcomes following radical prostatectomy using a validated pathology-based multimodal artificial intelligence biomarker.,"Matthew Cooperberg , Kevin Shee , Janet Cowan , Tamara Todorovic , Imelda Tenggara , Siyi Tang , Rikiya Yamashita , Trevor Royce , Emmalyn Chen , Meghan Tierney , Xiao Ma , Huei-Chung Rebecca Huang , Felix Feng , Chien-Kuang Ding , Timothy Showalter , Peter Carroll","University of California, San Francisco, Department of Urology, University of California, San Francisco, Artera"
412,L8,Application of canary histology classifier in prostate biopsies for risk stratification.,"Chien-Kuang Ding , Janet Cowan , Nancy Greenland , Bradley Stohr , Deepika Sirohi , Matthew Cooperberg , Jeff Simko , Peter Carroll","University of California, San Francisco, Department of Urology, University of California, San Francisco, Department of Pathology, University of California, San Francisco"
322,H22,Exploring social vulnerability in prostate cancer management: Insights into utilization of watchful waiting and active surveillance from 1998 to 2017.,"Nana Shakhnazaryan , Jenna Winebaum , Lufan Wang , Angad Jhandi , Nathan Nguyen , Janet Cowan , Peter Carroll , June Chan , Salma Shariff-Marco , Samuel Washington III","University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, Department of Urology, University of California, San Francisco, Eastern Virginia Medical School, Carle Illinois College of Medicine, University of California, San Francisco, Department of Epidemiology and Biostatistics, University of California, San Francisco"
331,H31,Can magnetic resonance imaging safely replace a confirmatory biopsy in patients on active surveillance for prostate cancer?,"Matthew Cooperberg , John Bihn , John Culnan , Jennifer La , Sergey Goryachev , June Corrigan , Karlynn Dulberger , Kaitlin Swinnerton , Grace Lee , Isla Garraway , Susan Halabi , Stacy Loeb , Tanya Dorff , Richard Hauger , Nicholas Nickols , Timothy Rebbeck , Matthew Rettig , Martin Schoen , Nathanael Fillmore , Channing Paller","University of California, San Francisco, VA Boston Healthcare System, Massachusetts Veterans Epidemiology Research and Information Center, University of California, San Fransisco, Veterans Affairs Greater Los Angeles Medical Center, Duke University School of Medicine, NYU Langone Health, City of Hope Comprehensive Cancer Center, VA San Diego Healthcare System, Department of Radiation Oncology, University of California, Los Angeles, Dana-Farber Cancer Institute, Harvard T. H. Chan School of Public Health, Department of Medical Oncology, University of California, Los Angeles, Saint Louis University School of Medicine, VA Boston Healthcare System and Harvard Medical School, Department of Medical Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine"
TPS273,L26,Patient satisfaction with geriatric and functional assessments and referral to frailty-related interventions among older adults presenting to the University of Colorado Urologic Oncology Multidisciplinary Clinic.,"Mohamoud Ahmed , Aditya Mantha , Stephanie Lakritz , Franchesca Konig , Elizabeth Kessler","University of Colorado Medicine, University of Colorado, University of Colorado Cancer Center, Anschutz Medical Campus"
329,H29,Computational pathology–based classifier for predicting Gleason grade group upgrading on radical prostatectomy from diagnostic biopsies.,"Abderrahim-Oussama Batouche , Sebastian Medina , Naoto Tokuyama , Kevin Sandeman , Antti Rannikko , Anant Madabhushi , Tuomas Mirtti","University of Helsinki, Wallace H Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, Department of Pathology, Division of Laboratory Medicine, Skåne University Hospital, Department of Urology and Research Program in Systems Oncology, University of Helsinki, Emory University, Helsinki University Hospital"
182,E21,GLP1R expression in prostate cancer patients and effects of GLP1R agonism on prostate cancer cells.,"Jordan Vellky , Natalie Reizine , Donald Vander Griend",University of Illinois Chicago
707,D4,Sociodemographic disparities in treatment (tx) patterns and clinical outcomes among real-world patients (pts) with locally advanced/metastatic urothelial carcinoma (la/mUC) in the US.,"Karine Tawagi , Jeanne Pierzynski , Emily Freeman , Kerstin Schmidt , Mitchell Sierecki , Jane Michelle Brockman , Mamta Parikh","University of Illinois Chicago, Gilead Sciences, Inc., Gilead Sciences, Inc, University of California, Davis Comprehensive Cancer Center"
54,A32,Real-world comparison of cost and adherence between patients receiving low-dose versus standard-dose abiraterone acetate (AA) in a safety-net hospital.,"Michael Weinfeld , Valerie Chuy , Syed Shahrukh Rizvi , Shaeker Chandran , Ekaterina Proskuriakova , Salimah Mohamed , Aseem . , Ruben Sauer Calvo , Lina Shao , Noor Naffakh , Christopher Schumpp , Charles Gaber , Natalie Reizine , Karine Tawagi","University of Illinois Chicago, Mount Sinai Hospital, Johns Hopkins, University of Illinois Chicago College of Pharmacy"
820,G16,Association between proto-oncogene N-RAS transcript level and overall survival in node-negative muscle-invasive urothelial bladder carcinoma.,"Donghyun Kim , Bilal Rahim",University of Iowa Holden Comprehensive Cancer Center
802,F29,"Preliminary results from LEGEND: A phase 2 study of detalimogene voraplasmid (EG-70), a novel, non-viral intravesical gene therapy for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS).","John Taylor III, Shreyas Joshi , Raj Satkunasivam , Rian Dickstein , Amirali Salmasi , Yair Lotan , Scott Johnson , Raj Pruthi , Christine Tosone , Anne Schuckman , Jen-Jane Liu","University of Kansas Medical Center Department of Internal Medicine, Department of Urology, Emory University, Department of Urology, Houston Methodist Hospital, Chesapeake Urology, University of California, San Diego, Department of Urology, UT Southwestern Medical Center, Medical College of Wisconsin, enGene Inc., EnGene Inc., University of Southern California, Oregon Health & Science University"
4,D3,Efficacy and safety of immune checkpoint inhibitors (ICI) for the treatment of metastatic penile squamous cell carcinoma (mPSCC).,"Tiewei Cheng , Timothy Schieber , Anna Clennon , Katie Bertken , Sunny Cai , Elizabeth Wulff-Burchfield , Saqib Abbasi , Rahul Parikh , Haoran Li","University of Kansas Medical Center, University of Kansas Cancer Center, Aurora St. Luke’s Medical Center, The University of Kansas Health System, The University Of Kansas Medical Center"
528,F26,Organ perforation and fistula formation as adverse events in patients receiving tyrosine kinase inhibitors: A post-market analysis.,"Zin Myint , Ning Li , Carleton Ellis , Ashlyn Whitesell , Donglin Yan","University of Kentucky, Department of Pharmacy, University of Kentucky HealthCare"
233,G6,Hydroxychloroquine effects on tumor suppressor PAR-4 levels in patients with oligometastatic prostate cancer: Results from a phase-2 trial.,"Joon Kyung Kim , Andrew James , Ravshan Burikhanov , Zhengyan Huang , Zin Myint , Don Cohen , Donglin Yan , Akosua Adu , Leigh Anne Faul , Ning Li , Peng Wang , Stephen Strup , William St. Clair , Vivek Rangnekar , Patrick Hensley","University of Kentucky, Texas Urology Group"
816,G12,Evaluation of systemic therapy and surgical consolidation in patients with node positive upper tract urothelial carcinoma.,"Joon Kyung Kim , Katelyn Spencer , Will Cranford , Justus Fleisch , Zin Myint , Derek Allison , Frances Martin , Stephen Strup , Christopher McLouth , Patrick Hensley","University of Kentucky, University of Freiburg"
TPS300,M19,Phase 1/2 OMAHA-01A substudy of oral CYP11A1 inhibitor opevesostat alone or in combination with other therapies for metastatic castration-resistant prostate cancer (mCRPC).,"Arif Hussain , Chris Garratt , Nan Li , Yingjie Liu , Christian Poehlein , Peter Fong","University of Maryland Medical Center, Greenebaum Comprehensive Cancer Center, Orion Corporation, MSD, China, Merck & Co., Inc., Auckland City Hospital and University of Auckland"
399,K29,Decipher score as a predictor of response to treatment intensification in the NRG Oncology-RTOG 0534 (SPPORT) phase III randomized post-prostatectomy salvage radiotherapy trial.,"Alan Pollack , Marla Johnson , James Proudfoot , Elai Davicioni , Alan Dal Pra , Jeff Simko , Andre-Guy Martin , Himanshu Lukka , Steve Angyalfi , Jeff Michalski , Marie Duclos , George Rodrigues , R. Lee , Kevin Roof , Angela Jia , Samantha Seaward , Nader Khaouam , Theodore Karrison , Felix Feng , Phuoc Tran","University of Miami Health System, Veracyte, Inc., University of Miami, University of California, San Francisco, CHU de Quebec, McMaster University, Tom Baker Cancer Centre, Washington University School of Medicine in St. Louis, Cedars Cancer Centre, McGill University Health Centre, Princess Margaret - University Health Network, Intermountain Medical Center, Southeast Radiation Oncology, Johns Hopkins University School of Medicine, Kaiser Permanente, Integrated University Health and Social Services Center of East Montreal Island, NRG Oncology Statistics and Data Management Center, Radiology School of Medicine, University of California, San Francisco, University of Maryland"
135,D9,Unraveling the dietary impact: Associations between ultra-processed foods and prostate cancer in a two-decade study.,"Elise Katsnelson , Derek Isrow , Crystal Taswell , Benjamin Rich , William Jin","University of Miami Miller School of Medicine, Department of Radiation Oncology, University of Miami Sylvester Comprehensive Cancer Center"
262,H3,Grade and volume progression and its association with the Decipher genomic classifier using patients enrolled in a prospective active surveillance protocol.,"David Lee , Tarek Ajami , Hui Yu , Nachiketh Soodana-Prakash , Joao Porto , Yuval Avda , Ankur Malpani , Dinno Mendiola , Pedro Freitas , Archan Khandekar , Sanjaya Swain , Sandra Gaston , Brandon Mahal , Sanoj Punnen","University of Miami Sylvester Comprehensive Cancer Center, University of Miami Hospital, University of Miami - Desai Sethi Urology Institute, University of Miami - Desai Sethi Urology Instutite, University of Miami Miller School of Medicine, Desai Sethi Urology Institute, University of Miami Sylvester Comprehensive Cancer Center"
240,G13,Assessing molecular heterogeneity of prostate cancer biopsy sampling: Insights from the MAST trial.,"David Lee , Brandon Mahal , Sanoj Punnen","University of Miami Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Desai Sethi Urology Institute, University of Miami Sylvester Comprehensive Cancer Center"
238,G11,Validation of PAM50 for predicting progression in active surveillance: Results from the Miami MAST prospective clinical trial.,"David Lee , Brandon Mahal , Sanoj Punnen","University of Miami Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Desai Sethi Urology Institute, University of Miami Sylvester Comprehensive Cancer Center"
239,G12,Gene expression signatures in biopsy cores as predictors of coexisting higher-grade disease in Gleason group 1 prostate cancer: Results from the Miami MAST prospective clinical trial.,"David Lee , Brandon Mahal , Sanoj Punnen","University of Miami Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Desai Sethi Urology Institute, University of Miami Sylvester Comprehensive Cancer Center"
255,G28,Molecular evolution of HRR gene alterations in metastatic prostate cancer: A ctDNA-based study.,"Chinmay Jani , Eli Tran , Nicole Zhang , Jill Tsai , Jianjie Dong , Elizabeth Pan , Justine Panian , Rana McKay","University of Miami Sylvester Comprehensive Cancer Center, University of San Diego, Guardant Health, Scripps Institutue, University of California, San Fransisco, University of California, San Diego, UC San Diego School of Medicine"
741,E3,Pathogenic germline variant prevalence and genetic testing outcomes in patients with urothelial carcinoma.,"Eugene Oh , Piroz Bahar , Ye Chua , Marie-Louise Accardo , Xiaochen Li , Erika Koeppe , Phillip Palmbos , Irene Tsung , Zachery Reichert , Ulka Vaishampayan , Tobias Else , Charles Nguyen","University of Michigan Medical School, Department of Internal Medicine, University of Michigan, City of Hope Comprehensive Cancer Center, Michigan Medicine, Division of Hematology/Oncology, University of Michigan, Department of Internal Medicine, Division of Metabolism, Endocrinology, and Diabetes, University of Michigan"
369,J33,Contemporary post-prostatectomy radiation therapy for prostate cancer within a statewide quality consortium.,"Samuel Regan , Michael Dykstra , Huiying Yin , Mark Zaki , Mazen Mislmani , Patrick McLaughlin , Danielle Kendrick , Sarah Paluch , Andrea Smith , David Heimburger , Matthew Schipper , William Jackson , Robert Dess","University of Michigan, Covenant Radiation Center, West Michigan Cancer Center, Covenant Healthcare, Munson Healthcare"
569,H4,Do tissue-based biomarkers in metastatic clear cell renal cell carcinoma perform better when derived from a metastatic site?,"Steven Monda , Ulka Vaishampayan , Samuel Kaffenberger , Daniel Triner , Srinivas Nallandhighal , Todd Morgan , Khaled Hafez , Zayne Knuth , Udit Singhal , Shuchi Gulati , Ganesh Palapattu , Simpa Salami","University of Michigan, Department of Urology, Division of Hematology/Oncology, University of Michigan, University of Michigan, Department of Urology, Michigan Medicine, University of Michigan (Ann Arbor, MI), UC Davis Comprehensive Cancer Center, University of Michigan Department of Urology"
357,J21,Evaluating the rates of surgical overtreatment of prostate cancer.,"Steven Monda , Timothy Demus , Sabir Meah , Arnav Srivastava , Richard Sarle , Kevin Ginsburg , Todd Morgan , Tudor Borza","University of Michigan, Department of Urology, Sparrow Healthy System, University of Michigan, Dow Division of Health Services Research, Department of Urology, University of Michigan, Sparrow Health System, Wayne State University"
578,H13,Validation of a 15-gene prognostic signature in metastatic clear cell renal cell carcinoma.,"Steven Monda , Srinivas Nallandhighal , Ulka Vaishampayan , Udit Singhal , Zayne Knuth , Rohit Mehra , Samuel Kaffenberger , Khaled Hafez , Aaron Udager , Ganesh Palapattu , Todd Morgan , Simpa Salami","University of Michigan, Department of Urology, University of Michigan, University of Michigan (Ann Arbor, MI), Department of Pathology, University of Michigan, University of Michigan Department of Urology"
396,K26,"Using AI to identify optimal clinical, genomic, and radiographic prognostic features and novel risk classifiers compared to routinely available risk classifiers.","Benjamin Tward , Skyler Johnson , Jonathan Tward","University of Michigan, Huntsman Cancer Institute at the University of Utah"
350,J14,Impact of PSMA PET staging on initial treatment in newly diagnosed prostate cancer: An emulated randomized controlled trial.,"Sean Miller , Rachel Tucker Gonzalez , William Jackson , Megan Caram , Phoebe Tsao , Kristian Stensland , Yashesh Shah , Daniel Wale , David Elliott , Ka Kit Wong , Benjamin Viglianti , Tanner Caverly , Timothy Hofer , Sameer Saini , Michael Green , Matthew Schipper , Robert Dess , Alex Bryant","University of Michigan, Michigan Medicine, Department of Nuclear Medicine, University of Michigan, Department of Internal Medicine, University of Michigan, University of Michigan School of Medicine, University of Michigan Health Management Research Center"
387,K17,"Androgen suppression with abiraterone acetate, leuprolide, PARP inhibition, and stereotactic body radiotherapy (ASCLEPIuS) in high-risk and node positive prostate cancer (PCa): Phase I multicenter results.","William Jackson , Robert Dess , Angela Jia , Himanshu Nagar , Neil Desai , Raquibul Hannan , Jason Hearn , Zachery Reichert , Ariel Marciscano , Brian Davis , Raed Zuhour , Nicholas Zaorsky , Jorge Garcia , Pedro Barata , Jason Brown , Prateek Mendiratta , Felix Feng , Arul Chinnaiyan , Krithika Suresh , Daniel Spratt","University of Michigan, Michigan Medicine, University Hospitals Seidman Cancer Center, Case Western Reserve University, Memorial Sloan Kettering Cancer Center, Department of Radiation Oncology, UT Southwestern Medical Center, UT Southwestern Medical Center, Division of Hematology/Oncology, University of Michigan, Weill Cornell Medical College, Department of Radiation Oncology, Mayo Clinic in Rochester, University Hospitals Seidman Cancer Center and Case Western Reserve University, University Hospitals Seidman Cancer Center, Division of Solid Tumor Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, University of Michigan Medical School, University Of Michigan"
220,F24,Carcinoma of prostate sequencing of tumor and clinical endpoints (CAPSTONE): Clinical implications of recurrent genomic alterations in lethal prostate cancer.,"Ryan Rebernick , Liat Hammer , Matthew McFarlane , Thomas Westbrook , Munna Hazime , Tanya Hammoud , Pin-en Chiu , Xavier Owens , Yi-Mi Wu , Dan Robinson , Daniel Spratt , Ajjai Alva , William Jackson , Zachery Reichert , Joshi Alumkal , Arul Chinnaiyan , Marcin Cieslik , Robert Dess","University of Michigan, Rush University Medical Center, UH Cleveland Medical Center, Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Division of Hematology/Oncology, University of Michigan, University of Michigan Rogel Cancer Center, University of Michigan Medical School, Michigan Medicine"
221,F25,Equal-depth sequencing of white blood cells (WBC) and plasma from prostate cancer (PCa) liquid biopsies (LBx) and association with clonal hematopoiesis (CH) confounders in clinically relevant genes.,"Emmanuel Antonarakis , Catherine Marshall , Derek Brown , Brennan Decker , Alexander Fine , Chang Xu , Kimberly Johnson , Daokun Sun , Michael McDevitt , Jason Hughes , Russell Madison , Ryon Graf , Lincoln Pasquina , Alexa Schrock , Amaya Gasco , Hanna Tukachinsky","University of Minnesota, Masonic Cancer Center, Johns Hopkins University School of Medicine, Foundation Medicine, Inc., Foundation Medicine Inc, Foundation Medicine Inc."
53,A31,Association of high ctDNA tumor fraction (TF) and detection of clinically significant copy number (CN) losses in liquid biopsies (LBx) from patients with advanced prostate cancer (PCa).,"Emmanuel Antonarakis , Scott Dehm , Gerald Li , Julia Quintanilha , Andrew Kelly , Mary Gearing , Lincoln Pasquina , Richard Huang , Ole Gjoerup , Jeffrey Ross , Julia Elvin , Ryon Graf","University of Minnesota, Masonic Cancer Center, Masonic Cancer Center, University of Minnesota, Foundation Medicine, Inc., Foundation Medicine, Inc"
236,G9,Evaluating RSPO2 activation and its association with outcomes and potential role as a driver in double-negative prostate cancer (DNPC).,"Aiden Deacon , Ava Gustafson , Ella Boytim , David Moline , Elin Kairies , Sam Kellen , Allison Makovec , Alexis Anike , Megan Ludwig , Justin Drake , Emmanuel Antonarakis , Justin Hwang","University of Minnesota, Masonic Cancer Center, University of Minnesota, Cornell College"
367,J31,Real-world discontinuation and efficacy data of abiraterone acetate/prednisone (AAP) plus androgen deprivation therapy and radiotherapy in localized prostate cancer.,"Fabrizio Di Costanzo , Xue Yan Jiang , John Frew , Ian Pedley , Emma Shakespeare , Mariajulia Lagonera , Noor Haris , Saira Bashir , Ruth Plummer , Alastair Greystoke , Christoph Oing , Luigi Formisano , Pasquale Rescigno , Robert Chandler","University of Naples ""Federico II"", Northern Centre for Cancer Care (NCCC), Newcastle Upon Tyne Hospital NHS Foundation Trust, The Sir Bobby Robson Cancer Trials Research Centre, Northern Centre for Cancer Care (NCCC), University Newcastle Northern Institute for Cancer Research, Newcastle University and Northern Centre for Cancer Care (NCCC), Freeman Hospital, Department of Clinical Medicine and Surgery, University of Naples ""Federico II"", Translational and Clinical Research Institute, Centre for Cancer, Newcastle University"
122,C32,Baseline fracture risk for prostate cancer patients initiating long-term androgen deprivation therapy.,"Jonathan Trinh , Sandra Frimpong , Yue Zhan , Kaeli Samson , Laura Graeff-Armas , Benjamin Teply",University of Nebraska Medical Center
242,G15,g-Rate–based machine learning model to predict overall survival (OS) in patients with metastatic prostate cancer (mPC) while on treatment.,"Harshraj Leuva , Jieqiong Wang , Mohamed Azzam , Mengxi Zhou , Benjamin Teply , Raymond Bergan , Susan Bates , Antonio Fojo","University of Nebraska Medical Center, Columbia University Medical Center, Fred & Pamela Buffett Cancer Center, Columbia University College of Physicians and Surgeons, James J. Peters VAMC"
188,E27,Comparison of PSA-based g-rate and conventional PSA metrics in veterans with metastatic prostate cancer (mPC).,"Harshraj Leuva , Mengxi Zhou , Benjamin Teply , Yeun-Hee Anna Park , Izak Faiena , Susan Bates , Antonio Fojo","University of Nebraska Medical Center, Columbia University Medical Center, James Peters Bronx Veterans Affairs Medical Center, Columbia University Herbert Irving Comprehensive Cancer Center, Columbia University"
200,F4,Somatic genomic landscape of prostate adenocarcinoma at a comprehensive cancer center in New Mexico: A retrospective study (2015-2022).,"Mahmoud Abdelsamia , Daniel Chavarin , Jonathan Coy , V. Shane Pankratz , Bernard Tawfik , Neda Hashemi-Sadraei , Jude Khatib","University of New Mexico Comprehensive Cancer Center, University of New Mexico, University of Utah"
779,F6,Additivity and the efficacy of immune checkpoint blockade-based combination regimens in urothelial cancer.,"Noah Schlachter , Eric Miller , Jonathan Anker , Matthew Galsky , Adam Palmer","University of North Carolina at Chapel Hill, Icahn School of Medicine at Mount Sinai"
754,E16,Non-muscle invasive bladder cancer treatment selection in an emerging treatment era: A patient preference study.,"Angela Smith , John Gore , Stephanie Chisolm , Patrick Squires , Haojie Li , Hema Dave , Caroline Vass , Xiaoying Liu , Carol Mansfield","University of North Carolina School of Medicine, Department of Urology, University of Washington, Bladder Cancer Advocacy Network, Merck & Co., Inc., RTI Health Solutions"
753,E15,Muscle invasive bladder cancer treatment selection in an emerging treatment era: A patient preference study.,"Angela Smith , John Gore , Stephanie Chisolm , Patrick Squires , Haojie Li , Sonia Franco , Caroline Vass , Xiaoying Liu , Carol Mansfield","University of North Carolina School of Medicine, Department of Urology, University of Washington, Bladder Cancer Advocacy Network, Merck & Co., Inc., RTI Health Solutions"
658,,Adjuvant nivolumab (NIVO) vs placebo (PBO) for high-risk muscle-invasive urothelial carcinoma (MIUC): Additional efficacy outcomes including overall survival (OS) in patients (pts) with muscle-invasive bladder cancer (MIBC) from CheckMate 274.,"Matthew Milowsky , Matthew Galsky , Johannes Witjes , Juergen Gschwend , Michael Schenker , Begona Perez Valderrama , Yoshihiko Tomita , Aristotelis Bamias , Thierry Lebret , Shahrokh Shariat , Se Hoon Park , Mads Agerbaek , Gautam Jha , Frank Stenner , Dingwei Ye , Fabio Giudici , Jessica Connors , Joshua Zhang , Dean Bajorin","University of North Carolina School of Medicine, Icahn School of Medicine at Mount Sinai, Department of Urology, Radboud University, Technical University Munich, Sf. Nectarie Oncology Center, Hospital Universitario Virgen del Rocío, Niigata University Graduate School of Medical and Dental Sciences, National and Kapodistrian University of Athens, Hôpital Foch, Paris-Saclay University UVSQ, Medical University of Vienna, Vienna General Hospital, Samsung Medical Center, Sungkyunkwan University School of Medicine, Aarhus University Hospital, M Health Fairview Clinics and Surgery Center, University Hospital Basel, Fudan University Shanghai Cancer Center, Bristol Myers Squibb, Memorial Sloan Kettering Cancer Center"
570,H5,The prognostic role of circulating tumor DNA (ctDNA) clearance as a biomarker in localized and metastatic renal cell carcinoma (RCC): A single-center experience.,"Adanma Ayanambakkam , Bibi Maryam , Priyanka Vallabhaneni , Haripriya Andanamala , Vishnu Nagalapuram , Joshua Glover , Tyler Gunter , Kelly Stratton , Michael Cookson , Brian Cross , Sanjay Patel , Andrew McIntosh , Hassan Abushukair , Minh Phan , Ryan Nipp , Arnab Basu , Rana McKay","University of Oklahoma Health Sciences Center, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Stephenson Cancer Center // University of Oklahoma Health Sciences Center, University of Oklahoma College of Medicine, The University of Texas at MD Anderson Cancer Center, University of Oklahoma, University of Alabama at Birmingham, University of California San Diego, Moores Cancer Center"
568,H3,ABCA1 and ABCG1 cholesterol transporters expression on metastatic renal cell carcinoma: Impact on immunotherapy outcomes (CHOMET study).,"Giulia Claire Giudice , Giulia Mazzaschi , Michele Maffezzoli , Alessandro Acunzo , Letizia Gnetti , Enrico Silini , Nicoletta Campanini , Elena Rapacchi , Giuseppe Caruso , Pietro Tuttobene , Sebastiano Buti","University of Parma, Department of Medicine and Surgery, University of Parma and Medical Oncology Unit, University Hospital of Parma, Department of Medicine and Surgery, University of Parma, Medical Oncology Unit, University Hospital of Parma, Pathology Unit, University Hospital of Parma"
TPS611,K12,Dose finding study of CBM588 in combination with nivolumab and ipilimumab in patients with metastatic renal cell carcinoma: A phase I study.,"Ruchi Agarwal , Hedyeh Ebrahimi , Zeynep Zengin , Regina Barragan-Carrillo , Nazli Dizman , Miguel Zugman , Salvador Jaime-Casas , Luis Meza , Xiaochen Li , Joann Hsu , Daniela Castro , Benjamin Mercier , Peter Lee , Motomichi Takahashi , Abhishek Tripathi , Tanya Dorff , Gregory Caporaso , Keehoon Lee , Sumanta Pal , Alex Chehrazi-Raffle","University of Pennsylvania, City of Hope Comprehensive Cancer Center, Yale University School of Medicine, The University of Texas MD Anderson Cancer Center, Miyarisan Pharmaceutical Co., Ltd., Translational Genomics Research Institute (TGen), Translational Genomics Research Institute (TGen North)"
426,L22,Initial biopsy results of the PATROL study: Prostate screening for people with inherited risk of developing aggressive prostate cancer.,"Daniel Lee , Caitlin Orr , Kara Maxwell , Andrew Amini , Christopher Amling , Aileen Feng , Stephanie Goettl , Kristin Follmer , Grace Jun , Chenee Holcomb , Shelley McCormick , Margaret O'Dea , Maxwell Poole , Linda Rodgers , Alexandra Sokolova , Maliha Tayeb , Erika Wolff , Keyan Salari , Heather Cheng , Daniel Lin","University of Pennsylvania, Massachusetts General Hospital, Harvard Medical School, Boston, MA, Oregon Health & Science University, University of Washington, Massachusetts General Hospital, Massachusetts General Hospital, Harvard Medical School, Center for Cancer Risk Assessment, Massachusetts General Hospital Cancer Center"
379,K9,The impact of pelvic radiotherapy on hematological outcomes in pediatric genitourinary rhabdomyosarcoma.,"Kamil Malshy , Zijin Cheng , Trevor Hunt , Timothy Campbell , Matthew Steidl , Jason Fairbourn , Ashley Li , Victor Kucherov , Jathin Bandari",University of Rochester Medical Center
231,G4,Evaluating associations between genomic classifier and digital pathology–based multi-modal AI biomarkers in oligometastatic castration-sensitive prostate cancer.,"Philip Sutera , Yang Song , Amol Shetty , Jarey Wang , Kim Van der Eecken , Alexander Hakansson , Yang Liu , Adrianna Mendes , Xiaolei Shi , Elai Davicioni , Emmalyn Chen , Rikiya Yamashita , Timothy Showalter , Tamara Lotan , Theodore DeWeese , Ana Kiess , Daniel Song , Matthew Deek , Piet Ost , Phuoc Tran","University of Rochester Medical Center, University of Maryland, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Ghent University Hospital, Veracyte, Inc., Johns Hopkins Hospital, University of Maryland School of Medicine, Artera, Johns Hopkins University School of Medicine, Johns Hopkins University, Robert Wood Johnson Medical School, Rutgers University, Ghent University"
580,H15,The feasibility of tumor-infiltrating lymphocyte expansion in non-clear cell renal cell carcinoma.,"Christopher Guske , Marine Potez , Justin Miller , Jeffrey Johnson , Johannes Ali , Michael Carter , Fatema Khambati , Adnan Fazili , Keerthi Gullapalli , Wade Sexton , Logan Zemp , Brandon Manley , Gabriel Roman Souza , Matthew Beatty , Philippe Spiess , Shari Pilon-Thomas , Jad Chahoud","University of South Florida Morsani College of Medicine, H. Lee Moffitt Cancer Center, Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, H. Lee Moffitt Cancer Center, Department of Hematology/Oncology, Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, H. Lee Moffitt Cancer Center and Research Institute/University of South Florida Morsani, Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center & Research Institute, Department of Immuno-Oncology, H. Lee Moffitt Cancer Center and Research Institute, Department of Genitourinary Medical Oncology, H. Lee Moffitt Cancer Center and Research Institute"
TPS887,J15,A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937—Updated design.,"Sarmad Sadeghi , Samuel Callis , Primo Lara Jr., Stephanie Berg , Jason Brown , Rick Bangs , Darrell Nakagawa , Siamak Daneshmand , Ian Thompson Jr., Thomas Flaig , Daniel Petrylak , Seth Lerner","University of Southern California, SWOG Statistical Center, Fred Hutchinson Cancer Research Center, University of California, Davis Comprehensive Cancer Center, Dana-Farber Cancer Institute, Division of Solid Tumor Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, SWOG Cancer Research Network, SWOG GU Bladder Patient Advocate, Department of Urology, University of Southern California Norris Comprehensive Cancer Center, UT Health San Antonio, University of Colorado Denver, Anschutz Medical Campus, Yale School of Medicine, Baylor College of Medicine"
211,F15,Prognostic impact of germline deleterious variants and variants of uncertain significance in advanced prostate cancer: A call for functional elucidation.,"Maitane Alonso Monasterio , Iñigo Tellaetxe Elorriaga , Ricardo Fernández , Sergio Carrera , Pablo Jiménez Labaig , Lorena Mosteiro , Manuela Vázquez , Jorge García-Olaverri , Ane Miren Iturregui , David Büchser , Alfonso Gómez-Iturriaga , Aranzazu Urresola , Iratxe Fernández , Estibaliz Iza , Eluska Iruarrizaga , Joan Manel Mañe , Xabier Elcoroaristizabal , Patricia Ruiz-Ontañón , Asier Erramuzpe , Eneko Novo","University of the Basque Country (UPV/EHU), Biobizkaia Health Research Institute (IIS), Department of Medical Oncology, Cruces University Hospital, Head and Neck Unit, The Royal Marsden NHS Foundation Trust, Department of Pathology, Cruces University Hospital, Department of Urology, Cruces University Hospital, Department of Radiation Oncology, Cruces University Hospital, Department of Radiodiagnostics, Cruces University Hospital, Department of Nuclear Medicine, Cruces University Hospital"
345,J9,Implementation of a digital multimedia tool for prostate cancer patient consultation.,"Kristin Walker , Samira Samadi , Joe Chen , Timothy Showalter , Christopher Luminais","University of Virginia Health System, University of Virginia"
655,K3,Efficacy and safety of CAR-T cell therapy in penile and urethral carcinomas: A meta-analysis of preliminary clinical trials and case studies.,"Hashim Talib Hashim , Ahmed Qasim Mohammed Alhatemi , Atif Hussain Sarwar , Muhammad Nabeel Saddique , Sheena Shamoon","University of Warith Al-Anbiyaa, College of Medicine, Al Nasiriyah Teaching Hospital, Duke University, Durham, King Edward Medical University, Rawalpindi Medical University"
769,E31,"Neoadjuvant pembrolizumab (pembro) and accelerated methotrexate, vinblastine, doxorubicin, cisplatin (aMVAC) in non-urothelial (non-UC) histologic subtype muscle invasive bladder cancer (MIBC): A phase 2 trial.","Ruben Raychaudhuri , Ali Khaki , Mary Redman , Kelsey Baker , Aaron Lin , Brianna Woo , Andrii Hannochka , Nathan Conrad , Funda Vakar-Lopez , Todd Yezefski , Michael Schweizer , Robert Montgomery , Evan Yu , Atreya Dash , Sarah Psutka , Daniel Lin , George Schade , John Gore , Jonathan Wright , Petros Grivas","University of Washington & Fred Hutchinson Cancer Center, Stanford University, Fred Hutchinson Cancer Center, Department of Pathology, University of Washington, Department of Urology, University of Washington, University of Washington and Fred Hutchinson Cancer Center"
77,B23,"Real world comparison of time-to-next-treatment (TTNT), time-to-castration-resistance (TTCR), and overall survival (OS) among patients with BRCA1/2 positive and homologous recombination repair (HRR) negative metastatic castration-sensitive prostate cancer (mCSPC).","Heather Cheng , Sabree Burbage , Carmine Rossi , Ibrahim Khilfeh , Lilian Diaz , Yuxi Wang , Dominic Pilon , Gordon Brown , Neal Shore , Benjamin Lowentritt , Daniel Lin , Mehmet Bilen","University of Washington, Johnson & Johnson Innovative Medicine, Analysis Group, Inc., New Jersey Urology, A Summit Health Company, and Rowan University School of Osteopathic Medicine, Carolina Urologic Research Center and Atlantic Urology Clinics, Chesapeake Urology, Winship Cancer Institute of Emory University"
181,E20,CTC and AR-V7 analysis in the ECOG-ACRIN 8153 (CHAARTED2) randomized trial: Abiraterone (Abi) with or without cabazitaxel (Abi-Cabazi) in extensive mCRPC following docetaxel.,"Christos Kyriakopoulos , Yu-Hui Chen , Robert Jeraj , Fenghai Duan , Abhishek Tripathi , David Kosoff , Rohan Garje , Russell Pachynski , Rahul Parikh , Andrea Harzstark , Nabil Adra , Benjamin Maughan , Yousef Zakharia , Paul Corn , Glenn Liu , Michael Carducci , Jun Luo , Emmanuel Antonarakis","University of Wisconsin Carbone Cancer Center, Dana-Farber Cancer Institute, University of Wisconsin-Madison, Brown University School of Public Health, City of Hope Comprehensive Cancer Center, Miami Cancer Institute, Baptist Health South Florida, Siteman Cancer Center; Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, University of Kansas Cancer Center, Kaiser Permanente, Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center, Huntsman Cancer Institute at the University of Utah, University of Iowa Holden Comprehensive Cancer Center, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, University of Minnesota, Masonic Cancer Center"
256,G29,Investigating clinical associations between genomic alterations and prostate cancer lineage states using circulating tumor cell RNA sequencing.,"Katharine Tippins , Joshua Lang , Marina Sharifi , Jamie Sperger , Shannon Reese , Amy Taylor , Viridiana Carreno , Alex Chang , Meghan Wells , John Floberg , Hamid Emamekhoo , Shuang Zhao , David Kosoff","University of Wisconsin Hospitals and Clinics, University of Wisconsin Carbone Cancer Center, University of Wisconsin, University of Wisconsin-Madison, Department of Medicine, University of Wisconsin-Madison, Hematology/Oncology Facility, University of Wisconsin-Madison, Department of Human Oncology, University of Wisconsin-Madison"
232,G5,Circulating tumor cell (CTC) expression patterns of cell surface targets in metastatic prostate cancer.,"Kendra Marr , Jamie Sperger , Amy Taylor , Katharine Tippins , Shannon Reese , Kyle Helzer , Matthew Bootsma , Grace Blitzer , John Floberg , David Kosoff , Rana McKay , Xiao Wei , Shuang Zhao , Joshua Lang , Marina Sharifi","University of Wisconsin Hospitals and Clinics, University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Department of Human Oncology, University of Wisconsin-Madison, University of California San Diego, Moores Cancer Center, Dana-Farber Cancer Institute, University of Wisconsin"
241,G14,"Characterizing immunogenicity of MYC-amplified, metastatic prostate cancer as reflected by the recovery rates of adaptive immune receptor recombinations from RNAseq files.","Sunny Kahlon , Vayda Barker , Mallika Varkhedi , Alex Wang , Taha Huda , George Blanck","University South Florida, USF Health Morsani College of Medicine
, University of South Florida, USF Health Morsani College of Medicine, HCA Healthcare/USF Morsani College of Medicine GME: Bayonet Point Hospital, Department of Molecular Medicine, Morsani College of Medicine, University of South Florida"
490,E23,Bone metastases and use of bone protective agents (BPA) for metastatic renal cell carcinoma (mRCC): A contemporary national real-world analysis.,"Braden Millan , Sunita Ghosh , Naveen Basappa , Lori Wood , Bimal Bhindi , Frederic Pouliot , Rodney Breau , Antonio Finelli , Rahul Bansal , Jeffrey Graham , Georg Bjarnason , Dominick Bosse , Vincent Castonguay , Eric Winquist , Daniel Heng , Christian Kollmannsberger , Aly-Khan Lalani","Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Department of Oncology, University of Alberta, Cross Cancer Institute, University of Alberta, Queen Elizabeth II Health Sciences Centre, Dalhousie University, Southern Alberta Institute of Urology, CHU de Québec-Université Laval Research Center, Ottawa Hospital, University of Toronto, St Joseph Healthcare Hamilton, CancerCare Manitoba, University of Manitoba, Sunnybrook Odette Cancer Centre, University of Ottawa, Hotel Dieu de Quebec, Division of Medical Oncology, London Health Sciences Centre & Western University, Tom Baker Cancer Centre, University of Calgary, British Columbia Cancer Agency, McMaster University"
469,E2,Exploring the efficacy of belzutifan in the treatment of renal cell carcinoma associated with von Hippel-Lindau disease: A comparative analysis with external control arm.,"W Linehan , Thomas Jemielita , Jerry Cornell , Ke Chen , Mark Ball , Ramaprasad Srinivasan , Yanfang Liu , Rodolfo Perini , Cathy Anne Pinto","Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Merck & Co., Inc., National Cancer Institute, National Institutes of Health, Merck and Co, Inc."
343,J7,Outcomes of high-risk prostate-specific antigen level during active surveillance with targeted and systematic prostate biopsy.,"Braden Millan , Jaskirat Saini , Mitchell Hwang , Charles Hesswani , Ruben Blachman-Braun , Christopher Koller , Daniel Nethala , Brad Wood , Baris Turkbey , Sandeep Gurram , Peter Pinto","Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, National Institutes of Health, Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, National Cancer Institute, National Institutes of Health"
850,H14,CD39 expression as a predictive biomarker for neoadjuvant treatment in muscle-invasive bladder cancer.,"Oscar Buisan , Jordi Senserrich , Pol Servian , Maria Sanchez , Elisabet Garcia , Joan Pagès , Roger Freixa , Anna Colomer , Jordi Cervera , Joan Areal , Bonaventura Clotet , Joaquim Bellmunt , Cecilia Cabrera","Urology Department. Institut Català d'Oncologia (ICO) Hospital Germans Trias i Pujol, IrsiCaixa, ICO - Institut Català d'Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Department of Urology, Institute for Health Science Research Germans Trias i Pujol (IGTP), Bladder Cancer Center, Dana Farber Cancer Institute, Harvard Medical School, Irsicaixa. Institute for Health Science Research Germans Trias i Pujol (IGTP)"
156,D30,Safety and tolerability of relugolix in combination with abiraterone or apalutamide for treatment of advanced prostate cancer: Data from a 52-week clinical trial.,"Jose De La Cerda , Laurence Belkoff , Kevin Courtney , Elan Diamond , James D'Olimpio , Curtis Dunshee , Lawrence Gervasi , Curtis Dunshee , Michael Goodman , Kriti Mittal , David Morris , Paul Sieber , Ronald Tutrone , Michael Ryan , Yi Zhong , Mike Ufer , Neal Shore","Urology San Antonio, Midlantic Urology, Department of Internal Medicine, Division of Hematology and Oncology, UT Southwestern, New Jersey Urology, Clinical Research Alliance, Urological Associates of Southern Arizona, Southwest Urology LLC, Arizona Urology Specialists, Wake Forest Baptist Medical Center, University of Massachusetts Chan Medical School, Urology Associates, Keystone Urology Specialists, Chesapeake Urologic Research Associates, Pfizer, Inc., Sumitomo Pharma America, Inc., Sumitomo Pharma Switzerland GmbH, Carolina Urologic Research Center"
758,E20,Safety of combining radiotherapy and antibody drug conjugates in advanced urothelial and other cancers.,"Derrick Lock , Yash Soni , Lindsay Hwang , Suzanne Cole , Anishka D'souza , Aurelie Garant , Daniel Yang , Waddah Arafat , Tian Zhang , Leslie Ballas , Neil Desai","USC Norris Comprehensive Cancer Center, UT Southwestern Medical Center, Los Angeles General Medical Center, Department of Internal Medicine, Division of Hematology and Oncology, UT Southwestern, Department of Radiation Oncology, UT Southwestern Medical Center, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Cedars-Sinai Medical Center"
577,H12,FGD1 splice variants as predictors of brain and bone metastatic organotropism in clear cell renal cell carcinoma.,"Justin Miller , Alyssa Obermayer , Mitchell Hayes , Roy Elias , Nirmish Singla , Michelle Churchman , George Grass , Ahmad Tarhini , Paola Ramos Echevarria , Alex Soupir , Youngchul Kim , Eric Singer , Sean Kern , Yousef Zakharia , Paul Viscuse , Patrick Hensley , Timothy Shaw , Brandon Manley","USF Health Morsani College of Medicine, H. Lee Moffitt Cancer Center and Research Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Aster Insights, H. Lee Moffitt Cancer Center, Department of Radiation Oncology, Departments of Cutaneous Oncology and Immunology, H. Lee Moffitt Cancer Center and Research Institute, The Ohio State University Comprehensive Cancer Center, Uniformed Services University/Murtha Cancer Center, University of Iowa Holden Comprehensive Cancer Center, Division of Hematology/Oncology, University of Virginia, University of Kentucky, Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center & Research Institute"
320,H20,Timely next-generation sequencing testing in patients with metastatic prostate cancer: A comparative analysis between Medicare Advantage and traditional Medicare.,"Jonathan Ji , Baqir Jafry , Chuan Lu , Raj Bhanvadia , Qian Qin , Joseph Vento , Kevin Courtney , Jue Wang , Waddah Arafat , Daniel Yang , Suzanne Cole , Tian Zhang , Changchuan Jiang","UT Southwestern Medical School, UT Southwestern Medical Center, Department of Urology, UT Southwestern Medical Center, Department of Internal Medicine, Division of Hematology and Oncology, UT Southwestern, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Department of Radiation Oncology, UT Southwestern Medical Center"
319,H19,Timely BRCA mutation testing in patients with metastatic prostate cancer: A comparative analysis between Medicare Advantage and traditional Medicare.,"Jonathan Ji , Chuan Lu , Baqir Jafry , Raj Bhanvadia , Qian Qin , Joseph Vento , Kevin Courtney , Jue Wang , Waddah Arafat , Daniel Yang , Suzanne Cole , Tian Zhang , Changchuan Jiang","UT Southwestern Medical School, UT Southwestern Medical Center, Department of Urology, UT Southwestern Medical Center, Department of Internal Medicine, Division of Hematology and Oncology, UT Southwestern, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Department of Radiation Oncology, UT Southwestern Medical Center"
TPS903,J31,SUBDUE-3: Sub-urothelial durvalumab-sirconium to investigate local and systemic distribution of durvalumab when injected in the sub-urothelium.,"Kevin Keane , Andrisha Inderjeeth , Roslyn Francis , Andrew Scott , Cynthia Hawks , Richard Gauci , Ian Davis , Andrew Redfern , Dickon Hayne","UWA Medical School, University of Western Australia, Sir Charles Gairdner Hospital, Australasian Radiopharmaceutical Trials Network (ARTnet), Olivia Newton-John Cancer Research Institute, The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, South Metropolitan Health Service, Monash University and Eastern Health"
TPS897,J25,G-DISCO: Gemcitabine-docetaxel intravesical instillation synchronous co-administration—A phase I study.,"Kevin Keane , Cynthia Hawks , Stephen McCombie , Ek Leone Oh , Andrew Redfern , Dickon Hayne","UWA Medical School, University of Western Australia, South Metropolitan Health Service, The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group"
312,,"A high omega-3, low omega-6 diet with fish oil for men with prostate cancer on active surveillance: The CAPFISH-3 randomized clinical trial.","William Aronson , Tristan Grogan , Pei Liang , Patricia Jardack , Amana Liddell , Claudia Perez , Mikayla Lerman , David Elashoff , Jonathan Said , Pinchas Cohen , Leonard Marks , Susanne Henning","VA Greater Los Angeles Healthcare System, Department of Medicine Statistics Core, UCLA, University of California, Los Angeles, David Geffen School of Medicine at UCLA, Leonard Davis School of Gerontology, University of Southern California, Los Angeles, Department of Urology, University of California, Los Angeles"
251,G24,Genome-wide burden survival tests for patients with metastatic prostate cancer on androgen receptor-targeted therapies in the Million Veterans Program dataset.,"Danielle Candelieri-Surette , Dan Berlowitz , Tyler Nelson , Hannah Carter , Brent Rose , Rana McKay , Jason Vassy , Richard Hauger , Julie Lynch , Craig Teerlink","VA Salt Lake City Health Care System, University of Massachusetts Lowell, Lowell MA, Salt Lake City VA Health System, University of California, San Diego, VA Boston Healthcare System, VA San Diego Healthcare System, VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System"
621,J6,Assessing racial disparities in testicular cancer survival: Evidence from a nationwide cohort.,"Kylie Morgan , Paul Riviere , Kshitij Pandit , Tyler Nelson , Daniel Sabater Minarim , Margaret Meagher , Dhruv Puri , Nuphat Yodkhunnatham , Frederick Millard , Rana McKay , Brent Rose , Aditya Bagrodia","VA San Diego Health Care System, Department of Radiation Medicine and Applied Sciences, University of California, San Diego, UCSD Health, Center for Health Equity Education and Research, UCSD Health, Department of Urology, University of California, San Diego, Department of Urology, University of California San Diego School of Medicine, UC San Diego Moores Cancer Center, Moores Cancer Center, University of California, San Diego, University of California San Diego Health"
143,D17,Age-related efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) and docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subgroup analysis of ARASENS.,"Joan Carles , Bertrand Tombal , Maha Hussain , Fred Saad , Karim Fizazi , Alvaro Montesa Pino , Maria Jose' Méndez-Vidal , Alejo Rodriguez-Vida , Daniel Castellano , Pablo Borrega , Patrick Adorjan , Cristina Moretones , Manjari Dissanayake , Matthew Smith","Vall d’Hebron Institute of Oncology, Hospital Universitari Vall d’Hebron, Division of Urology, IREC, Cliniques Universitaires Saint Luc, UCLouvain, Northwestern University, Feinberg School of Medicine, Centre Hospitalier de l'Université de Montréal, Université de Montréal, Institut Gustave Roussy, University of Paris-Saclay, UGC Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen Victoria, IBIMA, Reina Sofía University Hospital, Hospital del Mar, Hospital 12 de Octubre, Hospital San Pedro de Alcántara, Bayer Consumer Health AG, Bayer Hispania SL, Bayer HealthCare Pharmaceuticals, Inc., Massachusetts General Hospital Cancer Center and Harvard Medical School"
522,F20,Impact of belzutifan on anemia and hypoxia in sporadic and VHL-syndrome-associated renal cell carcinoma.,"Paulo Siqueira do Amaral , Aaron Winer , Katy Beckermann , Heidi Chen , Morgan Lambrecht , Elizabeth Kaiser , Brian Rini","Vandebilt University Medical Center, Vanderbilt University Medical Center"
468,D36,Extensive necrosis as a prognostic indicator in metastatic RCC patients undergoing deferred cytoreductive nephrectomy after immunologic checkpoint inhibitor treatment.,"Paulo Siqueira do Amaral , Katy Beckermann , Gabriel Polho , Kelvin Moses , Jennifer Gordetsky , Sam Chang , Amy Luckenbaugh , Kristin Ancell , Morgan Lambrecht , Kerry Schaffer , Elizabeth Kaiser , Daniel Joyce , Brian Rini","Vandebilt University Medical Center, Vanderbilt University Medical Center, Instituto do Câncer do Estado de São Paulo (ICESP), Universidade de São Paulo"
459,D27,Patient-reported outcomes (PROs) for tivozanib (TIVO) + nivolumab (NIVO) vs TIVO monotherapy in patients with renal cell carcinoma (RCC) following an immune checkpoint inhibitor (ICI): Results of the phase 3 TiNivo-2 study.,"Katy Beckermann , Toni Choueiri , Robert Motzer , Philippe Barthelemy , Roberto Iacovelli , Sheik Emambux , Javier Molina-Cerrillo , Benjamin Garmezy , Pedro Barata , Rana McKay , Alex Chehrazi-Raffle , Hans Hammers , Daniel Heng , Edgar Braendle , Claudia Lebedinsky , Bo Jin , Laurence Albiges , Bradley McGregor","Vanderbilt University, Department of Medical Oncology, Dana-Farber Cancer Institute, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College, Department of Medical Oncology, Institut de Cancérologie Strasbourg Europe (ICANS), Università Cattolica del Sacro Cuore, Centre Hospitalier Universitaire de Poitiers, Medical Oncology Department, Hospital Universitario Ramón y Cajal, Sarah Cannon Research Institute, University Hospitals Seidman Cancer Center, University of California, San Diego, City of Hope Comprehensive Cancer Center, Department of Internal Medicine, Division of Hematology and Oncology, UT Southwestern, Tom Baker Cancer Centre, University of Calgary, AVEO Oncology, Institut Gustave Roussy, Dana-Farber Cancer Institute"
860,H24,"Comprehensive bladder cancer molecular profiling and monitoring based on mutational, epigenomic, and expression data from real-world patients.","Alan Tan , Yong Huang , Giancarlo Bonora , Binggang Xiang , Chao Dai , Fang Liu , Ziqi Zhu , Shidong Jia , Pan Du","Vanderbilt-Ingram Cancer Center, Predicine, Inc., Predicine"
514,F12,First line treatment of pancreatic metastases in metastatic renal cell carcinoma: Insights from the UK Renal Oncology Collaborative (UK ROC)—Tyrosine kinase inhibitors time to shine?,"Ben Crosby , Ricky Frazer , John McGrane , Amarnath Challapalli , Natalie Charnley , Xue Yan Jiang , Jahangeer Malik , Anand Sharma , Justin Liu , Dominique Parslow , Tom Geldart , Claire Dyke , Mark Tuthill , G.J. Melendez-Torres , Wael Mohamed , Niall Moon , Caroline Forde , Eleanor Jones , Victoria Ford , Amit Bahl","Velindre Cancer Centre, Royal Cornwall Hospital NHS Trust, Bristol Haematology and Oncology Centre, University Hospitals Bristol and Weston NHS Foundation Trust, Royal Preston Hospital, Northern Centre for Cancer Care (NCCC), Edinburgh Cancer Centre, Mount Vernon Cancer Centre, Leeds Cancer Centre, University Hospitals Plymouth, Poole Hospital, Torbay and South Devon NHS Foundation Trust, Oxford University Hospitals NHS Foundation Trust, Exeter University, Singleton Hospital, Royal Cornwall Hospital, Northern Ireland Cancer Centre, University Hospital Southampton, Royal Devon University NHS Foundation Trust Hospital, Bristol Oncology Centre"
855,H19,A survival prediction model for veterans with advanced bladder cancer (BC) treated with immune checkpoint inhibitors (ICI).,"Daniel Sabater Minarim , Kylie Morgan , Leah Deshler , Brent Rose , Amirali Salmasi , Magalie Dosset , Matteo D’Antonio , Kit Yuen , Tyler Stewart","Veterans Health Administration San Diego Health Care System, VA San Diego Health Care System, UCSD Health, Department of Radiation Medicine and Applied Sciences, University of California, San Diego, Moores Cancer Center, University of California San Diego, UC San Diego Moores Cancer Center, Division of Biomedical Informatics, UCSD Health Sciences, Department of Urology, University of California San Diego School of Medicine, UC San Diego Health"
271,H12,Patient characteristics and survival in primary prostate sarcomas: An analysis of the SEER database.,"Ayush Kaushish , Hyun Lee , Joseph Han , Bohdan Baralo , Asit Paul","Virginia Commonwealth University - Massey Comprehensive Cancer Center, Virginia Commonwealth University - Massey Cancer Center"
878,J6,Primary sarcomas of urinary bladder: A SEER analysis.,"Joseph Han , Hyun Lee , Ayush Kaushish , Bohdan Baralo , Asit Paul","Virginia Commonwealth University - Massey Comprehensive Cancer Center, Virginia Commonwealth University - Massey Cancer Center"
602,J1,Presurgical treatment for inferior vena cava tumor thrombus in patients with renal cell carcinoma: A scoping review.,"Bohdan Baralo , Natasha Dziarnowski , Cody McIntire , Peter Daniels , Morgan Puglisi , Hyun Lee , John Melson , Asit Paul","Virginia Commonwealth University - Massey Comprehensive Cancer Center, Virginia Commonwealth University, Virginia Commonwealth University School of Medicine"
808,G4,ETCTN 10483: Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR3/2 genetic alterations (GAs).,"Rohit Jain , Faustine Ong , Bishoy Faltas , Scott Tagawa , Di Maria Jiang , Jazlyn Heiligh , Youngchul Kim , Lorraine Pelosof , Yuanquan Yang , Laura Graham , Waddah Arafat , Timothy Synold , Monica Chatwal , Jingsong Zhang , Jus Chadha , Guru Sonpavde , Syeda Mahrukh Hussnain Naqvi","Weill Cornell Medicine, Moffitt Cancer Center, Weill Cornell Medical College of Cornell University, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, H. Lee Moffitt Cancer Center and Research Institute, NIH-NCI, Pelotonia Institute for Immuno-Oncology and Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, University of Colorado Cancer Center Anschutz Medical Campus, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, City of Hope Beckman Research Institute, H. Lee Moffitt Cancer Center, AdventHealth Cancer Institute"
185,E24,Mature phase 1 follow up of alpha emitter 225Ac-J591 with 177Lu-PSMA-I&T in advanced prostate cancer.,"Gabriel Raab , Tobechukwu Okobi , Aaron Holmes , Sandra Huicochea Castellanos , Vasilios Avlonitis , Amie Patel , Charlene Thomas , Jones Nauseef , Ana Molina , Zachary Davidson , Cora Sternberg , David Nanus , Joseph Osborne , Neil Bander , Scott Tagawa","Weill Cornell Medicine, NewYork-Presbyterian Hospital, NewYork-Presbyterian Brooklyn Methodist Hospital, Department of Medicine, Weill Cornell Medicine, NewYork-Presbyterian Hospital, Molecular Imaging & Therapeutics, Department of Radiology, Weill Cornell Medicine, Ambulatory-Nuclear Med, Department of Radiology, Weill Cornell Medicine, Weill Cornell Medicine, Division of Hematology & Medical Oncology, Weill Cornell Medicine; Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College, NewYork-Presbyterian Hospital, Weill Cornell Medical College, Weill Cornell Medical Center, NewYork-Presbyterian Hospital, Division of Hematology & Medical Oncology, Weill Cornell Medicine, NewYork-Presbyterian Hospital"
318,H18,Does treatment (Tx) for mental health illness (MHI) impact prostate cancer (PC) Tx and outcomes?,"Zachary Klaassen , Jessica Janes , Joshua Parrish , Sydney McIntire , Rashid Sayyid , Edward Machen , Amanda De Hoedt , Cristiane Bergerot , Stephen Williams , Martha Terris , Stephen Freedland","Wellstar MCG Health/Georgia Cancer Center, Durham VA Health Care System, Department of Surgery, Section of Urology, Durham VA Health Care System, Department of Surgery, Durham Veterans Affairs Health Care System, University of Southern California, Department of Surgery, Durham VA Health Care System, Oncoclínicas & Co, Medica Scientia Innovation Research (MEDSIR), University of Texas Medical Branch at Galveston, Department of Urology, Medical College of Georgia at Augusta University, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center; Durham VA Medical Center"
340,J4,Optimizing the strategies to perform prostate biopsy in MRI-positive patients: A systematic review and network meta-analysis.,"Qiyou Wu , Xiang Tu , Bo Tang , Yige Bao , Qiang Wei","West China Hospital, Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Department of Urology and Institute of Urology, West China Hospital,  Sichuan University, Department of Urology, West China Hospital, Sichuan University"
TPS299,M18,Tislelizumab in combination with abiraterone/enzalutamide for metastatic castration-resistant prostate cancer with intraductal adenocarcinoma of the prostate after progression on prior androgen receptor pathway inhibitor.,"Qiyu Zhu , Jinge Zhao , Pengfei Shen , Ming Zhang , Qian Wang","West China Hospital, Department of Urology and Institute of Urology, West China Hospital, Sichuan University, West China Hospital, Sichuan University"
325,H25,Global spatiotemporal trends in prostate cancer burden and its socioeconomic disparities: An observational study from 1990 to 2021.,"Xianghong Zhou , Qiang Wei","West China Hospital, Sichuan University, Department of Urology and Institute of Urology, West China Hospital, Sichuan University"
786,F13,Long-term results of a phase 2 study of neoadjuvant chemotherapy combined with tislelizumab followed by radiotherapy for bladder-preserving treatment in selected high-risk/locally advanced muscle invasive urothelial bladder cancer (HOPE-02).,"Feng Wen , Tianhai Lin , Ping Tan , Jiani Deng , Min Ren , Mengni Zhang , Xiaonan Zheng , Peng Zhang , Yali Shen","West China Hospital, Sichuan University, Institute of Urology, West China Hospital, Sichuan University"
795,F22,A multi-center phase Ib/II study of RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive urothelial bladder cancer (Hope-03).,"Feng Wen , Tianhai Lin , Ping Tan , Jiani Deng , Min Ren , Mengni Zhang , Xiaonan Zheng , Peng Zhang , Yali Shen","West China Hospital, Sichuan University, Institute of Urology, West China Hospital, Sichuan University"
619,J4,Incidence and mortality trends in genitourinary cancer in Southeast Asia from 1990-2021.,"Rod Carlo Columbres , Aryan Selokar , Sybil Sha , Sruthi Ranganathan , James Wu , Erin Feliciano , Brandon Mahal , Paul Nguyen , Edward Christopher Dee","William Carey University College of Osteopathic Medicine, University of California, San Diego, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, University of Cambridge, Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, NYC Health + Hospitals/Elmhurst, University of Miami Miller School of Medicine, Dana-Farber Cancer Institute"
248,G21,Evaluating the role of cancer-associated fibroblasts in T cell–mediated proinflammatory reprogramming of tumor associated macrophages in the prostate cancer tumor microenvironment.,"David Kosoff , Erika Heninger , Matthew Breneman , Emma Recchia , Vilena Maklakova , Aaron Lebeau","William S. Middleton Memorial Veterans Hospital, University of Wisconsin Carbone Cancer Center"
512,F10,Non-clear cell renal cell carcinoma in the immune checkpoint era: A retrospective study on survival and treatment approaches.,"Ahmet Yildirim , Yuan Liu , Angelo Marra , Lauren Suh , Yujin Choi , Dylan Martini , Caitlin Hartman , Greta McClintock , Tony Zhuang , Wayne Harris , Jordan Ciuro , Jacob Berchuck , Jacqueline Brown , Bassel Nazha , Bradley Carthon , Omer Kucuk , Viraj Master , Mehmet Bilen","Winship Cancer Institute of Emory University, Department of Biostatistics and Bioinformatics, Emory University, Emory University, Dana-Farber Cancer Institute, Emory University School of Medicine"
326,H26,Initial report of a randomized trial of post-prostatectomy prostate cancer radiotherapy using either fluciclovine (18F) or PSMA (68Ga) PET/CT for target dose-escalation.,"Ashesh Jani , Vishal Dhere , Subir Goyal , Eduard Schreibmann , Pretesh Patel , Bruce Hershatter , Joseph Shelton , Sheela Hanasoge , Nikhil Sebastian , Sagar Patel , Raghuveer Halkar , Bridget Fielder , Olayinka Abiodun-Ojo , Ismaheel Lawal , Aliza Mushtaq , Viraj Master , Shreyas Joshi , Omer Kucuk , Mehmet Bilen , David Schuster","Winship Cancer Institute of Emory University, Emory University, Department of Biostatistics and Bioinformatics, Emory University School of Medicine, Emory University School of Medicine, Department of Radiation Oncology, Emory University, Emory Unversity School of Medicine, Emory University Hospital, Department of Urology, Emory University, Department of Radiology and Imaging Sciences, Division of Nuclear Medicine and Molecular Imaging, Emory University"
603,J2,Impact of concomitant medication use on treatment outcomes in patients with RCC treated with immune checkpoint inhibitors.,"Ahmet Yildirim , Mengting Wei , Yuan Liu , Yujin Choi , Lauren Suh , Dylan Martini , Caitlin Hartman , Greta McClintock , Tony Zhuang , Wayne Harris , Jordan Ciuro , Jacob Berchuck , Jacqueline Brown , Bassel Nazha , Bradley Carthon , Omer Kucuk , Viraj Master , Mehmet Bilen","Winship Cancer Institute of Emory University, Emory University, Department of Biostatistics and Bioinformatics, Emory University, Dana-Farber Cancer Institute, Emory University School of Medicine"
555,G22,Phase 2 study of perioperative lenvatinib (L) with pembrolizumab (P) in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.,"Mehmet Bilen , Yuan Liu , Amir Davarpanahfakhr , Bassel Nazha , Jacqueline Brown , Adeboya Osunkoya , Sierra Thomson , Wilena Session , Caitlin Hartman , Greta McClintock , Sarah Caulfield , Shreyas Joshi , Vikram Narayan , Kenneth Ogan , Omer Kucuk , Bradley Carthon , Haydn Kissick , Viraj Master","Winship Cancer Institute of Emory University, Emory University, Emory University School of Medicine, Department of Urology, Emory University, Department of Urology, Emory University School of Medicine"
44,A22,COBRA: Assessment of the efficacy of 64Cu-SAR-bisPSMA using histopathology as reference standard in patients with biochemical recurrence of prostate cancer following definitive therapy.,"Luke Nordquist , Eva Lengyelova , Daniel Saltzstein , David Josephson , Gregg Franklin , Glynn Morrish , Othon Gervasio , Robert Miller , Neal Shore","XCancer, Clarity Pharmaceuticals, Urology San Antonio, Tower Urology, New Mexico Cancer Center, Carolina Urologic Research Center and Atlantic Urology Clinics"
571,H6,Metabolic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma.,"Renee Maria Saliby , Chris Labaki , Tejas Jammihal , Hanna Soulati , Juan Gallegos , Arnau Peris , Dustin McCurry , Valisha Shah , Deepak Poduval , Talal El Zarif , Nourhan El Ahmar , Yasmin Nabil Laimon , Aseman Bagheri Sheshdeh , Marc Eid , Katherine Krajewski , Sabina Signoretti , Eliezer Van Allen , Sachet Shukla , Toni Choueiri , David Braun","Yale Cancer Center, Beth Israel Deaconess Medical Center, Children's Hospital of Philadelphia, Center of Molecular and Cellular Oncology, Yale School of Medicine, Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center, Dana-Farber Cancer Institute, Department of Internal Medicine, Yale New Haven Hospital, Brigham and Women's Hospital, Saint Joseph's University, Department of Radiology, Brigham and Women's Hospital, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Department of Medical Oncology, Dana-Farber Cancer Institute, Center of Molecular and Cellular Oncology, Yale University"
476,E9,Survival of patients with metastatic renal cell carcinoma with or without brain metastases.,"Michael Hurwitz , Bryden Considine , Nitzan Hasson , Noam Savion Gaiger , Melanie Nelson , Veronica Chiang , Harriet Kluger , David Braun , David Schoenfeld , Mario Sznol , Michael Leapman","Yale Cancer Center, Yale School of Medicine, St. Charles Cancer Center, Yale University, The Ohio State University College of Medicine, Department of Neurosurgery, Yale University, Yale Cancer Center, Center of Molecular and Cellular Oncology, Yale University, Department of Medical Oncology, Yale School of Medicine, Yale School of Medicine"
749,E11,Evaluating the therapeutic role of lymph node dissection in variant histology bladder cancer.,"Syed Rahman , David Hesse , Michael Jalfon , Victoria Kong , Fady Ghali","Yale New Haven Hospital, Yale School of Medicine, Yale"
517,F15,Modeling survival outcomes of KEYNOTE-564 with standard of care control arm treatment: A simulation study.,"Fady Ghali , Syed Rahman , Spencer James","Yale School of Medicine, Department of Urology, Yale School of Medicine, Docer.ai"
865,H29,Pilot study evaluating duplex sequencing of urinary DNA as a biomarker for recurrence in non-muscle invasive bladder cancer.,"Fady Ghali , Ondrej Blaha , Hung-Ming Lam , Scott Kennedy , Jonathan Wright","Yale School of Medicine, Yale University, University of Washington Medical Center, University of Washington"
